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1. Epigenetics 
As many evidence suggest, the DNA code its self is not the only one to guide the 
gene expression. Nowadays it is well know that this activity depends on a numerous 
biological phenomena that have been lumped into the category of epigenetics. The 
first definition of epigenetics is reliable to Conrad Waddington (1905-1975) that 
defined epigenetics as “the branch of biology which studies the causal interactions 
between genes and their products, which bring the phenotype into being”.1 
Epigenetics is like the bridge between genotype and phenotype: even though the vast 
majority of cells in a multicellular organism share an identical genotype, organismal 
development generates a diversity of cell types with disparate, yet stable, profiles of 
gene expression and distinct cellular functions.
2
 Nevertheless, the definition of 
epigenetics has evolved over time as it is implicated in a wide variety of biological 
processes: the current definition is “the study of heritable changes in gene expression 
that occur independently of changes in the primary DNA sequence”.3 Most of these 
changes are established during differentiation and are stably maintained through 
multiple cycles of cell division, enabling cells to have distinct identities while 
containing the same genetic information. This heritability of gene expression patterns 
is mediated, as we will see in detail below, by two major mechanisms, sometimes 
strictly interdependent, covalent modifications of histone proteins (chromatin 
remodeling) and methylation of cytosine bases in DNA.
4,5
 Failure of the proper 
maintenance of heritable epigenetic marks can result in inappropriate activation or 
inhibition of various signaling pathways and lead to disease states such as cancer.
6,7,8
 
Some researchers are investigating whether subtle modifications to the genome that 
do not alter its DNA sequence (i.e., epigenetic changes) may also underline common 
diseases such as diabetes, obesity, heart disease, and a host of psychiatric disorders 
like manic depression and schizophrenia. Many features of these conditions, such as 
the differences between pairs of twins in which only one suffers from schizophrenia, 
cannot be explained readily by DNA-sequence variation. Although some psychiatric 
disorders seem to run in families, the chance of succumbing depends in some cases 
on whether this story is on the mother’s or the father’s side, suggesting that parental 
imprinting is involved. Moreover, in the mentioned case of twins, substantial 
differences in their patterns of DNA methylation have been found.
9,10 
These findings 
have led to a global initiative to understand the role of epigenetics in the initiation 
and propagation of those diseases. The fact that epigenetic aberrations, unlike genetic 
mutations, are potentially reversible and can be restored to their normal state by 
epigenetic therapy makes such initiatives promising and therapeutically relevant.  
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2. DNA methylation 
Epigenetics acts mainly through three different mechanisms: DNA methylation, 
chromatin remodeling and histone modification. 
DNA methylation is probably the most extensively studied epigenetic mark. It plays 
an important part in genomic imprinting, in DNA repair, in X-chromosome 
inactivation, and in the silencing of retrotransposons, repetitive elements and tissue-
specific genes. DNA methylation in humans occurs almost exclusively in the context 
of CpG dinucleotides clustered in ~1 kb regions, termed CpG islands.
11-13
 In 
addition, it also occurs at regions of lower CpG density that lie in close proximity 
(~2 kb), termed “CpG island shores”.14,15 Only < 80% of the methylatable CpG 
population, which represent over 50% of promoters, is methylated. Different CpG 
sites are methylated in different tissues, creating a pattern of methylation that is gene 
and tissue specific.
16
 This pattern creates a layer of information that confers upon a 
genome its specific cell type identity.  
Moreover, DNA methylation patterns in vertebrates are distinguished by their tight 
correlation with chromatin structure. Active regions of the chromatin, which enable 
gene expression, are associated with hypomethylated DNA, whereas 
hypermethylated DNA is packaged in inactive chromatin. 
Therefore, DNA methylation is a highly effective mechanism for silencing of gene 
expression in vertebrates and plants, either by interfering with the binding of 
transcription factors, or by attracting methylated DNA-binding proteins (MBDs), 
able to recruit other proteins and histone modifying enzymes, which leads to 
formation of a closed chromatin configuration and silencing of gene expression.
17,18
 
Noteworthy, DNA methylation patterns are altered in the progression of cancer. Both 
the hypomethylation and hypermethylation of different regions of the genome play a 
crucial role in tumorigenesis. During the development of tumors, a genome-wide 
demethylation occurs and this can promote genomic instability possibly by activating 
silenced retrotransposons.
19
 On the other hand, focal hypermethylation of CpG 
islands has been intensively studied in cancer. Nearly all types of cancers have 
transcriptional inactivation of tumor suppressor genes due to DNA 
hypermethylation.
6
 However, the exact mechanism responsible for the appearance of 
DNA methylation in a given promoter is not fully understood. 
The establishment and maintenance of DNA methylation patterns are governed by 
catalytically active DNA methyltransferase (DNMT) enzymes.
20 
2.1. Chemistry of DNA methylation 
Methylation of DNA occurs immediately after replication by a transfer of a methyl 
moiety from the donor S-adenosyl-L-methionine (SAM, or AdoMet) in a reaction 
catalyzed by DNMT. In mammals, DNMTs preferentially methylate position 5 of a 
cytosine in a 5ꞌ-CpG-3ꞌ (CpG dinucleotide) context, although non- CpG methylation 
(CpA, CpT or CpC) has been described.
21  
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First, it has been shown that the targeted cytosine is flipped out of the DNA double 
helix into the catalytic site of the enzymes.
22 
The thiolate of the catalytic cysteine in 
motif IV performs a nucleophilic attack on the 6-position of the cytosine, leading to 
the formation of the corresponding enamine (Figure 2.1). The tripeptide in motif VI, 
containing a glutamine residue, allows the subsequent protonation in N3-position. A 
nucleophilic attack of the enamine on the SAM cofactor is followed by deprotonation 
of the C5 by a base (depending on the DNMT) in the active site, releasing a molecule 
of S-Adenosyl-L-Homocysteine (SAH). The methyl group creates a steric clash that 
favors the -elimination, allowing the recycling of the enzyme and release of the 
methylated DNA substrate.
23 
The added methyl group now allows the recruitment of 
regulatory proteins with affinity for methylcytosines. 
 
Figure 2.1. Mechanism of reaction catalyzed by cytosine C5 DNA methyltransferases. 
 2.2. DNA Methyltransferases (DNMTs) 
In mammals, DNA nucleotide methyltransferases (DNMTs) include four members, 
in two families that are structurally and functionally distinct. The DNMT3 family 
establishes the initial CpG methylation pattern,
 
whereas DNMT1 maintains this 
pattern during chromosome replication and repair.
24,25 
The DNMT3 family includes 
two active methyltransferases, DNMT3A and DNMT3B, and one regulatory factor, 
DNMT3-Like protein (DNMT3L). 
DNMT1 shows preference for hemimethylated DNA in vitro, which is consistent 
with its role as a maintenance DNMT, whereas DNMT3A and DNMT3B methylate 
unmethylated and methylated DNA at an equal rate, which is consistent with a de 
novo DNMT role.
26
 
DNMT 
SAM 
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DNMT2 appears to provide an example of divergent evolution: it was named based 
on its high sequence and structural similarity to known DNA MTases, but it actually 
methylates cytosine 38 in the anticodon loop of tRNA
Asp
.  
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The catalytically active DNMTs share common features, especially a regulating N-
terminal domain and a catalytic C-terminal domain, particularly conserved among 
different species, including ten sequence motifs (I to X), which form the binding site 
for the cofactor S-Adenosyl-L-Methionine (SAM).
27,28
 Motif IV includes the proline-
cysteine dipeptide bearing a catalytic thiolate group. Motif VI contains the glutamine 
residue allowing the protonation of the 3-position of the cytosine and motif IX 
maintains the recognition site of the targeted cytosine base (Figure 2.2).
29
  
 
Figure 2.2. Schematic representation of the human DNMT1, TRDMT1 and DNMT3s. 
On the other hand, the N-terminal part of DNMTs binds to DNA and has several 
protein recognition domains, guiding the DNMTs to the nucleus, to chromatin and to 
numerous proteins, hence tightly linking chromatin modulation and DNA 
methylation. 
2.3. Mammalian DNMTs: characterization and biological role 
2.3.1. DNMT1 
The DNMT1 (Figure 2.3) was the first DNMT to be purified and characterized.
30,31
 
This enzyme, the most abundant of all the DNMTs in somatic cells, has 1616 amino 
acids and can be found as three isoforms in almost every eukaryotes: DNMT1s 
(somatic cells), DNMT1o (oocyte) and DNMT1p (pachytene).
32, 33
 As it has a greater 
affinity for hemimethylated DNA than unmethylated, it intervenes mainly after DNA 
replication to methylate the newly synthesized strand.
34,35
 Therefore DNMT1 is 
called “the maintenance methyltransferase”.36  
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Figure 2.3. The crystal structure of the mDNMT1(650–1602)–DNA 19-nucleotide oligomer 
complex. The CXXC, BAH1, and BAH2 domains and CXXC-BAH1 linker of mDNMT1 have been 
removed for clarity. The bound DNA is in light brown, with the TRD and catalytic core in light and 
dark blue, respectively.  
Disruption of the Dnmt1 gene in mice can lead to significant demethylation of the 
genome and strong embryonic lethality. In non-tumoral cells, conditional or total 
knockout of DNMT1 leads to apoptosis,
37
 severe mitotic defects
 38 
and tumorigenesis 
through chromosomal instability.
39,40
 These results indicate that DNMT1 is essential, 
both during developmental stages and in somatic cells, to ensure cell proliferation 
and survival. In cancer cells, disruption of DNMT1 can stop tumor growth and 
reverse the non-differentiation state, without enhancing the invasiveness of cells, 
thus providing a very interesting therapeutic target.
41
  
DNMT1 is responsible for the maintenance DNA methylation via two different 
mechanisms: (i) through its direct interaction with the replication fork and (ii) as an 
interacting partner of UHRF1 (ubiquitin-like, containing PHD and RING finger 
domains 1).
42
 Indeed, at the beginning of the S phase in somatic cells, DNMT1 is 
transported to the nucleus, thanks to a nuclear location signal (NLS), and more 
precisely to the replication foci through a specific sequence located within its N-
terminal domain (Targeting Replication Foci: TRF) and its PCNA (Proliferating Cell 
Nuclear Antigen) binding domain (PBD). It then binds to hemimethylated DNA.
43,44
 
The cytosine to be methylated is flipped out into the catalytic pocket and the methyl 
group of the SAM cofactor is transferred to position 5. Once the first CpG has been 
entirely methylated, DNMT1 moves along the newly synthesized DNA strand to 
further methylate.  
The second mechanism implies UHRF1, a protein that has a specific affinity for 
hemimethylated CpG sites and recruits DNMT1 at these sites. Overall, the 
maintenance of DNA methylation patterns possesses a gross error frequency of circa 
5% per CpG site and per cellular division. This leaves to cells some flexibility for 
subtle but probable important changes in their methylation pattern. This is balanced 
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by DNMT3A and 3B that help DNMT1 in the maintenance of the methylation profile 
during replication.
45
  
DNMT1 has a number of sequence motifs shared with other proteins but of unknown 
or unconfirmed function. DNMT1 contains two bromo-adjacent homology (BAH) 
domains, which are also found in origin recognition complex proteins and other 
proteins involved in chromatin regulation. The BAH motif has been proposed to act 
as a protein-protein interaction module. Near the center of the N-terminal domain is a 
cysteine-rich region that binds zinc ions, present in all confirmed mammalian 
cytosine methyltransferases, known mammalian proteins affecting cytosine 
methylation, as well as the methyl-binding domain (MBD) proteins MBD1 and CpG 
binding protein.
46 
2.3.2. DNMT2/TRDMT1 
Figure 2.4. Structure of human DNMT2 
The DNMT2 enzyme (Figure 2.4) was originally assigned as a member of the DNA 
methyltransferase family on the basis of its very high degree of similarity in 
sequence and structure to eukaryotic and prokaryotic DNA-(cytosine C5)-
methyltransferases. DNMT2 is strongly conserved and can be found in species 
ranging from Schizosaccharomyces pombe to humans, suggesting a very important 
role in cellular homeostasis.  
The former DNMT2 has been recently renamed as TRDMT1 since it does not 
methylate DNA but rather a cytosine 38 in the anticodon loop of tRNA
Asp
.
47,48 
It has 
only a very small DNA methyltransferase activity in vitro and in vivo, suggesting 
that the N-terminal domain is not absolutely required for this activity, but more for 
its regulation.
49 
Whereas depletion of DNMT1, DNMT3A, DNMT3B and even DNMT3L genes lead 
to abnormal phenotypes (male sterility, developmental problems) or even to 
embryonic death,
50
 the depletion of the TRDMT1 gene does not lead to any 
phenotypic modification. It is, thereby, hypothesized that this enzyme might be 
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particularly useful not during the embryonic development, but rather during species 
evolution. 
2.3.3. DNMT3 family 
The mammalian genome encodes two functional cytosine methyltransferases of the 
DNMT3 family, DNMT3A and DNMT3B, which primarily methylate CpG 
dinucleotides, and a third homologue, DNMT3L, which lacks cytosine 
methyltransferase activity and functions as a regulatory factor in germ cells. 
DNMT3A has been identified as responsible for the imprinting of genes and 
methylates mainly pericentromeric regions of the DNA, while DNMT3B seems to 
methylate centromeric regions.
51
 Furthermore, mutations on this latter lead, among 
other defects, to immunodeficiency syndromes and centromeric instabilities. 
DNMT3L lacks the catalytic motif and thus shows no methylation activity by itself 
(Figure 2.2).
52,53
 Actually, it is a cofactor of DNMT3A and interacts with histone 
modifying proteins thus keeping DNA methylation connected to histone 
modifications. The X-ray crystal structure of the mouse catalytic DNMT3A/3L 
complex showed the formation of a tetramer: DNMT3L-3A-3A-3L, suggesting the 
simultaneous methylation of two CpG sites at one helix turn away from one another 
(circa 10 bp).
54
 In addition, it was shown that the complex oligomerizes on the 
DNA
55 
and that DNMT3A/3B are the only DNMTs to possess the proline-
tryptophane-tryptophane-proline (PWWP) sequence, which allows them to directly 
bind DNA.
56 
Finally, DNMTs can interact with one another. For example, the N-
terminal part of DNMT1 can bind to DNMT3A/3B N-terminal part, conferring to 
DNMT1 a de novo methylation activity.
57,58
 Similarly, DNMT3 enzymes can act as 
maintenance methyltransferases, in a DNMT1 deficient background.
59
 Therefore the 
strict separation of maintenance and de novo activity between DNMT1 and DNMT3 
is controversial and tend to be reconsidered.
60,61 
2.4. Structure of DNMT1-DNA complexes 
The crystal structure of an enzymatically active mouse DNMT1 (mDNMT1; residues 
650 to 1602) in complex with S-adenosyl homocysteine (AdoHcy) and a 19-base pair 
(bp) DNA duplex was solved (3.0 Å resolution). The DNA contained two 
unmethylated dinucleotide CpG, separated by 8 base pairs. From Figure 2.5,
 62
 we 
can clearly detect the CXXC domain (red), BAH1 and BAH2 domains ( purple and 
orange respectively), and the C- terminal methyltransferase catalytic domain (light 
blue) as also the DNA’s 19 bp. The catalytic domain forms the core of the complex 
and contacts both BAH domainsand the DNA. The CXXC and BAH1 domains are at 
opposite ends of the methyltransferase domain and are connected by a long linker 
segment (blu). The BAH1 and BAH2 domains are separated by an a-helical linker 
(grey), with both BAH domains positioned on the surface far from the bound DNA. 
There are four Zn
2+
 cations in the structure of the complex, two in coordination 
within the Cys of CXXC domain, whereas two others involved in coordination with 
Cys/His of BAH1 and the target recognition domain (TRD) of the methyltransferase.  
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Figure 2.5. mDNMT1(650–1602)-DNA (19-nucleotide oligomer) complex with AdoHcy. 
Mouse DNMT1 and human DNMT1 (hDNMT1) exhibit 85% sequence identity. The 
methyltransferase domain is repositioned relative to the CXXC domain and DNA by 
a 1-bp translation along the DNA axis (Figure 2.6). 
Figure 2.6. Comparison crystal structure human DNMT1 and mouse DNMT1. 
All sequence-specific contacts with DNA are made through the CXXC domainin the 
DNMT1-DNA complex. The CXXC domain targets both the minor and major 
grooves of the DNA over a CpG-containing 4-bp footprint. The loop segment 
(Arg
684
-Ser
685
-Lys
686
-Gln
687
) from the CXXC domain penetrates into the major 
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groove (Figure 2.7A and 2.7B) and forms base-specific and phosphodiester 
intermolecular interactions (Figure 2.7C). The guanine bases in the CpG dinucleotide 
are recognized by side-chain interactions involving Lys
686 
and Gln
687
 of the CXXC 
domain, whereas the cytosine bases in the CpG dinucleotide are recognized by 
backbone interactions involving Ser
685
 and Lys
686
 of the CXXC domain. DNA 
recognition is further anchored by salt bridges between arginine side chains of the 
CXXC domain and the phosphodiester backbone of the DNA. The CXXC domain 
has been reported to specifically bind unmethylated CpG dinucleotides.  
Figure 2.7. A) Ribbon representation of how CXXC domain bound to DNA. B) electrostatic surface 
representation of CXXC domain bound to DNA. C) intermolecular interaction in the mDNMT1-DNA 
complex. 
2.4.1 Autoinhibitory regulation of DNMT1 
The most important finding of Song et al., through the analysis of the crystal 
structure mDNMT1-DNA/ hDNMT1-DNA (supported by enzymatic assays) is that 
DNMT1 show an autoinhibitory regulation. The unmethylated DNA is excluded 
from the active site by the binding of the CXXC domain, because the acidic 
autoinhibitory CXXC-BAH1 linker move directly between the DNA and the active 
site, inhibiting the entrance of the DNA in the catalytic pocket. Moreover the BAH2-
TRD loops block the TRD in a retracted position and prevents it from binding the 
DNA major groove. Unmethylated CpG sites are protected from de novo methylation 
through binding by the CXXC domain as CpG dinucleotides emerge from the 
replication complex (Figure 2.8).
62 
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Figure 2.8. A) Representation of mDNMT1-CXXC domain and the CXXC-BAH1 linker in the 
complex mDNMT1 (1650-1602)-DNA 19-nucleotide oligomer. B) Proposed autoinhibitory regulation 
of DNMT1. 
2.5. DNA methylation and pathologies 
Considering their role in the regulation of gene transcription, DNA methylation (as 
the other epigenetic marks) is essential for crucial processes such as embryonic 
development or differentiation and is involved in various pathologies, from 
neurodegenerative diseases to cancers.
63
 With the increasing accessibility to genome-
wide techniques to study DNA methylation, numerous pathologies have been linked 
to epigenetic disruptions, particularly diseases that are influenced by the 
environment. Indeed, since DNA methylation is required in the memory process, it 
has recently been proved to have an important role, not only in Alzheimer’s 
disease,
64
 but also in psychiatric diseases (depression, bipolar disorder, 
schizophrenia).
65
 DNA methylation is clearly involved in auto-immune diseases 
66
 
and even in some genetic disorders (Facioscapulohumeral muscular dystrophy, 
Crohn disease, atherosclerosis.).
67,68  
Moreover, aberrant DNA methylation patterns have been extensively described in 
numerous cancers. It has been shown that cancer cells display a global 
hypomethylation
69
 and at the same time a hypermethylation of certain gene 
promoters.
70
 On the one hand, hypomethylation leads to chromosomal instability, 
since repeated sequences are no longer methylated. On the other hand, 
hypermethylation leads to silencing of Tumor Suppressor Genes (TSG). As 
mentioned above, the reversibility of DNA methylation represents an interesting 
strategy in oncology. Hence, the use of specific inhibitors of DNMT (DNMTi) might 
reactivate TSG and induce the reprogramming of cancer cells, leading to their 
proliferation arrest and ultimately to their death (Figure 2.9).
71
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Figure 2.9. Stability and reversibility of epigenetic mutations. 
Nevertheless, depleting either one DNMT is sufficient to suppress in vitro cell 
growth. In addition, several studies clearly demonstrated that DNMT1 depletion is 
sufficient to lead to tumor suppressor genes re-expression and cell growth arrest in 
various in vitro cancer cells such as lung, esophagus, stomach, breast, cervix, brain, 
head and neck.
72,73
 
Overall, these data strongly argue in favor of a selective inhibition of DNMT to 
achieve an antitumor effect.  
2.6. DNMT inhibitors (DNMTi) 
As elucidated above, tumor suppressor genes hypermethylation is often involved in 
cancers and, due to its reversibility, their demethylation can be an interesting 
therapeutic strategy. Many DNMT inhibitors have been described and are divided 
into two families: the nucleoside analogues, that have been known and studied for 
many years, and the non-nucleoside inhibitors, which structure varies according to 
their inhibitory mechanism. 
 2.6.1. Nucleoside analogues 
2.6.1.1. First generation molecules: Azacytidine, Decitabine and Zebularine 
Until now, several DNMT1 inhibitors have been identified. They can be divided into 
different groups. The first one includes cytidine analogs like 5-azacytidine, 5-aza-2ꞌ-
deoxycytidine and zebularine (Figure 2.10).
74
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Figure 2.10. Nucleoside analogues inhibitors of DNMTs. 
The nucleoside analogues 5-azacytidine (5-Aza-CR) and 5- aza-2ꞌ-deoxycytidine (5-
Aza-CdR), known clinically as azacytadine (Vidaza
®
) and decitabine (Dacogen
®
), 
respectively, are the two most potent DNMTi. In this molecules, the carbon atom in 
position 5 is replaced by a nitrogen atom and linked to a ribose or a deoxyribose, 
respectively (Figure 2.10).  
To be active, these compounds need to be integrated into the genome during the S 
phase (replication) of the cell cycle, allowing a certain specificity towards rapid 
proliferating cancer cells (Figure 2.11).  
Figure 2.11. Mechanism of action of nucleoside analogue inhibitors. Deoxynucleoside analogues 
are depicted by Z. Pink circles, methylated CpG; cream circles, unmethylated CpG. 
Once into the DNA, the cytosine analogues are recognized by the DNMTs and 
undergo the same reaction as normal cytosines, with the formation of the covalent 
intermediate between the catalytic cysteine of the enzyme and 6-position of cytosine 
analogues. However, unlike with cytosine, the -elimination reaction can no longer 
occur because of the presence of the nitrogen atom in 5-position, resulting in a 
covalent irreversible complex. The enzyme is thereby trapped by the suicide 
inhibitor, triggering its proteasomal degradation.  
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At higher doses, these compounds are cytotoxic, therefore they are used at low doses 
in order to achieve only the demethylation effect with little cytotoxicity. Besides the 
DNMT inhibition, the ribose analogues are also incorporated into RNA, decreasing 
the incorporation into DNA and disrupting protein synthesis. This might explain why 
decitabine is more active than azacytidine, but also why it has also less significant 
secondary effects, given that the latter can be incorporated not only in dividing cells, 
but also in quiescent cells. 
Together with the HDACi (Histone deacetylase inhibitors), these two compounds are 
the only “epidrugs” that have been approved, so far, against Myeloid Dysplasic 
Syndrome (MDS), Acute Myeloid Leukemia (AML) and Chronic Myelomonocytic 
Leukemia (CMML) for Vidaza
®
 by FDA in 2004 and the European Medicines 
Agency (EMA), and against MDS and AML for Dacogen
®
 by FDA in 2006. 
However, these two DNMT inhibitors are not selective towards the different DNMTs 
and have strong secondary effects, e.g. renal toxicity and myelotoxicity.
75
  
Moreover, 5-Aza-CR and 5-Aza-CdR are readily hydrolyzed in aqueous solution and 
subject to deamination by cytidine deaminase. The instabilities of these compounds 
inevitably present a challenge to their clinical applications. To improve the stability 
and efficacy of 5-Azanucleosides, several other cytidine analogues have been 
developed. For example, zebularine (a cytidine analogue that lacks an amino group 
in the 4 position of the pyrimidine ring) can inhibit DNMTs and cytidine deaminase 
after oral administration.
76
 The inefficient metabolic activation of this compound has, 
however, delayed its clinical use as a single agent.  
Compared to the suicide analogues, zebularine is used at higher concentrations to 
obtain the same demethylation levels in cells but is associated with lower 
cytotoxicity. Nevertheless, no new information related to a possible clinical 
development of zebularine has been published recently. Moreover, recent studies 
have shown that, depending on the used nucleoside analogue (azacytidine, decitabine 
or zebularine), demethylation patterns of tumor suppressor genes promoters are 
different, reflecting complex and partially overlapping mechanisms of action. 
The use of these drugs raises questions regarding their potential to affect non-
cancerous cells epigenetically. However, normal cells divide at a slower rate than 
malignant cells and incorporate less of these drugs into their DNA resulting in less of 
an effect on DNA methylation. Also, long-term negative effects of DNA methylation 
inhibitors in patients have not been found to date.
77
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2.6.1.2. Second generation molecules: pro-drugs 
          
Figure 2.12. Second generation nucleosidic inhibitors of DNMTs. 
Despite the advantages of 5-Aza-CR and 5-Aza-CdR, significant challenges stem 
from the instability of both compounds in aqueous solutions as well as in vivo 
deamination by cytidine deaminase. Efforts to circumvent problems of metabolic 
instability have yielded to two different pro-drugs (Figure 2.12). 
CP-4200 (Figure 2.12) is an elaidic acid ester of azacytidine that has been 
synthesized with the intention of rendering drug uptake less dependent 
unconventional nucleoside transport systems. CP-4200 effectively depletes DNMT1 
protein, which suggests that the added metabolic steps required for the activation of 
CP-4200 do not reduce the concentration of the active metabolite in human cancer 
cells. Overall, the epigenetic modulatory effects of CP-4200 seemed to be similar to 
that of azacytidine. It was demonstrated that CP-4200 acts as a pro-drug of 
azacytidine, presenting the advantage of a delayed delivery of the chemically instable 
azacytidine.
78
 
SGI-110 (formerly S-110, Figure 2.12) is a second generation DNMT inhibitor that 
acts as a decitabine pro-drug. Deamination of 5-aza-CdR by cytidine deaminase 
rapidly depletes the plasma level of the drug, resulting in low bioavailability that has 
been frequently pointed out as one of the major drawbacks of 5-aza-CdR. SGI-110 
dinucleotide is resistant to cytidine deaminase deamination due to the substrate 
specificity of the enzyme, which potentially increase the halflife of the drug, enhance 
bioavailability, and make the drug more efficacious.
79 
SGI-110 is currently in Phase 
II clinical trials for the treatment of MDS and AML.
80
  
Despite the successes of these nucleoside-like inhibitors, their lack of specificity and 
their strong secondary effects lead to an urgent need for novel more selective DNMT 
inhibitors. 
2.6.2. Non-nucleoside analogues 
There is a significant need for DNMT inhibitors that do not rely on DNA 
incorporation for activity. A recent study using a panel of human cancer cell lines 
showed a 1000-fold variability in 5-Aza-2′-deoxycytidin (DAC) potency, attributed 
to differential incorporation of DAC into DNA. As DNA hypomethylation correlates 
with clinical benefit of DAC in MDS,
81
 it is possible that some element of MDS 
resistance to AZA and DAC stems from the ability of tumor cells to block the 
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import, phosphorylation, and incorporation of the drugs into DNA. Non-
incorporating inhibitors could bypass these hurdles by targeting DNMT directly. 
Differently from nucleoside analogues, non-nucleoside inhibitors exhibit a wide 
structural diversity, and can be divided in the following groups. 
2.6.2.1. Natural compounds: flavonoids, Psammaplin A and Curcumin 
Flavonoids are polyphenolic compounds, mainly extracted from plant, and have 
enhanced considerable interest recently due to their potential antiviral, anti-
inflammatory and antitumor activity. 
              
Figure 2.13. Flavonoids as DNMT inhibitors. 
One of well-known polyphenol molecule is Genistein (Figure 2.13). It was first 
isolated from Dyer’s Broom (Genista tinctoria) in 1899 by Perkin and Newbury, 
then Baker and Robinson characterized and first synthesized the isoflavone nucleus 
in 1928.
82
 Initially, Genistein has been considered a phytoestrogenic molecule, then a 
potential anticancer agent because it showed in vitro activity against diverse enzymes 
such as topoisomerase I or II, histidine kinase, tyrosine kinases and protooncogene 
HER-2. 
Another important studied flavonoid is (-) epigallocatechin-3-O-gallate (EGCG, 
Figure 2.13), a major component of green tea extracts. EGCG is generally considered 
to be the biologically most active compound in vitro. The changes in the activities of 
various protein kinases, growth factors, and transcription factors represent a common 
mechanism involved in cellular effects of tea polyphenols. In addition to 
modification of intracellular signaling by activation of cellular receptors, it was 
shown that EGCG can enter the cells and directly interact with their molecular 
targets within cells.
83
 
Recently, EGCG and Genistein have been reported as enzymatic and cellular DNMT 
inhibitors: EGCG directly inhibited DNMT activity and partially reversed RAR-β 
methylation status, Genistein (20-50 mmol/L) dose-dependently inhibited DNMT 
activity, showing competitive and noncompetitive inhibition with respect to the 
substrate poly(dI-dC)· and noncompetitive inhibition with respect to SAM. Genistein 
was a weaker DNMT inhibitor than EGCG, yet it was just as active or more active in 
demethylating hypermethylated genes and reactivating their expression. One possible 
reason is that Genistein is more stable than EGCG in the cell culture medium, 
17 |DNA Methylation 
 
reaching so higher intracellular concentrations than EGCG. Another possibility is 
that Ggenistein is also an inhibitor of histone deacetylase (HDAC). The extent of 
demethylation was enhanced by extending the treatment period with EGCG or 
Genistein or by its combination with a HDAC inhibitor.
84
  
The supposed mechanism of action of flavonoids is that they inhibit enzymatic DNA 
methylation in vitro largely by increasing the formation of S-adenosyl-L-
homocysteine (a potent noncompetitive inhibitor of DNMTs) during the catechol-O-
methyltransferase-mediated O methylation of this flavonoids. In comparison, the 
strong inhibitory effect of EGCG on DNMT-mediated DNA methylation is 
independent of its own methylation and is largely due to its direct inhibition of the 
DNMTs.
85
 
These two flavonoids are now regarded more as chemopreventive drugs than actual 
treatment drugs, even though their metabolisms drastically decrease their 
biodisponibility, hence lowering their potential activity. 
 
Figure 2.14. Structure of Psammaplin A. 
Psammaplin A (Figure 2.14) is a natural compound extracted for the first time in 
1987 from a sponge, the Psammaplin Aplysilla. This dimer of two derivatives of 3-
bromotyrosine was synthesized primary in 1992 by Hoshino et al. and show both 
antibacterial and antitumor properties.
86 
Psammaplin A was described as inhibitor of almost ten different enzymes, such as 
leucine aminopeptidase, DNA gyrase, topoisomerase II, HDACs and DNMTs.
87
 
It has been shown that several natural derivatives of psammaplin A, have an activity 
against DNMT1 and HDACs. Moreover Psammaplin A have antiproliferative 
properties also on MDA-MB- 435 and A549 cell lines (breast and lung cancer, 
respectively) with promising results, indeed  it inhibits cell growth at low doses 
(IC50= 2 M). Nevertheless, no DNA demethylation has been highlighted in HCT116 
cells,
88
 and, in a recent study, Psammaplin A exhibited no activity on DNMT1 at 30 
and 120 M.89 
 
Figure 2.15. Structure of curcumin. 
Molecular docking of the interaction between curcumin and DNMT1 suggested 
that curcumin (Figure 2.15) covalently blocks the catalytic thiolate of DNMT1 to 
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exert its inhibitory effect on DNA methylation. This was validated by showing that 
curcumin inhibits the activity of M. SssI with an IC50 of 30 nM, but no inhibitory 
activity of hexahydrocurcumin up to 100 M. 90 Finally, curcumin at doses higher 
than 3 mM induced a decrease of global DNA demethylation of leukemia MV4-11 
cells. 
However, recent studies showed no curcumin-dependent demethylation, which 
suggested that curcumin has little or no pharmacologically relevant activity as a 
DNMT inhibitor.
91,92
 The fact that the number of studies showing positive effects of 
curcumin is much higher than that showing negative effects, it may just indicate that 
there are more researchers evaluating the beneficial effects of curcumin than 
evaluating its toxicity. Future research is needed to establish the benefit-risk profile 
of curcumin. Recently, the activity of novel curcumin analogues EF31 and UBS109 
as demethylating agents were investigated, by El-Rayes et al., in two pancreatic cell 
lines.
93
 They selected the pancreatic cell lines based on baseline level of DNA 
methylation. MiaPaCa-2 cells have high levels of DNA methylation associated with 
loss of tumor suppressor gene SPARC, p16 and E-cadherin. In contrast, PANC-1 cell 
lines have low levels of baseline DNA methylation and expression of SPARC, p16, 
and E-cadherin. The EF31 and UBS109 show several folds more potency than 
curcumin and inhibit DNMT-1, NF-B and HSP90. In addition, UBS109 and EF31 
analogues have better solubility and bioavailability. The unique properties of 
UBS109 and EF31 make them promising therapeutic agents better than the parent 
compound curcumin. 
2.6.2.2. Inhibitors identified by virtual screening: nanaomycin A and RG108 
 
Figure 2.16. Structure of nanaomycin A. 
Nanaomycin A (Figure 2.16) is a quinone antibiotic isolated from a Streptomyces 
strain, in 1975. Its DNMT1 potential inhibitory properties have been deduced after a 
virtual in silico screening,
94
 but exhibited no activity when evaluated on DNMT1 
biochemical assay. During further investigations, nanaomycin A demonstrated a 
selective inhibition of DNMT3B. Subsequent cellular characterization was 
undertaken, specifically cytotoxicity evaluations and DNA methylation level 
examination on three cancer cell lines (A549, HCT116 and HL60, lung, colon and 
leukemia cell lines, respectively). Molecular docking calculation using a homology 
model of DNMT3B resulted in a possible model of nanaomycin A into the catalytic 
domain. However, despite the effects observed on the enzyme and a weak but 
significant demethylation of the RASSF1A promoter region, the authors concluded 
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that DNMT3B inhibition is not the only mechanism of action of nanaomycin A and 
may share other cellular targets.
95
  
Figure 2.17. Structure of the phtalimido-L-tryptophan RG108. 
RG108 is a small-molecule inhibitor of DNMT1 that was discovered using a 
computational screening approach.
96
 The compound blocked DNA methyltransferase 
activity in vitro and in cells inhibited the methylation of tumor-suppressor gene 
promoter DNA, but not DNA in centromeric satellite elements, suggesting a context-
dependent DNA methylation inhibition.
97
 RG108, unlike the nucleoside analogs 
AZA, DAC, zebularine, procaine, and EGCG, did not demonstrate cytotoxic or 
genotoxic effects on cells even at high concentrations.
98
 A broad application of 
RG108 is however limited due to its high hydrophobicity.
99
 
2.6.2.3. Drugs used for other indications: hydralazine, procain, procainamide, SGI-
1027.  
 
Figure 2.18. Structure of the antihypertensive hydralazine. 
Hydralazine (Figure 2.18) is a cardiovascular drug that was shown to inhibit DNA 
methylation in cells,
100-102
 although not in an in vitro biochemical assay.
102
 Despite 
its frequent use for numerous years, its mechanism remains unknown. Indeed, 
hydralazine induces the erythematosus lupus in treated patients and this autoimmune 
disease is associated with a hypomethylation of T cells, confirmed on T cells in 
culture.
103
 The DNMT inhibitory activity of hydralazine is controversial, as a 
subsequent study was unable to reproduce DNMT inhibitory activity in cells.
104,105 
Clinical studies of hydralazine in combination with a histone deacetylase inhibitor 
(valproate) in MDS are undergoing, currently in phase II.
106
 Moreover, hydralazine is 
currently tested in phase III on patients that have developed brain or ovary tumors.
107 
Hydralazine is therefore, a promising molecule in anti-cancer treatments. 
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Figure 2.19. Structures of procaine and procainamide. 
Procainamide (Figure 2.19) is another cardiovascular drug with apparent activity 
against DNMT in cells.
100,101
 Like hydralazine, however, the DNA methylation 
inhibition of procainamide in cells has been disputed.
103
 Procaine, a closely related 
molecule, has also been reported to inhibit DNA methylation in cells,
108
 although this 
effect was not confirmed by an independent follow-up study.
109 
 
Figure 2.20. Structure of SGI-1027. 
SGI-1027 (Figure 2.20), a quinoline-based compound, has demonstrated 
inhibitory activity against DNMT1, DNMT3A, and DNMT3B in biochemical assays 
and resulted in decreased methylation at tumor suppressor gene CpG islands and 
corresponding gene upregulation.
110 
 
Quinolinium bisquaternary salts related to SGI-1027 are known to bind reversibly 
but strongly in the minor groove of DNA.
111,112
 The non quaternized, weakly basic 
compound SGI-1027 also binds reversibly but much less strongly to DNA, is 
indefinitely stable in aqueous solution, is highly lipophilic and has a low polar 
surface suggesting a good distribution and cell uptake abilities.  
SGI-1027 is not a competitive inhibitor of DNA but of the cofactor SAM, all 
DNMTs are inhibited by SGI-1027 due to the very conserved motifs I and X 
(involved in the recognition of the SAM cofactor). 
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3. The role of covalent histone modifications and chromatin 
remodeling 
Another very important mechanism in the epigenetic regulation of gene expression is 
the chromatin remodelling. The basic unit of chromatin is the nucleosome, which 
consists of 146 base pairs of DNA wrapped around an octamer of core histones, 
including two molecules of H2A, H2B, H3 and H4 (Figure 3.1).
113,114
 
Figure 3.1. The crystal structure of the nucleosome core particle consisting of H2A , H2B , H3 and 
H4 core histones, and DNA. The view is from the top through the superhelical axis. 
Chromatin can transit between ‘open’ (euchromatin) and ‘closed’ (heterochromatin) 
states. Heterochromatin mediates transcriptional repression, whereas 
transcriptionally active genes are in areas of open chromatin (Figure 3.2).
115,116 It is 
important to remember that nucleosomes are not static, and their dynamic nature, 
allowing nucleosomal DNA to transiently unwrap and rebind the histone octamer, 
can give transcription factor access to DNA, albeit at various rates.  
Figure 3.2. Heterochromatin (transcriptional repression) and euchromatin ( transcriptional activation).   
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Nuclear histones, are integral and dynamic components of the machinery responsible 
for regulating not only gene transcription, but also other DNA-templated processes 
such as replication, repair, recombination and chromosome segregation. There are 
four families of chromatin-remodeling enzymes, based on shared structural or 
functional domains outside the enzymatic core: SWI/SNF, ISWI, CHD, and inositol-
requiring 80 (INO80). The SWI/SNF family includes RSC and functions in the 
sliding and eviction of nucleosomes. ISWI remodelers function in nucleosome 
assembly and spacing. ISWI is also proposed to have functions in higher-level 
chromatin organization. CHD remodelers are associated with nucleosome sliding, 
eviction, spacing, and nucleosome assembly. The INO80 family is specialized for 
restructuring the nucleosome, including the sick with rat8ts (SWR1) family member, 
which is achieved by replacement of H2A-H2B dimers with dimers containing the 
histone variant H2A.Z and H2B.
117,118
 
Figure 3.3. Major modifications on histones: acetylation (A), methylation (M), phosphorylation (P) 
and ubiquitination (U). 
An extensive literature shows an elaborate collection of post-translational 
modifications including acetylation, phosphorylation, methylation, ubiquitylation and 
ADP-ribosylation that take place on the ‘tail’ domains of histones.119-121 These tails, 
which protrude from the surface of the chromatin polymer and are protease sensitive, 
comprise ~25-30% of the mass of individual histones,
122 
thus providing an exposed 
surface for potential interactions with other proteins.
123,124 
 Histone tails of H3 and 
H4 particularly are targeted from the mentioned covalent modifications. These 
modifications performed by histone acetyltransferases (HATs), deacetylases 
(HDACs), methyltransferases (HMTs) and kinases (HKs) offer a mechanism by 
which upstream signalling pathways can converge on common targets to regulate 
gene expression. Because of their implications in the pathogenesis and treatment of 
human diseases, a deeper understanding of the coordinated and antagonistic 
functions of chromatin remodeling and modifying enzymes is likely to have 
significant human health impacts.  
22 |Histone modification 
 
4. Histone phosphorylation 
Histone phosphorylation controls many important cellular processes, including 
transcription, apoptosis, DNA repair, and chromosome condensation. Histone 
phosphorylation involving Ser-10 of histone H3 is critical during interphase because 
it confers transcriptional activation on a number of genes depending on upstream 
signaling pathways, the location of Ser-10 residue in close proximity to other 
modifiable residues in the H3 tail enables a variety of crosstalk between 
phosphorylation and other modifications such as methylation and acetylation. 
For gene activation, it is well known that H3S10 phosphorylation inhibits H3K9 
methylation, facilitates H3K4 methylation, and enhances H3K14 acetylation, which 
allows further chromatin decondensation. A variety of H3S10 kinases, including 
Aurora B, are involved in this crosstalk.
125
 
Furthermore there  is a strong crosstalk between phosporylation and methylation 
during AR-dependent gene activation process in prostate cancer. Importantly, PKC-
dependent phosphorylation of H3T6 prevents LSD1 from demethylating H3K4 and 
accelerates the demethylation of H3K9 by altering substrate specificity of LSD1.
126
 
5. Histone ubiquitylation 
Unlike the small covalent additions ubiquitin adds approximately 8.5 kDa to the 
overall mass of a histone (∼11–15 kDa). Currently, histone ubiquitination has only 
been observed within the C-terminal domains and only at a single lysine residue 
within histones H2A (K119) and H2B (K120) in vivo.
127-129 
The addition of ubiquitin 
occurs through a multistep process that involves three distinct enzymatic reactions. 
Alterations in the enzymes that regulate histone ubiquitination and deubiquitination 
pathways directly impact higher-order chromatin structure.
130,131 
Ubiquitination of 
mammalian H2B occurs at K120 and is predominantly regulated through the 
enzymatic activities of ubiquitin-conjugating enzyme E2A (UBE2A or RAD6A) and 
the RNF20/RNF40 ubiquitin ligase complex.
132,133
 Altered expression of UBE2A and 
RNF20/RNF40 is suggested to be a pathogenic event that contributes to the 
development and progression of various tumor types. Recently the ubiquitination of 
H2B has been implicated in DNA doublestrand break (DSB) repair. Furthermore, 
cells in which either RNF20 or RNF40 were independently or simultaneously 
silenced exhibited significant increases in DSBs which strongly implicates H2Bub1 
in DNA DSB repair.
134 
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6. Histone acetylation  
Acetylation of the lysine ε-amino group, first discovered on histones, is a dynamic 
post-translational modification regulated by the opposing activities of lysine 
acetyltransferases (HATs) and histone deacetylases (HDACs).
135,136
 
Figure 6.1. Acetylation/deacetylation reactions on lysine ε-amino groups. 
The substrates for HATs and HDACs are the ε-amino groups of lysine residues in the 
N-terminal regions of histones. A highly acetylated core histones is associated to 
transcriptionally active genes whereas transcriptional repression is associated with 
low levels of histone acetylation. Inside the nucleosome, hypoacetylated histones 
(positevily charged) are tightly bound to the phosphate backbone of DNA, 
maintaining chromatin in a transcriptionally silent state. Acetylation, however, 
neutralizes the positive charge on histones, disrupting higher-order structures in 
chromatin, thereby enhancing access of transcription factors, transcriptional 
regulatory complexes and RNA polymerases to promoter regions of DNA.
137-139 
Figure 6.2. Status acetylation of histone.
 
6.1. Histone acetyltransferase 
Allfrey and colleagues, back in 1964, showed that histones can be modified by the 
addition of acetyl groups. Over the course of the next 15 years, a number of studies 
correlated the acetylation of histones with gene activity, but only in the 90’s the 
enzymes that mediate histone acetylation and deacetylation have been identified and 
characterized.
140
  
Histone acetyltransferases are a diverse set of enzymes that can be grouped on the 
basis of their catalytic domains. Gcn5 is the founding member of the Gcn5 N-
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acetyltransferases (GNATs), and this family includes Gcn5, PCAF, Elp3, Hat1, Hpa2 
and Nut1. The MYST HATs are named for the founding members of this family: 
Morf, Ybf2 (Sas3), Sas2 and Tip60.
141
 These two families of HATs are the 
predominant ones, but other proteins including p300/CBP (CREB: cyclic AMP 
response element-binding), Taf1 and a number of nuclear receptor co-activators, 
have also been shown to possess intrinsic HAT activity.  
The multiprotein complexes in which HATs reside also vary. Different HAT 
complexes are composed of various unique subunits. The combinations of these 
subunits contribute to the unique features of each HAT complex. For example, some 
subunits have domains that cooperate to recruit the HAT to the appropriate location 
in the genome; these include bromodomains, chromodomains, WD40 repeats, Tudor 
domains and PHD fingers. For example, Gcn5 contains a bromodomain that is 
important for the binding, recognition and retention of SAGA on acetylated promoter 
nucleosomes. 
The discovery that the tumour suppressor p53 is acetylated by p300/CBP, a member 
of the orphan class of HATs, showed that some HATs can also acetylate non-histone 
substrates.
142
 It is now known that binding of p53 to p300/CBP through its PXXP 
proline rich domain mediates the DNA-dependent acetylation of p53, thereby 
stabilizing the acetylated p53-p300/CBP complex.
143 
HATs can function in both transcriptional activation and repression, further analyses 
are needed to understand how these single enzymes associated with other proteins, 
can regulate this swicth. 
6.2. Histone deacetylase 
Until now eighteen mammalian deacetylase enzymes have been identified, and these 
can be divided into four classes: class I, II, IV and III, based on their sequence 
homology to their yeast orthologues Rpd3, HdaI and Sir2, respectively.
144-146  
Class I (HDAC1, 2, 3, 8) are expressed ubiquitously in various cell lines and they are 
all located in nucleus. Based on sequence homology among their deacetylase 
domains, class II is further divided into two subclasses: IIa (HDAC4, HDAC5, 
HDAC7 and HDAC9 are believed to shuttle between nucleus and cytoplasm) and IIb 
(HDAC6 and HDAC10 contain two catalytic domains and are also shown to shuttle 
between nucleus and cytoplasm, but mainly in cytoplasm).
147-149
 As for class IV, 
there is only one member, HDAC11, about which little is known.
150
 All these 11 
isoforms are dependent on Zn
2+
 for them deacetylase activity.
151 
 
These enzymes possess a highly conserved catalytic domain of approximately 390 
amino acids but the class II proteins are two to three times larger in size than the 
class I proteins (120-130 kDa and 42-55 kDa, respectively) and there are certain 
conserved sequence motifs in the catalytic domain that differ between the two 
classes.  
25 |Histone acetylation 
 
CLASS HDAC INTERACTION 
CELLULAR 
LOCALIZATION 
TISSUE 
EXPRESSION 
I 
HDAC1 
DNMT1, ATM, 
BRCA1, MECP2, 
MyoD, p53, pRb, 
NF-kB 
Nuclear Ubiquitous 
HDAC2 
DNMT1, BRCA1, 
pRb, NF-kB, 
GATA-2, Bcl-6 
Nuclear Ubiquitous 
HDAC3 pRb, NF-kB n/c Ubiquitous 
HDAC8 a-SMA n/c Ubiquitous 
IIA 
HDAC4 
14-3-3, MEF2, 
calmodulin, 
GCMa, GATA-1, 
HP-1 
Shuttling n/c 
Heart, muscle, 
brain 
HDAC5 
14-3-3, MEF2, 
calmodulin, 
Smad7, HP-1, 
GCMa 
Shuttling n/c 
Heart, muscle, 
brain 
HDAC7 
14-3-3, MEF2, 
calmodulin, 
FLAG1&2, HIFa, 
Bcl-6 
Shuttling n/c 
Heart, placenta, 
pancreas, muscle 
HDAC9 FOX3P Shuttling n/c Muscle, brain 
IIB 
HDAC6 
a-tubulin, HSP90, 
SHP, Smad7 
Cytoplasmic 
Kidey, liver, 
heart, pancreas 
HDAC10 HSP90, PP1, LcoR Cytoplasmic 
Sleen, kidney, 
liver 
IV HDAC11 HDAC6 n/c 
Heart, muscle, 
kidney, brain 
n/c: nuclear and cytoplasmic 
Table 6.1. HDAC isoforms. 
Members of class I and II HDACs are subunits of multiprotein nuclear complexes 
that play a crucial role in repression of DNA transcription. HDAC1 and 2 have been 
found in the CoREST complex that inactivates the expression of neuronal genes in 
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non-neuronal tissues and also as components of NURD and SIN3 repressor 
complexes.
152,153 
The cellular trafficking of class IIa members (HDAC4, 5, 7, 9) are defined by 
intrinsic nuclear import and export signals as well as binding sites for 14-3-3 
proteins, indeed these isoforms contain three conserved 14-3-3 binding sites. Binding 
of the 14-3-3 proteins stimulate the nuclear export or cytoplasmatic retention of the 
class IIa HDACs in a phosphorylation dependent manner that consequently regulates 
the activity of transcription factors like the myocyte enhancing factor-2 
(MEF2).
150,154,155
 Moreover the phosphorylation of these 14-3-3 binding sites depend 
on several signalling pathways including salt-inducible kinases,
156
 microtubule 
affinity-regulating kinases 
157
 and Ca
2+
/calmodulin-dependent kinases (CaMKs).
154 
In addition, class II HDACs differ from class I proteins depending on their tissue 
expression, subcellular localization and consequently biological roles. Class I 
HDACs are ubiquitously expressed, whereas class II enzymes display tissue-specific 
expression in humans and mice.
158,159  
The Class III isoforms is known also as Sirtuin family. Humans contain seven 
different sirtuins, all share a conserved catalytic core domain, of about 275 amino 
acids, and operate by a very different mechanism that requires NAD
+
 as 
cosubstrate.
160
 
Sequence-based phylogenetic analysis revealed that mammalian sirtuins can be 
divided into four classes: SIRT1- SIRT3 belong to class I, SIRT4 to class II, SIRT5 
to class III, and SIRT6 and SIRT7 to class IV.
161 
Despite these structural and mechanistic differences, HDAC and Sirtuin have been
 
shown to silence transcription at specific promoters or chromosomal domains by 
localized histone deacetylation and function in other cellular processes with non-
histone substrates.
 
6.2.1. Class I HDACs  
Class I HDACs are components of multiprotein complexes. HDAC1 and HDAC2 
show a high degree of omology, with an overall sequence identity of approx. 85%, 
have undergone little functional divergence, although specific and distinct roles have 
also been identified for each of them.
162,163 
In a recent series of 140 colorectal cancer samples, high HDAC1, 2, 3 expression 
levels implicated significantly reduced patient survival, with HDAC2 expression 
being an independent prognostic factor.
164 
In hepatocellular carcinoma, high HDAC1 
expression was associated with cancer cell invasion into the portal vein.
165
 Most of 
the studies show that HDAC1 overexpression appears especially common in cancers 
of the gastrointestinal system and is associated with enhanced proliferation, invasion, 
advanced disease and poor prognosis. However, these studies mostly investigated 
only HDAC1 and not other HDAC family member. In cancer cells, HDAC1 is 
involved in controlling cell proliferation, knocking down HDAC1 resulted in 
inhibition of cell proliferation of HeLa cells, whereas knockdown of HDAC4 and 7 
did not lead to decreased cell numbers.
166 
Knockdown of HDAC1 results in arrest 
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either at the G(1) phase of the cell cycle or at the G(2)/M transition, causes loss of 
mitotic cells, cell growth inhibition, and an increase in the percentage of apoptotic 
cells in osteosarcoma and breast cancer cells. On the contrary, HDAC2 knockdown 
showed no such effects in these cells.
167 
In colorectal cancer, at the early polyp stage, the upregulation of HDAC2 is stronger 
than that of HDAC1. Similarly, in cervical dysplasia and invasive carcinoma, 
HDAC2 expression is more intense compared to that of HDAC1. The knockdown of 
HDAC2, in the cervical cancer cells caused a differentiated phenotype, subsequently 
induces apoptosis associated with increased p21Cip1/WAF1 expression that was 
independent of p53.
168 
In breast cancer cells if HDAC2 is knockdown, the functional 
DNA binding activity of p53 increases leading to inhibition of proliferation and 
induction of cellular senescence.
169 
HDAC1 and HDAC2 form homo- and heterodimers between each other. The dimer 
is a requirement for HDAC activity.
162,170,171 
HDAC1 and HDAC2 not only are 
protein modifiers, but they are widely post- translationally modified. HDAC1 and 
HDAC2 are regulated differently because HDAC1 can be acetylated and HDAC2 
cannot. This differential regulation of HDAC1 and HDAC2 is due to a sequence 
difference at the C terminus of the two proteins. A major role for the acetylation of 
HDAC1 is exerted by lysine 432, which is an arginine at the corresponding position 
in HDAC2. More importantly, the acetylation of HDAC1 inhibits the activity of 
itself and also the activity of HDAC2. Dissociation of the dimer with a HDAC1 N-
terminal peptide will inhibit HDAC activity. HDAC1 and HDAC2 heterodimer 
levels seem to depend on the cell type, because it was shown that 40% to 60% of 
HDAC1 and HDAC2 proteins were found to be free from each other in mouse 
embryonic fibroblasts 
172
 whereas 80% to 90% of HDAC1 and HDAC2 proteins 
were associated with each other in the nucleus of human breast cancer MCF-7 
cells.
173
  
HDAC1 and HDAC2, together with the retinoblastoma-associated proteins RbAP46 
and RbAP48, are part of the catalytic core of many multiprotein transcriptional 
complexes, and this association is fundamental for their enzymatic activity.
174
 The 
Sin3a bind a spectrum of different cofactors such as Sds3 and SAP proteins.
175,176
 
The NuRD complex is the only complex holding both HDAC- and ATP-dependent 
chromatin-remodeling activities, which are carried out by HDAC1 and/or HDAC2 
and Mi-2a and/or Mi-2b, respectively. Other components of this complex have been 
identified, such as the methyl-CpG-binding domain-containing proteins (MBD2 -able 
to recognize methylated DNA) and the three members of the metastasis associated 
protein family (MTA1, MTA2 or MTA3). Lysine-specific demethylase 1 (KDM1/ 
LSD1) has also been identified as a component of NuRD.
177-179 
On the other hand, the REST/CoREST complex has more specific functions: it 
recruits HDAC1 and HDAC2 to suppress the transcription of neural genes in non-
neural tissues. As a component of the CoREST complex and as a consequence of 
histone H3 deacetylation, KDM1/LSD1 promotes demethylation of H3 dimethylated 
on lysine 4 (H3K4me2), an event that facilitates the formation of a repressive 
28 |Histone acetylation 
 
chromatin structure. Interestingly, CoREST appears to be involved in the negative 
regulation of synaptic plasticity and memory formation by HDAC2.
180,181 
Both activity and complex-formation are regulated by phosphorylation. 
Phosphorylation of HDAC1 and/or HDAC2 in interphase cells is required for the 
formation of HDAC corepressor complexes. In a recent study, Davie et al. 
demostrate that during mitosis, HDAC2 and, to a lesser extent, HDAC1 
phosphorylation levels dramatically increase. When HDAC1 and -2 are displaced 
from the chromosome during metaphase, they dissociate from each other, but each 
enzyme remains in association with components of the HDAC corepressor 
complexes Sin3, NuRD, and CoREST as homodimers. Enzyme inhibition studies and 
mutational analyses show that protein kinase CK2-catalyzed phosphorylation of 
HDAC1 and -2 is crucial for the dissociation of these two enzymes.
182
 
Together with HDAC1 and 2, HDAC3 expression was significantly associated with 
poor prognosis in large series of gastric, prostate and colorectal cancer samples. 
HDAC3 shares 63% identical amino acids with HDAC1/HDAC2 and has 43% 
overall sequence identity to HDAC8. The non-conserved C-terminal region of 
HDAC3 is required for both deacetylase activity and transcriptional repression. In 
addition the nuclear localization signal ( NLS) that other class I HDACs possess, has 
a NES (nuclear export signal) associated to its ability to localize both to the nucleus 
as well as to the cytoplasm. HDAC3 is the catalytic component of the N-CoR 
(nuclear receptor co-repressor ) and SMRT (silencing mediator for retinoic acid and 
thyroid hormone receptors) complex.
 
Both act as co-repressors and have a conserved 
deacetylase- activating domain for HDAC3 activation.
183,184
 
Of all the class I HDACs, HDAC8 is the most recently identified and comprises the 
NLS in the center of the catalytic domain and locates to the nucleus (when 
overexpressed) in human cells and also has a cytosolic localization in smooth muscle 
cells.
185
 
Recombinantly purified HDAC8 catalyzes deacetylation and displays substrate 
selectivity in the absence of additional protein cofactors suggesting that HDAC8 can 
catalyze deacetylation in vivo in the absence of a protein complex. Distinguishing 
between HDAC8 substrates and binding partners in the cell is currently difficult.
186 
HDAC8 is able to deacetylate all core histone in vitro, is inhibited by TSA
187
 and it 
has recently been found to be a non-nuclear marker of smooth muscle differentiation 
and associates with smooth muscle α-actin (α-SMA).188 HDAC8 may exhibit specific 
intracellular localization within smooth muscle cells and have a major regulatory 
function in controlling their contractile capacities. It is currently unclear whether 
Hsp20 or cofilin are acetylated and/or substrates for HDAC8. However, HDAC8 
associates better with the nonacetylated form of myosin heavy chain, suggesting that 
this protein is not an HDAC8 substrate. Because HDAC8 enhances cell contractility 
and associates with three proteins important for actin function, it is likely that 
HDAC8 is a component of a complex that modulates actin dynamics.
188  
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6.2.2. Class II HDACs  
Class IIa HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) are characterized by the 
presence in their regulatory N-terminal domains of two or three conserved serine 
residues subject to reversible phosphorylation. Phosphorylation leads to the binding 
of the 14-3-3 proteins, the nuclear export of HDACs and the derepression of their 
target genes. A range of kinases and phosphatases acting downstream of diverse 
biological pathways have been shown to regulate the nucleo-cytoplasmic distribution 
of class IIa HDACs.
189 
HDAC4, 5 and 7 have their catalytic domain on the C-terminal half of the protein, 
and the NLS is situated close to the N-terminus. Binding domains for C-terminal 
binding protein (CtBP), myocyte enhancer factor 2 (MEF2) and 14-3-3 proteins are 
conserved in all three HDACs on the N-terminus.  
Figure 6.3. Interaction partners of class IIa histone deacetylases (HDACs). 
The initial examination of the sequences surrounding the conserved phosphorylation 
residues in class IIa HDACs revealed that they are closely related to consensus 
phosphorylation sites for the calcium/calmodulin-dependent protein kinases 
(CaMKs). CaMK I and CaMK IV phosphorylate all four class IIa HDACs and in 
cell-culture models CaMKs induced the re-localization of class IIa HDACs from the 
nucleus to the cytoplasm.
190 
 
In cardiomyocytes, CaMK II is the specific and endogenous HDAC4 kinase. 
HDAC4 and HDAC5 form homo-oligomers and hetero-oligomers, and by interacting 
with each other acquires CaMK II responsiveness, either by phosphorylation of 
HDAC4 or by transphosphorylation of HDAC5.
191 
CaMK II is involved with HDACs 
in other tissues as well. In the nervous system, HDAC4 is highly expressed in the 
brain, it is mainly localized in the cytoplasm of cultured cerebellar granule neurons 
but translocates to the nucleus under neuronal death conditions. Moreover the 
treatment with a proapoptotic CaMK inhibitor (KN-93) stimulates HDAC4 nuclear 
accumulation. These experiments suggest that CaMK induces neuronal survival by 
phosphorylating HDAC4 and leading to its cytoplasmic localization.
192 
Recently 
Hardingham et al., demonstrate that the association of HDAC class IIa with the co-
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repressor Silencing Mediator Of Retinoic and Thyroid Hormone Receptors (SMRT) 
allows the nuclear export of these enzymes and not the direct phosporylation due to 
CaMK.
193 
Class IIa HDACs interact with various transcription factors but the biological 
relevance of these associations has been established only for the MEF2-regulated 
processes.
194,195
 MEF2 plays a central role in the development and adaptive response 
of diverse tissues and organs, it is also selectively targeted for mutations in several 
types of cancers.
196-198 
Class IIa HDACs do not bind directly to DNA but depend on 
their interaction with the sequence-specific transcription factor MEF2 for genomic 
targeting.
199,200 
This interaction is mediated by a short amphipathic helix conserved in 
the N-terminal regulatory domain of class IIa HDACs. Crystallography analyses and 
in vitro biochemical studies reveal that the amphipathic helix binds to a highly 
conserved hydrophobic groove on the MADS-box/MEF2 domain of MEF2.
201 
These 
studies suggest that small molecules binding to the hydrophobic pocket of MEF2 
could block the recruitment of class IIa HDACs to DNA, thereby inhibiting the 
function of class IIa HDACs.
202
 
HDAC4, which is expressed in prehypertrophic chondrocytes, regulates 
chondrocyte hypertrophy and endochondral bone formation by interacting with and 
inhibiting the activity of Runx2 (transcription factor necessary for chondrocyte 
hypertrophy). Overexpression of HDAC4 in proliferating chondrocytes in vivo 
inhibits chondrocyte hypertrophy and differentiation, mimicking a Runx2 loss of 
function phenotype. These results suggest that HDAC4 is a central regulator of 
chondrocyte hypertrophy and skeletogenesis.
203 
Moreover, HDAC4 inhibit fusion 
protein PLZF-RAR (promyelocytic leukemia zinc finger-retinoic acid receptor 
alpha) in APL (acute promyelocytic leukemia).
204 
Evidence also suggest that HDAC4 
is the mediator which induced neuronal cell death in normal neurons.
192
 
When HDAC5, as well as HDAC9, were knocked down, severe cardiac responses 
are observed, such as hypertrophy and fibrosis. So they might play a crucial role in 
heart development.
205,206
 
HDAC7 is reported as a thymus-specific isoform. In developing thymocytes, 
Nur77 which is associated with apoptosis and negative selection, is inhibited.
207 
Nevertheless, Chang S et al. reported that HDAC7 disruption led to blood vessels 
rupture, resulting in embryonic lethality. The process of maintaining vascular 
integrity by HDAC7 is achieved by repressing MMP10 (matrix metalloproteinase- 
10).
208 
Knockdown of HDAC7 result in significant G1/S arrest in different cancer 
cell lines.
209
 The expression of HDAC7 protein plays an important role in the 
apoptosis and vascular tubulogenesis of hepatocellular carcinoma by upregulation of 
P21 and HIF-1 (hypoxia inducible factor-1) and downregulation of cyclin E and 
MMP10.
210
 
The phylogenetic tree shows that HDAC9 splice variants are clustered as a 
separate group related to HDAC4, 5, 7 within class II of the classical HDAC family. 
The HDAC9 catalytic domain is located on the N-terminus, as for the class I 
HDACs.
211 
There are three known splice variants, HDAC9a, HDAC9b and 
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HDRP/HDAC9c. HDAC9c/HDRP lacks the catalytic domain and is 50% similar to 
the N-terminus of HDAC4 and HDAC5. By analogy with HDAC4, 5 and 7, HDRP is 
able to recruit HDAC3, thus circumventing the lack of a catalytic domain. In 
addition, HDAC9 is also able to interact with MEF2, CaMK and 14-3-3 proteins, 
indicating that HDAC9 may have an important function in muscle differentiation. 
HDAC6 is evolutionarily most closely related to HDAC10, indeed they belong to 
the so called Class IIb. HDAC6 contains two tandem deacetylase domains and a C-
terminal zinc finger. HDAC6 has emerged as a major cytoplasmic deacetylase 
functioning as an -tubulin deacetylase 212 and HSP90 deacetylase thereby regulating 
cell motility, adhesion and chaperone function.
213 
In 2010, Mandana et al. reported 
that when HDAC6 is selectively inhibited by tubacin, cell death induced by 
etoposide and SAHA (suberoylanilide hydroxamic acid) would be significantly 
enhanced in LNCaP (human prostatic adenocarcinoma cell line) and MCF-7 (breast 
cancer cell line) tumor cells.
214
 In
 
addition, HDAC6 exerts cellular functions 
independently from
 
its deacetylase activity. The binding to ubiquitin via its zinc 
finger
 
domain regulates aggresome function, autophagy, heat
 
shock factor-1 (HSF-1) 
and platelet derived growth factor
 
(PDGF) function.
215,216 
HDAC10 is structurally related to HDAC6, but contains one additional 
catalytically inactive domain. HDAC10 was found in both the nucleus and 
cytoplasm. When it is knockdown, TXNIP (thioredoxin-interacting protein) 
expression is significantly increasing in SNU-620 gastric cancer cells, while 
HDAC1, 2 and 6 not. TXNIP is the endogenous inhibitor of a cellular antioxidant 
TRX (thioredoxin). In addition, HDAC10 inhibition induce release of cytochrome C 
and activate apoptotic signaling molecules through accumulation of ROS (reactive 
oxygen species).
217 
6.2.3. Class IV HDAC  
HDAC11 has sequence similarity to classes I and II HDACs. Aside from its 
evolutionary conservation’s implying a vital role across species and a study 
suggesting a role in the decision between immune activation and immune tolerance, 
little is known of HDAC11 functions.
148,218
 Recently has been reported that HDAC11 
is overexpressed in several carcinomas as compared to corresponding healthy tissues. 
HDAC11 depletion is sufficient to cause cell death and to inhibit metabolic activity 
in HCT-116 colon, PC-3 prostate, MCF-7 breast and SKOV-3 ovarian cancer cell 
lines. The antitumoral effect induced can be mimicked by enforced expression of a 
catalytically impaired HDAC11 variant, suggesting that inhibition of the enzymatic 
activity of HDAC11 by small molecules could trigger the desired phenotypic 
changes.
219  
6.2.4. Class III HDACs: Sirtuin family 
The sirtuins are a family of proteins homologous to yeast silent information regulator 
2 (Sir2) that in 1984 was cloned and characterized as a gene required for maintaining 
silent chromatin in yeast.
220
 The discovery of the longevity-promoting effect of Sir2 
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in yeast, in higher eukaryotes nematode worm and in the fruit fly led to start a search 
of mammalians homologues.
221,222
 Sirtuins were initially thought to function as 
mono-ADP-ribosyl transferases, it is widely accepted that their primary function is 
lysine deacetylation. Because of their unique NAD
+
 dependence, they have been 
grouped in a class of their own, HDAC Class III. Recent research has also shown that 
some isoforms can in fact desuccinylate and demalonylate lysine residues in 
proteins.
160
 Sirtuin appear to play important roles in many physiological and 
pathological processes. 
6.2.4.1. Mammalian Sirtuins: function, classification and localization 
In mammals the sirtuin family comprises seven proteins (SIRT1-SIRT7), which vary 
in tissue specificity, subcellular localization, enzymatic activity and targets. Sirtuins 
carry a conserved catalytic domain consisting of about 275 residues. Based on 
phylogenetic analysis mammalian Sirtuins are grouped into four different classes (I-
IV).
160,223 
SIRT1, SIRT2 and SIRT3 belong to class I along with most eukaryotic 
Sirtuins such as Sir2.1 from Drosophila melanogaster and the founding member 
yeast Sir2, HST1 and 2 from yeast. SIRT4 belongs to class II, SIRT5 to class III, and 
SIRT6 and SIRT7 are placed in class IV. Additionally, a novel class (“U”) has been 
created to include sirtuins with unique features, such as gram-positive bacteria and 
Termoga maritime sirtuins. Mammalian Sirtuins are localized in different 
compartment of the cells (Figure 6.4).
224,225
 SIRT1 is predominantly localized in the 
nucleus but is also present in the cytosol and mithochondria.
226
 Under specific 
circumstances, in particular when the insulin pathway is inhibited, the shuttling from 
nuclear to cytosol it is allowed.
227
 SIRT2 is mainly cytosolic but is also present in the 
nucleus during the transition from G2 phase to M phase of the cell cycle.
228 
SIRT3, 
SIRT4 and SIRT5 have a mitochondrial targeting sequence, and are localized in 
different compartments of this organelle.
229,230 
SIRT6 is mainly nuclear 
231
 and 
SIRT7 is present in the nucleolus.
232 
 
Figure 6.4. Mammalian sirtuin localization and target in the cell.  
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Potential sirtuins substrates range from histone to various acetylated proteins 
involved in cell metabolism, apoptosis and regulation of gene transcription. 
SIRT1, the most-studied mammalian sirtuin, was originally described to just 
deacetylate histones (H3, H4) but soon after was also shown to deacetylate other 
protein targets. The first non-histone target described for SIRT1 was p53, which is 
deacetylated on lysine 382 and repressed resulting in impaired apoptosis.
233
 This 
suggested that increased SIRT1 activity could be tumorigenic, but actually seems 
true the contrary.
234
 The PGC1α (peroxisome proliferator-activated receptor-γ co-
activator 1 α) is a transcriptional co-regulator that regulate mitochondrial biogenesis 
and activity. When PGC1α is deacetylated by SIRT1, its activation induce a 
downstream pathways that control mitochondrial gene expression.
235
 Moreover 
SIRT1 controls the acetylation of forkhead box O (FOXO) transcription factors, 
which is linked to glucose and lipidic metabolism and stress responses. As a fact, 
SIRT1 promotes insulin secretion and pancreatic beta cell survival by suppressing 
uncoupling protein (UCP2) expression and interact with FOXO. SIRT1 knockout 
animals showed a lower level of ATP in pancreatic β-cells as a result of increased 
UCP2 level and they exhibited a decrease insulin secretion in response to 
glucose.
236,237 
Lipid metabolism (HDL biogenesis) in the liver is also stimulated by 
SIRT1-dependent Liver's X receptor (LXR) deacetylation suggesting a mechanism 
that affects atherosclerosis and other aging-associated diseases.
238
 
With regard to SIRT2, in vitro studies demonstrated that SIRT2, similarly to 
SIRT1, preferentially deacetylates histone H4.
239
 In the cytosol, SIRT2 is associated 
with microtubules, where it deacetylates α-tubulin. During the mitotic phase, SIRT2 
increases and colocalizes with chromatin during the transition from G2 to M phase, 
suggesting that this sirtuin is involved in the regulation of the cell cycle in response 
to stress.
240-242
 More detailed studies on sirtuins show that SIRT2 plays an important 
role in glial cells development, microtubule dynamics in oligodendrocytes and 
maintenance of axonal integrity, which makes this isoform an attractive therapeutic 
target in neurodegenerative diseases.
243,244 
The most characterized mitochondrial sirtuin is SIRT3. Lombard et al. show that 
the absence of SIRT3 leads to protein hyperacetylation in mitochondrial fractions of 
liver and other tissues.
245 
Functional association analyses of the targeted proteins 
revealed that SIRT3 is involved in the regulation of all major mitochondrial 
processes, including protection from reactive oxygen species (ROS), maintenance of 
mtDNA integrity and metabolic pathways.
246 
For example, mitochondrial acetyl-CoA 
production is stimulated by SIRT3-mediated deacetylation, and hence catalytic 
activation of acetyl-CoA synthase 2.
247,248 
Acetyl-CoA can then enter the Krebs 
cycle, which is further regulated by SIRT3-dependent deacetylation of succinate 
dehydrogenase.
249 
During calorie restriction period, the liver releases a large amount 
of acetate into the blood. The heart and the muscles express acetyl-CoA synthase 2 
and use acetate in an efficient way as an energy source. Deacetylation of acetyl-CoA 
synthetase switches on its activity so it is relevant that SIRT3 is indeed activated 
during CR.
250 
Several other SIRT3 targets involved in metabolism have been recently 
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described. Hallows et al. identified the urea cycle enzyme ornithine 
transcarbomoylase (OTC) and other enzymes involved in β-oxidation as likely 
SIRT3 targets. Fasted mice lacking SIRT3 revealed alterations in β-oxidation and in 
the urea cycle; this study also suggest that under low energy input conditions, SIRT3 
modulates mitochondria by promoting amino acid catabolism and β-oxidation.250 
Even if the knowledge about SIRT3-dependent deacetylation has expanded rapidly, 
it’s still questionable why this enzyme has such a broad spectrum of targets.251  
SIRT4 exhibits an efficient ADP-ribosyltransferase activity on histones and 
bovine serum albumin but no detectable deacetylation activity. Although this may be 
due to a very specific substrate spectrum for the deacetylation reaction, another 
NAD
+
-dependent enzymatic activity, namely mono-ADP-ribosylation, was identified 
for SIRT4. SIRT4 is expressed in islets of Langerhans and colocalizes with insulin-
expressing beta cells. SIRT4 is reported to down-regulate insulin secretion.
252,253 
Glutamate dehydrogenase (GDH) is a substrate of SIRT4.
254 
By ADP-ribosylating 
GDH, SIRT4 suppresses its activity and
 
prevents the usage of amino acids as an 
energy source. During calorie
 
restriction SIRT4 expression is decreased, 
consequently GDH is activated and it induces the usage of glutamate and glutamine 
in order to generate ATP. GDH can also be deacetylated by SIRT3, although the 
functional link between acetylation and ADP-ribosylation of this important enzyme 
is not yet well understood. Nasrin et al. investigated whether the depletion of SIRT4 
would enhance liver and muscle metabolism. When SIRT4 is knockdown (KO) there 
is a significant increase in gene expression of mitochondrial and fatty acid 
metabolism enzymes in hepatocytes. Fatty acid oxidation (FAO) was increased in 
SIRT4 KO primary hepatocytes and this effect was dependent on SIRT1-SIRT4 KO, 
in primary myotubes, resulted in increased FAO, cellular respiration, and pAMPK 
levels. In conclusion taken together these findings, SIRT4 inhibition increases fat 
oxidative capacity in liver (in contrast with the functions of SIRT1 and SIRT3) and 
mitochondrial function in muscle.
254 
In a study of Laurent et al. has been highlighted 
a novel function for SIRT4 in the regulation of lipid metabolism. SIRT4 represses 
fatty acid oxidation in skeletal muscle and stimulates lipogenesis in white adipose 
tissue, indicating that SIRT4 can regulate the balance between fat oxidation and fat 
synthesis. SIRT4 directly binds, deacetylates (K471) and represses malonyl CoA 
deacarboxylase (MCD). Malonyl CoA is the carbon skeleton for lipogenesis and also 
inhibits fat oxidation. The K471 is at close distance to the malonyl CoA entry point 
of MCD and its acetylation might help gate the ligand entry. When SIRT4 is 
knockdown in mice, they display a deregulation of crucial physiologic aspects of 
lipid metabolism.
255
 
SIRT5 appears to primarily remove acylation marks in proteins other than acetyl 
groups. Originally, SIRT5 was found to be a NAD
+
-dependent deacetylase and 
involved in the regulation of the urea cycle by deacetylation of carbamoylphosphate 
synthase 1 (CPS1).
256,257 
The urate oxidase is also a SIRT5 substrate and its 
deacetylation stimulate purine catabolism in mice via deacetylation of urate oxidase, 
but the urate oxidase is not expressed in hominoid primates including humans.
258,259  
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SIRT5 revealed a weak deacetylation activity, in line with the lack of 
hyperacetylation in mitochondrial fractions from SIRT5 knockout mice. SIRT5 
reveal rather deacylase activity with higher affinity for malonylated and succinylated 
targets.
223
 Du et al. show that while CPS1 is both acetylated and succinylated at three 
lysine residues (K44, K287, and K1291), in the absence of SIRT5 succinylation of 
K1291 increases, whereas succinylation of K44 and K287 or acetylation of K44, 
K287, and K1291 remain unchanged. These new succinylation data suggests that 
SIRT5 regulates the enzymatic activity of CPS1 by desuccinylating K1291. Because 
acetylation and succinylation can occur on the same CPS1 lysine residues, further 
studies are needed to resolve which modification is regulatory. The preference for 
succinyl and malonyl groups is due to the presence of an arginine residue (Arg105) 
and tyrosine residue (Tyr102) in the acyl pocket of Sirt5. Analogous to the 
deacetylation reaction, the deacylation reaction releases O-malonyl-ADPR or O-
succinyl- ADPR as products. Sirt5 deficiency in mice leads to hyperammonemia 
after a period of caloric restriction. This effect is due to the lack of Sirt5-dependent 
deacylation and thereby activation of its first and so far only identified physiological 
substrate carbamoyl phosphate synthetase 1 (CPS1). Sirt5 activity is triggered by 
higher NAD
+
 availability in times of nutrient deprivation, when amino acids are 
catabolized as an alternative energy source and CPS1 is needed to detoxicate the by-
product ammonia through catalyzing the first step of the urea cycle.
260,261 
SIRT6 was originally found to have both deacetylase and mono-ADP-ribosyl 
transferase catalytic activities.
262
 It is capable to deacetylate H3K9-Ac and H3K56-
Ac substrates. On the contrary, its mono ADP-ribosyl transferase activity is poorly 
understood, and it’s only known substrates are itself and poly ADP-ribose 
polymerase 1 (PARP1).
263
 Recently, Gil et al. show that the binding to nucleosomes 
significantly enhances SIRT6 deacetylation of H3K9 and H3K56. Thus, these 
findings suggest that its binding to the nucleosome in vivo might convert it into an 
active structure.
264
 A recent study by Jiang et al. show that SIRT6 hydrolyses long-
chain fatty acyl groups from lysine residues. SIRT6 was tested with acylated histone 
H3K9 substrates. The longer the aliphatic tail was, the stronger was the catalytic 
efficiency of SIRT6. Palmitoyl, octanoyl and butyryl are all better substrates than 
acetylated H3K9-Ac substrates.
265 
A number of evidence correlates SIRT6 to 
metabolism, aging and genome stability. SIRT6 regulates the expression of glycolitic 
genes like the glucose transporter GLUT1 mediated by hypoxia-inducible factor 1α 
(HIF1α).266 SIRT6 deficiency promotes tumorigenesis by promoting increased 
glycolysis.
267
 SIRT6 is involved in several DNA repair pathways, for example it 
regulates the DNA double-strand break repair by deacetylating the histone 
H3K9Ac.
268  
The enzymatic activity, molecular targets, and physiological functions of SIRT7 
are poorly defined. SIRT7 was reported to activate RNA polymerase I transcription, 
although its protein substrate is still uncertain.
232
 A recent study has shown that 
SIRT7 deacetylates histone H3 acetylated at lysine 18 (H3K18ac), hypoacetylation 
of H3K18 compromising transcription of genes that are linked to oncogenic 
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transformation.
269 
Consistent with an important role of SIRT7 in cell proliferation 
and tumor initiation, SIRT7 was found to be upregulated in human hepatocellular 
carcinomas, whereas suppression of SIRT7 reduced tumor growth in a mouse 
xenograft model.
270
 Recently Chen et al. have identified PAF53 as a new nonhistone 
substrate of SIRT7. PAF53 is a subunit of Pol I that is not shared by Pol II and III, 
providing a class-specific mechanism for SIRT7-dependent regulation of RNA 
polymerase activity.
271 
SIRT7 may also deacetylate p53: SIRT7 knockout  mice 
display cardiac hypertrophy, which is linked to p53 hyperacetylation.
272
 However, 
further studies will have to determine whether p53 is indeed deacetylated by both 
SIRT1 and SIRT7 and, if so, whether and how these two sirtuins interconnect on this 
target. 
HDAC 
III 
Sirtuin Localization Substrates 
Catalytic 
activity 
        Function 
Class I 
SIRT1 
Cytosol, 
nucleus 
PGC1, 
eNOS, 
FOXO, 
p53, 
MyoD, NF-
kB, histone 
H3 and H4 
NAD
+
- 
dependent 
protein 
deacetylation 
Cell survival, 
insulin, signaling, 
inflammation, 
metabolism 
regulation 
oxidative stress 
response, lifespan 
regulation 
SIRT2 
Cytosol, 
nucleus 
-tubulin, 
histone H4 
NAD
+
- 
dependent 
protein 
deacetylation 
Cell cycle 
regulation, 
nervous system 
development 
SIRT3 
MItochondria, 
nucleus 
AceC2, 
IDH2, 
ShdhA 
NAD
+
- 
dependent 
protein 
deacetylation 
Regulation of 
mitochondrial 
energetic 
metabolism 
Class II SIRT4 Mitochondria 
GDH, 
MCD 
Mono- ADP-
ribosyl 
transferase, 
NAD
+
- 
dependent 
protein 
deacetylation 
Regulation of 
mitochondrial 
energetic 
metabolism/ lipid 
metabolism, 
insulin secretion 
Class III SIRT5 Mitochiondria 
Histone 
H4, CPS1, 
cyt c 
NAD
+
-
dependent 
protein 
deacylation 
Urea cycle 
regulation, 
apoptosis 
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Class IV 
SIRT6 Nucleus 
Histone 
H3K9, 
PARP1 
NAD
+
- 
dependent 
protein 
deacetylation
, Mono- 
ADP-ribosyl 
transferase 
Genome stability, 
DNA repair, 
nutrient-
dependent 
metabolism 
regulation 
SIRT7 Nucleoli 
RNA pol I, 
p53, 
histone 
H3K18 
NAD
+
- 
dependent 
protein 
deacetylation 
Regulation of 
rRNA 
trascription, cell 
cycle regulation 
Table 6.2. Characterization of seven mammalian sirtuins.
273
 Abbreviation: AceC2, 
acetylcoenzyme synthetase2; CPS1, carbamoyl synthetase 1; cyt, cytocrome; FOXO, forkhead 
transcription factors; GDH, glutamate dehydrogenase; IDH2, isocitrate dehydrogenase; MCD, 
malonyl CoA deacarboxylase; MyoD, Myogenic differentiation 1 factor; eNOS, epithelial nitric oxide 
synthase; NF-kB nuclear factor kB; PGC1, Peroxisome proliferator-activated receptor gamma co 
activator  1- alpha; ShdhA, succinate dehydrogenase flavoprotein.  
6.2.4.2. Structural features of Sirtuins 
Primary sequence alignment of sirtuins shows that they share a highly conserved 
catalytic core and N- and C-terminal segments with divergent lengths and sequences. 
The overall structures of these core domains, determined by X-ray, are highly similar 
displaying a conserved large Rossmann fold domain for NAD
+
 binding and a more 
variant small domain, unique for each sirtuins, that contains a zinc-binding ribbon 
module. The two domains are connected by four loops that arise from the Rossmann 
fold and include a flexible loop called the co-substrate binding loop. Both the 
connection and the position of the small domain with respect to the large domain 
varies among different Sirtuins and is often influenced by the presence of ligands and 
other small molecules which can affect the co-substrate loop. The most interesting 
part of the Sirtuin structure is the cleft between the large and small domain. The 
substrate and NAD
+
 insert from opposite sides into a hydrophobic tunnel within the 
cleft, where catalysis takes place (Figure 6.5).
274 
The zinc ion does not directly participate to the catalysis, as for the other classical 
HDACs, because it is too remote from the active site but seems to be required for 
structural stability, indeed the zinc atom coordinate with four conserved Cysteins 
holding the three -strands together. There is a lack of deacetylase activity by 
removing the zinc through mutation of the coordinating cysteine or by using 
chelating reagent due to partial collapse of the structure, matter of fact the 
subsequent supplementation of zinc restores activity.
275
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Figure 6.5. Overall sirtuin structure represented by Hst2. 
The large domain has a classical open α/β Rossmann-fold structure for NAD+ to 
bind. It consists of a central -sheet with six parallel -strands sandwiched by several 
-helices on each side (the number of those helices depends upon the different 
sirtuins).
276
 The four loops that connect the small and large domains form the cleft 
that acts as the enzyme active site. The elongated NAD
+
 molecule inserts its 
nicotinamide ribose moiety into the cleft, lays the pyrophosphate group along the 
edge of the -sheet in a positively charged groove, and places the adenine base in a 
pocket remote from the cleft. The orientation of NAD
+
 here is inverted compared 
with most Rossmann fold-containing enzymes, where the adenine base of NAD
+ 
binds to the C-terminal half, and the nicotinamide group of NAD
+
 binds to the N-
terminal half of the -sheet.277 The peptide/substrate orientation and backbone 
interactions observed in several crystal structures of sirtuins suggests that sirtuins 
discriminate between different substrates and on the protein level there might be 
other interactions between sirtuins (especially the N and C-terminal domains) and its 
substrates that can lead to a substrate specificity. The nicotinamide ring of NAD
+
 
while bound in the strained conformation makes contacts with the co-substrate 
binding loop and lead to a decrease in the deacetylation activity of the Sirtuin, 
highlighting its importance.
278
 When there is no NAD
+
 present, the co-substrate loop 
adopts a relaxed/ open state, but switches to an ordered/ closed state when the 
acetyllysine and NAD
+ 
are present in the cleft. 
6.2.5. Histone deacetylase and cancer 
Mutation and/or aberrant expression of various HDACs have often been observed in 
human disease, in particular cancer, making them an important target in cancer 
therapy. Indeed, in 2005 Esteller and colleagues have reported that a lost of 
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acetylation of histone H4 at lysine 16 is a common event in human cancer in 
particulary in tumorogenesis.
279
  
Class I subfamily of HDACs are deregulated in many cancers. In several studies 
analyzing patient cancer samples, overexpression of HDAC1 has been found in 
gastric, breast, pancreatic, hepatocellular, lung and prostate carcinomas.
280,281
 Other 
studies have reported a high expression of HDAC1, HDAC2 and HDAC3 in 
colorectal and gastric cancer, in renal cell cancer even in classical Hodgkin’s 
lymphoma.
164,282,283
 HDAC2 is also aberrantly expressed in lung cancer tissues.
284
 
Taken together, these studies point out that overexpression of class I HDACs, in 
particular HDAC1, is a cancer marker associated with poor prognosis. In contrast to 
other members of the class I subfamily, HDAC8 expression seems to be cancer-type 
specific. Oehme et al. have reported overexpression of HDAC8 in childhood 
neuroblastoma.
285
 In these patients, HDAC8 expression correlates with advance stage 
disease, poor prognosis and poor survival. There are hundreds of studies that link 
class I HDACs with cancer. siRNA-mediated knockdown of HDAC1 and HDAC3 in 
HeLa cells results in inhibition of cell proliferation, whereas knockdown of HDAC4 
and HDAC7 has no effect.
166
 In breast cancer cell lines, overexpression of HDAC1, 
HDAC6 or HDAC8 increases cell invasion and the level of matrix metalloproteinase-
9 (MMP9).
286 
Recently, HDAC1 has been reported to be overexpressed in a subset of 
hepatocellular and liver cancer cell lines. HDAC1 inactivation results in the 
regression of tumor cell growth, the induction of autophagic cell death and the 
increase of p21 and p27 gene expression.
287
  
In recent years class IIa HDACs have started to be linked to several types of cancer. 
In contrast to class I HDACs, some members of the class IIa subfamily seem to exert 
a dual role in cancer.  
HDAC4 along with HDAC9 and SIRT5 are found to be overexpressed in patients 
with Waldenstrom’s macroglobulinemia.288 HDAC4 expression is also upregulated 
in breast cancer samples compared with renal, bladder and colorectal cancer.
289
 
However, HDAC4 has not only been reported to be over-represented in cancer, 
several studies demonstrate that HDAC4 dysfunction and downregulation are 
associated with cancer development. Indeed Stark et al. in 2007 have observed a 
HDAC4 homozygous deletion in melanoma cell lines and Sjoblom et al. have found 
HDAC4 mutations in breast cancer cells.
290,291
 
HDAC5 and HDAC9 are overexpressed in high-risk medulloblastoma patients, 
demonstrating a clear relationship between their expression and poor survival. The 
knockdown of these two enzymes in medulloblastoma cells is sufficient to promote 
cell death, but their molecular role in this type of cancer is still to be clarified.
292
 
HDAC5, together with HDAC3, is also aberrantly expressed in hepatocellular 
carcinoma (HCC). Treatment with the HDAC inhibitor panobinostat is found to be 
highly efficient in preclinical models of HCC, confirming the importance of these 
HDACs in HCC progression.
293 
High levels of cytoplasmic HDAC7 have been reported in pancreatic cancer patients 
and in children with acute lymphoblastic leukemia.
294,295
 In contrast, Skov and 
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colleagues have reported HDAC7 to be significantly downregulated in 
myeloproliferative neoplasms.
296
  
Overexpression of HDAC6 have been associated with tumorigenesis.
297 
Significantly 
higher HDAC6 expression was found in oral squamous cell carcinoma, versus 
normal oral squamous tissue, and HDAC6 expression was augmented in advanced 
stage cancers compared to early stage.
298 
In breast cancer, HDAC6 expression was 
associated with better survival and was higher in small tumors, in estrogen and 
progesterone receptor-positive tumors.
299
 However, in another study analyzing breast 
cancer tissues, HDAC6 protein expression revealed no significant use as prognostic 
indicator for breast cancer progression.
300
 HDAC6 deacetylates the chaperone 
Hsp90, resulting in the inhibition of steroid receptor mediated transcriptional 
activation. This mechanism has been reported to affect the growth of prostate cancer 
cells and breast stem cells.
301,302
 Two other studies by Kaluza and Li reported that 
HDAC6 promotes angiogenesis by regulating the polarization and migration of 
vascular epithelial cells, in particularly by deacetylating the cortactin.
303,304 
When tubacin, a HDAC6 specific inhibitor is used in the treatment of acute 
lymphoblastic leukemia cells there is an anti-proliferative effect, enhancing the 
effects of chemotherapy in vitro and in vivo.
305
 A similar mechanism has been 
attributed to the induction of apoptosis after treatment of multiple myeloma cells 
with the HDAC6 inhibitor ACY-1225.
306
 In conclusion, targeting HDAC6 with 
specific HDAC inhibitorss should be considered for treating cancer cells, alone or in 
combination with other chemotherapeutic agents.
 
Sirtuins, as in the case for other HDACs, seem to play both a pro-oncogenic as well 
as a tumor suppressor role in cancer. Similarly to classical HDACs, aberrant 
expression of several sirtuins is found in many types of cancer. 
SIRT1 upregulation in breast cancer cells is associated with inactivation of tumor 
suppressor hypermethylated in cancer 1 (HIC1) by DNA hypermethylation.
307 
In 
addition, SIRT1 can promote cell migration by directly interacting and deacetylating 
cortactin.
308 
SIRT1 activator SRT1720 promotes the migration and pulmonary 
metastasis of subcutaneously-implanted breast cancer cells in mice, further 
supporting the cancer promoting effect of SIRT1 in breast cancer.
309
 There is also a 
body of evidence, particularly from mouse model studies, pointing to a tumor 
suppressor role of SIRT1. For example SIRT1 expression is significantly 
downregulated in human head and neck squamous cell carcinoma (HNSCC). High 
SIRT1 expression is associated with good prognosis for HNSCC patients.
310
  
Similar to SIRT1, SIRT2 may have both tumor suppression and promotion function. 
SIRT2 expression is reduced in gliomas, in esophageal adenocarcinomas, gastric 
adenocarcinomas, HNSCC and in human breast cancer.
311-313
 On the other hand, 
SIRT2 knockdown leads to both necrotic and apoptotic cell death in C6 glioma 
cells.
314
 Similarly, in response to SIRT2 downregulation, cervical carcinoma HeLa 
cells undergo apoptosis.
315  
SIRT3 plays crucial roles in metabolism and oxidative stress response, and is 
considered a mitochondrial tumor suppressor. SIRT3 levels are reduced in colon, 
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human breast carcinoma and HNSCC.
316,317
 Mechanistically, SIRT3 may inhibit 
tumor growth by reducing production of reactive oxygen species (ROS) through 
regulating electron transport, superoxide dismutase, mitochondrial IDH2, and 
FOXO3a.
318
 Anyway, potential roles of SIRT3 in tumor promotion have also been 
reported. SIRT3 expression is higher in oral squamous cell carcinoma (OSCC) and in 
human lymph-node-positive breast cancer.
319,320 
The selective inhibition of SIRT3 in 
OSCC cells inhibits cell growth and sensitizes OSCC cells to radiation and cisplatin 
treatments in vitro.
319  
SIRT4 in cancer is a potential tumor suppressor.
321 
SIRT4 expression is found to be 
significantly lower in human bladder, breast, colon, gastric, ovarian, and thyroid 
carcinomas, relative to normal tissues. In his recent study, Jeong has reported that the 
loss of SIRT4 led to increased glutamine-dependent cell proliferation and stress-
induced genomic instability, resulting in tumorigenic phenotypes. Indeed SIRT4 
knockout mice spontaneously develop lung tumors. This study highlights a crucial 
role of SIRT4 in linking the glutamine metabolism with tumorigenesis.
321
  
The biological significance of demalonylation and desuccinylation of carbamoyl 
phosphate synthetase 1 by SIRT5 remains unknown.
322
 To date, there are no studies 
evaluating the role of SIRT5 in tumorigenesis.  
There is a growing evidence suggesting SIRT6 as tumor suppressor. SIRT6 
deacetylates histone H3K9 and H3K56.
323
 H3K56 has been shown to be 
hyperacetylated in skin, thyroid, liver and breast cancer.
324 
Overexpression of SIRT6 
leads to a massive apoptosis in a variety of cancer cell lines but not in normal 
cells.
325
 In any case, there are some evidence incongruent with SIRT6 tumor 
suppression function. Indeed, there is a study by Bauer et al. that report how SIRT6 
enhance cytokine production and migration in pancreatic cells by regulating the Ca
2+
 
responses.
326 
 
Several groups show that SIRT7 expression is upregulated in human cancers of liver, 
thyroid, breast.
232,327,328 
In 2006 Ford et al. have demonstrated that knockdown of 
SIRT7 inhibits cell growth and induces apoptosis.
232 
Barber et al. have confirmed 
that knockdown of SIRT7 in cancer cell lines reduces cell growth both in vitro and in 
vivo, and moreover have demonstrated a novel oncogenic mechanism of SIRT7 by 
deacetylating H3K18.
329 
Interestingly, many different cancers display global 
hypoacetylation of H3K18, but further in vivo studies are needed to evaluate the role 
of SIRT7 in cancer. 
Very few studies have reported a potential role for class IV HDAC11 in cancer. 
HDAC11 is involved in Hodgkin lymphoma (HL); indeed by using small interfering 
RNAs (siRNAs) that selectively inhibit HDAC11 expression, induced apoptosis in 
HL cell lines and boost the production of tumor necrosis- (TNF-).330 Future 
studies should be undertaken tot elucidate the pathways controlled by HDAC11 in 
other tumor entities.  
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6.2.6. Mechanism of deacetylation 
In 1999, was reported the crystal structure of a bacterial HDAC homolog, HDLP 
(histone-deacetylase-like protein), bound to the HDAC inhibitor trichostatin A (TSA) 
(Figure 6.6).
331
 The catalytic domain of HDLP is very closely related to both classes 
I and II of HDACs, and thus the mechanism of deacetylation is presumably 
conserved as well. HDLP has a single domain structure related to the open α/ β class 
of folds. It contains a central eight-stranded parallel β sheet, with four α helices 
packed on either face. Eight additional α helices and large loops in the β sheet further 
extend the structure and result in the formation of a deep narrow pocket with an 
adjacent internal cavity. TSA binds to this pocket, which thus represents the active 
site of the enzyme. HDLP requires Zn
2+ 
for activity, this cation is positioned near the 
bottom of the pocket and is coordinated by several histidine and aspartate residues. 
The channel leads to the active site being surrounded by hydrophobic residues, which 
is presumably where the aliphatic chain of the acetyl-lysine residue is nestled. 
Figure 6.6. Crystal structure of HDLP bound to an HDAC inhibitor, trichostatin A. 
The cocrystallization of TSA with HDLP (Figure 6.7) allows an analysis of the 
structural properties of this HDAC inhibitor.
332
 The hydroxamic acid coordinates the 
zinc cation in a bidentate fashion and hydrogen bonds with some of the active site 
residues. Fitting into the channel, the aliphatic chain makes several van der Waals 
contacts with the channel residues, the cap group contacts residues on the rim of the 
pocket and possibly mimics the amino acids adjacent to the acetylated lysine residue 
in the histone. The binding of TSA causes a conformational change in the Tyr91 and 
thereby allows tighter packing of the cap group. The proposed deacetylase 
mechanism
 
is consistent with the contacts TSA or SAHA make in the active site. 
Specifically, the carbonyl oxygen of the N-acetyl amide bond could bind the zinc, 
and the carbonyl carbon could be positioned in close proximity to the water 
molecule. The zinc ion could polarize the carbonyl group so that the carbon is a 
better electrophile, and could also help orient the water molecule.  
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Figure 6.7. Cocrystallization of TSA with HDLP 
The nucleophilicity of the water molecule would be increased by the negative charge 
of the buried Asp 166-His 131 charge-relay system to which the water is hydrogen 
bonded. The nucleophilic attack of the water on the carbonyl carbon would result in a 
tetrahedral carbon. This oxyanion intermediate could be stabilized by two zinc-
oxygen interactions, and possibly by a hydrogen bond from the Tyr 297 hydroxyl 
group. In the final step, the carbon-nitrogen bond of the intermediate would break, 
and the nitrogen of the scissile bond would accept a proton from the exposed Asp 
173-His 132 charge relay, yielding the acetate and lysine products (Figure 6.8).
332-336 
Figure 6.8. Proposed mechanism for HDAC deacetylation.  
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Sirtuins have been shown to possess both deacylase activity and ADP-ribosyl 
transferase activity. The Sirtuin mechanism is unique due to the involvement of two 
substrates and release of three products (Figure 6.9).
337 
Several biochemical and 
structural data suggest multiple enzyme/intermediate and enzyme/transition state 
complexes.
274,338 
The deacetylation is considered as the main function of the Sirtuins 
and the ADP-ribosyl transferase activity is often considered as a secondary reaction 
but the ADP-ribosyl transferase mechanism is still subject to debate.
338
  
Figure 6.9. NAD
+
 dependent reaction catalyzed by sirtuin enzymes. NAD
+
 is consumed as a 
substrate, along with an acetylated protein substrate and a water molecule. Upon reaction, the acetyl-
group at the N-()-position is removed and nicotinamide and 2´-O-AADPR are formed as co-products. 
In Figure 6.10, it is shown the deacetylation mechanism, ADPR-peptidyl-imidate 
mechanism, proposed by Sauve and colleagues. Central to the mechanism is an 1--
O-ADPR-peptidylimidate intermediate formed by ADP ribosylation of the 
acetyllysine oxygen. The imidate complex can react reversibly to reform NAD
+ 
or 
react forward to form 2´-AADPR product. Equilibrative binding of nicotinamide 
causes the imidate to be in two forms, one with nicotinamide bound and the other 
with nicotinamide dissociated. Both forms are proposed to be competent to form the 
subsequent tetrahedral intermediate formed by reaction of the 2´-OH with the imidate 
carbon. To verify which decomposition form is promoted they used 
18
O water that 
can lead to two possible decompositions, one of which is observed, leading to 
formation of 2´-AADPR. The other non-observed decomposition generates 1´--
AADPR.
337 
Direct observation of the imidate species on a sirtuin enzyme still 
remains to be obtained. 
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Figure 6.10. Sirtuin deacetylation: proposed ADPR-peptidyl-imidate mechanism 
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6.2.7. HDAC inhibitors  
From the TSA/HDLP complex data,
331
 described above, it is possible to elaborate a 
structural model (common pharmacophore) for class I/II HDAC inhibition. This 
pharmacophore consists of a metal binding domain (zinc binding group ZBG), which 
interacts with the active site, a linker domain, which occupies the channel, and a 
surface recognition domain, which interacts with residues on the rim of the active 
site (Figure 6.11). 
In all known natural or synthetic inhibitors it is possible to see an extremely variable 
cap group. This moiety contacts residues on the rim of the catalytic pocket and is 
generally connected to an electronegative group that is able to interact by hydrogen 
bond with other residues. 
Such portion is bound to an hydrocarbon linker interacting with the channel residues 
of the active site of the enzyme and finishing with the enzyme inhibiting group, that 
in many cases chelate the zinc cation near the bottom of the catalytic pocket. The cap 
groups can be, for example, represented by substituted benzene rings, pyridine, 
pyridylmethyl groups, a portion of tricyclic systems or of cyclic tetrapeptides. The 
electronegative group is generally a ketone, an amide, a reverse amide, a carbamate, 
or a sulfonamide. The linker is a saturated or unsaturated aliphatic chain, which 
mimics that of the lysine substrate, with an optimal length of 4-6 carbon residues. In 
some cases, it is possible to find an aromatic or heteroaromatic ring inserted into the 
hydrocarbon chain. To date, the most useful ZBG is the hydroxamic acid moiety but 
also ethyl ketone, trifluoromethyl ketone, α-ketoamide, 2-aminoanilide, thiol and its 
acetyl derivative (which in vivo is rapidly hydrolyzed) are effectively able to chelate 
the zinc ion. 
Figure 6.11. Pharmacophore model for HDAC inhibitors based on TSA structure. 
HDAC inhibitors can be structurally grouped into at least four classes:  
- hydroxamates, 
- cyclic peptides,  
- aliphatic acids, 
- benzamides.  
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6.2.7.1. Hydroxamates 
Hydroxamates were the first compounds to be identified as histone deacetylase 
inhibitors, and these agents helped to define the pharmacophore model for HDAC 
inhibitors (Figure 6.12). The linker domain can consist of linear or cyclic structures, 
either saturated or unsaturated, and the surface recognition domain is generally a 
hydrophobic group, most often aromatic.  
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Figure 6.12. HDACi: Hydroxamic acids. 
TSA (2) and its glucopyranosyl derivative trichostatin C were first isolated from 
cultures of Streptomyces hygroscopicus as antifungal antibiotics active against 
Trichophyton species.
332
 Many years later, the trichostatins were found to have 
potent antiproliferative and differentiating activity at nanomolar concentrations 
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against Friend murine erythroleukemia cells in culture. Between the two possible 
enantiomers the (R)-TSA is 70 fold more pontent of (S)-TSA. In later studies, TSA 
was active in a number of normal and tumour cell lines, arresting the growth of rat 
fibroblast cells in G1 and G2 phases of the cell cycle. Nuclear histones from cells 
treated with TSA were highly acetylated and this was not due to increased 
acetylation but rather, to decreased deacetylation. In experiments using partially 
purified mouse HDAC, TSA was a potent, reversible, noncompetitive inhibitor with 
Ki = 3.4 nM, closely related to the effective antiproliferative concentration in cell 
lines. Furthermore, the Ki was 10-fold higher for HDAC purified from a mutant cell 
line resistant to TSA, suggesting that HDAC was the likely primary target of 
TSA.
334-336
 
SAHA (suberoylanilide hydroxamic acid 1) is the prototype of a series of 
synthetic hydroxamic acid-based HDAC inhibitors with nanomolar potency. 
Structure-activity studies have shown that the hydroxamic acid is the crucial moiety 
to obtain high inhibiting activity, since substitution or modification at this site 
reduces their anti-HDAC effect.
331
 SAHA ( Zolinza ®) is the first of the new HDACi 
to be approved by the Food and Drug Administration for clinical use in cancer 
patients for the treatment of cutaneous T-cell lymphoma. It is reported to be active in 
patients with solid tumors and with Hodgkin’s disease at non-toxic doses. A recent 
study show that Vorinostat monotherapy demonstrate minimal activity in a group of 
patients with acute myeloid leukemia. Although clinical results with Vorinostat used 
as a single agent have been unsuccessful in treatment of solid malignancies, 
preclinical data strongly suggest combination with conventional cancer therapies 
would be beneficial.
339
 
A phase I/II multicenter study was conducted in advanced HCC with PXD-101 
(Belinostat 3) by Yeo et al.. In phase I 18 patients were accrued with no dose limiting 
toxicities (DLTs) observed at 1400mg/m
2
/day intravenously for 5 days every 3 
weeks. Therefore, this dose was selected for phase II development with 42 patients 
enrolled. Pharmacokinetics showed that Belinostat does not have saturable kinetics, 
despite liver impairment at the doses studied, and it undergoes rapid clearance, with 
modest interindividual variability. The most frequent higher toxicities included 
abdominal pain, hyperbilirubinemia, anemia and vomiting. However, it is noted that 
the short PFS (Progression Free Survival) and the phase II design of this study 
preclude definitive assessment of antitumor activity of Belinostat.
340 
In another phase 
II study, Belinostat was used in patients with advanced thymoma or thymic 
carcinoma. It was administered intravenously at 1 g/m
2
 on days 1 to 5 of a 21-day 
cycle until disease progression or development of intolerance. Treatment was well 
tolerated, with nausea, vomiting, and fatigue being the most frequent adverse effects. 
Over 41 patients, two patients achieved partial response (both had thymoma), 25 had 
stable disease, and 13 had progressive disease; there were no responses among 
patients with thymic carcinoma. In conclusion Belinostat has modest antitumor 
49 |Histone acetylation 
 
activity in this group of heavily pretreated thymic malignancies, however additional 
testing of belinostat in this disease is warranted.
341 
LBH-589 (Panobinostat 4) is a cinnamic hydroxamic acid-based HDACi, 
developed by Novartis, with a structure similar to Vorinostat. It was in phase II trial 
for the treatment of patients with refractory metastatic renal cell carcinoma. They 
were treated with 45 mg orally twice a week, and were reevaluated after 8 weeks. 
Panobinostat was generally well tolerated but had no activity in this group of patients 
with refractory renal carcinoma.
342
 LBH-589 is also in phase I clinical trials for 
cutaneous T-cell lymphoma as an oral agent administered three times a week. It has a 
longer half life than Vorinostat. Responses were seen in 6 or 10 patients including 
two complete responses and one partial response. Toxicities were similar to those 
observed with Vorinostat.
343 
ITF2357 (Givinostat 5) is a synthetic HDACi containing a hydroxamic acid 
moiety linked to an aromatic ring. In vitro and in vivo studies involving human tumor 
cell lines have shown that ITF2357 (used alone or in combination with other agents) 
has cytotoxic effects and inhibitory effects on proinflammatory cytokines.
344,345
 In a 
phase II open-label nonrandomized clinical study involving heavily pretreated, 
relapsed, or refractory Hodgkin’s lymphoma patients, preliminary data showed that 
the oral application of ITF2375 had antitumor activity with an acceptable safety 
profile. The toxicity profile included leucopenia, thrombocytopenia, fatigue, diarrhea 
and cardiac QT persistence leading to drug discontinuation in 20% of treated 
patients.
346
 
PCI-24781 (6) is a broad-spectrum phenyl hydroxamate. Preclinical studies 
involving combination with radiotherapy have suggested it may act in DNA-repair 
mechanisms, leading to apoptosis.
347
 In a phase I clinical study involving refractory 
advanced solid tumors, patients were relatively successful, with adverse side effects 
including anemia, thrombocytopenia, diarrhea, nausea, vomiting, and fatigue.
348 
Phase I study of R306465 (7) about its absorption, breakdown, elimination in 
patients with advanced solid malignancies was completed in October 2006, but no 
further clinical study had been conducted later.
349 
ACY1215 (8) is a HDAC6-selective inhibitor, a series of studies are carried out in 
combination with bortezomib and dexamethasone in multiple myeloma.
306,350  
4SC201 (Resminostat 9) has been used in a phase I trial in patients with advanced 
refractory solid tumors.
351,352 
Nausea, vomiting and fatigue represented the most 
common drug-related toxicities. The recommended dose for phase II evaluation was 
600 mg once daily in a 14 day cycle. Resminostat is currently being tested in phase 
I/II clinical trials in hepatocellular carcinoma in monotherapy or in combination with 
Sorafenib 
353
 and as a second-line treatment option in patients with KRAS tumor 
mutations in combination with the FOLFIRI regimen colorectal cancer,
354
 but data 
have not yet been published.   
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Since 2001 a new class of HDAC inhibitors, namely aroyl-pyrrolyl-hydroxy-
amides (APHAs), have been described by Mai et al.
355 
Performing some chemical 
modification, they were able to synthesize two compound MC1568 (10) and 
MC1575 (11), gained in potency and selectivity, indeed these two molecule are class 
II selective inhibitors. Illy and colleagues, reported that in human umbilical vein ECs 
(HUVECs) NO inhibited serum-induced histone acetylation and enhanced histone 
deacetylase (HDAC) activity. In particular by immunofluorescence and Western blot 
analyses it was found that NO induced class II HDAC4 and 5 nuclear shuttling and 
that class II HDACs selective inhibitor MC1568 rescued serum-dependent histone 
acetylation above control level in NO-treated HUVECs. In contrast, class I HDACs 
inhibitor MS-275 had no effect, indicating a specific role for class II HDACs in NO-
dependent histone deacetylation.
356 
In 2012 Venza et al. showed that MC1568 and 
MC1575 inhibited IL-8 levels and cell proliferation in melanoma cells, suggesting 
that class II-specific HDACis may constitute a novel therapeutic strategy for 
improving the treatment of this cancer.
357 
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6.2.7.2. Cyclic peptides 
The cyclic peptide class is a structurally complex group of HDACi, which includes 
the natural product depsipeptide (Romidepsin, FK-228, 15, Gloucester 
Pharmaceutical Inc.), Apicidin (13), and the cyclic hydroxamic acid- containing 
peptide group of molecules, all active at nanomolar concentrations. All compounds 
are conforming to the pharmacophore model for HDAC inhibitors and possess a 
macrocycle containing hydrophobic amino acids in the surface recognition domain, 
an alkyl chain in the linker domain, and a functional group in the metal binding 
domain (Figure 6.13).  
Figure 6.13. Cyclic peptides 
The first examples of the cyclic peptide class arose from the screening of natural 
products for antiparasitic or antiproliferation activity, bearing (S)-2-amino-9,10-
epoxy-8-oxodecanoic acid on the surface, as for Chlamydocin (12). Later studies 
demonstrate that the potentially reactive epoxy ketone moiety is not required for 
HDAC inhibition.
358  
Apicidin (13), a fungal metabolite, contains an (S)-2-amino-8-oxodecanyl side 
chain lacking the epoxide group.
359
 Apicidin has broad spectrum activity (ranging 
from 4 to 125 ng/mL) against the apicomplexan family of parasites, presumably via 
inhibition of protozoan histone deacetylases (IC50=1-2 nM), and demonstrates 
efficacy against Plasmodium berghei malaria in mice. Colletti and coworkers 
conducted SAR studies on the side chain of apicidin. They found that reduction of 
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the C-8 keto group to alcohol or CH2 group or conversion to olefin or epoxide 
resulted in the attenuation of the anti-HDAC activity of apicidin. However, 
substitution of the ethyl ketone moiety of apicidin side chain with hydroxamic acid, 
epimeric epoxide, and hydroxyketone resulted in analogs with improved HDAC 
activity relative to apicidin. Some of these derivates were tested for HDAC inhibition 
using partially purified extracts of both human HeLa cells and Eimeria tenella 
protozoa, and they showed a picomolar cytotoxic activity.
360 
 
Komatsu and colleagues, synthetized a series of hybrids between TSA and cyclic 
tetrapeptides defined as Cyclic Hydroxamic-Acid containing Peptides (CHAPs 14). 
All CHAPs synthesized in this study were potent inhibitors of HDAC1 with 
chlamydocin-type CHAP showing the highest inhibition of HDAC1 (IC50= 0.44 nM) 
among all of them. Concerning their selectivity, these compounds showed 86-fold 
higher selectivity for HDAC1 versus HDAC6.
361
 
FK-228 (Romidepsin 15) is the most well studied depsipeptide HDACi to date. 
FK-228 and his closely related FR901375, are naturally occurring depsipeptides 
isolated from Chromobacterium violaceum.
362 
FK-228 has a unique structural feature 
which includes a 16-membered cyclic depsipeptide bridged by a 15-membered 
macrocyclic disulfide ring. FK-228 is a stable prodrug which is activated by 
glutathione reductase in vivo by reduction of the disulfide bond to reveal a butenyl 
thiol moiety which then interacts with zinc at the HDAC active site.
363
 It shows high 
selectivity toward class I HDACs compared to HDAC4 and HDAC6. In November 
2009, FK228 has been approved by FDA for the treatment of relapsed and refractory 
cutaneous T-cell lymphoma. In contrast to SAHA, FK228 is approved as second-line 
therapy. Promising results have been demonstrated in Phase II testing of peripheral 
T-cell lymphoma subtypes. Future directions include expanded indications in T-cell 
lymphomas as well as novel combinations with other HDAC inhibitors and other 
therapeutic agents.
364 
6.2.7.3. Aliphatic acids 
The aliphatic acids, such as butyrate, phenylbutyrate, and valproic acid, are relatively 
weak inhibitors of the HDACs, with activity at millimolar concentrations (Figure 
6.14).  
Figure 6.14. Aliphatic acids.  
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The butyric acid (15), a product generated in man by metabolism of fatty acids 
and bacterial fermentation of fiber in the colon, has long been known to be an 
antiproliferative and differentiating agent.
365
 In 1933, it was first reported his 
anticancer activity on solid tumors, afterwards additional observations highlighted 
that it possessed differentiating activity at high micromolar concentrations on several 
cancer cell types.
366
 It was later determined that butyric acid is a millimolar HDAC 
inhibitor, and this observation is thought to explain its mechanism of action.  
Others short-chain fatty acids such as sodium phenylacetate (16), sodium 
phenylbutyrate (17), and the anticonvulsant valproic acid (18) have also been 
identified as antiproliferative agents and HDAC inhibitors.
367
 Despite poor 
enzymatic inhibitory activity, a number of carboxylates, including butyric (19) and 
phenylbutyric acid (20), have undergone phase II clinical trials for cancer treatment 
alone and in combination with other agents.
368
 However, the application of these 
acids in cancer therapy has been limited by their low potency (requiring millimolar 
drug concentrations in plasma) and rapid clearance, requiring continuous 
administration of high doses to achieve suitable plasma concentrations. 
Valproic acid (VPA) is a short-chain fatty acid that has been used in clinic for the 
treatment of epilepsy. VPA, after the finding as HDACi,
369
 has been extensively 
tested as a monotherapy, but also in combination with other anticancer modalities. In 
phase I clinical trials, patients with acute myeloid leukemia or myelodysplastic 
showed an improvement of 24%.
 
In separate studies, to patients who had acute 
myeloid leukemia or high-risk myelodysplastic syndrome were administered the 
combination therapy of the azacitidine, all-trans retinoic acid, and VPA. The study 
reported significant clinical activity and a safe combination. Phase I clinical studies 
have also been performed on solid malignancies.
370,371 
6.2.7.4. Benzamides  
Among non hydroxamate HDAC inhibitors there are O-Aminoanilides (Figure 6.15), 
indeed Suzuki and co-workers identified MS-275 (19) from a set of synthetic 
benzamide derivatives.
372 
MS-275 inhibited HDACs with an IC50 of 4.8 μM and 
showed significant oral anticancer activity without severe side effects in animal 
models.
373 
Phase I clinical studies were performed in patients with relapsed or 
refractory acute myeloid leukemia or refractory solid tumors. Results demonstrated 
safety and were well tolerated up to 8 mg/m
2
. Dose-limiting toxicities were 
reversible with no long-term adverse outcomes. Common low-grade toxicities 
included nausea/vomiting, constipation, fatigue, and cytopenias. HDAC inhibition 
was observed in peripheral blood mononuclear cells (PBMCs), and pharmacokinetic 
analysis suggested a 39 to 80-hour half-life.
374-376  
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Figure 6.15. Benzamides. 
CI-994 (20) is an acetylated derivative of dinaline that inhibits HDAC1 with IC50 
of 0.57 μM and causes G1 cell cycle arrest. Several data using CI-994 in the 
treatment of advanced NSCLC (Non-small-cell lung cancer) patients are available. In 
a phase II trial, CI-994 at the continuously oral daily dose of 8 mg/m
2
, was 
administered to 32 pretreated NSCLC patients. Two patients achieved a partial 
response, eight a stable disease lasting more than 8 weeks. CI-994 treatment was 
well-tolerated.
377
 Further evaluation investigated CI-994 in a phase II randomized 
trials in NSCLC patients but in association with gemcitabin.
378 
Currently CI-994 is in 
Phase III clinical trial in patients with lung cancer.
339 
MGCD0103 (Mocetinostat 21) MGCD010 is an isoform-selective aminophenyl 
benzamide that inhibits HDAC classes I and IV, with almost no effect on class II.
379 
The compound is currently in Phase I combination clinical trial with Docetaxel for 
solid tumors, Phase I/II combination trials with Azacitidina for hematological 
malignancies and with Gemcitabine for pancreatic cancer and Phase II clinical trials 
in hematological malignancies.
339 
6.2.7.5. Sirtuin inhibitors 
Initially research’s effort to find out sirtuin inhibitors were focus on the evaluation 
of substrate or product mimetics. Nicotinamide (20), one product of sirtuins 
deacetylation reaction, is a physiological inhibitor of Sir2 with a Ki value of 50 M. 
In a screening of nicotinamide analogs no potent inhibitor was identified.
380  
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Figure 6.16. Sirtuin inhibitors. 
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Inhibitors based on peptides have been actively pursued. Zheng and coworkers 
incorporate an N-thiocetyl lysine into an 18-residue peptide derived from C-terminal 
region of human p53 protein, leading to 21 (Figure 6.16) which inhibited SIRT1with 
an IC50= 2 M.
381 
Thioacetyllysine derived inhibitors have been demonstrated to be 
potent general sirtuin inhibitors as shown by numerous studies. The mechanism of 
action for inhibitors bearing a thioacetyl lysine was investigated by mass 
spectrometry and crystal structure studies. Incubation of enzyme with NAD
+
 and 
thioacetyllysine peptide led to slower enzymatic turnovers; it has been proposed that 
the thioacetyl analogues follow the same reaction coordinate as their acetyl 
counterparts but form stalled thioimidate intermediate.
382 
Kiviranta
 
et al. in their 
study investigated short peptides based on the protein sequence of human p53 and -
tubulin bearing the N-thioacetyl lysine, and possessing a sub-micromolar IC50. 
Generally were more potent the petides derived from the p53 sequence. Remarkably 
truncation of the pentapeptides into a tripeptides enhanced the selectivity toward 
SIRT2.
383 
Suzuki and colleagues discovered a non- peptide sirtuin inhibitor (22) in 
which the peptide backbone was simplified and replaced by a N-thioacetyl lysine. 
This compound selectively inhibited SIRT1 in the micromolar range and induced a 
dose- response acetylation of p53 in HCT116 cells.
384
  
In a cell-based screen, Grozinger et al. discovered another sirtuin inhibitor, 
Sirtinol (2-[(2-hydroxynaphthalen-1-ylmethylene)-amino]-N-(1-phenyl-ethyl)-
benzamide) (23) that inhibited both yeast Sir2 and human SIRT2 activity in vitro. 
The 2-hydroxyl-1-napthol moiety was demonstrated to be sufficient for inhibition.
385 
Sirtinol induced senescence-like growth arrest in human breast cancer MCF-7 and 
lung cancer H1299 cells.
386
 Moreover, Sirtinol treatment also reduced inflammation 
in human dermal microvascular endothelial cells, modulating the expression of 
adhesion molecules and monocyte adhesion in primary human dermal microvascular 
endothelial cells.
387 
 
Through an extensive SAR study, Mai and colleagues identified Salermide (24), a 
reverse amide m-sirtinol analogue, with a more potent inhibitory effect than sirtinol 
against human SIRT1 and SIRT2. Salermide was well tolerated by mice at 
concentrations up to 100 M and induced p53-independent apoptosis in cancer but 
not in normal cells, by reactivation of proapoptotic genes that had been 
epigenetically repressed exclusively in cancer cells by SIRT1.
388
 
Cambinol (25) showed micromolar inhibitor activity against SIRT1 and SIRT2 
without relevant activities toward SIRT3 and SIRT5. It was well tolerated in mice 
and inhibited growth of Burkitt lymphoma xenografts, inducing apoptosis via 
hyperacetylation of BCL6 oncoprotein and p53.
389 A SAR study indicated that the β-
naphthol moiety is crucial to cambinol's inhibitory activity. Incorporation of either 
methyl or fluoro substituents on the phenyl ring of cambinol resulted in SIRT1 
selective inhibitors with equal cambinol’s potency. Substitutions on the N-1 position 
provided SIRT2 selective inhibitors.
390
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Suramin (26) was discovered as a potent SIRT1 inhibitor during a screening for 
sirtuin activators using a fluorescence based deacetylation assay.
391
 Suramin is a 
symmetric polyanionic naphthylurea. Further structure–activity studies identified 
several suramin analogues as selective inhibitors of SIRT1 and SIRT2 with 
nanomolar potency.
392 
Unlike cambinol, Suramin is a more potent inhibitor towards 
SIRT5 NAD
+
-dependent deacetylase activity, with an IC50 value of 22 M. The X-
ray structure of SIRT5 bound to suramin suggested that the interaction between 
suramin, the nicotinamide binding pocket and the acetyllysine binding cleft is 
responsible for its inhibitory effect on this enzyme.
393 
 
Splitomicin (27) was discovered in a cell-based screening for inhibitors of the 
yeast Sir2 and showed an IC50 of 60 M.
394
 However, splitomicin showed rather 
weak inhibition on human SIRT1. HR73 (28), a splitomicin analog which contains a 
phenyl group at position 2, was reported to inhibit SIRT1 with an IC50 value of less 
than 5 M.395 These observations suggest that position 2 of splitomicin is a 
promising site for further SAR study. 
EX-527 (29) is an indol derivative discovered by in vitro HST screening using a 
fluorescent assay. It inhibits SIRT1 (IC50= 98nM) 100-fold more potently than 
SIRT2 and SIRT3.
396
 EX-527, as expected, increased the acetylation level of p53, 
but it failed to affect cell survival after DNA damage.
397 
Evaluation of the 
stereochemistry of position 1 indicated that the S enantiomer is the active isomer. In 
addition, EX-527 showed no activity against NADase, and NAD
+
-hydrolyzing 
enzyme. In a recent study, Gertz et al. explain the mechanism of Sirtuin inhibition by 
Ex-527, collecting a set of Sirtuin/ligand crystal structures together with activity and 
binding data.
398
 
Kazantsev and colleagues identified, through an in vitro screening employing 
fluorometric assays, a selective SIRT2 inhibitor AGK2 (30) with IC50= 3.5 μM. A 
follow-up assay showed hyperacetylation of α-tubulin, a SIRT2 physiological 
substrate, upon cell treatment with AGK2. In a Parkinson disease model, AGK2 
rescued dopamine neurons from α-synuclein toxicity in a dose-dependent manner. 
This study suggests that pharmacological inhibition of SIRT2 is a promising strategy 
for the treatment of Parkinson’s disease.399,400 
SRT1720 (31), was initially described as an activator for human SIRT1. 
Recentlty, Nguyen et al. confirm that SRT1720 is able to inhibit human SIRT3 with 
an IC50= 11M.
401
 To identify the hSIRT3 binding site for SRT1720 and to reveal 
the compound’s inhibition mechanism, the crystal structure hSirt3/carba-
NAD
+
/SRT1720 complex was solved. The complex structure indicates the 
compound’ s molecular inhibition mechanism, rationalizing its un-competitive 
inhibition behavior with NAD
+
. SRT1720 forms a tightly packed π-stacking 
sandwich with Phe157 and NAD
+
. All these findings can provide a structural basis 
for compound improvement and selective hSIRT3 inhibitors.
402
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Based on the rationale that ATP and NAD
+ 
share the adenosine moiety, Jung and 
collegues tested a series of known kinase and phosphatase inhibitors, using a 
homogeneous fluorescent assay, and identified several sirtuin inhibitors including 
GW5074 (32).
403
 In a recent study, carried out by Suenkel et al., it has been found 
that GW5074 is able to inhibit Sirt5 desuccinylation activity with an IC50 of 20 M; 
so a first pharmacological scaffold has been identified in order to develop Sirt5 
specific inhibitors.
404
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7. Histone methylation 
Histone methylation occurs on all basic residues: arginines, lysines and histidines. 
Lysines can be mono-, di- or trimethylated on their ε-amine group,405,406 arginines 
can be monomethylated, symmetrically dimethylated or asymmetrically dimethylated 
on their guanidinyl group, and histidines have been reported to be monomethylated, 
although this methylation appears to be rare and has not been further 
characterized.
407,408
 The most extensively studied histone methylation sites include 
histone H3 lysine 9 (H3K9), H3K4, H3K27, H3K36, H3K79 and H4K20. Sites of 
arginine (R) methylation include H3R2, H3R8, H3R17, H3R26 and H4R3. However, 
many other basic residues beside the histone proteins H1, H2A, H2B, H3 and H4 
have also recently been identified as methylated by mass spectrometry and 
quantitative proteomic analyses. Histone methylation had been thought to be an 
irreversible process until the discovery of an H3K4 demethylase, lysine-specific 
demethylase 1A (KDM1A or LSD1), revealed that histone methylation is, in fact, 
reversible.
409,410
 Up to now, a large number of methyltransferases and demethylases 
have been identified. Unlike acetylation, which eliminates the lysine’s positive 
charge and generally correlates with transcriptional activation, lysine methylation 
preserves the positive charge on the lysine side chain and can act as either activating 
or repressing signal, depending on the sites of methylation.
411 
This chapter will focus 
specifically on the histone lysine methylation and demethylation pathways.  
7.1. Histone lysines methyltransferases 
Three families of enzymes have been identified thus far that catalyse the addition of 
methyl groups donated from S-adenosylmethionine (SAM) to histones. The SET-
domain-containing proteins and DOT1-like proteins, have been shown to methylate 
lysines, and members of the protein arginine N-methyltransferase (PRMT) family 
have been shown to methylate arginines (Table 7.1). These histone 
methyltransferases have been reported to methylate histones that are incorporated 
into chromatin and also free histones and non-histone proteins. Except for the 
H3K79-specific DOT1L methylase, all known lysine methyltransferases (KMTs) 
have a conserved catalytic SET (Suppressor of variegation, Enhancer of Zeste, 
Trithorax) domain harboring the enzymatic activity. 
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Histone and residue Homo sapiens 
me3 me2 me1 
H3R2  CARM1 CARM1 
  PRMT6 PRMT2 
  PRMT5 PRMT5 
  PRMT7 PRMT7 
H3K4 SETD1A SETD1A SETD1A 
 SETD1B SETD1B SETD1B 
 ASH1L MLL ASH1L 
 MLL MLL2 MLL 
 MLL2 MLL3 MLL2 
 MLL3 MLL4 MLL3 
 MLL4 SMYD3 MLL4 
 SMYD3  SETD7 
 PRMD9   
H3R8  PRMT5(s) PRMT5 
H3H9 SUV39H1 SUV39H1 SETDB1 
 SUV39H2 SUV39H2 G9a 
 SETDB1 SETDB1 EHMT1 
 PRDM2 G9a PRMD2 
  EHMT1  
  PRMD2  
H3R17  CARM1(a) CARM1 
H3R26  CARM1(a) CARM1 
H3K27 EZH2 EZH2  
 EZH1 EZH1  
H3K36 SETD2 NSD3 SETD2 
  NSD2 NSD3 
  NSD1 NSD2 
  SMYD2 NSD1 
  SETD2  
H3K79 DOT1L DOT1L DOTL1 
HAR3  PRMT1(a) PRMT1 
  PRMT6(A) PRMT6 
  PRMT5(s) PRMT5 
  PRMT7(s) PRMT7 
H4K20 SUV420H1 SUV420H1 SETD8 
 SUV420H2 SUV420H2  
Table 7.1. Histone (H) methyltransferases for various lysine (K) and arginine (R) residues. 
Trimethylation (me3); dimethylation (me2); monomethylation (me1); asymmetric (a) or symmetric (s) 
dimethylation. 
7.1.2. MLL1  
The mixed lineage leukemia (MLL1) gene is a frequent target for recurrent 
chromosomal translocations found in lymphoid and myeloid leukemias.
412 
MLL is a 
large multi-domain protein with several putative DNA-binding domains at the N-
terminus and a C-terminal SET domain specific for H4K3me1/2/3. More than 50 
functionally diverse MLL-fusion proteins have been identified in human leukemias. 
MLL-fusion proteins may induce leukemogenesis by misregulating genes important 
for proliferation and differentiation of hematopoietic cells. During normal 
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hematopoiesis, expression of HoxA7, HoxA9 and HoxA10 promote stem cell self-
renewal, and the downregulation of these genes correlates with terminal 
differentiation.
413
 In mouse and human leukemias however, these genes are 
frequently overexpressed together with Meis1, HOX co-factor. Indeed, in mice 
MLL-fusion mediated transformation requires HoxA7 and HoxA9, and forced 
expression of HoxA9 and Meis1 is sufficient to induce acute myeloid leukemia.
414 
The most frequent MLL translocation partners, are AF4, AF9, ENL, AF10 and AF6. 
AF10 has been found to interact with the non-SET histone methyltransferase 
DOT1L. DOT1L and its HMT activity are required for transformation by MLL-
AF10. Direct fusion of enzymatical active DOT1L to MLL enables immortalization 
of myeloid progenitor cells. In cells transformed by either MLL-AF10 or MLL-
DOT1L, HoxA9, HoxA7 and Meis1 are upregulated. Indeed, HoxA9 is required for 
immortalization of bone marrow progenitor cells. Upregulation of HoxA9 coincides 
with H3K79 hypermethylation and reduced H3K4me2 levels associated with the 
HoxA9 gene, suggesting that mistargeting of DOT1L contributes to upregulation of 
leukemia-relevant genes. 
415 
Beside MLL1, the mammalian MLL family consists of four other members, MLL2-
5. The family shares a distinct SET domain, which in MLL1-4 encodes the H3K4 
methylation activity. MLL1 and MLL2 are highly homologous and form similar 
KMT complexes, which are distinct from MLL3/MLL4 complexes. Mutations and 
amplifications in MLL2, MLL3 and MLL4 have also been implicated in 
tumorigenesis. MLL5 is a distantly related family member and it seems to lack KMT 
activity. 
416,417 
7.1.2. The NSD family 
The NSD (Nuclear receptor SET-Domain) family is implicated in different human 
malignancies. The NSD proteins are related to the Saccharomyces cerevisae SET2 
HMT, which has been shown to repress transcription through the interaction with the 
phosphorylated C-terminal domain of RNA polymerase II.
418
 The members of this 
family NSD1 and NSD2 catalyze H3K36 methylation a modification that is enriched 
in the body of actively transcribed genes.
419 
Together with the results suggesting that 
SET2 works as a transcriptional repressor, these data suggest that H3K36 
methylation participates in suppressing erroneous transcriptional initiation inside 
actively transcribed genes. 
NSD1 is a large protein containing several motifs involved in transcriptional 
regulation, including a SET domain and five PHD fingers. Still there is a lack of 
information regarding the mechanism and role of this protein in cell proliferation and 
differentiation. However NSD1 is required for normal development, since 
homozygous mutant Nsd1
−/−
 embryos die during gastrulation displaying high levels 
of apoptosis.
420
 Recently has been demonstrated that in mice the NUP98-NSD1 
fusion protein can be a driving oncogene in acute myeloid leukemia.
421
 Expression of 
the fusion protein is sufficient for sustaining the self-renewal of myeloid stem cells in 
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vitro and to enforce the expression of the HoxA7, HoxA9, HoxA10 and the Meis1 
proto-oncogenes.  
The NSD2 protein contains a SET domain, a PHD finger, a PWWP domain and an 
HMG box. Various activities have been associated with NSD2, including the ability 
to trimethylate H3K4 and H4K20, to mono- and trimethylate H3K27, and to mono-, 
di- and trimethylate H3K36. Of these activities, the trimethylation of H3K36 appears 
best supported by in vivo observations. In contrast to S. cerevisae SET2, NSD2 
protein showed a really weak interaction with RNA polymerase II but interacted with 
several developmental transcription factors and chromatin modifying enzymes such 
as HDAC1, HDAC2, SIN3A and LSD1. These data suggest that NSD2 is part of a 
co-repressor complex, which regulate cell fate decisions.
422,423
 
NSD3 is genetically amplified in a few cases of breast carcinomas and expressed in 
acute myeloid leukemia as fusion protein NUP98–NSD3. The high homology in the 
conserved domains between NSD3 and its two relatives, suggests that NSD3 most 
likely catalyzes the methylation of H3K36.
424,425
 
7.1.3. Polycomb group proteins 
At the molecular level, PcG proteins act through the concerted function of at least 
two distinct classes of multimeric complexes, termed Polycomb Repressive 
Complexes (PRCs). The catalytic subunit of this complex is EZH2 (Enhancer of 
Zeste 2) which is highly conserved and can catalyze di- and trimethylation of H3K27 
but is dependent on the other complex members EED and SUZ12.
426,427
 PRC1 
consists of Ring1B, Bmi1, PH1 and CBX4, it binds to the H3K27 methylation mark 
and mediates H2A ubiquitination. Together, through the histone modification, PRC1 
and PRC2 implement and maintain transcription silencing. EZH2 was found to be 
significantly upregulated in metastatic prostate cancer suggesting that EZH2 levels 
could serve as a prognostic indicator of clinical outcome of prostate cancer patients. 
EZH2 was also significantly increased in invasive carcinoma and breast cancer 
metastases compared to normal breast tissues.
428 
More recently, somatic mutations in 
EZH2 leading to the replacement of a single tyrosine in the SET domain of EZH2 
protein (Tyr 641) have been found in the follicular lymphoma and the germinal 
centre B cell subtype of diffuse large B-cell lymphoma cases.
429 
7.1.4. G9a and other histone methyltransferases 
G9a and GLP are members of the Suv39h subgroup of SET domain-containing 
molecules, and together they are the key HKMTs for H3K9me1 and H3K9me2. G9a 
is a major H3K9me1 and H3K9me2 HKMT of euchromatin. It is also involved in 
H3K9me3 modification in vivo and it has been shown recently that G9a is indeed 
involved in H1 and H3K27 methylation in vivo.
430-432
 GLP was in initially described 
as a gene encoding a G9a like protein. Later various studies have demonstrated that 
GLP and G9a possess the same substrate specificities on histones. Tachida and 
colleagues reported that the double knock out of G9a and GLP does not further 
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reduce H3K9me1 and H3K9me2 levels. Moreover, through biochemical 
characterization of G9a and GLP, they showed that G9a and GLP can form a 
homomeric and heteromeric complex via their SET domains and that the G9a-GLP 
heteromeric complex seems to be the functional H3K9 HKMT in vivo.
430 
In 
Neurospora, H3K9 methylation controls DNA methylation.
433
 There are different 
studies that report functional links between H3K9 methylation and DNA methylation 
in mammals as well.
434 
G9a and GLP have also both been found to be up-regulated in 
various types of human cancer cells, indeed knockdown of G9a suppresses tumor cell 
growth in vitro and the invasion of cancer cells in nude mice.
435,436 
Suv39h1 represents the first histone methyltransferase that was identified and 
characterized in 2000.
437 
Suv39h1 is one of the two mammalian orthologs of the 
Drosophila Su(var)3-9. The other homolog has been named Suv39h2 and both 
Suv39h1 and Suv39h2 direct trimethylation of H3K9 at pericentric 
heterochromatin.
438,439
 Differential expression profiles of Suv39h1 were found in 
colorectal cancers versus normal colorectal mucosa.
289,440
 Moreover in a study of 
NiIeles et al. is reported that the interaction of Suv39h1 with the retinoblastoma 
protein (pRB) is disrupted in cancers with RB1 mutations.
441
  
The pRB-interacting zing finger gene (RIZ1) is a tumor suppressor that also 
methylates histone H3K9. The protein was initially identified as an interaction 
partner of the retinoblastoma protein (PR). An intact PR domain is known to be 
important for RIZ1 tumor suppressor function in mice.
442
 Naturally occurring 
mutations in the PR domain that altered its tumor suppressor function also 
inactivated its HMT activity suggesting a role for the HMT activity of RIZ1 in many 
human cancers including liver,breast and gastric cancers.
443,444 
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7.2 Histone lysine demethylases 
Lysine-specific demethylases (KDMs) work in coordination with histone lysine 
methylases to maintain global histone methylation patterns (Figure 7.1).
444
 
Figure 7.1. Histone lysine methylation patters. Lighter shades: monomethylation by KMTs or 
demethylation of mono and di-methylated lysine. Darker shades: mono-, di-, tri-methylation by KMTs 
or demthylation of di- and tri-methylated lysine residues by KDMs.
  
Thus far two evolutionarily conserved families of histone demethylases, which 
utilize different reaction mechanisms to establish demethylation, have been 
identified. One are the amine oxidases LSD1/2 and the other the iron- and -
ketoglutarate dependent JmJC-domain containing proteins (Table 7.2).
444 
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Histone 
demethylases 
Other 
names 
Histone 
substrates 
Association with human disease 
LSD1 
KDM1A, 
AOF2, 
BHC110 
H3K4me2/1 
H3K9me2/1 
-Overexpressed in prostate cancer, 
undifferentiated malignant 
neuroblastoma, oestrogen-receptor-
negative breast cancer, bladder 
cancer, lung carcinoma and 
colorectal carcinoma  
-Silenced or downregulated in 
breast cancer  
LSD2 
KDM1B, 
AOF1 
H3K4me2/1 
Amplified and overexpressed in 
urothelial carcinoma 
JMJD1A  
KDM3A, 
JHDM2A, 
TSGA  
H3K9me2/me1  
Overexpressed in malignant 
colorectal cancer, metastasized 
prostate adenocarcinoma, renal cell 
carcinoma and hepatocellular 
carcinoma  
JMJD1B  KDM3B  H3K9me2/me1 - 
JMJD1C   H3K9me2/me1 Target of MLL–AF4  
JMJD2A  
KDM4A, 
JHDM3A  
H3K9me3/2 
H3K36me3/2 
H1.4K26me3/2 
-Silenced or downregulated in 
bladder cancer  
-Overexpressed in breast cancer 
JMJD2B  
KDM4B, 
JHDM3B  
H3K9me3/me2  
H3K36 me3/me2 
H1.4K26 
me3/me2  
Overexpressed in malignant 
peripheral nerve sheath tumour 
JMJD2C  
KDM4C, 
JHDM3C, 
GASC1  
H3K9me3/me2  
H3K36me3/me2  
H1.4K26me3/me2 
-Amplified in oesophageal cancer, 
breast cancer and medulloblastoma  
-Translocated in lymphoma1  
JMJD2D  
KDM4D, 
JHDM3D  
H3K9me3  - 
JMJD3  KDM6B H3K27me3/me2 
-Overexpressed in various cancers 
including lung and liver 
carcinomas and several 
haematological malignancies  
-Overexpressed in neutrophils of 
patients with ANCA-associated 
vasculitis  
-Overexpressed in primary 
Hodgkin’s lymphoma  
UTX  KDM6A  
H3K27me2, 
H3K27me3  
-Mutated in multiple tumour types 
including multiple myeloma, 
oesophageal squamous cell 
carcinoma, renal clear cell 
carcinoma, transitional cell 
carcinoma and chronic 
myelomonocytic leukaemia  
-Overexpressed in breast cancer  
-Deleted in Kabuki syndrome  
UTY  - - - 
JMJD4  - - - 
JMJD5  KDM8  H3K36me2 - 
JMJD6 - H3R2, H4R3 - 
66 |Histone methylation 
 
JMJD7  - - - 
JMJD8  - - - 
FBXL11  
KDM2A, 
JHDM1A  
H3K36me2/1 - 
FBXL10  
KDM2B, 
JHDM1B  
H3K36me2/1 
H3K4me3 
Overexpressed in various 
leukaemias and bladder carcinoma  
KIAA1718  
KDM7A, 
JHDM1D  
H3K9me2/1 
H3K27me2/1  
- 
PHF2  JHDM1E  H3K9me2  
Mutated, silenced or 
downregulated in breast carcinoma 
as well as head and neck squamous 
cell carcinoma 
PHF8  JHDM1F  
H3K9me2/1  
H4K20me1  
Mutation and deletion associated 
with X-linked mental retardation 
and cleft lip/palate  
JARID1A  
KDM5A, 
JARID1A, 
RBP2  
H3K4me3/2 
-Silenced, downregulated or 
deleted in melanoma  
-Translocated in acute leukaemia  
-Mutated in ankylosing spondylitis  
JARID1B  
KDM5B, 
PLU1  
H3K4me3/2 
Overexpressed in bladder cancer, 
prostate cancer and breast cancer  
JARID1C  
KDM5C, 
SMCX  
H3K4me3/2 
-Mutated in intellectual disability  
-Mutated in autism  
-Mutated in renal carcinoma  
JARID1D  
KDM5D, 
SMCY  
H3K4me3/2  Deleted in prostate cancer  
JARID2  - - - 
HIF1AN  - - - 
HSPBAP1  - - - 
HR  - - - 
NO66  - 
H3K4me3/2 
H3K36me3/2  
Overexpressed in non-small-cell 
lung cancer 
MINA  - - 
Overexpressed in non-small-cell 
lung cancer 
Table 7.2. Histone Lysine Demethylases (KDMs): specificity and role in human diseases.  
ANCA, anti-neutrophil cytoplasmic antibody; FBXL10, F-box and leucine-rich repeat protein 10; 
HIF1AN, hypoxia-inducible factor 1α inhibitor; HR, hairless homolog; HSPBAP1, HSPB1 (27 kDa 
heat shock protein)-associated protein 1; JARID, Jumonji/ARID domain-containing protein; JMJD, 
Jumonji domain-containing protein; LSD1, lysine-specific demethylase 1; MINA, MYC-induced 
nuclear antigen; MLL, mixed lineage leukaemia; NO66, nucleolar protein 66; PHF2, PHD finger 
protein 2; UTX, ubiquitously transcribed TPR protein on the X chromosome; UTY, ubiquitously 
transcribed TPR protein on the Y chromosome.  
7.2.1. LSD demethylases 
LSD1 is a FAD-dependent amine oxidase which was first characterized by Shi et al. 
in 2004.
410
 This enzyme is able to remove methyl groups from histone 3 lysine 4 
when mono- or di-methylated (H3K4me1/2) at the ε-position, but not the 
trimethylated lysine. One year later from its discovery, Metzger et al. demonstrate 
that the substrate specificity of LSD1 can change to mono- or di-methyl H3K9 
(H3K9me1/2) when co-localizing with the androgen receptor (AR).
445 
In addition, 
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LSD1 can demethylate non-histone targets, such as K370me1 and K370me2 on 
p53,
446
 Lys1096 on DNA methyltransferase 1 (DNMT1)
447
 and Lys185 on E2F1.
448
 
The other LSD family member, LSD2, has so far only been shown to demethylate 
H3K4me1 and H3K4me2.
449 
7.2.1.2. LSD1  
LSD1 is typically associated with a transcriptional corepressor protein (CoREST) 
and histone deacetylase (HDAC) 1 or 2, forming a stable core subcomplex recruited 
by many chromatin remodeling multiprotein complexes.
450 
However, LSD1 is also 
involved in some gene activation processes, thus highlighting its multifaceted 
function in chromatin regulation. Moreover LSD1 participates in several growth 
promoting pathways, and it is upregulated in certain high-risk tumors.
451,452
 An 
important feature in the LSD1-mediated demethylation process is the mechanism for 
substrate recognition. The crystal structure of the LSD1-CoREST-histone peptide 
ternary complex reveals that the peptide binds to the amine oxidase domain (Figure 
7.2),
453
 adopting a folded conformation that enables the binding site to accommodate 
the relatively long stretch of the N-terminal H3 tail. Biochemical evidence indicates 
that substrate recognition by LSD1 requires a peptide comprising at least the first 20 
N-terminal amino acids of H3. This ability of recognizing a “long” and “heavily 
charged” segment of the histone N-terminal tail enables LSD1 to detect the presence 
of multiple post-translational modifications written in the H3 tail. Indeed some 
evidence show that the charge distribution on the histone N-terminal tail appears to 
be determinant in the readout of the histone code by LSD1, for example Lys9 
deacetylation significantly improves LSD1 activity mainly through an increase in 
substrate affinity.
454  
Figure 7.2. Structural biology of LSD1 in complex with CoREST and a peptide substrate. 
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As a member of monoamine oxidase (MAO) family, LSD1 catalyzes the specific 
demethylation of mono- or dimethylated histone H3 lysine 4 (H3K4) and H3 lysine 9 
(H3K9) via a redox process. The reason why LSD1 is not able to demethylate a 
trimethyl lysine is caused by the FAD dependent catalytic mechanism. This is limited 
by the initial step, the oxidation of the ε-amine to form an iminium intermediate with 
the concurrent reduction of the flavin. The intermediate can then be attacked by a 
water molecule close to the iminium ion to react to an unstable hemiaminal 
intermediate which decomposes into formaldehyde and the demethylated H3K4. The 
reduced FADH2 is reoxidized by oxygen in a subsequent step to form FAD and 
hydrogen peroxide. The lysine residue requires a lone electron pair that can be 
protonated and then form the iminium intermediate. Thus, a trimethylated lysine 
cannot be demethylated by LSD1/2 (Figure 7.3).
455 
 
 
Figure 7.3. LSD1 reaction mechanism. 
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7.2.1.2.1. LSD1 crystal structure 
In 2006 Chen et al. solved the crystal structure of LSD1.
456
 The structure of LSD1 
contains three domains. Two of them, the SWIRM (residues 172-270) and AOL 
(residues 271-417 and 523-833) domains, pack together through extensive 
interactions resulting in a globular structure. The SWIRM domain consists mostly of 
α-helices and is a newly identified structural module often found in chromatin-
associated proteins. The AOL domain folds into a compact structure that exhibits a 
topology found in several flavin-dependent oxidases. It contains a large insertion 
(residues 418-522) that forms an additional domain and adopts a tower-like structure 
(Tower domain) protruding away from the AOL domain by 75 Å. The Tower 
consists of a pair of long helices that adopts a typical antiparallel coiled-coil 
conformation (Figure 7.4A and 7.4B).
457
 
Figure 7.4. (A) Ribbon diagram of the LSD1 structure. (B) Domain organization of LSD1. 
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The SWIRM domain of LSD1 is characterized by a long helix, SW4, in the 
center surrounded by five other helices, moreover it has an additional two-stranded 
-sheet formed between the SW4-SW5 loop and the C terminus of the SWIRM 
domain (Figure 7.5A).  
Figure 7.5. A) Ribbon diagram of the SWIRM domain. B) A three-amino-acid motif (F264G265I266) 
of the SWIRM domain mediates the interactions between the SWIRM (blue) and AOL (green) 
domains. C ) and D) Superposition of the LSD1 SWIRM domain (green) with those of Swi3 (red) and 
Ada2 (blue). 
The LSD1 SWIRM domain is structurally most similar to those of the chromatin-
remodeling proteins Swi3 and ADA2. The three SWIRM domains have very 
similar hydrophobic core packing but SW1 and SW2, which are not conserved, 
are positioned further away from the hydrophobic core (Figure 7.5C and D). The 
SWIRM domain is located far away from both the FAD-binding site and the catalytic 
center of LSD1 (Figure 7.4A). The -sheet helps anchor the SWIRM and AOL 
domains by forcing the SW6–SW2 loop to protrude out into a hydrophobic pocket 
formed by helices F1, F2, F3, and F8 of the AOL domain (Figure 7.5B). A 
three-amino-acid motif (F264-G265-I266) between SW6 and SW2 anchors the 
binding through extensive interactions with the AOL domain, involving both 
hydrophobic contacts and hydrogen bonding interactions (Figure 7.5B). The side 
chains of F264 and I266 and the main chain C atom of G265 stack against a 
hydrophobic pocket from the AOL domain. These hydrophobic contacts are 
reinforced by extensive hydrogen-bonding interactions between the backbone of this 
motif and the side chains of R295 and Q348. The SWIRM-AOL packing buries a 
total surface area of 1.115 Å
2
, and the residues that form the interface are highly 
conserved across species. 
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The AOL domain of LSD1 folds into two well defined subdomains, one to bind 
the FAD and the other one to identify and interact with the substrate (Figure 7.6). 
Figure 7.6. Ribbon diagram of the AOL domain in LSD1. 
The FAD-binding subdomain has three fragments (residues 271-356, 559-657, and 
770-833) and adopts a mixed  structure. The substrate-binding subdomain 
comprises three fragments (residues 357-417, 523-558, and 658-769) and is 
characterized by a six-stranded mixed -sheet flanked by six -helices. The two 
subdomains create a big cavity that defines the enzyme activity center at their 
interface. The catalytic cavity is framed by many structural elements that surround 
the catalytic center: a six-stranded -sheet (S1 and S6-S9) and a long helix (S3) 
form the left side and the bottom surfaces, respectively, whereas a short one-turn 
helix (S4), a two-stranded -sheet (F5-F7), and several loops with variable 
lengths cover the rest of the cavity (Figure 7.6). The cavity goes deep into the 
protein, extending for a length of 23 Å from its entrance to the core of the catalytic 
site where the flavin ring is located (Figure 7.7). Inside the active site cavity, there 
are four major invaginations with distinct chemical properties that could be used for 
the specific binding of side chains. Furthermore, it seems plausible that these pockets 
can sense not only the histone tail sequence but also its chemical modifications.
410
 
The first pocket exposes the isoalloxazine ring of the FAD cofactor and forms the 
catalytic chamber of LSD1. 
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The residues that create this hydrophobic chamber and lie close to the isoalloxazine 
ring are Val317, Gly330, Ala331, Met332, Val333, Phe538, Leu659, Asn660, 
Lys661, Trp695, Ser749, Ser760 and Tyr761 (Figure 7.8). These residues are 
required for the exact positioning of both the FAD cofactor and the substrate lysine. 
In other oxidases, the isoalloxazine ring is usually found in conjunction with a 
positively charged residue, which is required for proper FAD binding and 
stabilization of the anionic form of the reduced cofactor. In LSD1 the residue that 
fulfils this function is Lys661. The remaining three pockets of the active site cavity 
are probably required for the binding of histone tail residues directly adjacent to the 
substrate lysine. Compared with other flavin-dependent oxidases, as PAO (maize 
polyamine oxidase), LSD1 has a unique structural feature. 
Figure 7.7. Three-dimensional representation of the catalytic cavity. 
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Figure 7.8. Location of the various pockets within the active site cavity. 
 
Figure 7.9. A) Superposition of LSD1 (cyan) on the structure of PAO (blue). The Tower domain of 
LSD1 is colored in yellow. B) Superposition of the AOL domain of LSD1(cyan and purple) on the 
structure of PAO ( blue and orange) highlighting the differences in the catalytic cavity. 
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Although the similarity is evident in the FAD-binding subdomain, the structure of 
LSD1 substrate-binding subdomain differs from that of PAO in several aspects (Fig. 
7.9A and B). LSD1 comprises a long insertion between S2 and S3 and contains a 
large catalytic cavity between the FAD- and substrate-binding subdomains with a 
volume of 1.245 Å
3
. In contrast, the catalytic center of PAO is located in a narrow U-
shaped tunnel with a significantly smaller volume (716 Å
3
).
456 
The difference in the 
shape of the substrate-binding site reflects the different substrate specificities of the 
two enzymes; indeed the substrates of LSD1 are methylated histone peptides which 
are bulkier than the linear-shaped substrates of PAO, like spermidine.
457 
Furthermore 
the two diagonally interacting helices, S1 and S3, form a highly acidic flat surface 
at the entrance of the catalytic cavity, serving as an additional binding site for the 
basic histone H3 tail. Most of the residues forming this surface and the catalytic 
cavity are highly conserved not only among LSD1 orthologs in different species but 
also in LSD2, a close homolog of LSD1.
449  
The tower domain is formed by two long -helices, TA and TB, which pack 
against each other without coiling, forming a left-handed superhelix. The sequence of 
the Tower domain reveals a repeating pattern of seven residues, (abcdefg)n, the 
characteristic of coiled-coil proteins with hydrophobic amino acids predominating at 
positions a and d of the heptad repeat (Figure 7.10). A deletion mutant of LSD1 
(LSD1Tower), in which the Tower domain was deleted and replaced by a 
pentaglycine loop, wasn’t able to reduce the methylation level at K4. This result 
support the notion that the Tower domain is indispensable for the histone 
demethylase activity of LSD1. The Tower domain of LSD1 may also act as an 
adaptor to recruit other proteins. One of these proteins, CoREST, endows LSD1 with 
the ability to demethylate nucleosomal substrates and protects LSD1 from 
proteasomal degradation.
180
 The Tower domain of LSD1 is, by itself, sufficient for a 
stable interaction with CoREST. The fact that LSD1Tower does not interact with 
CoREST indicates that the SWIRM and AOL domains of LSD1 do not significantly 
contribute to the interaction with CoREST. Based on these observations it is possible 
to conclude that the tower domain of LSD1 contains the binding site for CoREST. 
Figure 7.10. Ribbon diagram of the coiled coil of the Tower domain. The amino acids at the d 
positions of the heptad repeat of the two helices are in space-filling representation and colored in red 
(T1) and purple (T2), respectively.  
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7.2.1.2.2. The role of LSD1 in gene activation and repression 
LSD1 transcriptional regulation remains confuse, essentially because LSD1 
associates with different complexes and it can function as co-repressor or co-
activator in a target specific manner. LSD1 has been found in different 
transcriptional complexes involved in transcription repression such as CoREST and 
NuRD. Consistent with its role in transcription repression, LSD1 demethylates 
monomethyl and dimethyl histone H3 lysine 4 (H3K4me1 and H3K4me2), which are 
marks of active chromatin transcription state. LSD1 has also been found to have a 
role in transcriptional activation as exemplified by the nuclear hormone receptors 
induced transcription (Figure 7.11).
498
 
Figure 7.11. LSD1-associated complexes and their demethylation targets. 
Recent studies report LSD1 in transcriptional activation mediated by nuclear 
receptors (the androgen and estrogen receptors, AR and ER) functioning as an H3K9 
demethylase.
451,452
 This function was firstly described by Metzger et al. who showed 
that activation of AR target genes requires LSD1-dependent histone H3K9 
demethylation. They demonstrated that, following hormone treatment, AR and LSD1 
colocalize on promoters and stimulate H3K9 demethylation without altering the 
H3K4 methylation status and promote ligand dependent transcription of AR target 
genes resulting in enhanced tumor cell growth.
445
 Consistently, LSD1 knock-down 
resulted in decreased activation of AR-responsive promoters. Recently, a genome-
wide analysis of LSD1 promoter occupancy following estrogen treatment of MCF7 
cells has revealed striking results regarding the activatory role of LSD1.
451
 LSD1 
occupies nearly 20 % of the total assayed promoters and 84 % of these promoters are 
associated with RNA polymerase II and additionally with activation markers such as 
dimethyl-H3K4 and acetyl-H3K9 suggesting that LSD1 is extensively involved in 
gene activation. The dual role of LSD1 in gene repression and activation is also 
demonstrated by the fine regulation of growth hormone expression during pituitary 
development.
447
 Activation of growth hormone expression is regulated by the 
transcriptional activator pituitary transcription factor 1 (Pit1) during the early phases 
through recruitment of a LSD1-containing mixed lineage leukemia 1 (MLL1) 
coactivator complex. Pit1 is later replaced by zinc finger E-box binding homeobox 1 
(ZEB1), a transcriptional repressor which recruits a co-repressor complex containing 
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C-terminal binding protein (CtBP), CoREST and LSD1, switching off growth 
hormone expression. Until now it is not clear how LSD1 functions as a H3K9 
demethylase in association with AR, ER or other transcription factors. Alternatively 
and more likely, other H3K9-specific histone demethylases could be recruited by 
LSD1 or by a LSD1-associated protein. In this case, LSD1 might act as a docking or 
adaptor module for different coactivator complexes that might contain a demethylase 
specific for H3K9. Indeed, it was observed that some chromatin-remodeling 
complexes contain both LSD1 and a H3K9 demethylase of the Jumonji-containing 
class JMJD2C.
458
 JMJD2C assembles into the AR complex and collaborates in AR-
target-gene transcription together with LSD1. In addition to its transcriptional 
regulation of individual genes, LSD1 plays an important role in interchromosomal 
interaction and nuclear rearrangement. Hu et al. showed that upon treatment of 
estrogen, LSD1 is recruited to distinct interchromatin granules, long thought to serve 
as “storage” site for the splicing machinery, some transcription elongation factors 
and various chromatin remodeling complexes, enhancing nuclear receptor-induced 
transcription.
459
 
LSD1, as already mentioned, was originally identified as a component of 
transcriptional repressor complexes comprising transcriptional corepressor protein 
(CoREST) and HDAC1/2. In association with the transcription factor repressor 
element 1-silencing transcription factor (REST), the LSD1-CoREST-HDAC core 
mediates long-term repression of neuronal genes in nonneuronal cells and in 
neuronal precursors. The LSD1-CoREST-HDAC core is functionally and structurally 
conserved and was shown to be also involved in various biological processes.
460
 In 
hematopoiesis, the LSD1-CoREST-HDAC core associates with growth factor 
independent 1 transcription repressor (Gfi-1) repressing Gfi-1 target genes.
461 
LSD1-
CoREST-HDAC core is also involved in silencing mature B-cell genes through 
direct interaction with the transcriptional repressor B lymphocyte-induced maturation 
protein-1 (Blimp-1).
462
 Moreover, LSD1 can directly interact with p53 to confer p53-
mediated transcriptional repression, such as the repression of the alpha-fetoprotein 
(AFP), whereas the well known p53 target gene p21 can be actively transcribed 
without recruitment of LSD1. This finding suggests that LSD1 is targeted to 
chromatin by p53 but likely in a gene-specific manner.
463 
Liu et al. have reported that 
the amine oxidase domain of LSD1 is important in suppressing SALL4-mediated 
reporter transcription. The stem cell protein SALL4 plays a critical role in 
hematopoiesis by regulating the cell fate. This study revealed that LSD1 may 
negatively regulate SALL4-mediated transcription, and the dynamic regulation of 
SALL4-associated epigenetic factors cooperatively modulates early hematopoietic 
precursor proliferation.
464
 Another important indication of LSD1 involvement in 
gene repression is that the DNA methylase regulator DNMT3L recognizes histone 
H3 tails that are unmethylated at H3K4. This finding suggests the importance of 
LSD1 in the formation and propagation of heterochromatin through LSD1-dependent 
H3K4 demethylation and following de novo DNA methylation.
465   
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In 2010 Lin and colleagues first investigated the interaction between LSD1 and the
 
transcription factor SNAIL1 that has a key roles in development and oncogenesis. On 
the basis of a weak sequence similarity between SNAIL1 and the histone H3 N-
terminal tail they proposed that SNAIL1 could bind to LSD1 in the same site of the 
histone H3 substrate. This model for SNAIL1-LSD1 interactions implied that 
SNAIL1 should inhibit LSD1 enzymatic activity.
466 
Consistently, Baron et al. found 
that a 20-amino-acid peptide corresponding to SNAIL1 N-terminal residues 
effectively inhibits LSD1-CoREST.
467
 Moreover to explain the mechanism of 
SNAIL1 recognition by LSD1 they determined the crystal structure of the ternary 
complex LSD1-CoREST/SNAIL1 peptide at 3.0 Å resolution (Figure 7.12).
467
 The 
peptide occupies the open cleft that has been shown to form the binding site for the 
H3 tail.
468
 The comparative analysis of the H3 and SNAIL1 complexes clearly 
indicates that Arg7 of SNAIL1 occupies the same position and establishes similar 
interactions (with Cys360, Asp375, and Glu379) as Arg8 of H3. In conclusion 
SNAIL1 N-terminal residues act as a mimic of H3 being able to effectively bind to 
the enzyme active-site cleft. Alignment of the N-terminal sequences of the common 
SNAG domain of SNAIL1 and H3 reveals that the residues that are key for binding 
to LSD1, as gathered from the SNAIL1/LSD1/CoREST crystal structure, are 
conserved among almost all SNAIL1-related proteins. This feature predicts that other 
transcription factors of the SNAIL/Scratch family are likely to associate to LSD1 
(and possibly LSD2) following the same molecular mechanism highlighted by 
SNAIL1. SNAIL1 directly interacts with the LSD1 histone demethylase and recruits 
the LSD1 complex to the E-cadherin and other epithelial gene promoters, resulting in 
downregulation of the active H3K4m2 mark and promoter activity. LSD1 serves as 
an essential effector of SNAIL1-dependent transcriptional repression of epithelial 
genes, suggesting that the LSD1 complex could be a potential therapeutic target for 
Epithelial-mesenchymal transition (EMT) and tumor invasion.
469,470 
Figure 7.12. Ribbon representation of the ternary complex of LSD1 (cyan), CoREST (blue), and the 
SNAIL1 peptide (orange).The cofactor FAD is in yellow sticks.  
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7.2.1.2.3. LSD1 and cancer 
LSD1 has been reported to be associated with cancer only few years ago and it has 
been found to possess oncogenic properties in several cancers ranging from 
prostate,
471
 bladder,
472
 neuroblastomas,
473
 lung cancers,
474
 sarcomas and hepato-
carcinomas.
475
 LSD1 inhibition reduces or blocks cell growth in many of these 
tumors, while its over-expression has been found to contribute to human 
carcinogenesis through chromatin modification.
476
 Recent advances in leukemia 
biology come from studies that investigated on genetic and epigenetic abnormalities 
in leukemic cells.
477
 The role of LSD1 as essential regulator of leukemia stem cells 
(LSC) potential has been described in a mouse and human models of human MLL-
AF9 leukemia.
478
 The extent of LSD1 knockdown significantly correlated with loss 
of the LSC potential of acute myeloid leukemia (AML) cells through impairment of 
differentiation and apoptosis. Cells without active LSD1 are unable to form colonies 
(consistent with loss of LSC potential) exhibit differentiated cell morphology and are 
not able to cause leukemia when introduced into mice.
479
 It is clearly demonstrated 
that in AML demethylation by LSD1 is related with activation of LSC associated to 
oncogenic target genes. The mechanisms by which LSD1 functions at its target genes 
and the protein complexes recruited by LSD1 at these loci require further 
investigations.
480
 In T-cell acute lymphoblastic leukemia (T-ALL), Notch mediated 
regulation of its targets is the first example of the dual role of LSD1 as activator or 
repressor; it is known that the DNA-binding factor CSL binds and represses Notch 
targets in the absence of Notch, while the presence of Notch converts CSL in a 
transcriptional activator. The finding that LSD1 interacts with CSL explains the 
mechanism through which Notch determines gene repression by removing the 
H3K4me2 marks at Notch targets in the absence of Notch. Indeed, a functional 
switch of LSD1 activity is observed upon Notch activation. In the absence of Notch, 
LSD1 triggers H3K4me2 demethylation while in its presence the enzyme acts 
preferentially on H3K9me2 leading to activation of target genes. Thus, LSD1 
inhibition in T-ALL reproduces cell growth arrest and alteration of growth, and a 
phenotype was previously attributed to Notch silencing.
481
 High levels of LSD1 
protein have been found in several types of solid tumors and are associated with poor 
prognosis. This is the reason why LSD1 has been proposed as a biomarker for 
neuroblastoma, non-small cell lung carcinomas (NSCLC), breast and prostate 
cancers. In NSCLC it has been shown that down regulation of LSD1 expression by 
the pharmacological inhibitor pargyline or by specific siRNAs determines 
suppression of cell growth, migration and invasion. Similarly, LSD1 immuno-
reactivity is increased in a substantial fraction of hepato-carcinomas (HCC), and 
LSD1 knockdown in HCC cells decreases substantial cell proliferation. 
471-473 
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7.2.1.3. LSD2 
LSD2 (AOF1 or KDM1B) has been recently identified as a homolog of LSD1 and it 
demethylates H3K4me2/1 like LSD1. In LSD2 the SWIRM domain is involved in an 
interaction with glyoxylate reductase 1 homolog (GLYR1; also known as NPAC), 
which positively stimulates demethylase activity. This interaction is mediated 
through a unique coiled loop that is not found in the SWIRM domain of LSD1, thus 
NPAC does not associate with LSD1. Apart from sharing the AOL and SWIRM 
domains, LSD1 and LSD2 have different domain architectures, associate with 
different proteins and show different genomic distribution profiles. One of the most 
striking differences is that LSD1 forms part CoREST complex and this interaction is 
due to the presence of a coiled-coil ‘Tower’ domain inserted into the AOL domain of 
LSD1. LSD2 does not have a Tower domain but instead has an a unique N-terminal 
zinc finger domain of unknown function (Figure 7.13).
482-484
  
Figure 7.13. (A) Ribbon diagram of the LSD2 structure. (B) Domain organization of LSD2. 
A genome-wide mapping analysis has revealed that LSD2 primarily resides in the 
intragenic regions of actively expressed genes. LSD2 may activate its target genes, 
possibly via its association with transcriptional elongation factors.
485
 LSD2 seems to 
be not essential for mouse development. However, the DNA methylation of several 
imprinted genes is lost in oocytes from LSD2-deleted females. Consequently, the 
embryos derived from these oocytes exhibited biallelic expression or silencing (i.e., 
loss of monoallelic expression) of the affected imprinted genes and died before 
midgestation.
486
 The molecular mechanism underlying the functional link between 
H3K4 demethylation and DNA methylation for expression of imprinted genes 
remains to be investigated.  
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7.2.2. The Jumonji C domain-containing demethylases 
The second family of histone lysine demethylases is characterized by the presence of 
the catalytic Jumonji C (JmjC) domain. The first JmjC domain protein was identified 
in a gene trap screen for factors involved in neural tube formation. The homozygous 
mutant mice showed abnormal groove formation on the neural plate and a defect in 
neural tube closure. Takeuchi et al. called this mutation jumonji (Jmj), since 
homozygous mutant mice usually form an additional groove at the future midbrain–
hindbrain boundary that intersects the normal neural groove, resulting in a ‘‘cross’’-
shaped cut on the neural plate (in Japanese jumonji means cruciform).
487
 The 
Jumonji protein family demethylases is named this way because it contains the 
conserved JmjC catalytic domain that was first identified in the so called Jumonji 
protein JARID2.
488 
The JmjC domain is present in 31 human proteins, about 20 have 
been published to demethylate specific lysines in the histone (Table 7.2). Depending 
on the homology of the JmjC domain and the presence of other domains, these 
histone lysine demethylases can be divided into seven subfamilies ( Figure 7.14).
489
 
Figure 7.14. 
Phylogenetic tree of 
Jumonji C (JmjC) 
domain-containing 
proteins. Proteins 
demonstrated to be 
histone lysine 
demethylases are 
marked in bold and 
their histone residue and 
methylation-level 
specificities are 
indicated. Proteins with 
a non-canonical amino 
acid at a position 
involved in cofactor 
binding are marked with 
an asterisk and may be 
catalytically inactive. 
7.2.2.1. Catalytic mechanism and structural studies 
In contrast to the flavin-dependent demethylases LSD1/2, which require the presence 
of an intermediate iminium cation in their catalytic cycle, the demethylases 
containing a JmjC domain act via a fundamentally different reaction mechanism. 
This also allows the removal of a trimethyl mark, which is not possible for LSD1-
type demethylases due to chemical reasons.
490
 Jumonji-type demethylases belong to 
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the cupin superfamily of oxygenases and contain an Fe
2+
 ion in their catalytic domain 
and use -ketoglutarate as co-substrate. The proposed mechanism of action of JmjC 
domain containing demethylases is commonly assumed to be similar to that of other 
Fe(II)-containing and -ketoglutarate-dependent hydroxylases. A plausible sequence 
of reaction steps is outlined in Figure 7.15.
491,492
 
 
Figure 7.15. Catalytic mechanism of JumonjiC domain ontaining demethylases. 
The catalytically active iron ion in the unbound state is in the 2
+
 oxidation state and 
coordinated by two histidine residues, a glutamate residue, and three molecules of 
water. Initially, the co-substrate -ketoglutarate as well as dioxygen are coordinated 
onto the iron center, displacing the water ligands (step 1). Most likely, a single 
electron transfer occurs next from the iron(II) ion onto the coordinated oxygen 
yielding a reactive peroxide radical anion species (step 2). This can, in turn, attack 
the -ketoglutarate ligand leading to a mixed anhydride bound to the remaining 
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iron(III)-hydroxyl radical anion (step 3). This highly reactive hydroxyl radical is able 
to activate the stable C-H bond in the adjacent methyl group of the substrate 
methyllysine and to form hydroxymethyllysine via abstraction of a proton and 
subsequent transfer of the hydroxyl group onto the methyl carbon atom (step 4) 
leaving behind a coordinative gap on the central iron (II) ion. Upon dissociation of 
the bound mixed anhydride from the central iron, it decomposes into carbon dioxide 
and succinate as byproducts (step 5). Binding of three molecules of water regenerates 
the original catalytic species. This reaction cycle could, in principle, be repeated 
resulting in removal of one methyl group after the other.
491
 
Crystal structures have been described for -ketoglutarate histone demethylases 
with different selectivities. In Figure 7.16, the crystal structures of JMJD2A and 
PHF8 
 
are reported.
493-495
 These structures reveal the target lysine residue to be bound 
in an extended form in a relatively wide cleft formed primarily by the side chains of 
hydrophobic residues, which position the N-methyl group adjacent to the active site 
Fe(II). Variations in the size of the active site region binding the N-methyl group 
are proposed, in part, to confer methylation state selectivity; the degree of selectivity 
varies with the particular enzyme or subfamily. 
Figure 7.16. Crystal structures of -ketoglutarate histone demethylases. a) Catalytic domain of 
the histone demethylase JMJD2A in complex with a fragment of H3K9me3. b) Catalytic and methyl-
lysine binding PHD (green) domains of PHF8 in complex with H3K4me3 and H3K9me2 substrate 
fragment. 
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The crystal structure of the catalytic core of JMJD2A shows that, although the JmjC 
domain contains the sites of interaction for the two cofactors, Fe(II) and α-
ketoglutarate, additional domains are needed for catalytic activity. In the JMJD2 
family, two regions within the N terminus and a region immediately upstream of the 
JmjC domain complete the catalytic centre.
496,497
 In contrast to LSD1, the structure of 
the JmjC demethylase JMJD2A shows that the binding pocket specifically 
recognizes and fits trimethylated Lys residues. H3K36me3 and H3K9me3 are both 
substrates for JMJD2A, but they are bound in different conformations with a broad 
conformation for H3K9me3 and a more tightly bent, U-shaped conformation for 
H3K36me3.
498
 The structural data of JMJD2A in complex with different H3 peptides 
further shows that it is the sequence of the H3 peptide surrounding the Lys residues 
that is important for substrate specificity: for H3K9me3, the preferred substrate of 
JMJD2A, two nearby Gly residues seem to be important for acquiring the required 
conformation, whereas two Gly residues and a Pro residue provide binding 
specificity for H3K36me3. Other Lys residues that lack these adjacent amino acids in 
their primary structure cannot access the catalytic centre.  
The importance of binding domains was first illustrated for the histone demethylases 
PHF8. In addition to JmjC catalytic domain, PHF8 has a plant homeobox domain 
that binds to the N-trimethylated form of lysine 4 of histone H3; this interaction 
increases the activity of the catalytic domain with regards to demethylation of N-
dimethylated lysine9 histone H3.
499
 Crystallographic analyses have revealed the 
structural basis for this activation process (Figure 7.16b).
494
  
7.2.2.2. FBXL subfamily 
The first JmjC domain-containing protein shown to be a histone lysine demethylase 
was FBXL11 (F-box and leucine-rich repeat protein 11). FBXL11 and FBLX10 have 
been demonstrated to catalyze H3K36me2/me1 demethylation.
500
 In addition, 
mammalian FBXL10 has been suggested to act as an H3K4me3 demethylase, but 
this activity is still controversial.
501
 FBXL10 besides having the catalytic JmjC 
domain, contain an F-box (which is a signature domain for a component of SCF 
(SKP1–cullin-1–F-box) E3 ligases) and a CXXC DNA-binding domain. The recent 
demonstration that FBXL10 regulates the expression of Polycomb target genes 
suggests that FBXL10 might contribute to tumorigenesis through the regulation of 
these genes.
502 
 
Moreover retroviral insertional mutagenesis within the FBXL10 gene has been 
shown to cause lymphoma in BLM (Bloom syndrome RecQ protein-like-3 DNA 
helicase)-deficient mice so indicating FBLX10 as a candidate tumour suppressor.
503 
Other studies have proposed FBXL10, along with FBXL11, as a putative proto-
oncogene.
504
 Expression data from human cancers show over-expression of FBXL10 
in lymphomas and adenocarcinomas,
504
 but reduced expression of FBLX10 and 
FBXL11 in prostate cancer and in the most aggressive of the primary brain tumours, 
the glioblastoma multiform, respectively.
505 
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7.2.2.3. JMJD1 subfamily 
JMJD1A is a histone demethylase specific for H3K9me2/me1.
506
 Two JMJD1A 
homologues exist in human cells: JMJD1B and JMJD1C. JMJD1A has a 
characteristic LXXLL motif that is involved in nuclear receptor interactions.
507
 The 
expression of JMJD1A has been implicated in demethylation of H3K9me2 of 
androgen receptor (AR) target genes.
506
 Indeed, JMJD1A was found to interact with 
the AR in a ligand-dependent manner.  
Studies of knockout mice have demonstrated important roles for JMJD1 in germ cell 
development and metabolism.
508,509
 JMJD1A knockout mice also exhibit an adult 
onset obesity phenotype and, in this context, JMJD1A has been implicated in the 
transcriptional control of metabolic genes in muscle and adipose tissues.
508 
JMJD1A 
is highly and dynamically expressed during spermatogenesis, and male JMJD1A 
genetrap mice are infertile, with small testes and a severe reduction in sperm count. 
This defect has been linked to JMJD1A positively regulating expression of genes 
involved in sperm chromatin condensation and maturation through demethylation of 
H3K9me2/me1.
509 
 During hypoxia JMJD1A stimulates the expression of HIF target 
genes such as adrenomedullin (ADM). Krieg et al. showed that the expression of 
ADM is regulated by JMJD1A under hypoxia in colon cancer, and that ADM 
facilitates the growth of colon carcinoma cells. However, the regulatory mechanisms 
of JMJD1A and its target gene ADM during hypoxia have not yet been elucidated in 
hepatocellular carcinoma (HCC) and breast cancer cells.
510,511
 Frequent deletion of 
5q31 locating JMJD1B gene or reduced expression of JMJD1C in various 
malignancies suggest possible roles of JMJD1 proteins in tumor suppression.
512
 
7.2.2.4. JMJD2 subfamily 
JMJD2 subfamily, containing four expressed members JMJD2A to JMJD2D, are 
selective for the demethylation of the tri- and di-Nε- methylation states of specific 
lysines on histone H3. Interestingly, different members of this family have slightly 
different substrate preferences.
513 
Thus, JMJD2D can demethylate H3K9me2 and 
H3K9me3 but not H3K36me2 and H3K36me3. Sequence alignment of JMJD2A and 
JMJD2D shows that a variable Ser/Ala position in the binding pocket is responsible 
for this different selectivity, and by generating Ser288Ala and Ala291Ser mutations 
in JMJD2A and JMJD2D, respectively, it is possible to switch the substrate 
specificity of the two enzymes.
496 
Strong genetic data have linked the loss of H3K9 
trimethylation to the development of cancer in various mouse models, thus a 
decrease in H3K9me3 levels can accelerate carcinogenesis in a mouse model of T 
cell lymphoma.
514 
Given that the JMJD2 family of proteins are H3K9me3 and 
H3K9me2 demethylases, it is plausible that overexpression of these proteins would 
result in similar effects. Furthermore several studies have shown that JMJD2C is 
required for growth in an array of different cancer cell lines, including squamous cell 
carcinoma,
515
 prostate carcinoma,
458
 breast carcinoma
516
 and diffuse large B cell 
lymphoma.
517
 Introduction of JMJD2C gene in normal breast MCF10A cells could 
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increase the capacity to generate mammospheres, a phenotype of cancer stem cells, 
suggesting that GASC1 acts as a transforming gene.
516 
The involvement of JMJD2C 
in tumorigenesis has been supported further by a recent study demonstrating the 
functional interaction between JMJD2C and AR in prostate carcinoma.
458
 It was 
already known the cooperation between LSD1 and JMJD1A for the transcriptional 
activation of AR responsive genes, and for proliferation of prostate cancer cells. 
Although LSD1 and JMJD1A only demethylate H3K9me2/1, JMJD2C is especially 
capable of efficiently demethylating H3K9me3, inducing a robust cooperative 
stimulation of AR transcriptional activity. Thus, specific modulation of JMJD2C 
activity alone, or in combination with LSD1, may be a promising therapeutic strategy 
to control AR activity in tissues where AR has a key physiological role. 
7.2.2.5. JARID1 subfamily 
The members of the JARID1 subfamily (JARID1A-D) are able to demethylase tri- 
and dimethylated H3K4. Despite the fact that other members of JARID1 family 
catalyze the demethylation of the same histone mark, they appear to have unique 
functional properties probably due to their divergent expression profiles and presence 
in distinct protein complexes. 
JARID1A has a role in the regulation of circadian clock length that is not the result 
of its catalytic demethylase activity but possibly depends on JARID1A mediated 
inhibition of histone deacetylase HDAC1.
517,518 
JARID1A forms a complex with 
CLOCK and BMAL1, transcription factors that are key in the regulation of animal 
circadian rhythms. In mammalian cells, deletion of JARID1A causes a reduction in 
the activation of circadian genes and a shortening of the circadian rhythm. These 
changes in gene expression are accompanied by reduced histone H3K9 acetylation 
and can be rescued by catalytically inactive JARID1A.
518 
Moreover JARID1A has 
been shown to be a key effector of retinoblastoma protein (pRB) mediated cell cycle 
withdrawal and differentiation by interacting with the tumor suppressor pRB.
519 
 
A recent study found that it is overexpressed in gastric cancer and that its inhibition 
leads to cellular senescence of gastric and cervical cancer cells by derepressing 
cyclin dependent kinase inhibitors like p27, p21 and p16.
520
 Enhanced JARID1A 
expression was found to contribute to drug tolerance in a non-small cell lung 
carcinoma (NSCLC) cell-system. These drug-tolerant NSCLC cells display reduced 
levels of H3K4me2 and H3K4me3 which is reminiscent of the prognostic value of 
reduced H3K4me3 in NSCLC.
521 
This also indicates that acquired drug resistances 
are accompanied by epigenetic changes, and combining a chromatin modifying agent 
with a single rationally targeted agent would prevent the development of drug 
resistance. 
JARID1B, which targets H3K4me2 and H3K4me3, is mainly associated with 
transcription start sites (TSSs) and coding regions in embryonic stem (ES) cells.
522
 
Knockdown of JARID1B results in an average 2.2 fold increase of H3K4me3 at 
JARID1B targets. However, only 3.4% of JARID1B target genes are differentially 
expressed following its depletion in these cells. Nonetheless, depletion of JARID1B 
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results in a failure to properly initiate ectodermal differentiation in vitro. Thus, it has 
been hypothesized that the function of JARID1B is to maintain H3K4me3 at low or 
intermediate levels at its target genes, thereby fine-tuning transcription levels and 
ensuring the proper execution of differentiation programmes.
522
 This protein is 
overexpressed in various different cancers, including breast, prostate and bladder 
carcinoma.
523-525
 It has been reported that JARID1B is required for the growth of a 
breast cancer cell line and for the continuous growth of melanoma.
526,527 
 
JARID1C has been implicated in X-linked mental retardation and epilepsy.
528
 Its role 
in the pathogenesis of human papillomavirus (HPV)-associated cancers has been 
very recently identified by a genome-wide siRNA screen showing JARID1C as one 
of the E2-dependent regulators of HPV oncogene expression.
529
 
7.2.2.6.UTX- JMJD3 subfamily 
The JmjC domain-containing proteins, UTX (ubiquitously transcribed 
tetratricopeptide repeat, X chromosome) and JMJD3, can specifically remove di- and 
trimethyl marks from H3K27 and, thereby counteract PcG-mediated histone 
modification by EZH2. JMJD3 is recruited to promoters that have increased 
H3K4me3 levels following lipopolysaccharide (LPS) treatment of 
macrophages.
530,531
 Interestingly, most of the promoters bound by JMJD3 are not 
associated with H3K27me3 before JMJD3 binding, and only a minor fraction of the 
H3K27me3 positive promoters that are bound by JMJD3 shows decreased levels of 
H3K27me3 after LPS treatment. Moreover, JMJD3 depletion only affects the 
expression of relatively few genes and does not result in an increase of H3K27me3. 
Thus, JMJD3 might instead serve as a safeguard against further H3K27 methylation, 
thereby ensuring the activation of target genes in response to LPS treatment.
531
 UTX 
is associated with MLL3/4 complexes and was the first reported mutated histone 
demethylase gene associated with cancer.
532,533
 Biallelic somatic mutations of UTX 
in several human cancers (with highest prevalence in multiple myeloma) clearly 
suggested UTX role as a tumor suppressor gene.
534 
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7.2.2.7. The PHF2- PHF8 subfamily 
The PHF2⁄PHF8 subfamily includes PHF2, PHF8 and KIAA1718; they have a plant 
homeo domain (PHD)-type zinc finger motif in addition to a JmjC domain (Figure 
7.17).
535
 
Figure 7.17. Schematic representation of mouse KIAA1718 and the PHF2 ⁄ PHF8 protein family. 
The percentage identity is indicated in the aligned sequences for the PHD finger and jumonjiC 
domains. 
PHF8 targets H3K9me1 and H3K9me2, whereas its close relative KIAA1718 
catalyses demethylation of both mono-and dimethylated H3K9 and H3K27.
499
 This 
difference in substrate specificity has been ascribed to different distances between 
the JmjC and PHD finger domains. Both enzymes associate with H3K4me3 through 
their PHD domain, but PHF8 has a shorter, more flexible linker that assumes a bent 
conformation, allowing its JmjC domain to interact with and demethylate H3K9me1 
and H3K9me2. For KIAA1718, the linker is longer and more rigid, resulting in an 
extended conformation that renders it inactive towards H3K9me1 and H3K9me2 in 
the presence of nearby H3K4me3, and leads to selectivity towards H3K27me1 and 
H3K27me2 in vitro.
536
  
In this model for substrate recognition by PHF8 and KIAA1718, the presence of 
H3K4me3 seems to lead demethylase activity towards Lys27 and Lys9 residues on 
the same tail in vitro. However, in a study of the C. elegans homologue of 
KIAA1718 (ceKDM7A), the PHD domain of ceKDM7A binds to H3K4me3 on one 
H3 tail and to the substrate H3K9me2 or H3K27me2 on another H3 tail. Moreover, 
the PHD domain of ceKDM7A and its binding to H3K4me3 is required for the in 
vivo demethylase activity towards both H3K27me2 and H3K9me2, suggesting that 
the presence of H3K4me3 does not necessarily lead to preferential demethylation of 
H3K27me2 by ceKDM7A in vivo.
537
 
PHF8 also binds to H3K4me3-positive genes but not necessarily to regions that carry 
its target histone modifications. The loss of PHF8 most often affects the expression 
of genes to which it binds, but the expression of 95% of PHF8 target genes remains 
unchanged. Furthermore, the depletion of PHF8 does not lead to detectable changes 
in H3K9me2 levels and only produces minor changes in H3K9me1 and H4K20me1 
levels associated with target genes.
538 
In 2010, Huang et al. demonstrate that KIAA1718 plays an important role in neural 
differentiation, using a mouse embryonic stem cell (ESC) differentiation system. The 
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neural promoting effect is mediated by FGF4, a molecule involved in neural 
differentiation. How KIAA1718 is recruited to the promoter region of FGF4 gene 
remains to be determined.
539
 It is possible that KIAA1718 is recruited by a protein 
complex that contains DNA- or histone-binding activities, but it is also possible that 
KIAA1718 is recruited by pre-existing epigenetic marks. Since H3K9me2 and 
H3K27me2 are important epigenetic marks associated with transcription repression, 
a histone demethylase for these two marks may have many biological functions. 
However, futher studies using transgenic and knockout mouse models are needed to 
reveal other biological functions of KIAA1718.  
7.2.3. KMD Inhibitors 
7.2.3.1. LSD1 inhibitors 
The first generation of LSD1 inhibitors that were discovered, was based on its 
homology with monoamine oxidases, which also use FAD as cofactor. Since MAO 
enzymes are established targets for the treatment of neurological disorders, a large 
number of inhibitors have been synthesized and tested for specificity towards MAO 
enzymes. MAO inhibitors were tested for their ability to inhibit LSD1 and 
tranylcypromine and phenelzine were shown to inhibit LSD1 activity with the 
highest potency (IC50=21 μM) (Figure 7.18). In addition, chemically synthesized 
propargyl lysine-derivatised histone H3 tail peptide could irreversibly inhibit LSD1. 
Recently, polyamine analogues (bisguanidine and biguanidine types) have also been 
characterized as potent non-competitive inhibitors of LSD1 (Figure 7.19). 
Anti-MAO-Based Small Molecules 
Due to the high sequence similarity between LSD1 and MAO, some known anti-
MAO agents were tested against LSD1. Pargyline (1), a propargylamine-based anti-
MAO initially suggested as a valuable LSD1 inhibitor prototype, failed in further 
studies to inhibit the lysine demethylase.
540
 Phenelzine (2), an anti-MAO agent 
bearing a hydrazine moiety, has a potency against LSD1 (Ki= 17.6 μM), similar to 
that displayed versus MAOs.
541
 Tranylcypromine (trans-2-phenylcyclopropyl-1-
amine, trans-2-PCPA, 3) was reported to inhibit LSD1 with a Ki value ranging from 
477 to 22 μM, depending on the type of assay and condition used for testing.542,543 
Nevertheless, trans-2-PCPA became a useful lead to develop highly potent small-
molecule inhibitors of LSD1. Interestingly, the introduction of a bulky branched 
substituent at the 4 position of the benzene ring, able to occupy the wide space 
present in the LSD1 cavity surrounding the FAD cofactor and the AO domain, 
furnished tranylcypromine-based compounds such as 4-9 endowed with high potency 
against LSD1 and weak or no activity against MAOs.
544,545 
Compounds 4 and 5 were 
also reported to be active against a panel of cancer cell lines (HeLa cervix cancer, 
PC3 prostate cancer, KYSE150 esophagus cancer) with growth inhibition 50% (GI50) 
values ranging from 6.0 to 67 μM,544 whereas 8 was able to inhibit cell growth and 
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induce differentiation in murine acute promyelocytic leukemia (APL) blasts as a 
single agent and in APL-derived NB4 cells in synergy with retinoic acid (RA).
545
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Figure 7.18. Anti-MAO- Based small molecules. 
As trans-2-PCPA is the racemic mixture of 2 enantiomers, (+)-trans-2-PCPA and (–
)-trans-2-PCPA, Mai and colleagues prepared large amounts of trans- and cis-2-
PCPA, separated the 2 trans- and 2 cis-enantiomers, and tested them against LSD1 
and MAOs, determining their binding to FAD through X-ray crystallography.
544
 
They reporter that the 2 trans-enantiomers of 2-PCPA were slightly more potent than 
the 2 cis congeners against LSD1, with (–)-trans-2-PCPA (3b) being 1.7- fold more 
efficient than (+)-trans-2-PCPA (3a). Conversely, against MAO-B, (+)-trans-2-
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PCPA was 20-fold more potent than the corresponding (–) enantiomer, highlighting 
the crucial role of stereochemistry in MAO-B inhibition by trans-2-PCPA. Recently, 
a novel PCPA derivative named OG-L002 (10) has been identified to be a highly 
specific LSD1 inhibitor (IC50≈ 0.02 M), showing a >36-fold selectivity over 
MAOases.
545 
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Figure 7.19. Substrates analogues and polyamines.  
Substrates analogues  
In search of more selective inhibitors, a series of peptide-based inhibitors, such as 
compounds with the propargylamine or hydrazine functionality were synthesized in 
the context of a histone H3 peptide. H3-tail peptides require at least 15 amino acid 
residues for efficient reaction (Figure 7.19). Based on this observation the propargyl- 
Lys-derivatized peptide 11 was designed as a mechanism-based LSD1 inhibitor. This 
compound 11 exhibited Ki= 16.6 and then 0.77 μM against LSD1, showing a clear 
time and concentration dependent inhibition of the enzyme.
 
X-ray crystal structure of 
the LSD1/12 complex suggested that LSD1 inactivation involves amine oxidation 
followed by Michael addition of the FADH2 N
5
 to the propargylic imine.
546
 The 
analog bearing a hydrazine (13) exhibit the most potent LSD1 inhibitory activity 
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(Ki=4.35 nM).
547
 However, poor membrane permeability limited the usage of these 
peptide-based inhibitors in cellular assays. 
Polyamines 
LSD1 was identified in part because its C-terminal domain shares significant 
sequence homology with the polyamine oxidases APAO and SMO.
548
 APAO and 
SMO are not inhibited by the classical MAO inhibitor pargyline but several groups 
have identified polyamine analogues that act as inhibitors of these two polyamine 
oxidases.
549
 A series of (bis)guanidines and (bis)biguanides, previously synthesized 
as potential antitrypanosomal agents, were tested as inhibitors of LSD1 (Figure 
7.19).
550 
Huang et al. reported that ,within a series of compounds, analog 14 showed 
high noncompetitive LSD1 inhibition at < 2.5 μM and was able to induce the 
reexpression of aberrantly silenced tumor suppressor genes in colon cancer cells in 
vitro, together with an increase of H3K4me2 and acetyl-H3K9 marks, and a decrease 
of the repressive H3K9me1 and H3K9me2 marks. The same effects on recombinant 
LSD1 as well as human colon cancer HCT116 and RKO cell growth were observed 
for compound 15.
551
 The series of polyamine analogues was further expanded with 
some (bis)urea and (bis)thiourea derivatives among them 16 and 17 were also able to 
inhibit the growth of Calu-6 non-small cell lung carcinoma cells in vitro.
552  
7.2.3.2. JmjC demethylases inhibitors 
Several inhibitors of JmjC demethylases have been reported (Figure 7.20), but few 
have sufficient potency and selectivity to be considered lead structures for drug 
development. JmjC demethylases could be expected to share some similarities with 
HDACs, whose substrates also present a lysine side chain with its N-terminus in the 
proximity of a bivalent metal ion. HDAC inhibitors are, however, poor inhibitors of 
the JMJD2 family of demethylases.
553
 The α-ketoglutarate analogue, N-oxalylglycine 
(NOG 19), could weakly inhibit JMJD2C and the catalytic core of JMJD2A.
554
 
JMJD2A was also found to be specifically inhibited by disruption of its Zn-binding 
site by Zn-ejecting compounds such as disufiram (21) and ebselen (22).
555
 
Interestingly, Zn-ion ejection seemed to be selective for the JMJD2 subfamily as 
other KDMs do not contain a Zn-binding site near their catalytic domain.  
Besides NOG, another -KG analog, the oncometabolite -hydroxyglutarate (-HG 
20) was found to inhibit JMJD2A, JMJD2C and JHDM1A with IC50 values ranging 
from 24 M to 106 M.556 A screen using known inhibitors from other Fe2+/-KG 
dependent oxygenases identified 2,4-pyridinedicarboxylic acid (23), which showed 
potent inhibitory activity on JMJD2E (IC50=1.4 M).
553 
High-throughput screening 
also identified PDCA-related compound 5-carboxy-8-hydroxyquinoline (24), which 
has a greater potency for JMJD2E (IC50=200 nM).
557 
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Figure 7.20. JmjC demethylases inhibitors. 
Another family of pyridine-based compounds, with a 4-carboxy-2,2’-bipyridyl 
scaffold (25) have also been reported to show enhanced inhibitory activity toward 
JMJD2 subfamily of demethylases.
558
 Structural characterization validated that this 
bipyridine compound also functions through -KG competition. The carboxylate 
group of the compound is positioned to interact with the same manner observed for 
-KG, whereas the active site Ni2+ cation was chelated through both pyridinyl 
nitrogen atoms. Based on the crystal structure of JMJD2A and on homology model 
of JMJD2C, Hamada and colleagues designed a series of hydroxamate analogs 
bearing a tertiary amine and identified analog 26 to be a potent and selective JMJD2 
inhibitor, showing 500-fold greater JMJD2C inhibitory activity over NOG.
559 
One of 
the most encouraging potential lead compounds reported is GSK-J1 (27), which is an 
inhibitor of the JMJD3 subfamily. This compound has an IC50 of 60 nM and is 
remarkably selective for the JMJD3 subfamily, although the JARID1 subfamily was 
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not included in the selectivity studies, despite being the closest subfamily to JMJD3. 
The propanoic acid of GSK-J1, mimicking -KG, binds competitively to the 2-
oxoglutarate cofactor and has the functionality to chelate the active site metal. This 
chelating interaction is likely to be a significant factor that contributes to the affinity 
of the inhibitor, and it is encouraging to see that specificity is possible for molecules 
that bind to the highly conserved features within the JmjC demethylase family and 
oxygenase superfamily.
560
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8. Selective non-nucleoside inhibitors of human DNA 
methyltransferases analogs of SGI-1027
*
 
8.1. Research project 
Reactivation of silenced tumor suppressor genes by 5- azacytidine (Vidaza) and its 
congener 5-aza-2-deoxycytidine (decitabine) has provided an alternate approach to 
cancer therapy. As reported previously (See Sec. 2.6.1.1.), these drugs selectively 
and rapidly induce degradation of the maintenance DNA methyltransferase 1 
(DNMT1) by a proteasomal pathway. Although 5-azacytidine and 5-aza-2-
deoxycytidine have been used for nearly 25 years as DNA hypomethylating agents in 
experimental systems and more recently for treating some cancer patients, their 
relative instability and toxicity due to incorporation into DNA have limited their 
clinical applications.  
Some compounds have been reported as non-nucleoside DNMTi (See Sec. 2.6.2.), 
but typically they share low potency and/or low selectivity for DNMTs, and their 
mechanism of inhibition is unknown. Among them SGI-1027 (Figure 8.1, 1), 
identified in a series of quinoline-based compounds developed as anticancer drugs, 
has attracted our attention because of its high potency in both enzyme and cell 
assays.
110  
Quinolinium bisquaternary salts related to SGI-1027 are known to bind reversibly in 
the minor groove of DNA as shown by NMR (nuclear magnetic resonance) and X-
ray crystallographic studies.
561,562 
Originally, the bisquaternary salts were developed 
as anticancer drugs,
563 
in which the quaternary functions is required for their activity 
and for DNA binding but their mechanism of action was not defined. The 
nonquaternized, weakly basic compound SGI-1027, it is reported to bind reversibly 
but less strongly to DNA [IC50= 0.51 mol/L for binding to poly(dA-dT) determined 
by fluorescence quenching assay] and is indefinitely stable in aqueous solution. It is 
highly lipophilic (Clog= 5.93) and has a low polar surface area of 116 indicating a 
good distribution and cell uptake abilities. SGI-1027 exhibits poor solubility and 
excellent stability in rat and human plasma and microsomes (at 1 mol/L).110 In 
2009, Datta et al. reported that SGI-1027 has a really prominent inhibitory effect on 
mammalian DNMTs (IC50= 6-12.5 mol/L), displaying comparable inhibitory 
activity toward DNMT1, DNMT3A, and DNMT3B.
110 
SGI-1027 (1) shows four fragments (4-aminoquinoline + 4-aminobenzoic acid + 1,4-
phenylenediamine + 2,4-diamino-6-methylpyrimidine) linked in sequence with 
para/para orientation, we prepared a series of regioisomers of 1 by shifting each 
fragment’s linkage from para to meta or ortho position, so obtaining compounds 2-9 
(Figure 8.1). In addition, we prepared two related compounds (10, 11) showing either 
a bis-quinoline or bis-pyrimidine structure and two truncated compounds (12, 13) 
lacking the “right” pyrimidine or the “left” quinolone portion, respectively (Figure 
8.1).  
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Figure 8.1. Chemical structures of SGI-1027 (1) and the related analogs 2-13. Their IC50 values 
(µM) from nanoscale HTS against human DNMT1 are reported into brackets. 
  
N
HN
N
H
O
H
N
N
N NH2
CH3
                  1
(SGI-1027, para/para analog)
                   (0.85) N
HN
N
H
N
H
NNO
NH2
CH3
N
HN
N
H
O
HN
N
N NH2
CH3
           2
(para/meta analog)
           (0.37)
           3
(para/ortho analog)
           (35.0)
N
HN
H
N
N
H
NN
NH2
CH3
O
N
HN
H
N
O
H
N
N
N NH2
CH3
N
HN
H
N
O
HN
NN
NH2
CH3
           4
(meta/para analog)
          (4.11)
           5
(meta/meta analog)
          (0.12)
           6
(meta/ortho analog)
          (174.0)
N
HN
NH
H
N
O
N
N
H2N
CH3
N
HN
NH
O
N
H
NN
NH2
H3C
N
HN
NH
O
NHN
N
H2N
CH3
           7
(ortho/para analog)
          (12.3)
           8
(ortho/meta analog)
          (38.6)
           9
(ortho/ortho analog)
       (no activity)
N
HN
N
H
O
H
N
N
  10
 (0.65) H3C N
N
HN
N
H
O
H
N
N
N NH2
CH3
NH2
  11
 (2.23)
Reference drugs: SAH (0.28), sinefungin (7.4)
N
HN
N
H
O
NH2
H2N
N
H
O
H
N
N
N NH2
CH3
  12
 (27.9)
   13
 (173.0)
96 |SGI-1027 analogs 
 
8.2. Chemistry 
Compounds 1-9 were prepared by coupling the 2-, 3-, or 4-(quinolin-4-
ylamino)benzoic acid 14a-c with the N
4
-(2-, 3-, or 4-aminophenyl)-6-
methylpyrimidine-2,4-diamine 15a-c, in the presence of benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) and triethylamine, in 
dry N,N-dimethylformamide as solvent (Scheme 1). The intermediate compounds 
14a-c were prepared by reaction between 4-chloroquinoline with the appropriate 
ethyl 2-, 3-, or 4-aminobenzoate and 37% hydrochloric acid in ethanol at 80 °C. The 
obtained ethyl benzoates 16a-c underwent basic hydrolysis using 2N potassium 
hydroxide to afford the corresponding acids 14a-c. The same reaction conducted 
with 4-chloro-6-methylpyrimidin-2-amine and the opportune 2-, 3-, or 4-nitroanilines 
in the presence of 37% hydrochloric acid and ethanol at 80 °C furnished the nitro-
intermediates 17a-c which were in turn reduced with stannous chloride dihydrate and 
37% hydrochloric acid in ethanol to the corresponding anilines 15a-c. 
Scheme 1 
 
Reagents and conditions: (a): 37% HCl, CH3CH2OH, 80 °C, 2 h; (b): 2N KOH, CH3CH2OH; (c): 
stannous chloride dihydrate, 37% HCl, CH3CH2OH, 1 h, 80 °C; (d): (C2H5)3N, PyBOP, anhydrous 
DMF, N2 atmosphere, room temperature, 1 h. 
The bisquinoline 10 was obtained by treating 4-chloroquinoline with 4-nitroaniline 
and, after reduction of the nitro group of the resulting intermediate 18 to the 
corresponding aniline 19, by coupling 19 with 16c (Scheme 2A). Treatment of 4-
chloro-6-methylpyrimidin-2-amine with ethyl 4-aminobenzoate afforded the 
intermediate ester 20, which was hydrolyzed to the acid 21 and then was coupled 
with 17c to furnish the bispyrimidine 11 (Scheme 2B). The truncated compounds 12 
and 13 were prepared by reaction of 16c with 4-phenylendiamine (12), or by reaction 
of 17c with 4-nitrobenzoic acid and subsequent reduction of the nitro group of the 
intermediate 22 to the corresponding amine (13) (Scheme 3). 
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Scheme 2 
 
 
Reagents and conditions: (a): 37% HCl, CH3CH2OH, 80 °C, 2 h; (b): stannous chloride dihydrate, 
37% HCl, CH3CH2OH, 80 °C, 1 h; (c): (C2H5)3N, PyBOP, anhydrous DMF, N2 atmosphere, room 
temperature, 1 h; (d): 2 N KOH, CH3CH2OH. 
Scheme 3 
 
Reagents and conditions: (a): (C2H5)3N, PyBOP, anhydrous DMF, N2 atmosphere, room 
temperature, 1 h; (b): stannous chloride dihydrate, 37% HCl, CH3CH2OH, 80 °C, 1 h. 
The chemical and physical data of final compounds 1-13 and those of the 
intermediate compounds 14-22 are shown in Table 8.1 and 8.2 respectively.  
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Table 8.1. Chemical and physical properties of compounds 1-13. 
Cpd molecolar structure mp, °C 
recrystall. 
solvent 
Yield % 
SGI-1027
 
1 
N
HN
N
H
O
H
N
N N
NH2
CH3
 
>300 C 79 
2 
N
HN
N
H
O
N
H
N N
NH2
CH3
 
270-275 C 81 
3 
HN
N N
NH2
CH3
N
H
O
HN
N  
200-205 B 72 
4 
N
NH
NH
O
NH
N N
NH2
CH3
 
>300 C 83 
5 
N
H
N
H
O
N
N
NH
N
NH2
CH3
 
270-272 C 80 
6 HN
N N
NH2
CH3
N
H
O
NH
N
 
170-172 A 66 
7 
N
H
O
NH
N
N N
NH2
CH3
H
N
 
274-279 C 78 
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8 
N
H
O
NH
N
N
N
NH2
CH3
N
H
 
158-161 A 74 
9 
N
H
O
NH
N
HN
N N
NH2
CH3
 
252-255 C 68 
10 
N
HN
N
H
O
H
N
N
 
>300 C 77 
11 
N
N
HN
N
H
O
H
N
N N
NH2
CH3
H2N CH3  
>300 C 73 
12 
N
H
O
NH2
HN
N  
264-267 C 83 
13 
N
H
O
H
N
H2N
N N
NH2
CH3
 
>300 C 75 
A: acetonitrile; B: acetonitrile/metanol; C: metanol 
 
  
100 |SGI-1027 analogs 
 
 
Table 8.2. Chemical and physical properties of compounds 14-22. 
Cpd molecolar structure mp, °C 
recrystall. 
solvent 
Yield % 
14 
N
HN
COOH
 
>300 D 88 
14b 
N
HN COOH
 
>300 D 90 
14c
 
N
HN
COOH
 
>300 D 85 
15 
N
N
HN
H3C NH2
NH2
 
213-215 C 64 
15b
 
N
N
HN
H3C NH2
NH2
 
140-142 B 73 
15c
 
N
N
HN
H3C NH2
NH2
 
88-90 A 79 
16 
N
HN
COOEt
 
235-237 C 71 
16b 
N
HN COOEt
 
260-263 D 80 
16c 
N
HN
COOEt
 
262-265 D 83 
17 
N
N
HN
H3C NH2
NO2
 
251-253 D 63 
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17b
 
N
N
HN
H3C NH2
NO2
 
290-292 D 72 
17c
 
N
N
HN
H3C NH2
NO2
 
>300 D 67 
18 
N
HN
COOH
 
>300 D 74 
19 
N
HN
NH2
 
168-170 B 77 
20 
N
N
HN
H3C NH2
NO2
 
238-240 C 65 
21 
N
N
HN
H3C NH2
COOH
 
>300 D 87 
22 
O2N
O
N
H
H
N
N
N
CH3
NH2
 
>300 D 76 
A: acetonitrile; B: acetonitrile/metanol; C: metanol 
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8.3. Experimental section 
Chemistry. Melting points were determined on a Buchi 530 melting point 
apparatus and are uncorrected. 
1
H NMR and 
13
C NMR spectra were recorded at 400 
MHz on a Bruker AC 400 spectrometer; chemical shifts are reported in δ (ppm) units 
relative to the internal reference tetramethylsilane (Me4Si). EIMS spectra were 
recorded with a Fisons Trio 1000 spectrometer; only molecular ions (M+) and base 
peaks are given. All compounds were routinely checked by TLC, 
1
H NMR and 
13
C 
NMR spectra. TLC was performed on aluminum-backed silica gel plates (Merck DC, 
Alufolien Kieselgel 60 F254) with spots visualized by UV light. All solvents were 
reagent grade and, when necessary, were purified and dried by standard methods. 
Concentration of solutions after reactions and extractions involved the use of a rotary 
evaporator operating at reduced pressure of ca. 20 Torr. Organic solutions were dried 
over anhydrous sodium sulfate. Elemental analysis has been used to determine purity 
of the described compounds, that is >95%. Analytical results are within ± 0.40% of 
the theoretical values. All chemicals were purchased from Aldrich Chimica, Milan 
(Italy), or from Alfa Aesar, Milan (Italy), and were of the highest purity. 
General Procedure for the Synthesis of the Ester Intermediates 16a-c, 20, and 
the Nitro Intermediates 17a-c, 18. Example: Synthesis of Ethyl 3-(Quinolin-4-
ylamino)benzoate (16b). 4-Chloroquinoline (6.11 mmol, 1 g), ethyl 3-
aminobenzoate (6.11 mmol, 1 g) and catalytic amount (4 drops) of 37% hydrochloric 
acid are refluxed for 2 h. The reaction was allowed to cool down to room 
temperature and the precipitated solid was filtered off, washed with water (3 × 5 mL) 
and recrystallized by methanol to afford pure 16b as hydrochloride salt. 
1
H NMR 
(DMSO-d6, 400 MHz, δ; ppm) δ 1.34 (t, 3H, J = 7.2 Hz, -COOCH2CH3), 4.36 (q, 
2H, J = 7.2 Hz, -COOCH2CH3), 6.88 (d, 1H, J = 5.2 Hz, quinoline proton), 7.74 (m, 
2H, benzene protons), 7.84 (t, 1H, J = 7.4 Hz, benzene proton), 8.00 (d, 1H, J = 8.2 
Hz, quinoline proton), 8.06-8.12 (m, 3H, quinoline and benzene protons), 8.56 (d, 
1H, J = 8.2 Hz, quinoline proton), 8.81 (d, 1H, J = 5.2 Hz, quinoline proton), 11.08 
(bs, 1H, -NH), 14.68 (bs, 1H, H
+
) ppm; 
13
C NMR (DMSO-d6, 100 MHz, δ; ppm) δ 
14.1, 60.9, 112.8, 114.2, 119.9, 121.6, 122.1, 124.2, 125.7, 129.2, 129.6, 130.9, 
133.7, 138.7, 142.3, 149.7, 151.6, 165.9 ppm; MS (EI), m/z [M]
+
 C18H16N2O2 calcd 
292.1212, found 292.1218. 
General Procedure for the Synthesis of the Acid Intermediates 14a-c, 21. 
Example: Synthesis of 3-(Quinolin-4-ylamino)benzoic acid (14b). A solution of 
ethyl 3-(quinolin-4-ylamino)benzoate 16b (1.71 mmol, 0.5 g) and 2N KOH (6.84 
mmol, 0.38 g) in ethanol (15 mL) was stirred overnight at room temperature. Then 
the solvent was evaporated, and 2N HCl was slowly added untill the aqueous phase 
reached the pH value of 5.0. The colorless solid was filtered, washed with water and 
recrystallized by methanol to obtain pure 14b. 
1
H NMR (DMSO-d6, 400 MHz, δ; 
ppm) δ 7.00 (d, 1H, J = 5.2 Hz, quinoline proton), 7.51-7.58 (m, 2H, quinoline and 
benzene protons), 7.63 (d, 1H, benzene proton), 7.68-7.75 (m, 2H, quinoline and 
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benzene protons), 7.90-7.93 (m, 2H, quinoline and benzene protons), 8.39 (d, 1H, J = 
8.0 Hz, quinoline proton), 8.51 (d, 1H, J = 5.2 Hz, quinoline proton), 9.17 (bs, 1H, 
NH) ppm; 
13
C NMR (DMSO-d6, 100 MHz, δ; ppm) δ 112.8, 119.5 (2C), 120.2, 
121.6, 124.2, 125.7, 129.2, 129.6, 131.1 (2C), 138.7, 149.7, 151.1, 151.6, 169.3 ppm; 
MS (EI), m/z [M]
+
 C16H12N2O2 calcd 264.0899, found 264.0902. 
General Procedure for the Synthesis of the Anilines 15a-c, 19 and 13. Example: 
Synthesis of N
4
-(3-Aminophenyl)-6-methylpyrimidine-2,4-diamine (15b). To a 
cooled solution of 6-methyl-N
4
-(3-nitrophenyl)pyrimidine-2,4-diamine 17b (1.63 
mmol, 0.5 g) and stannous chloride dihydrate (8.15 mmol, 1.84 g) in ethanol (10 
mL), 37 % hydrochloric acid solution (0.3 mL) was slowly added at 0 °C. The 
reaction was then kept at 80 °C for 1 h. Afterwards, the reaction was quenched at 
room temperature by 2N sodium carbonate solution (20 mL) and mixture was 
extracted with ethyl acetate (3 × 30 mL), washed with brine (3 × 30 mL), then dried 
with anhydrous sodium sulfate, filtered and concentrated under reduced pressure. 
The crude solid was recrystallized by cyclohexane to give the pure product 15b. 
1
H 
NMR (DMSO-d6, 400 MHz, δ; ppm) δ 2.06 (s, 3H, -CH3), 4.92 (bs, 2H, -NH2-
aniline), 5.87 (s, 1H, pyrimidine proton), 5.97 (bs, 2H, -NH2-pyrimidine), 6.19 (d, 
1H, J = 8.0 Hz, aniline proton), 6.80 (d, 1H, J = 8.0 Hz, aniline proton), 6.87-6.91 
(m, 2H, aniline protons), 8.64 (bs, 1H, -NH) ppm; 
13
C NMR (DMSO-d6, 100 MHz, 
δ; ppm) δ 23.9, 93.8, 102.7, 105.0, 107.8, 130.3, 143.2, 147.8, 163.1, 164.5, 170.2 
ppm; MS (EI), m/z [M]
+
 C11H13N5 calcd 215.1171, found 215.1167. 
General Procedure for the Synthesis of the Compounds 1-12 and 22. Example: 
Synthesis of N-(3-(2-Amino-6-methylpyrimidin-4-ylamino)phenyl)-3-(quinolin-
4-ylamino)benzamide (5). Triethylamine (3.04 mmol, 0.42 mL) and benzotriazol-1-
yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (0.91 mmol, 0.47 g) 
were added to a solution of 3-(quinolin-4-ylamino)benzoic acid 14b (0.76 mmol, 0.2 
g) in anhydrous N,N-dimethylformamide (5 mL) under nitrogen atmosphere. The 
resulting mixture was stirred for 30 minutes at room temperature, afterwards N
4
-(3-
aminophenyl)-6-methylpyrimidine-2,4-diamine 15b (0.76 mmol, 0.16 g) was added 
under nitrogen atmosphere and the reaction was stirred overnight. The reaction was 
quenched with water (50 mL) and extracted with ethyl acetate (3 × 30 mL). The 
combined organic extracts were dried and the residue obtained upon evaporation of 
solvent was purified by column chromatography (SiO2 eluting with ethyl 
acetate/methanol 10/1) to provide pure 5. 
1
H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 
2.10 (s, 3H, -CH3), 5.94 (s, 1H, pyrimidine proton), 6.07 (bs, 2H, -NH2-pyrimidine), 
7.06 (d, 1H, J = 4.8 Hz, quinoline proton), 7.26 (t, 1H, J = 8.0 Hz, benzene proton), 
7.35 (d, 1H, J = 7.6 Hz, quinoline proton), 7.55-7.61 (m, 4H, benzene and quinoline 
protons), 7.72-7.75 (m, 2H, benzene protons), 7.91 (d, 1H, J = 8.0 Hz, quinoline 
proton), 7.95 (s, 1H, benzene proton), 8.03 (s, 1H, benzene proton), 8.42 (d, 1H, J 
=8.4 Hz, quinoline proton), 8.52 (d, 1H, J = 5.6 Hz, quinoline proton), 9.04 (bs, 1H, -
NH-pyrimidine), 9.16 (bs, 1H, -NH-quinoline), 10.18 (s, 1H, -CONH-) ppm; 
13
C 
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NMR (DMSO-d6, 100 MHz, δ; ppm) δ 23.9, 93.8, 108.0, 111.6, 111.8, 112.8, 113.4, 
117.5, 121.2, 121.6, 124.2, 125.7, 129.2, 129.6, 129.7, 133.9, 135.0, 136.7, 138.7, 
142.5, 142.6, 149.7, 151.6, 163.1, 164.5, 164.7, 170.2 ppm; MS (EI), m/z [M]
+
 
C27H23N7O calcd 461.1964, found 461.1969. 
N-(4-(2-Amino-6-methylpyrimidin-4-ylamino)phenyl)-4-(quinolin-4-ylamino) 
benzamide (1, SGI-1027). 
1
H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 2.10 (s, 3H, -
CH3), 5.88 (s, 1H, pyrimidine proton), 6.14 (bs, 2H, -NH2-pyrimidine), 7.21 (d, 1H, J 
= 5.4 Hz, quinoline proton), 7.48-7.81 (m, 8H, benzene and quinoline protons), 7.93-
8.03 (m, 3H, benzene and quinoline protons), 8.42 (d, 1H, J =8.4 Hz, quinoline 
proton), 8.52 (d, 1H, J = 5.6 Hz, quinoline proton), 8.97 (bs, 1H, -NH-pyrimidine), 
9.25 (bs, 1H, -NH-quinoline), 10.06 (bs, 1H, -CONH-) ppm; 
13
C NMR (DMSO-d6, 
100 MHz, δ; ppm) δ 23.9, 93.8, 111.4 (2C), 112.8, 117.7 (2C), 121.6, 122.4 (2C), 
124.2 (2C), 125.7, 127.9, 129.2, 129.6, 130.2 (2C), 136.5, 138.7, 149.3, 149.7, 151.6, 
163.1, 164.5, 164.7, 170.2 ppm; MS (EI), m/z [M]
+
 C27H23N7O calcd 461.1964, 
found 461.1969. 
N-(3-(2-Amino-6-methylpyrimidin-4-ylamino)phenyl)-4-(quinolin-4-
ylamino)benzamide (2). 
1
H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 2.10 (s, 3H, -
CH3), 5.95 (s, 1H, pyrimidine proton), 6.07 (bs, 2H, -NH2-pyrimidine), 7.21-7.25 (m, 
2H, benzene and quinoline protons), 7.37 (d, 1H, J = 8.2 Hz, benzene proton), 7.50-
7.61 (m, 4H, benzene and quinoline protons), 7.75 (t, 1H, J = 7.4 Hz, quinoline 
proton), 7.93-8.03 (m, 4H, benzene and quinoline protons), 8.42 (d, 1H, J =8.4 Hz, 
quinoline proton), 8.52 (d, 1H, J = 5.6 Hz, quinoline proton), 9.03 (bs, 1H, -NH-
pyrimidine), 9.25 (bs, 1H, -NH-quinoline), 10.05 (bs, 1H, -CONH-) ppm; 
13
C NMR 
(DMSO-d6, 100 MHz, δ; ppm) δ 23.9, 93.8, 108.0, 111.4 (2C), 111.6, 112.8, 113.4, 
121.6, 124.2 (2C), 125.7, 129.2, 129.6, 129.7, 130.2 (2C), 136.7, 138.7, 142.6, 149.3, 
149.7, 151.6, 163.1, 164.5, 164.7, 170.2 ppm; MS (EI), m/z [M]
+
 C27H23N7O calcd 
461.1964, found 461.1969. 
N-(2-(2-Amino-6-methylpyrimidin-4-ylamino)phenyl)-4-(quinolin-4-
ylamino)benzamide (3). 
1
H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 2.09 (s, 3H, -
CH3), 5.88 (s, 1H, pyrimidine proton), 6.31 (bs, 2H, -NH2-pyrimidine), 7.18-7.22 (m, 
2H, benzene and quinoline protons), 7.37-7.50 (m, 4H, 7.58-7.65 (m, 2H benzene 
and quinoline protons), 7.72-7.77 (m, 2H, benzene protons), 7.94-7.96 (m, 2H, 
quinoline protons), 8.37 (d, 1H, J = 7.6 Hz, quinoline proton), 8.55 (bs, 1H, -NH-
pyrimidine), 8.58 (d, 1H, J = 4.8 Hz, quinoline proton), 9.25 (bs, 1H, -NH-
quinoline), 10.15 (bs, 1H, -CONH-) ppm; 
13
C NMR (DMSO-d6, 100 MHz, δ; ppm) δ 
23.9, 93.8, 111.4 (2C), 112.8, 118.9, 121.6, 122.8, 124.2 (2C), 125.5, 125.7, 126.1, 
129.2, 129.6, 130.2 (2C), 137.9, 138.7, 147.6, 149.3, 149.7, 151.6, 163.1, 164.5, 
170.2, 172.5 ppm; MS (EI), m/z [M]
+
 C27H23N7O calcd 461.1964, found 461.1969. 
N-(4-(2-Amino-6-methylpyrimidin-4-ylamino)phenyl)-3-(quinolin-4-
ylamino)benzamide (4). 
1
H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 2.08 (s, 3H, -
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CH3), 5.87 (s, 1H, pyrimidine proton), 6.10 (bs, 2H, -NH2-pyrimidine), 7.06 (d, 1H, J 
= 5.6 Hz, quinoline proton), 7.54-7.74 (m, 9H, benzene and quinoline protons), 7.90 
(d, 1H, J = 8.4 Hz quinoline proton), 8.01 (s, 1H, benzene proton), 8.46 (d, 1H, J = 
8.4 Hz, quinoline proton), 8.51 (d, 1H, J = 4.0 Hz, quinoline proton), 9.01 (bs, 1H, -
NH-pyrimidine), 9.28 (bs, 1H, -NH-quinoline), 10.30 (s, 1H, -CONH-) ppm; 
13
C 
NMR (DMSO-d6, 100 MHz, δ; ppm) δ 23.9, 93.8, 111.8, 112.8, 117.5, 117.7 (2C), 
121.2, 121.6, 122.4 (2C), 124.2, 125.7, 127.9, 129.2, 129.6, 133.9, 135.0, 136.5, 
138.7, 142.5, 149.7, 151.6, 163.1, 164.5, 164.7, 170.2 ppm; MS (EI), m/z [M]
+
 
C27H23N7O calcd 461.1964, found 461.1969. 
N-(2-(2-Amino-6-methylpyrimidin-4-ylamino)phenyl)-3-(quinolin-4-
ylamino)benzamide (6). 
1
H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 2.05 (s, 3H, -
CH3), 5.86 (s, 1H, pyrimidine proton), 6.23 (bs, 2H, -NH2-pyrimidine), 7.04 (d, 1H, J 
= 5.6 Hz, quinoline proton), 7.20 (m, 2H, benzene and quinoline protons), 7.51-7.74 
(m, 7H, benzene and quinoline protons), 7.90-7.92 (m, 2H, benzene and quinoline 
protons), 8.40 (d, 1H, J = 8.4 Hz, quinoline proton), 8.47 (bs, 1H, -NH-pyrimidine), 
8.51 (d, 1H, J = 5.4 quinoline proton), 9.11 (bs, 1H, -NH-quinoline), 10.19 (bs, 1H, -
CONH-) ppm; 
13
C NMR (DMSO-d6, 100 MHz, δ; ppm) δ 23.9, 93.8, 111.8, 112.8, 
117.5, 118.9, 121.2, 121.6, 122.8, 124.2, 125.5, 125.7, 126.1, 129.2, 129.6, 133.9, 
135.0, 137.9, 138.7, 142.5, 147.6, 149.7, 151.6, 163.1, 164.5, 164.7, 170.2 ppm; MS 
(EI), m/z [M]
+
 C27H23N7O calcd 461.1964, found 461.1969. 
N-(4-(2-Amino-6-methylpyrimidin-4-ylamino)phenyl)-2-(quinolin-4-
ylamino)benzamide (7). 
1
H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 2.07 (s, 3H, -
CH3), 5.85 (s, 1H, pyrimidine proton), 6.08 (bs, 2H, -NH2-pyrimidine), 7.15 (d, 1H, J 
= 5.4 Hz, quinoline proton), 7.26 (t, 1H, J = 6.8 Hz, quinoline proton), 7.48-7.75 (m, 
9H, benzene and quinoline protons), 7.92 (m, 2H, quinoline protons), 8.16 (d, 1H, J 
= 8.0 Hz, quinoline proton), 8.55 (d, 1H, J = 4.0 Hz, quinoline proton), 8.95 (bs,1H, -
NH-pyrimidine), 10.26 (bs, 1H, -NH- quinoline), 10.41 (bs, 1H, -CONH-) ppm; 
13
C 
NMR (DMSO-d6, 100 MHz, δ; ppm) δ 23.9, 93.8, 112.8, 116.4, 117.7 (2C), 117.9, 
118.8, 121.6, 122.4 (2C), 124.2, 125.7, 127.9, 128.3, 129.2, 129.6, 132.9, 136.5, 
138.7, 149.7, 151.6, 151.9, 163.1, 164.5, 167.5, 170.2 ppm; MS (EI), m/z [M]
+
 
C27H23N7O calcd 461.1964, found 461.1969. 
N-(3-(2-Amino-6-methylpyrimidin-4-ylamino)phenyl)-2-(quinolin-4-
ylamino)benzamide (8). 
1
H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 2.08 (s, 3H, -
CH3), 5.91 (s, 1H, pyrimidine proton), 6.05 (bs, 2H, -NH2-pyrimidine), 7.12-7.28 (m, 
3H, benzene and quinoline protons), 7.61-7.73 (m, 3H, benzene and quinoline 
protons), 7.71-7.76 (m, 3H, benzene protons), 7.91-7.96 (m, 2H, benzene and 
quinoline protons), 8.16 (d, 1H, J = 8.0 Hz, quinoline proton), 8.55 (d, 1H, J = 4.8 
Hz, quinoline proton), 9.02 (bs, 1H, -NH-pyrimidine), 10.10 (bs, 1H, -NH-
quinoline), 10.40 (bs, 1H, -CONH-) ppm; 
13
C NMR (DMSO-d6, 100 MHz, δ; ppm) δ 
23.9, 93.8, 108.0, 111.6, 112.8, 113.4, 116.4, 117.9, 118.8, 121.6, 124.2, 125.7, 
128.3, 129.2, 129.6, 129.7, 132.9, 136.7, 138.7, 142.6, 149.7, 151.6, 151.9, 163.1, 
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164.5, 167.5, 170.2 ppm; MS (EI), m/z [M]
+
 C27H23N7O calcd 461.1964, found 
461.1969. 
N-(2-(2-Amino-6-methylpyrimidin-4-ylamino)phenyl)-2-(quinolin-4-
ylamino)benzamide (9). 
1
H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 2.01 (s, 3H, -
CH3), 5.81 (s, 1H, pyrimidine proton), 6.27 (s, 2H, -NH2-pyrimidine), 7.12-7.24 (m, 
4H, benzene and quinoline protons), 7.48 (d, 1H, J = 7.6 Hz, benzene proton), 7.54-
7.61 (m, 3H, benzene protons), 7.71-7.76 (m, 2H, benzene and quinoline protons), 
7.92-7.97 (m, 2H, benzene and quinoline protons), 8.08 (d, 1H, J = 8.8 Hz, quinoline 
protons), 8.57 (m, 2H, quinoline and -NH-pyrimidine protons), 10.44 (bs, 1H, -NH-
quinoline), 10.57 (bs, 1H, -CONH-) ppm; 
13
C NMR (DMSO-d6, 100 MHz, δ; ppm) δ 
23.9, 93.8, 112.8, 116.4, 117.9, 118.8, 118.9, 121.6, 122.8, 124.2, 125.5, 125.7, 
126.1, 128.3, 129.2, 129.6, 132.9, 137.9, 138.7, 147.6, 149.7, 151.6, 151.9, 163.1, 
164.5, 167.5, 170.2 ppm; MS (EI), m/z [M]
+
 C27H23N7O calcd 461.1964, found 
461.1969. 
4-(Quinolin-4-ylamino)-N-(4-(quinolin-4-ylamino)phenyl)benzamide (10). 
1
H 
NMR (DMSO-d6, 400 MHz, δ; ppm) δ 6.83 (d, 1H, J = 6.0 Hz, quinoline proton), 
7.20 (d, 1H, J = 4.8 Hz, quinoline proton), 7.42 (d, 2H, J = 8.8 Hz, benzene protons), 
7.53 (d, 2H, J = 8.4 Hz, benzene protons), 7.60-7.68 (m, 2H, quinoline protons ), 
7.79 (t, 1H, J = 7.2 Hz, quinoline proton), 7.83 (t, 1H, J = 7.2 Hz, quinoline proton ), 
7.94-7.97 (m, 4H, benzene and quinoline protons), 8.07 (d, 2H, J = 7.6 Hz, benzene 
protons), 8.45-8.49 (m, 2H, quinoline protons), 8.57-8.61 (m, 2H, quinoline protons), 
9.49 (bs, 1H, -NH-quinoline), 9.82 (bs, 1H, -NH-quinoline), 10.35 (bs, 1H, -CONH-) 
ppm; 
13
C NMR (DMSO-d6, 100 MHz, δ; ppm) δ 111.4 (2C), 112.8 (2C), 117.7 (2C), 
121.6 (2C), 122.4 (2C), 124.2 (3C), 125.7 (2C), 127.9, 129.2 (2C), 129.6 (2C), 130.2 
(2C), 138.7 (2C), 141.5, 149.3, 149.7 (2C), 151.6 (2C), 164.7 ppm; MS (EI), m/z 
[M]
+
 C31H23N5O calcd 481.1903, found 481.1908. 
4-(2-Amino-6-methylpyrimidin-4-ylamino)-N-(4-(2-amino-6-methylpyrimidin-4-
ylamino) phenyl)benzamide (11). 
1
H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 2.09 
(s, 3H, -CH3), 2.13 (s, 3H, -CH3), 5.86 (s, 1H, pyrimidine proton), 5.95 (s, 1H, 
pyrimidine proton), 6.10 (bs, 2H, -NH2-pyrimidine), 6.26 (bs, 2H, -NH2-pyrimidine), 
7.65 (m, 4H, benzene protons), 7.89 (m, 4H, benzene protons), 8.91 (bs, 1H, -NH-
pyrimidine), 9.32 (bs, 1H, -NH-pyrimidine), 9.96 (bs, 1H, -CONH-) ppm; 
13
C NMR 
(DMSO-d6, 100 MHz, δ; ppm) δ 23.9 (2C), 93.8 (2C), 111.4 (2C), 117.7 (2C), 122.4 
(2C), 124.2, 127.9, 130.2 (2C), 136.5, 144.3, 163.1 (2C), 164.5, 164.7, 167.0, 167.7, 
170.2 ppm; MS (EI), m/z [M]
+
 C23H23N9O calcd 441.2026, found 441.2023. 
N-(4-Aminophenyl)-4-(quinolin-4-ylamino)benzamide (12). 
1
H NMR (DMSO-d6, 
400 MHz, δ; ppm) δ 4.91 (bs, 2H, -NH2-benzene), 6.56 (d, 2H, J = 7.6 Hz, benzene 
protons), 7.18 (d, 1H, J = 4.8 Hz, quinoline proton), 7.38 (d, 2H, J = 8.4 Hz, benzene 
protons), 7.46 (d, 2H, J = 8.4 Hz, benzene protons), 7.60 (t, 1H, J = 7.2 Hz, quinoline 
proton), 7.74 (t, 1H, J = 7.2 Hz, quinoline proton), 7.93 (d, 1H, J = 8.0 Hz, quinoline 
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proton), 7.97 (d, 2H, J = 8.4 Hz, benzene protons), 8.38 (d, 1H, J = 8.4 Hz, quinoline 
proton), 8.57 (d, 1H, J = 4.4 Hz, quinoline proton), 9.20 (bs, 1H, -NH-quinoline), 
9.79 (bs, 1H, -CONH-) ppm; 
13
C NMR (DMSO-d6, 100 MHz, δ; ppm) δ 111.4 (2C), 
112.8, 116.5 (2C), 121.6, 122.4 (2C), 124.2 (2C), 125.7, 127.9, 129.2, 129.6, 130.2 
(2C), 138.7, 144.0, 149.3, 149.7, 151.6, 164.7 ppm; MS (EI), m/z [M]
+
 C22H18N4O 
calcd 354.1481, found 354.1486. 
4-Amino-N-(4-(2-amino-6-methylpyrimidin-4-ylamino)phenyl)benzamide (13). 
1
H NMR (DMSO-d6, 400 MHz, δ; ppm) δ 2.06 (s, 3H, -CH3), 5.71 (bs, 2H, -NH2-
benzene), 5.85 (s, 1H, pyrimidine proton), 6.08 (bs, 2H, -NH2-pyrimidine), 6.60 (d, 
2H, J = 8.4 Hz, benzene protons), 7.59-7.64 (m, 4H, benzene protons), 7.71 (d, 2H, J 
= 8.4 Hz, benzene protons), 8.88 (bs, 1H, -NH-pyrimidine), 9.66 (bs, 1H, -CONH-) 
ppm; 
13
C NMR (DMSO-d6, 100 MHz, δ; ppm) δ 23.9, 93.8, 114.3 (2C), 117.7 (2C), 
122.4 (2C), 124.2, 127.9, 130.2 (2C), 136.5, 151.8, 163.1, 164.5, 164.7, 170.2 ppm; 
MS (EI), m/z [M]
+
 C18H18N6O calcd 334.1542, found 334.1545. 
8.4. Biological evaluation, results and discussion 
8.4.1. Nanoscale DNMT1 pre-screen 
Compounds 1-13 were tested in 10-dose IC50 mode with 2-fold serial dilution at 
starting concentration of 500 μM against human DNMT1, using poly(dI-dC) (0.001 
mg/mL) as substrate in the presence of AdoMet (1 µM) as cofactor. Control 
compounds, AdoHcy (S-(5'-adenosyl)-l-homocysteine) and sinefungin, were tested 
in 10-dose IC50 mode with 3-fold serial dilution starting at 100 μM. Their IC50 values 
(µM) from nanoscale HTS against human DNMT1 are reported in Figure 8.2. 
Compounds 2, 4 and 5, obtained by replacing either or both the para with the meta 
linkages in the 1 structure, emerged as highly efficient DNMT1 inhibitors; whereas 
the ortho regioisomers were less potent (3, 6-8) or totally inactive (9). The 
bisquinoline 10 displayed similar potency as SGI-127 (1) against DNMT1, while the 
bispyrimidine 11 was less efficient, and the truncated compounds 12 and 13 showed 
a severe drop of inhibition (Figure 8.2). 
8.4.2. DNMT1, DNMT3A2/3L, PRMT1 and GLP assays 
To perform wider and more accurate assays against DNMTs, the most potent 
compounds 2, 4, 5, 10 and 11, in comparison with 1, were tested against human 
DNMT1 using a hemimethylated substrate and human DNMT3A2/DNMT3L 
complex using an unmethylated substrate (Figure 8.2b). Under these assay 
conditions, the meta/meta analog 5 (IC50= 9 µM) displayed a 4-fold higher activity 
than 1 against DNMT1, while the para/meta (2) and the meta/para (4) analogs were 
2.5- and 7.6-fold less potent, respectively. The bisquinoline 10 showed the same 
DNMT1 inhibiting activity as 1, while the bispyrimidine 11 was 2-fold less active. 
Against DNMT3A2/DNMT3L, all the inhibitors were more efficient than against 
DNMT1, and 5 was again the most potent with IC50 = 2.8 µM, compared to lead 
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compound 1 [IC50= 10 µM]. Among the remaining compounds, 11 and 2 were 2-fold 
less potent than 1, and lower activities were registered with 10 and 4 (Figure 8.2b). 
 
Figure 8.2. Novel quinoline-based non-nucleoside DNMTi. (a) Design of 1 regioisomers. (b) 
Inhibitory activities of 1, 2, 4, 5, 10 and 11 against human DNMT1 (hemimethylated substrate) and 
the DNMT3A2/DNMT3L complex (unmethylated substrate). (c) Inhibitory activities of 1, 2, 4, 5, 10 
and 11 against PRMT1 and GLP. The DNMT1-selectivity (as PRMT or GLP/DNMT1 IC50 ratio) for 
each compound is reported. 
To determine the specificity of 1, 2, 4, 5, 10 and 11 for DNMTs among other 
AdoMet-dependent enzymes, these compound were tested against PRMT1, a protein 
arginine methyltransferase,
564
 and G9a-like protein (GLP), a histone H3 lysine 9 
methyltransferase.
436
 Under the tested conditions, the new derivatives displayed very 
low (or none) PRMT1 and GLP inhibiting activities, resulting in all cases more 
DNMTs-selective than 1, that shared only 4- and 1.9-fold lower activities against 
PRMT1 and GLP, respectively, when compared with DNMTs inhibition. In contrast, 
5 was 33- and 11-fold less potent against PRMT1 and GLP than against DNMT1 
(Figure 8.2c). 
8.4.2.1.Methods  
Protein purification. Expression and purification of human DNMT1 N-
terminal deletion of 600 residues (residues 601-1600) and human 
DNMT3A2/DNMT3L complex have been described.
565
 Recombinant rat PRMT1
564 
and human G9a-like protein (GLP) C-terminal fragment containing both the ankyrin 
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repeats and catalytic SET domain (residues 734-1235; pXC758) were purified as 
described.
566
  
DNMT1 inhibition assay. For DNMT1, methyl transfer activity inhibition assays 
were performed in 20 μL reactions containing 4.6 mM [methyl-3H]-AdoMet (10.0 
Ci/mmol; Perkin Elmer), 1 mM DNA oligonucleotides, 0.2 μM DNMT1, 1 mM 
EDTA and 50 mM Tris-HCl pH 7.5. The DNA substrates were 36-base pair hemi-
methylated (GAC)12. Enzymes were pre-incubated with AdoMet and various 
concentrations of inhibitors for 5 min at 37 
o
C before the addition of substrate DNA. 
After 15 min incubation, the reactions were terminated by the addition of 1% sodium 
dodecyl sulfate and 1 mg/mL of protease K and heat at 50 
o
C for 15 min. The 
reaction mixtures were spotted on DE81 paper circles (Whatman), washed with 5 ml 
of cold 0.2 M NH4HCO3 (twice), 5 mL of deionized water (twice) and 5 mL of 
ethanol (once). The dried circles were subjected to liquid-scintillation counting with 
Cytoscint scintillant. All curves were fit individually using Origin 7.5 software 
(OriginLab).  
DNMT3A inhibition assay. For DNMT3a2/3L complex, the inhibition assays were 
performed 20 μL reactions containing 4.6 mM [methyl-3H]-AdoMet, 1.0 mM DNA 
oligonucleotides, 0.3 μM enzyme, 0.5 mM tris(2-carboxyethyl)phosphine (TCEP), 
2.5% (v/v) glycerol and 50 mM Tris–HCl pH 7.5. The DNA substrates were 28-base 
pair containing two CpG sites: 5'-ACA GTA CGT CAA GAT CTT GAC GTA CTG 
T-3' and the complimentary strand. 
PRMT1 and GLP inhibition assays. For histone methylation inhibitions, the assays 
were performed in 20 μL reactions containing 4.6 mM [methyl-3H]-AdoMet, 50 
μg/mL histone from calf thymus (SIGMA), 12 μg/mL (0.3 μM) PRMT1 or 10 μg/mL 
(0.17 μM) GLP, 100 mM KCl, 5 mM dithiothreitol (DTT) and 50 mM Tris-HCl pH 
8.5. Enzymes were pre-incubated with AdoMet and various concentrations of 
inhibitors for 5 min at 37 
o
C (for PRMT1) or 30 
o
C (for GLP) before the addition of 
histone substrates. After incubation (6.5 min for PRMT1 or 5 min for GLP), the 
reactions were terminated by the addition of 20% trichloroacetic acid (TCA, Fisher 
Scientific). The reaction mixtures were spotted on GF/A paper circles (Whatman), 
washed three times with 3 mL of 10% TCA and once with 3 ml of ethanol. The dried 
circles were subjected to liquid-scintillation counting with Cytoscint scintillant. All 
curves were fit individually using Origin 7.5 software (OriginLab). 
8.4.3. Docking studies of 1 and 5 in DNMT1 alone and in DNMT1/DNA complex 
structures 
Mechanism of action of 5. To better understand the mechanism of inhibition of our 
compounds against DNMT1, 1 and 5 were docked in two different DNMT1 
structures available in Protein Data Bank (PDB), first using DNMT1 (residues 600-
1600) crystallized in complex with the cofactor analog sinefungin (PDB 3SWR, 
Hashimoto and Cheng, unpublished data), and then using DNMT1 (residues 646-
1600) in complex with both AdoMet and a 19-base pair DNA duplex (PDB 3PTA).
62
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These two structures share a similar overall three-dimensional arrangement with 
some conformational differences mainly in the DNA binding CXXC domain region 
(residues 646–692, Figure 8.3).  
Figure 8.3. Superimposition of the DNMT1 structures crystallized in complex (PDB 3PTA) and 
unliganded to DNA (PDB 3SWR). Both the catalytic regions are depicted as grey ribbons, in the 
3PTA structure SAH, the CXXC domain and the DNA are depicted as brown spheres, red ribbons and 
cyan ribbons and ellipsoids, respectively. In the 3SWR structure the CXXC domain is represented as 
red ribbons. 
Docking results achieved on the DNMT1 structure alone (unbound to DNA) revealed 
that both 1 and 5 were able to spam between the AdoMet binding site and the CXXC 
region (Figure 8.4a), inserting their 4-aminoquinoline fragments in a lipophilic 
region normally occupied by AdoMet, and establishing with their 2,4-diamino-6-
methylpyrimidine terminal heads a number of hydrogen-bonds at the CXXC domain 
region. In particular, 5 is able to establish hydrophobic contacts with I1167, M1169, 
P1225, I1247 and T-shaped interaction with F1145, thus clarifying why 5 is more 
potent than its structural congener 1. Indeed, substitution of the quinoline ring with a 
smaller pyrimidine one (11) or with a hydrogen (13) would cause the loss of the 
interactions within the cleft thus explaining the drop in inhibitory potency. Moreover, 
the attached central fragments (4-aminobenzoic acid + 1,4-phenylenediamine of 1 
and 3-aminobenzoic acid + 1,3-phenylenediamine of 5) are embedded in a region in 
which cation- and - interactions are established with R1574 and W1170, 
respectively. The intrinsic rigidity of these fragments allows to project the 2,4-
diamino-6-methylpyrimidine terminal at the crevice between CXXC and 
methyltransferase domains. In this position, the terminal hydrophilic heads of 1 and 5 
H-bond with M694 (backbone CO) and N1568 (side-chain) and with M694 and P692 
(backbone COs) and D1571 (side-chain), respectively. Comparison between the two 
predicted complexes would suggest that in 5 the 4 ligand fragments are optimally 
assembled so as to maximize the interactions in this enzyme region, thus clarifying 
why 5 is more active than its structural parent compound 1. Almost the same binding 
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orientation was obtained when docking 1 in the enzyme/DNA structure in line with 
experimental data demonstrating that this ligand inhibits DNMT1 by competing with 
AdoMet but not with the substrate DNA (Figure 8.4b). On the contrary, the same 
calculations did not succeed in suggesting a well-defined binding pose for 5; indeed, 
when superimposing the coordinates of 5, achieved in the absence of DNA, in the 
DNMT1/DNA complex it seems clear that the subtle rearrangements of the CXXC 
domain induced by the presence of DNA would sterically hamper 5 to spam from the 
AdoMet interaction site to the cleft between CXXC and methyltransferase domains 
(Figure 8.4b). These data allow postulating that, differently from 1, 5 binds the 
enzyme when the DNA is absent thereby inhibiting the enzyme by competing with 
this target substrate. Competition experiments performed with 5 and DNMT1 by 
varying concentration of either DNA or AdoMet confirmed that the mechanism of 
inhibition of 5 was competitive with the DNA substrate and not with the AdoMet 
cofactor (Figure 8.4c). 
 
Figure 8.4. Binding mode and mechanism of action of compound 5. (a) Binding modes of 1 (top) and 
5 (bottom) to DNA-unliganded DNMT1 (PDB 3SWR). (b) Binding modes of 1 (top) and 5 (bottom) 
to DNA/DNMT1 complex (PDB 3PTA). (c) Competition experiments performed with 5 and DNMT1 
by varying DNA (top) or AdoMet (bottom) concentrations. 
8.4.3.1.Methods 
Molecular modelling. Prior to docking calculations, the Epik software was used to 
calculate the most relevant ionization and tautomeric state of compounds 1 and 5. 
Then the Glide program of the Schröedinger package was used to dock these 
compounds into the two selected DNMT1 X-ray structures (PDBs 3SWR
, 
Hashimoto 
and Cheng, unpublished results, and 3PTA). The receptor grid generation was 
performed for the box with a center in the putative binding sites of the two structures. 
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The size of the box was determined automatically. The extra precision mode (XP) of 
Glide was used for docking. The ligand scaling factor was set to 1.0. The geometry 
of the ligand binding site of the complex between 1 and 5 and the DNMT1 structures 
was then optimized. The binding site was defined as 1 or 5 and all amino acid 
residues located within 8 Å from the ligands. All the receptor residues located within 
2 Å from the binding site were used as a shell. The following parameters of energy 
minimization were used: OPLS2005 force field was used. Water was used as an 
implicit solvent, and a maximum of 5000 iterations of the Polak-Ribier conjugate 
gradient minimization method was used with a convergence threshold of 0.01 kJ 
mol
–1
 Å
–1
. All complex pictures were rendered employing the UCSF Chimera 
software. 
Competition studies. In AdoMet-competition assays, AdoMet (0.6TBq/mmol) was 
varied between 0.5 μM and 15 μM with an isotopic dilution of 1*:1 at a fixed DNA 
duplex concentration of 1.0 μM. For each AdoMet concentration, the tested 
compound concentration was adjusted between its IC10 and its IC80. In DNA-
competition assays, the DNA duplex concentration was varied between 0.05 μM and 
1.0 μM whereas AdoMet (0.6TBq/mmol) concentration was hold at 15 μM with an 
isotopic dilution of 1*:2. For each DNA duplex concentration, the tested compound 
concentration was adjusted between its IC10 and its IC80. For each substrate 
concentration, the IC50 of tested compound was calculated by non-linear regression 
fitting with sigmoidal dose-response (variable slope). For each compound 
concentration, Km
app
 and Vm
app
 of each substrate were approximated by non-linear 
fitting of the data with the Michaelis-Menten equation on GraphPad Prism 4.03. 
8.4.4. Effects of quinoline-based DNMTi in a panel of cancer cell lines 
To study the effects in a cellular context, the DNMTi 1, 2, 4, 5, 10 and 11 were tested 
in a panel of cancer cells (histiocytic lymphoma U-937, breast cancer MDA-MB-
231, Burkitt’s lymphoma RAJI and prostate cancer PC-3). Trypan blue exclusion 
assays were carried out to determine their effects on cell proliferation and viability. 
The effect of the tested compounds in peripheral blood mononuclear cells (PBMCs) 
was also determined to assess for differential toxicity. In full agreement with their 
DNMT inhibition potency, compounds 1, 2 and 5 displayed the highest 
antiproliferative effects and the strongest cell death induction in all the cancer cells 
tested (Figure 8.5a-d). Compounds 4, 10 and 11 showed both lower activity and 
cytotoxicity in these assays (Figure 8.1). Compounds 1 and 5 showed comparable 
potency against tumor cells, but 5 was the less toxic in PBMCs (Figure 8.5e, f). 
Nuclear morphological changes were further observed by fluorescence microscopy 
after Hoechst and propidium iodide (PI) staining in both U-937 and RAJI cells 
treated with increasing doses of 5, to assess levels of necrosis and apoptosis induced 
by the compound (Figure 8.5g). In U-937 cells, 5 displayed massive apoptosis at 10 
µM followed by necrosis at 25µM, while in RAJI cells 5 mainly let to necrosis at 25 
µM without triggering any apoptotic response at lower concentrations.  
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Figure 8.5. Cellular studies on quinoline-based DNMTi. (a-e) Antiproliferative effects (left) and cell 
death induction (right) of 1, 2 and 5 on U-937 (a), RAJI (b), MDA-MB-231 (c), PC-3 (d) and PBM (e) 
cells. (f) IC50 values of cell viability relative to the above cells treated with 1, 2 and 5 for 48 h. (g) 
Nuclear morphology analysis after Hoechst and PI staining in U-937 and RAJI cells treated with 
increasing doses of 5 for 72 h. Data represent the mean (±SD) of at least three independent 
experiments. Pictures are representative of three independent experiments.  
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8.4.4. 1. Effects of 2 and 5 in medulloblastoma stem cells (MbSCs) 
Further results were collected to evaluate the effect of the compound 2 and 5 on 
murine stem tumor medulloblastoma (MBSC), which express high levels of 
DNMT.
567 
When tested in mouse MbSCs, expressing high levels of DNMTs, 
compound 5 arrested the cell clonogenic activity and induced cell adhesion and 
differentiation, significantly impairing MbSC growth rate, evaluated by 
quantification of PCNA levels and MTT assay (Figure 8.6a, b). MbSCs 
dfferentiation was evaluated by βIII-tubulin and phase contrast images (Figure 8.6c, 
d). In these assays, 5 displayed the highest growth arrest, while 2 showed higher 
differentiation already after treatment with lower doses. To the best of our 
knowledge, these are the first examples of non-nucleoside DNMTi tested in cancer 
stem cells (CSCs).  
Figure 8.6. Effects of 2 and 5 in MbSCs. (a) PCNA mRNA levels and (b) MTT assay of MbSCs after 
48 h of 2 and 5 treatment or DMSO as control (Ctr). *P<0.05 versus untreated cells (ctr). (c) mRNA 
levels of βIII-tubulin (βIIItub) in 2- and 5-treated MbSCs for 48 h. DMSO was used as 
control.*P<0.05 versus untreated cells (ctr). (d) Representative bright field images of MbSCs after 2 
or 5 (48 h, 10 μM) or DMSO as control. 
8.4.4.2. Methods 
U-937, RAJI, PC-3, MDA-MB-231 and PBM cellular assays. U-937 (histiocytic 
lymphoma), RAJI (Burkitt's lymphoma), PC-3 (prostate cancer), MDA-MB-231 
(breast cancer) cell lines were purchased from Deutsche Sammlung für 
Mikroorganismen und Zellkulturen (DSZM). Cells were cultured in RPMI 1640 
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(Lonza), supplemented with 10% fetal calf serum (Lonza) and 1% antibiotic 
antimycotic (Lonza). Peripheral blood mononuclear cells (PBMCs) were isolated and 
cultured as previously reported by our collaborators.
568
 Cells in exponential growth 
phase were treated with compounds at the indicated concentrations. Proliferation and 
viability were assessed by trypan blue exclusion analysis at the indicated time points. 
Morphological determination of apoptosis and necrosis was performed as described 
previously.
569
  
Stem cell cultures and treatments. Medulloblastoma cancer stem cells (MbSCs) 
were isolated and cultivated as already described.
569
 More in detail, MbSCs were 
isolated from fresh tumor specimens from Ptch1+/-. Cells were obtained after 
mechanical and enzymatic dissociation and cultured in serum-free DMEM-F12 plus 
glucose 0.6%, insulin 25 mg/mL, N-acetyl-L-cystein 60 mg/mL, heparin 2 mg/mL, 
B271X, EGF 20 ng/mL and bFGF 20 ng/mL. MbSCs were also treated to 
differentiate in vitro after withdrawal of EGF/bFGF and addition of differentiating 
factors (Platelet Derived Growth Factor, PDGF) for 48 h. Compounds 2 and 5 were 
resuspended in DMSO at 1 mM. Cells were treated with increasing concentration of 
2 or 5 (1, 10 and 50 µM) for 48 h and DMSO was used as control. Unless otherwise 
indicated, media and supplements were purchased from Gibco-Invitrogen (Life 
Science) and chemicals were from Sigma-Aldrich (St. Louis, MO). 
MTT assay. MbSC were treated with 1, 10 and 50 µM of compound 2 or 5 for 48 h. 
Growth of drug-treated cells relative to untreated cells was measured by MTT assay. 
Each sample was measured in triplicates and repeated at least three times. 
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8.4.5. Conclusion 
Through chemical manipulation applied on the structure 1 we identified compound 5, 
a novel non-nucleoside DNMTi more potent of 1 and more selective towards other 
AdoMet-dependent methyltransferases (PRMT1, GLP). Differently from 1, 
competitive with AdoMet, 5 was found to be competitive with DNA for its DNMT1 
inhibition. Tested on a panel of cancer cells (leukemia U937, breast cancer MDA-
MB-231, Burkitt’s lymphoma RAJI, and prostate cancer PC-3) as well as on PBMCs, 
5 displayed comparable activity as 1 and less toxicity. In MbSCs, at 10 μM 5 
significantly blocked proliferation but required higher doses (50 μM) to induce 
differentiation, while the related compound 2, less potent as antiproliferative agent, 
showed high differentiating activity. The anticancer activity displayed by 2 and 5 in 
the tested cancer cells including CSCs suggests their use as potent and selective non-
nucleoside DNMTi for cancer therapy. 
* Adapted with the permission from Valente, S.,
 
 Liu, Y., Schnekenburger, M., 
Zwergel, C.,
 
Cosconati, S., Gros, C., Tardugno, M., Labella, D., Florean, C., Minden, 
S.,
 
Hashimoto, H., Chang,Y., Zhang, X., Kirsch, G., Novellino, E., Arimondo, P.B., 
Miele, E., Ferretti, E., Gulino, A., Diederich, M., Cheng, X., Mai, A.
 
Selective non-
nucleoside inhibitors of human dna methyltransferases active in cancer including 
cancer stem cells, J. Med. Chem., accepted.
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9. Quinazoline analogues as Novel DNA methyltransferase 3A 
inhibitors
*
 
9.1. Research project 
DNMT3A and DNMT3B are de novo methyltransferases, adding methyl groups in 
unmethylated genomic sequences at CpG dinucleotides, and are highly expressed in 
early embryonic cells, downregulated after differentiation and in adult somatic tissues, 
and overexpressed in cancer.
571,572 
During our investigation of small molecule 
epigenetic modulators, we recently described various series of compounds able to 
inhibit protein/histone methyltransferases, a subfamily of AdoMet-dependent 
methyltransferases catalyzing the (poly)methylation of arginine (Arg) or lysine (Lys) 
residues in both histone and in non-histone proteins.
573,574
 In particular, chemical 
manipulation of BIX-012946 (1) (Figure 9.1), a specific G9a/G9a-like protein (GLP) 
histone H3 Lys9 (H3K9) methyltransferase inhibitor, led to E67
575
 (2) (Figure 9.1), 
bearing a 5-amminopentyloxy substituent at the C7 position of the quinazoline ring 
with enhanced G9a/GLP inhibitory activity in vitro and reduced toxicity in vivo. X-ray 
crystal structures of 1 and 2 complexed with GLP 
564,575,576
 showed that for both 
compounds the quinazoline scaffold, linked to the C4-(1-benzyl-4-piperidinylamino) 
and the C2-diazepane (1) or C2-(3-dimethylaminopropylamino) (2) moieties, 
resembles the bound conformation of histone H3 Lys4 to Arg8, while the C6-(5-
aminopentyloxy) chain of 2 mimics the target Lys9 of histone H3 in the substrate 
peptide binding groove. For both compounds, the C6-methoxy group is inserted into a 
shallow surface pocket mimicking the H3A7 side chain, and is crucial for binding to 
H3K9 modification enzymes (methyltransferases as well as demethylases), 
discriminating them from other enzymes, such as for example H3K4 
methyltransferases and demethylases.
564,575,576  
 
Figure 9.1. Known quinazolines (1-3) as G9a/GLP inhibitors, and novel 6,7-
desmethoxyquinazolines 4-18.  
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Chemical changes performed by other authors on 1 led to UNC0638 
577
 (Figure 9.1, 
3), a potent and selective G9a/GLP inhibitor featuring the 1-iso-propyl-4-
piperidinylamino moiety at C4, the cyclohexyl group at C2, the 3-(1-
pyrrolidino)propyloxy chain at C7, and the methoxy group at C6 position of the 
quinazoline ring. Compound 3 showed nanomolar potency against G9a, excellent cell 
permeability and robust on-target activity in cells.
577
 Interestingly, compound 3 was 
found to be inactive against other histone lysine methyltransferases, but displayed 
high micromolar activity against DNMT1.
577
 This suggested that the quinazoline 
moiety, used to develop lysine methyltransferase and demethylase inhibitors, could 
also be suitable to design, with appropriate substitutions, compounds able to inhibit 
DNMTs. In addition, we thought that such quinazoline-based compounds lacking the 
C6 methoxy group should be devoid of anti-H3K9 methyltransferase activity. Thus, 
we prepared the series of 6,7-desmethoxy quinazolines 4-18 (Figure 9.1) by 
maintaining the 1-benzyl-4-piperidinylamino moiety (typical of 1 and 2) at the C4 
position of the quinazoline ring and changing the substituent at C2, spanning from 
differently sized cyclic amines (containing or not heteroatoms and/or lipophilic 
groups) to open-chain amines. Compounds 4-18 were tested against hDNMT1, 
catalytic hDNMT3A and hGLP, to assess their activities and selectivity. Molecular 
modeling studies were performed on the most potent 4 and 14 compounds, using the 
DNMT3A crystal structure,
54
 to gain insight on their binding modes. In addition, 
cellular studies were carried out to determine their anticancer effects. 
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9.2. Chemistry 
The synthetic route followed for the preparation of 4-18 is depicted in Scheme 1. The 
2,4- dichloroquinazoline 19 
578
 was treated with 4-amino-1-benzylpiperidine at room 
temperature providing the 4-substituted intermediate 20, which underwent C2-chloro 
displacement at the quinazoline ring with the proper amines at 110 °C in a sealed 
tube to provide the desired 2,4-disubstituted quinazolines.  
Scheme 1 
 
Reagents and conditions: (a) 4-amino-1-benzylpiperidine, dry THF, room temperature; (b) various 
amines, 110 °C, sealed tube. 
The chemical and physical data of the intermediate 20 and those of the final 
compounds 4-18 are shown in Table 9.1 and 9.2, respectively.  
Table 9.1. Chemical and physical properties of compound 20. 
Cpd molecolar structure mp, °C 
recrystall. 
solvent 
Yield % 
20 
N
N
HN
Cl
N
 
158-160 A 86 
A: benzene/cyclohexane 
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Table 9.2. Chemical and physical properties of compound 4-18. 
Cpd molecolar structure mp, °C 
recrystall. 
solvent 
Yield % 
4 
N
N
HN
N
N
N
CH3  
96-98 A 65 
5 
N
N
HN
N
N
N
CH3  
114-118 A 68 
6 
N
N
HN
N
N
 
118-120 A 61 
7 
N
N
HN
N
N
 
119-122 A 71 
8 
N
N
HN
N
N
CH3  
106-108 B 57 
9 
N
N
HN
N
N
CH3
 
128-129 A 45 
10 
N
N
HN
N
N
 
112-115 B 68 
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11 
N
N
HN
N
N
S  
155-157 A 59 
12 
N
N
HN
N
N
O
 
110-112 B 70 
13 
N
N
HN
N
N
N
N  
98-100 B 58 
14 
N
N
HN
N
N
N
 
143-145 A 63 
15 
N
N
HN
N
N
N
O  
213-215 C 50 
16 
N
N
HN
N
N
H
OH
 
116-118 B 61 
17 
N
N
HN
N
N
H
N
CH3
CH3
 
120-122 A 51 
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18 
N
N
HN
N
N
H
N
CH3
CH3  
Oil - 51 
A: cyclohexane; B: petroleum ether; C: acetonitrile 
 
9.3. Experimental section 
Chemistry. Melting points were determined on a Buchi 530 melting point apparatus. 
1
H- and 
13
C-NMR spectra were recorded at 400 MHz on a Bruker AC 400 
spectrometer; chemical shifts are reported in δ (ppm) units relative to the internal 
reference tetramethylsilane (Me4Si). All compounds were routinely checked by TLC 
and 
1
H-NMR. TLC was performed on aluminium-backed silica gel plates (Merck 
DC, Alufolien Kieselgel 60 F254) with spots visualized by UV light. Mass spectra 
were recorded on a API-TOF Mariner by Perspective Biosystem (Stratford, Texas, 
USA), samples were injected by an Harvard pump using a flow rate of 5-10 μL/min, 
infused in the Electrospray system. All solvents were reagent grade and, when 
necessary, were purified and dried by standard methods. Concentration of solutions 
after reactions and extractions involved the use of a rotary evaporator operating at 
reduced pressure of ~ 20 Torr. Organic solutions were dried over anhydrous sodium 
sulphate. Elemental analysis has been used to determine purity of the described 
compounds, that is > 95%. Analytical results are within ± 0.4% of the theoretical 
values. All chemicals were purchased from Aldrich Chimica, Milan (Italy), or from 
Lancaster Synthesis GmbH, Milan (Italy), and were of the highest purity. 
Preparation of N-(1-benzylpiperidin-4-yl)-2-chloroquinazolin-4-amine (20). 2,4-
dichloroquinazoline 19 
578
 (1 eq, 6.2 mmol, 1.2 g) was dissolved in dry 
tetrahydrofuran (THF, 50 mL) and 4-amino-1- benzylpiperidine (2.5 eq, 15.4 mmol, 
2.9 mL) was added to the clear solution. The mixture was stirred at room temperature 
and the reaction was completed after 30 min. The resulting white salt in suspension 
was filtered off and washed with dry THF. The filtrate and the washings were 
concentrated in vacuum and the crude solid triturated with petroleum ether, collected 
by filtration, washed with petroleum ether and dried to give 20 as a pure white solid.
 
1
H-NMR (CDCl3): δ 1.65-1.69 (m, 2H, CH-piperidine ring), 2.14-2.16 (m, 2H, CH-
piperidine ring), 2.26-2.31 (m, 2H, CH-piperidine ring), 2.90-2.93 (m, 2H, CH-
piperidine ring), 3.58 (s, 2H, CH2Ph), 4.33 (m, 1H, NHC4-H-piperidine ring), 5.78 
(d, 1H, NH), 7.29-7.36 (m, 5H, CH-phenyl ring), 7.66-7.68 (t, 1H, C6-H quinazoline 
ring), 7.74-7.76 (m, 3H, C5,7,8-H quinazoline ring). 
13
C-NMR (CDCl3) δ 30.3, 51.8, 
56.8, 64.6, 114.2, 122.5, 126.6, 127.2, 127.6, 128.4, 128.8, 133.1, 138.6, 150.7, 
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157.6, 160.3 ppm. HR-MS (ESI) calculated for C20H22ClN4 [M + H]
+
, 353.1533; 
found, 353.1537. 
 
General Procedure for the Preparation of 4-(1-Benzylpiperidin-4-yl)-2-
(cyclo/alkylamino)quinazolin-4-amines (4-21). Example: N-(1-Benzylpiperidin-
4-yl)-2- morpholinoquinazolin-4-amine (12). A mixture of N-(1-benzylpiperidin-4-
yl)-2-chloroquinazolin-4-amine 23 (1 eq, 0.6 mmol, 0.2 g) and morpholine (5 eq, 2.8 
mmol, 0.25 mL) was placed in a sealed tube and stirred at 110 °C for 1 h. After 
cooling to room temperature, 5 mL of water were added and the resulting precipitate 
was filtered and washed with water. The obtained solid residue was recrystallized 
from petroleum ether to provide pure 12 as a white solid. 
1
H-NMR (CDCl3): δ 1.71-
1.76 (m, 2H, CH-piperidine ring), 2.14-2.31 (m, 4H, CH-piperidine ring), 2.96 (m, 
2H, CH-piperidine ring), 3.61 (s, 2H, CH2Ph), 3.80-3.87 (m, 8H, CH-morpholine 
ring), 4.18 (m, 1H, NHC4-H-piperidine), 5.56 (d, 1H, NH), 7.11 (m, 1H, C6-H 
quinazoline ring), 7.31-7.38 (m, 5H, C-H phenyl ring), 7.50-7.53 (m, 3H, C5,7,8-H 
quinazoline ring). 
13
C-NMR (CDCl3) δ 30.3, 48.7, 51.9, 56.8, 64.7, 66.3, 110.3, 
123.0, 127.2, 127.7, 127.8, 128.4, 128.8, 132.7, 138.6, 152.3, 160.1, 184.6 ppm. HR-
MS (ESI) calculated for C24H30N5O [M + H]
+
, 404.2450; found, 404.2446. 
 
N-(1-Benzylpiperidin-4-yl)-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine 
(4). 
1
H-NMR (DMSO) δ 1.63-1.65 (m, 2H, CH-piperidine ring), 1.86 (m, 2H, CH-
diazepan ring), 1.94-1.97 (m, 2H, CH-piperidine ring), 2.05 (m, 2H, CH-piperidine 
ring), 2.24 (s, 3H, N-CH3), 2.43-2.44 (m, 2H CH-diazepane ring), 2.58 (m, 2H, CH-
diazepane ring), 2.86-2.88 (m, 2H, CH-piperidine ring), 3.48 (s, 2H, CH2Ph), 3.76-
3.79 (m, 2H, CH-diazepane ring), 3.84 (m, 2H, CH-diazepane ring), 4.02 (m, 1H, 
NHCH-piperidine), 7.00 (t, 1H, CH quinazoline ring ), 7.22-7.27 (m, 2H, CH phenyl 
ring), 7.32-7.36 (m, 4H, CH phenyl ring and NH), 7.44-7.48 (m, 1H, CH quinazoline 
ring ), 7.51-7.53 (d, 1H, CH quinazoline ring), 8.02-8.04 (d, 1H, CH, quinazoline 
ring). 
13
C-NMR (DMSO) δ 26.5, 30.2, 46.8, 51.6, 51.9, 56.9, 57.5, 59.2, 61.9, 64.8, 
110.4, 123.1, 127.3, 127.7, 127.8, 128.4, 128.8, 132.8, 138.5, 152.1, 160.1, 184.5 
ppm. HR-MS (ESI) calculated for C26H35N6 [M + H]
+
, 431.2923; found, 431.2928.  
N-(1-Benzylpiperidin-4-yl)-2-(4-methylpiperazin-1-yl)quinazolin-4-amine (5). 
1
H-NMR (CDCl3) δ 1.62-1.64 (m, 2H, CH-piperidine ring), 2.11 (m, 2H, CH-
piperidine ring), 2.22 (m, 2H, CH-piperidine ring), 2.34 (s, 3H, N-CH3), 2.49 (m, 4H, 
CH-piperazine ring), 2.87-2.90 (m, 2H, CH-piperidine ring), 3.54 (s, 2H, CH2Ph), 
3.91 (m, 4H, CH-piperazine ring), 4.13 (m, 1H, NHC4-H-piperidine), 5.45 (s, 1H, 
NH), 7.05 (m, 1H, CH quinazoline ring), 7.32-7.33 (m, 5H, CH phenyl ring), 7.42-
7.49 (m, 3H, CH quinazoline ring). 
13
C-NMR (CDCl3) δ 30.3, 46.6, 51.9, 52.0, 56.8, 
57.2, 64.7, 110.3, 123.1, 127.3, 127.6, 127.9, 128.5, 128.8, 132.3, 138.5, 152.8, 
160.4, 184.6 ppm. HR-MS (ESI) calculated for C25H33N6 [M + H]
+
, 417.2767; found, 
417.2761.  
N-(1-Benzylpiperidin-4-yl)-2-(piperidin-1-yl)quinazolin-4-amine (6). 
1
H-NMR 
(CDCl3) δ 1.68-1.72 (m, 8H, CH-piperidine rings), 2.14-2.17 (m, 2H, CH-piperidine 
ring), 2.24-2.29 (m, 2H, CH-piperidine ring), 2.93 (m, 2H, CH-piperidine ring), 3.59 
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(s, 2H, CH2Ph), 3.89-3.90 (m, 4H, CH-piperidine ring at C2), 4.16 (m, 1H, NHC4-H-
piperidine), 5.52 (s, 1H, NH), 7.05 (m, 1H, CH quinazoline ring), 7.33-7.38 (m, 5H, 
C-H phenyl ring), 7.49-7.53 (m, 3H, C-H quinazoline ring). 
13
C-NMR (CDCl3) δ 
24.5, 25.5, 30.3, 51.8, 54.8, 56.8, 64.8, 110.1, 123.3, 127.3, 127.7, 127.8, 128.5, 
128.8, 132.7, 138.9, 152.3, 160.2, 184.5 ppm. HR-MS (ESI) calculated for C25H32N5 
[M + H]
+
, 402.2658; found, 402.2664.
 
2-(Azepan-1-yl)-N-(1-benzylpiperidin-4-yl)quinazolin-4-amine (7). 
1
H-NMR 
(CDCl3) δ 1.57-1.67 (m, 6H, CH azepane and piperidine rings), 1.82 (m, 4H, CH-
azepane ring), 2.15-2.25 (m, 4H, CH-piperidine ring), 2.90-2.93 (m, 2H, CH-
piperidine ring), 3.57 (s, 2H, CH2Ph), 3.83-3.85 (m, 4H, CH azepane ring), 4.14-4.16 
(m, 1H, NHC4-H-piperidine), 5.40 (s, 1H, NH), 7.03 (m, 1H, C-H quinazoline ring), 
7.34-7.37 (m, 5H, CH phenyl ring), 7.47-7.51 (m, 3H, C-H quinazoline ring). 
13
C-
NMR (CDCl3) δ 26.8, 28.0, 30.3, 51.9, 54.2, 56.7, 64.7, 110.3, 123.4, 127.3, 127.7, 
127.9, 128.7, 128.9, 132.9, 138.6, 152.5, 160.5, 184.3 ppm. HR-MS (ESI) calculated 
for C26H34N5 [M + H]
+
, 416.2814; found, 416.2819.  
N-(1-Benzylpiperidin-4-yl)-2-(4-methylpiperidin-1-yl)quinazolin-4-amine (8). 
1
H-NMR (CDCl3) δ 0.97-0.99 (d, 3H, CHCH3), 1.19-1.23 (m, 2H, CH-piperidine 
ring at C2), 1.65-1.76 (m, 5H, CH-piperidine rings), 2.15-2.26 (m, 4H, CH-
piperidine ring), 2.90-2.94 (m, 4H, CH-piperidine rings), 3.58 (s, 2H, CH2Ph), 4.15 
(m, 1H, NHC4- H-piperidine), 4.86-4.89 (m, 2H, CH-piperidine ring at C2), 5.40 (s, 
1H, NH), 7.05 (m, 1H, C-H quinazoline ring), 7.30-7.37 (m, 5H, CH-phenyl ring), 
7.46-7.52 (m, 3H, C-H quinazoline ring). 
13
C-NMR (CDCl3) δ 20.4, 30.2, 32.3, 34.3, 
51.9, 52.3, 56.5, 64.9, 110.6, 123.5, 127.6, 127.9, 127.8, 128.4, 128.8, 132.5, 138.6, 
152.3, 160.4, 184.7 ppm. HR-MS (ESI) calculated for C26H34N5 [M + H]
+
, 416.2814; 
found, 416.2808.  
N-(1-Benzylpiperidin-4-yl)-2-(2-methylpiperidin-1-yl)quinazolin-4-amine (9). 
1
H-NMR (CDCl3) δ 1.22-1.24 (d, 3H, CHCH3), 1.53-1.54 (m, 2H, CH piperidine 
ring at C2), 1.64-1.77 (m, 6H, CH piperidine rings), 2.14-2.27 (m, 4H, CH-piperidine 
ring), 2.91-3.02 (m, 3H, CH-piperidine rings), 3.59 (s, 2H, CH2Ph), 4.15 (m, 1H, 
NHC4-H piperidine), 4.77-4.81 (m, 1H, CH-piperidine ring at C2), 5.21 (s, 1H, NH), 
7.06 (m, 1H, C-H quinazoline ring), 7.31-7.39 (m, 5H, C-H phenyl ring), 7.50-7.52 
(m, 3H, C-H quinazoline ring). 
13
C-NMR (CDCl3) δ 18.6, 23.3, 25.7, 30.2, 33.8, 
51.9, 52.3, 56.8, 62.6, 64.5, 110.3, 123.2, 127.0, 127.2, 127.5, 128.1, 128.8, 132.7, 
138.8, 152.3, 160.2, 184.5 ppm. HR-MS (ESI) calculated for C26H34N5 [M + H]
+
, 
416.2814; found, 416.2818.  
N-(1-Benzylpiperidin-4-yl)-2-(pyrrolidin-1-yl)quinazolin-4-amine (10). 
1
H-NMR 
(CDCl3) δ 1.62-1.66 (m, 2H, CH-piperidine ring), 1.98-2.00 (m, 4H, CH-pyrrolidine 
ring), 2.17-2.27 (m, 4H, CH-piperidine ring), 2.91 (m, 2H, CH piperidine ring), 3.57 
(s, 2H, CH2Ph), 3.67 (m, 4H, CH-pyrrolidine ring), 4.19-4.20 (m, 1H, NHC4- H-
piperidine), 5.30 (s, 1H, NH), 7.03 (m, 1H, C-H quinazoline ring), 7.28 (m, 2H, CH-
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phenyl ring), 7.36 (m, 3H, CH-phenyl ring), 7.44-7.50 (m, 3H, C-H quinazoline 
ring). 
13
C-NMR (CDCl3) δ 25.5, 30.5, 51.9, 54.5, 56.9, 64.8, 110.6, 123.0, 127.2, 
127.6, 127.9, 128.4, 128.6, 132.7, 138.5, 152.4, 160.5, 184.3 ppm. HR-MS (ESI) 
calculated for C24H30N5 [M + H]
+
, 388.2501; found, 388.2507. 
N-(1-Benzylpiperidin-4-yl)-2-thiomorpholinoquinazolin-4-amine (11). 
1
H-NMR 
(CDCl3) δ 1.71-1.73 (m, 2H, CH-piperidine ring), 2.15-2.17 (m, 2H, CH-piperidine 
ring), 2.26-2.32 (m, 2H, CH-piperidine ring), 2.69-2.71 (m, 4H, CH-thiomorpholine 
ring), 2.95-2.98 (m, 2H, CH-piperidine ring), 3.61 (s, 2H, CH2Ph), 4.14-4.17 (m, 1H, 
NHC4-H-piperidine), 4.23-4.25 (m, 4H, CH-thiomorpholine ring), 5.53 (s, 1H, NH), 
7.09-7.12 (m, 1H, C-H quinazoline ring), 7.28-7.38 (m, 5H, CH-phenyl ring), 7.50-
7.54 (m, 3H, C-H quinazoline ring). 
13
C-NMR (CDCl3) δ 27.7, 30.5, 51.7, 53.6, 56.8, 
64.5, 110.7, 123.5, 127.2, 127.7, 127.9, 128 HR-MS (ESI) calculated for C24H30N5S 
[M + H]
+
, 420.2222; found, 420.2229.  
N-(1-Benzylpiperidin-4-yl)-2-(4-(pyridin-2-yl)piperazin-1-yl)quinazolin-4-amine 
(13). 
1
H-NMR (DMSO) δ 1.65-1.67 (m, 2H, CH-piperidine ring), 1.95-1.98 (m, 2H, 
CH-piperidine ring), 2.10-2.13 (m, 2H, CH-piperidine ring), 2.87-2.90 (m, 2H, CH-
piperidine ring), 3.51 (s, 2H, CH2Ph), 3.57-3.60 (m, 4H, CH-piperazine ring), 3.87 
(m, 4H, CH piperazine ring), 4.08 (m, 1H, NHC4-H-piperidine), 6.65-6.67 (t, 1H, C-
H pyridine ring), 6.87-6.89 (d, 1H, C-H pyridine ring), 7.07 (t, 1H, C-H quinazoline 
ring), 7.29-7.33 (m, 6H, CH-phenyl ring and NH), 7.53 (m, 2H, C-H quinazoline and 
pyridine rings), 7.63-7.64 (d, 1H, C-H quinazoline ring), 8.07-8.09 (d, 1H, C6-H 
pyridine ring), 8.13-8.14 (d, 1H, C-H quinazoline ring). 
13
C-NMR (DMSO) δ 30.3, 
48.5, 49.5, 51.9, 56.8, 64.8, 106.2, 110.3, 117.9, 123.3, 127.3, 127.7, 127.8, 128.4, 
128.8, 132.6, 138.2, 138.7, 148.1, 152.3, 158.3, 160.2, 184.3 ppm. HR-MS (ESI) 
calculated for C29H34N7 [M + H]
+
, 480.2876; found, 480.2871.  
N-(1-Benzylpiperidin-4-yl)-2-(4-phenylpiperazin-1-yl)quinazolin-4-amine (14). 
1
H-NMR (CDCl3) δ 1.68-1.71 (m, 2H, CH-piperidine ring), 2.17-2.20 (m, 2H, CH-
piperidine ring), 2.26-2.32 (m, 2H, CH-piperidine ring), 2.94-2.97 (m, 2H, CH 
piperidine ring), 3.30 (m, 4H, CH-piperazine ring), 3.61 (s, 2H, CH2Ph), 4.08 (m, 
4H, CH-piperazine ring), 4.21 (m, 1H, NHC4-H-piperidine), 5.45 (s, 1H, NH), 6.89-
6.93 (m, 1H, C-H phenyl ring), 7.01-7.03 (m, 2H, C-H phenyl ring), 7.11 (m, 1H, C-
H quinazoline ring), 7.28-7.41 (m, 7H, C-H phenyl rings), 7.49-7.54 (m, 3H, C-H 
quinazoline ring). 
13
C-NMR (CDCl3) δ 30.3, 49.4, 51.9, 56.6, 64.7, 110.5, 114.7, 
121.6, 123.1, 127.2, 127.7, 127.9, 128.5, 128.8, 129.5, 132.7, 138.6, 149.8, 152.5, 
160.2, 184.7 ppm. HR-MS (ESI) calculated for C30H35N6 [M + H]
+
, 479.2923; found, 
479.2928. 
N-(1-Benzylpiperidin-4-yl)-2-(4-benzoylpiperazin-1-yl)quinazolin-4-amine (15). 
1
H-NMR (DMSO) δ 1.63-1.65 (m, 2H, CH-piperidine ring), 1.90-1.93 (m, 2H, CH-
piperidine ring), 2.07 (m, 2H, CH-piperidine ring), 2.83-2.86 (m, 2H, CH-piperidine 
ring), 3.32 (m, 2H, CH-piperazine ring), 3.47 (s, 2H, CH2Ph), 3.69-3.78 (m, 6H, CH-
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piperazine ring), 4.05 (m, 1H, NHC4-H-piperidine), 7.08 (m, 1H, C-H quinazoline 
ring), 7.24-7.32 (m, 6H, CH-phenyl ring and NH), 7.45-7.52 (m, 6H, CH-phenyl and 
quinazoline rings), 7.64-7.66 (m, 1H, C-H quinazoline ring), 8.07-8.09 (d, 1H, C-H 
quinazoline ring). 
13
C-NMR (DMSO) δ 30.5, 50.1, 51.3, 51.9, 56.8, 64.9, 110.7, 
123.0, 127.2, 127.3, 127.7, 127.8, 128.4, 128.5, 128.8, 129.5, 132.6, 135.2, 138.6, 
152.5, 160.3, 168.9, 184.5 ppm. HR-MS (ESI) calculated for C31H35N6O [M + H]
+
, 
507.2872; found, 507.2879. 
N-(1-Benzylpiperidin-4-yl)-2-(ethanolamino)quinazolin-4-amine (16). 
1
H-NMR 
(CDCl3) δ 1.60-1.65 (m, 2H, CH-piperidine ring), 2.09-2.12 (m, 2H, CH-piperidine 
ring), 2.20-2.23 (m, 2H, CH-piperidine ring), 2.89-2.92 (m, 2H, CH-piperidine ring), 
3.52 (s, 2H, CH2Ph), 3.62-3.73 (m, 2H, NHCH2CH2OH), 3.87 (t, 2H, 
NHCH2CH2OH), 4.16 (m, 1H, NHC-H-piperidine), 5.37-5.42 (s, 1H, NH), 5.48-5.51 
(s, 1H, NHCH2CH2OH), 7.10-7.12 (m, 1H, C-H quinazoline ring), 7.30-7.36 (m, 5H, 
CH-phenyl ring), 7.50-7.56 (m, 3H, C-H quinazoline ring). 
13
C-NMR (CDCl3) δ 
30.1, 46.0, 51.7, 56.8, 61.1, 64.5, 109.2, 121.3, 125.2, 126.1, 127.0, 128.4, 128.6, 
131.0, 138.3, 149.8, 158.5, 177.7 ppm. HR-MS (ESI) calculated for C22H28N5O [M + 
H]
+
, 378.2294; found, 378.2299. 
N
4
-(1-Benzylpiperidin-4-yl)-N
2
-(2-(dimethylamino)ethyl)quinazoline-2,4-
diamine (17). 
1
H-NMR (DMSO) δ 1.63-1.69 (m, 2H, CH-piperidine ring), 1.88 (m, 
2H, CH-piperidine ring), 2.01-2.07 (m, 2H, CH-piperidine ring), 2.13-2.17 (s, 6H, 
N(CH3)2), 2.38-2.42 (t, 2H, NHCH2CH2N(CH3)2), 2.85-2.88 (m, 2H, CH-piperidine 
ring), 3.30-3.34 (t, 2H, NHCH2CH2N(CH3)2), 3.42 (s, 2H, CH2Ph), 4.17-4.18 (m, 1H, 
NHC4-H-piperidine), 6.21-6.24 (s, 1H, NHCH2CH2N(CH3)2), 6.98-7.01 (m, 1H, C-H 
quinazoline ring), 7.32-7.39 (m, 6H, C-H phenyl ring and NH), 7.44-7.47 (m, 2H, C-
H quinazoline ring), 8.00-8.03 (m, 1H, C-H quinazoline ring). 
13
C-NMR (DMSO) δ 
30.0, 46.6, 46.7, 51.7, 56.8, 60.5, 64.5, 109.2, 121.4, 125.2, 126.1, 127.0, 128.2, 
128.5, 131.0, 138.3, 149.8, 158.5, 177.6 ppm. HR-MS (ESI) calculated for C24H33N6 
[M + H]
+
, 405.2767; found, 405.2761. 
N
4
-(1-Benzylpiperidin-4-yl)-N
2
-(3-(dimethylamino)propyl)quinazoline-2,4-
diamine (18). Oil. Yield: 59%. 
1
H-NMR (CDCl3) δ 1.64-1.66 (m, 2H, 
CH2CH2N(CH3)2), 1.82 (m, 2H, CH-piperidine ring), 2.10-2.14 (m, 2H, CH-
piperidine ring), 2.20-2.267 (m, 8H, NHCH2CH2CH2N(CH3)2 and CH-piperidine 
ring), 2.40-2.44 (m, 4H, CH2CH2N(CH3)2 and CH-piperidine ring), 2.90-2.93 (m, 2H, 
CH-piperidine ring), 3.53-3.57 (m, 4H, CH2Ph and NHCH2CH2CH2N(CH3)2), 4.19-
4.22 (m, 1H, NHC4-H-piperidine), 5.51 (s, 1H, NH), 7.10-7.12 (m, 1H, C-H 
quinazoline ring), 7.30-7.36 (m, 5H, C-H phenyl ring), 7.48-7.54 (m, 3H, C-H 
quinazoline ring). 
13
C-NMR (CDCl3) δ 26.5, 30.3, 40.2, 46.5, 51.8, 55.3, 56.4, 64.7, 
109.3, 121.3, 125.4, 126.1, 127.0, 128.2, 128.7, 131.3, 138.1, 149.8, 158.4, 177.5 
ppm. HR-MS (ESI) calculated for C25H35N6 [M + H]
+
, 419.2923; found, 419.2928.  
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9.4 Biological evaluation, results and discussion 
9.4.1. DNMT1, DNMT3A and GLP assays 
Human DNMT1 and human DNMT3A catalytic domain (hDNMT3A) were used as 
enzyme sources to test 4-18, in comparison with 1 as reference drug. In Table 9.3 the 
percent of inhibition of DNMT1 (at 100 M) and DNMT3A (at 100, 33, 10, and 3.3 
M) for 4-18 are reported.  
Table 9.3. Percent of inhibition of 4-18 against hDNMT1 and hDNMT3A.
a
 
% inhibition 
Compound 
hDNMT1 hDNMT3A 
100 M 100 M 32 M 10 M 3.2 M 
4 NA
b
 67 ± 3 55 ± 3 39 ± 2 16 ± 4 
5 NA 30 ± 8 14 ± 3 0 ND
c
 
6 NA 57 ± 8 33 ± 6 14 ± 6 11 ± 5 
7 NA 57 ± 3 32 ± 3 16 ± 2 7 ± 2 
8 NA 53 ± 3 35 ± 5 14 ± 2 7 ± 1 
9 NA 47 ± 5 14 ± 7 5 ± 2 1 ± 0.5 
10 47 ± 2 66 ± 4 43 ± 6 21 ± 8 8 ± 4 
11 NA 42 ± 3 ND 8 ± 2 ND 
12 NA 0 ND ND ND 
13 NA 62 ± 3 52 ± 5 19 ± 13 8 ± 0.4 
14 NA 63 ± 4 54 ± 3 40 ± 4 13 ± 2 
15 NA 0 ND ND ND 
16 NA 0 ND ND ND 
17 NA 0 ND ND ND 
18 NA 0 ND ND ND 
1 35 ± 8 0 ND ND ND 
a
 Values are means of two to six experiments ± standard errors. 
b
 NA, not active (% 
inhibition < 30%).
c
 ND, not determined. 
 
Most of the tested compounds were unable to significantly inhibit DNMT1 at 100 
M, with the exception of the N-(1-benzylpiperidin-4-yl)-2-(pyrrolidin-1 
yl)quinazolin-4-amine 10, that showed at 100 M almost 50% DNMT1 inhibition. 
For comparison SGI-1027, known DNMT1 inhibitor,
110
 gave 95% of DNMT1 
inhibition at 100 M. Surprisingly, the majority of the synthesized quinazolines (4, 
6-10, 13 and 14) selectively inhibited catalytic human DNMT3A with an inhibition 
at 100 μM ranging from 47 to 70% (Table 9.3). EC50 values for the most potent 
compounds (4, 10, 13 and 14) are reported in Table 9.4. 
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Table 9.4. EC50 values for 4, 10, 13 and 14 against DNMT3A.
a
 
Compound EC50 (μM) 
4 10.2   (7.8 to 13.2) 
10 35.4  (22.0 to 56.8) 
13 12.2   (8.6 to 15.8) 
14 8.7     (8.9 to 11.0) 
a
Values are means of at least three experiments. 
Comparing chemical structures of active versus inactive quinazolines, it is clear that 
the C2 position of the quinazoline scaffold should be substituted with a large 
hydrophobic moiety, typically a diazepane (4) or piperazine carrying an aryl (phenyl, 
pyridyl) ring decreasing its basicity (13, 14), or an azacycloalkane such as piperidine 
(6) eventually carrying a methyl group at C4 position (8), azepane (7), or pyrrolidine 
(10) to obtain the highest inhibition. The presence of a heteroatom different from N 
(i.e., S or O) in the C2-ring decreased the DNMT3A inhibitory activity of the 
compound (11) or abrogated it completely (12). Increasing the hydrophilic status of 
the molecules, either by adding a carbonyl group (15) at the C2 substituent or by 
introducing hydroxy- (16) or dimethylamino- (17, 18) alkylamino open side chains at 
C2 gave scarcely active (16) or totally inactive (15, 17, 18) compounds. 
Compounds 4, 10, 13, and 14 were tested at 8 μM against the H3K9 
methyltransferase GLP in comparison with 1, used as reference drug, to determine if 
the absence of the C6/C7 dimethoxy substitution could abolish the inhibitory effect 
of such derivatives against H3K9 methyltransferases (Figure 9.2). As expected, in 
opposition to BIX-10294 (1), 4 was totally inactive against GLP, and 10, 13 and 14 
showed scarce GLP inhibition. 
 
Figure 9.2. Inhibition of GLP by 1, 4, 10, 13 and 14 (measured at 8 µM).  
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9.4.1.1. Methods 
DNMT1 Assay. His-DNMT1 (182kDa, human) was cloned, expressed and purified 
as described by Lee et al.
579
 The DNMT1 assay was performed according to Gros et 
al.
580
 Briefly, the reaction was started by addition of 90 nM of DNMT1 on a mix 
containing the tested compound (up to 1% DMSO), 1 µM of a AdoMet/[methyl-
3
H]-
AdoMet mix in a ratio of 3-to-1 (isotopic dilution 1*:3) and 0.3 µM of biotinylated 
DNA duplex in 10 µL final volume. The reaction was incubated at 37 °C for 2 h in 
reaction buffer (20 mM HEPES pH 7.2, 1 mM EDTA, 50 mM KCl, 25 µg/mL BSA). 
8 µL are then transferred into a streptavidin-coated Flashplate PLUS (PerkinElmer) 
containing 190 µL of 20 µM AdoHcy (Sigma-Aldrich) in 50 mM Tris-HCl pH 7.4. 
The Flashplate was agitated at room temperature for 1 h, washed three times with 
200 µL of 0.05% Tween-20 in 50 mM Tris-HCl pH 7.4, and read in 200 µL of 50 
mM Tris-HCl pH 7.4 on TopCount NXT (PerkinElmer). Percentages of inhibition 
were calculated with the same formula as in DNMT3A assay. 
DNMT3A assay. DNMT3A enzyme inhibition was adapted from the restriction-
based fluorescence assay protocol described in Ceccaldi et al.
581
 Briefly, a 5'-labelled 
biotin oligonucleotide is hybridized to its complementary strand labelled with 6-
carboxyfluorescein at the 3'-end into a 384 well microplate (black Optiplates; Perkin 
Elmer) pre-coated with avidin. The duplex contains a unique CpG site overlapping 
with a restriction site of a methylation sensitive restriction enzyme. The C-terminal 
catalytic domain of human DNMT3A (residues 623-908), produced as described,
54 
was added in each well (200 ng/well) and mixed with the chemical compounds at 
desired concentrations and freshly prepared AdoMet (20 μM final concentration) to 
start the reaction in a total volume of 50 μL. After 1 hour incubation at 37 °C each 
well were washed three times with PBS, 0.05% Tween-20, 500 mM NaCl and three 
more times with PBST. Specific fluorescent signals were detected with the 
methylation-sensitive restriction enzyme HpyCH4IV (NEB) as described and 
measured on a Perkin Elmer Envision detector. The percentage of inhibition is 
reported. The formula used to calculate the percentage of inhibition is [(X-Y)/ X] x 
100, where X is the signal determined in the absence of the inhibitor and Y is the 
signal obtained in the presence of the inhibitor. The concentration at which 50% of 
efficacy of inhibition is observed (EC50) was determined by analysis of a 
concentration range of the tested compound in triplicates. The non-linear regression 
fittings with sigmoidal dose-response (variable slope) were performed with 
GraphPad Prism 4.03 (GraphPad Software). 
GLP Assay. Recombinant human G9a-like protein (GLP) C-terminal fragment 
containing both the ankyrin repeats and catalytic SET domain (residues 734-1235; 
pXC758) were purified as described.
566
 For histone methylation inhibition, the assay 
was performed in 20 μL reaction containing 4.6 mM [methyl-3H]-AdoMet, 50 μg/mL 
histone from calf thymus (SIGMA), 10 μg/mL (0.17 μM) GLP, 100 mM KCl, 5 mM 
dithiothreitol (DTT) and 50 mM Tris-HCl pH 8.5. GLP was pre-incubated with 
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AdoMet and 8 µM inhibitors for 5 min at 30 
o
C before the addition of the histone 
substrate. After incubation (5 min), the reaction was terminated by the addition of 
20% trichloroacetic acid (TCA, Fisher Scientific). The reaction mixture was spotted 
on GF/A paper circles (Whatman), washed three times with 3 mL of 10% TCA and 
once with 3 mL of ethanol. The dried circles were subjected to liquid-scintillation 
counting with Cytoscint scintillant. 
9.4.2. Molecular Modeling Studies 
Molecular modeling studies were performed to explain the reasons behind the 
DNMT3A inhibitory activity of the newly discovered analogues of 1. In particular, 
the most potent and structurally diverse DNMT3A inhibitors 4 and 14 were docked 
into the active site of the enzyme using the Glide software which has been already 
successfully used to suggest a binding conformation for other DNMT3A 
inhibitors.
582
 To this end, the 2.89 Å resolution X-ray crystal structure of the catalytic 
hDNMT3A-hDNMT3L tetrameric complex bound to S-adenosyl- L-homocysteine 
(AdoHcy) was used (PDB code 2QRV).
54
 Docking simulations achieved for 4 placed 
the ligand in the enzyme’s binding cleft of AdoHcy with a calculated docking score 
of -7.232 kcal/mol (Figures 9.3a and 9.3b).  
 
Figure 9.3. Experimental (a) and theoretical (b and c) binding mode of AdoHcy (a), 4 (b) and 14 (c) 
in the DNMT3A active site. Protein is depicted as light yellow ribbons and sticks while ligands are 
depicted as red sticks. Hydrogen-bonds are depicted as dashed blue lines. 
In this conformation, the quinazoline core scaffold is embedded in a rather lipophilic 
and narrow cleft made up by I639, S665, and L884 (Figure 9.3b, highlighted as L1). 
Indeed, the limited room available in the aforementioned cleft would not allow 
hosting of the C6- and C7-methoxy groups of 1 thus explaining why the latter 
compound is inactive against DNMT3A. The achieved binding pose also allowed 
explaining the contribution to ligand binding of the C2- and C4-substituents. In 
particular, the C2-diazepane moiety takes favorable hydrophobic contact with T641 
and I701 residues (herein referred to as L2) explaining why substitution of the C2 
position with neutral azacycloalkane rings (6-10) by favorably filling the L2 cleft still 
results in effective DNMT3A inhibitors. Interestingly, unlike 6-10, 4 bears a 
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protonated nitrogen (N4 of the diazepane ring) that is able to engage with the 
adjacent W889 forming a cation- interaction which was also detected, through X-
ray studies,
54
 for the terminal positively charged nitrogen atom of AdoHcy in the 
interaction with DNMT3A (Figure 9.3a). In agreement with this binding orientation, 
the absence of hydrophobic and/or cation- interactions in this region is detrimental 
for enzyme inhibition (11, 12, 16-18). Regarding the C4 substituent, the 1-benzyl-4-
piperidinylamino group is optimally oriented to engage a long-range ionic interaction 
with E660 so that the terminal aromatic ring is able to form a well-oriented T-shaped 
charge-transfer interaction with F636 and additional hydrophobic contacts in the cleft 
made up by V661, C662, V683, and L726 (herein referred to as L3). Also in this 
case, the same contacts were already detected for the adenine ring of AdoHcy in its 
interaction with the enzyme (Figure 9.3a).
54
 Interestingly, docking results achieved 
for 14 (docking score -6.353 kcal/mol) placed the ligand in a reverted binding pose in 
which the C2 and C4 substituents are now lodged in the L3 and L2 pockets, 
respectively. Such a binding position places the conformationally rigid C-2 
phenylpiperazinyl moiety of 14 so as to recapitulate the interaction pattern 
established by the C4-substituent of 4 and the adenine ring of AdoHcy with the 
enzyme (Figures 9.3c, 9.3b and 9.3a, respectively). Accordingly, increasing of the 
steric demands of the C4-substituent (15-18) should disrupt the interactions with the 
L3 pocket thus being detrimental for the ligand inhibitory potency. On the other hand, 
the L2 pocket is now favorably contacted by the C2 1-benzyl-4-piperidinylamino 
moiety of 14 through a parallel displaced - interaction with W889 aromatic ring. 
In this position, the above mentioned L1 pocket does not seem to be contacted by the 
ligand quinazoline ring that is now forming a hydrogen-bond between its N1 atom 
and R887 side chain; the latter residue is also forming an additional hydrogen-bond 
through its backbone carbonyl oxygen with the ligand exocyclic NH in C4. 
Figure 9.4. a) Binding mode of 4 (yellow sticks) in the GLP binding site (green ribbons) as predicted 
by Glide. The co-crystal ligand 1 (cyan sticks) was also reported for comparison as well as the co-
factor analogue S-adenosyl-L-homocysteine (blue sticks and surface). b) Superimposition of the 
experimental binding pose of the dimethylated H3K9 peptide (pink sticks, PDB code 2RFI) and 1 
(cyan sticks) in the GLP binding site (green ribbons).  
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To rationalize the lack of inhibition potency of the analogues of 1 against GLP, 
compound 4 was docked into the X-ray structure of the enzyme obtained in complex 
with 1 (PDB code 3FPD). Glide results indicated that 4 is indeed able to recapitulate 
the experimental binding position of 1 (Figure 9.4a). Interestingly, in the latter 
compound the C6- and C7- methoxy groups are demonstrated to play a critical role 
in the ligand inhibition as they provide further interactions to better mimic the 
substrate/GLP recognition (Figure 9.4b) thus explaining why their absence in 4 
results in no GLP inhibition.
436
 
9.4.2.1. Methods 
Docking Studies. Prior to docking calculations, the Epik software was used to 
calculate the most relevant ionization and tautomeric state of compounds 4 and 14. 
Then the Glide program of the Schrodinger package was used to dock 4 and 14 to the 
DNMT3A structure (PDB 2QRV). The receptor grid generation was performed for 
the box with a center in the putative binding site. The size of the box was determined 
automatically. The extra precision mode (XP) of Glide was used for docking. The 
ligand scaling factor was set to 1.0. The geometry of the ligand binding site of the 
complex between 10 and the receptor was then optimized. The binding site was 
defined as 10 and all amino acid residues located within 8 Å from the ligand. All the 
receptor residues located within 2 Å from the binding site were used as a shell. The 
OPLS2005 force field was used for energy minimization. Water was used as an 
implicit solvent, and a maximum of 5000 iterations of the Polak–Ribier conjugate 
gradient minimization method was used with a convergence threshold of 0.01 kJ 
mol
–1
 Å
–1
. All complex pictures were rendered employing the UCSF Chimera 
software. 
9.4.3. Studies on different cancer cell lines 
Next we investigated the effects of the most active DNMTi 4, 6-8, 10 and 14 on 
proliferation and viability of U-937 and RAJI lymphoma cells (Figure 9.5a,b). In 
order to assess the differential toxicity of these DNMTi, we then tested their effects 
on peripheral blood mononuclear cells (PBMCs) (Figure 9.5c). Globally, all 
compounds were cytotoxic as they decreased cell proliferation as a consequence of a 
loss of cell viability. IC50 values of 4, 6- 8, 10 and 14 on the cell viability at 48 h on 
PBMCs and on lymphoma cells are reported in Table 9.5. In agreement with its 
DNMT inhibitory potential, compound 14 is the most potent compound in cancer 
cells.  
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Figure 9.5. Cellular effect of 
selected quinazoline analogues. 
Cells were treated with the 
indicated concentration of 
compounds for up to 72 h. 
Antiproliferative effects (left) and 
cell death induction (right) on (a) 
U-937 and (b) RAJI lymphoma cell 
lines. (c) Viability of PBMCs. 
Results are the mean ± SD of at 
least three independent 
experiments. *, **, *** indicate 
p<0.05, p<0.01, p<0.005 versus 
untreated cells, respectively. 
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Table 9.5. Effect of selected quinazolines 4, 6-8, 10, 13 and 14 on PBMC and human 
lymphoma U-937 and RAJI cell viability at 48h. 
Compound 
IC50 ( mean ± SD, M) 
PBMCs U-937 RAJI 
4 31.6 ± 5.8 16.6 ± 3.8 21.1 ± 2.5 
6 18..9 ± 3.2 10.0 ± 4.0 31.0 ± 1.2 
7 11.2 ± 2.3 5.6 ± 0.1 5.9 ± 4.3 
8 10.0 ± 4.3 5.2 ± 0.6 24.1 ± 2.2 
10 24.2 ± 6.9 14.7 ± 3.8 18.7 ± 4.3 
13 11.2 ± 2.2 18.8 ± 1.2 19.7 ± 1.4 
14 9.5 ± 1.2 4.4 ± 1.4 3.4 ± 0.3 
9.4.3.1. Methods 
Cellular Assays. U-937 and RAJI cell lines were purchased from Deutsche 
Sammlung für Mikroorganismen und Zellkulturen (DSZM). Cells were maintained 
in RPMI 1640 (Lonza) supplemented with 10% fetal calf serum (Lonza) and 1% 
antibiotic–antimycotic (Lonza). Peripheral blood mononuclear cells (PBMCs) were 
purified and processed as previously described.
567
 Cells were treated with 
compounds at the indicated concentrations in exponential growth phase. Proliferation 
and viability were assessed by trypan blue exclusion analysis at the indicated time 
points. 
9.4.4. Conclusion 
Quinazoline is a known valuable scaffold for designing histone H3K9 
methyltransferase inhibitors and, when properly substituted (a methoxy group at C6 
and a methoxy/aminoalkyloxy group at C7 position, a 1-alkyl-4-piperidinylamino 
moiety at C4 and a bulky (aza)cycloalkane at C2) provided highly potent G9a/GLP 
inhibitors such as 1-3. Since compound 3 has been reported to be inactive towards 
other protein lysine methyltransferases but able to inhibit DNMT1 at high 
micromolar concentration, we explored the possibility to design new quinazoline 
derivatives as novel DNMT inhibitors. Such compounds should be related to 1-3 
regarding to C2 and C4-substitution, but lacking the C6/C7 dimethoxy group, crucial 
for the interaction with G9a/GLP enzymes. The obtained compounds 4-21 were 
tested against human DNMT1 and C-terminal human DNMT3A and, surprisingly, 
they showed little (if any) inhibiting activity against DNMT1, excepted compound 
10, but were in some cases (4, 6-8, 13 and 14) potent and selective inhibitors of 
DNMT3A. Structure-activity relationship (SAR) data, supported by molecular 
modeling studies performed on the DNMT3A crystal structure (PDB 2QRV), 
highlighted the crucial role of the insertion of a large hydrophobic moiety 
(azacycloalkane, diazepane) or a poorly basic piperazine group at the C2 position of 
the quinazoline scaffold to obtain potent inhibitors. The most efficient DNMT3A 
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inhibitors 4, 13 and 14, in opposite to 1, failed in inhibiting GLP at 8 μM. When 
tested in human lymphoma U-937 and RAJI cells, compounds 4, 6-8 and 14 
displayed high antiproliferative and cell death induction properties already at 10 μM 
concentration, they being less able to decrease viability in PBMCs, taken as model 
for differential toxicity. In agreement with the anti-DNMT3A activity, 14 was the 
most potent in lymphoma cells too, and it represents our lead compound for further 
optimization.
583 
*Adapted with the permission from Rotili, D., Tarantino, D., Marrocco, B., Gros, C., 
Masson, V., Gregoire, J-M., Ausseil, F., Chang, Y., Labella, D., Cosconati, S., Di Maro, S., 
Novellino, E., Schnekenburger, M., Grandjenette, C., Bouvy, C., Diederich, M., Cheng, X., 
Arimondo, P. B., Mai. A. Identification of quinazoline analogues as novel dna 
methyltransferase 3a inhibitors. J. Med. Chem. submitted.583 
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10. tert-Butylcarbamate-containing histone deacetylase inhibitors
*
 
10.1. Research project  
Overexpression of specific HDACs has been observed in many types of cancer, and 
often correlates with poor prognosis.
584
 HDAC inhibition induced by HDAC 
inhibitors (HDACi) may regulate gene expression, both directly and indirectly, by 
hyperacetylation of histones and/or transcription factors such as NF-B, STAT1, 
STAT3, YY1, E2F, and Rb. In cancer cells, HDACi induce cell-cycle arrest by up-
regulation of p21 and/ or down-regulation of cyclins, suppress angiogenesis by 
decreased expression of pro-angiogenic factors (VEGF, HIF-1a), and modulate the 
release of cytokines (TNF-, interleukin-1).585 Thus, HDACi and their development 
have become the subject of intense interest by both academic and industrial 
scientists, and many of them have now entered the clinical arena (see Sec. 6.2.7).  
According to the well-known pharmacophore model for HDACi, a deacetylase 
inhibitor should bear a CAP group to interact with the rim of the catalytic tunnel of 
the enzyme, a connection unit, linking the CAP to a hydrophobic spacer (HS) and 
lying into the tunnel, and an enzyme inhibiting group (EIG), able to complex the zinc 
ion, crucial for the catalysis at the bottom of the tunnel. From 2001, our research 
group has described various chemically different series of HDACi, 
aroylpyrrolylhydroxamates (APHAs) and (aryloxopropenyl)pyrrolylhydroxamates 
1,
586
 aroyl/arylamino-, (phenyloxopropenyl)-, (amidopropenyl)cinnamyl and -
pyridinylpropenoic hydroxamates 2,
587
 and uracil-based hydroxamates and 2-
aminoanilides (UBHAs) 3,
588 
fitting with this pharmacophore model (Figure 10.1).  
Figure 10.1. Design of novel HDAC inhibitors.  
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Some analogues of 1, namely MC1575 and MC1568, displayed class-II-selective 
HDAC inhibitory activity, and have been used as valuable tools to dissect the role of 
class II HDACs in a number of different biological contexts.
355
 Some derivatives of 2 
and 3 showed high anticancer effects. Recently, several authors highlighted 
structurally different HDACi bearing the N-tert-butyloxycarbonyl (Boc)-amino 
group at the CAP moiety (compounds 4-7; Figure 10.1). Such compounds showed 
anti-HDAC6 specific activity and synergistic inhibition of HCT116 cancer cell 
growth when used in combination with paclitaxel, inhibition of the estrogen-
stimulated growth of human breast cancer MCF7 cells, and block the proliferation of 
a panel of pancreatic cancer cell lines.
589
 Thus, we designed and synthesized a series 
of analogues of 1 and 2 containing this chemical feature at the CAP benzene ring, 
and carrying as EIG either the hydroxamate (8, 10) or the 2- aminoanilide (9, 11) 
moiety (Figure 10.1). All the new derivatives 8-11 were tested at 5 M against 
human recombinant (hr) HDAC1 and HDAC4, and for selected compounds IC50 
values were determined against all the HDAC1-11 isoforms. Compounds 8-11 were 
also assayed in human leukemia U937 cells to determine their effects on cell cycle, 
apoptosis induction, and granulocytic differentiation after treatment for 30 h. The 
most pro-apoptotic derivatives were then tested in three different cancer cell lines to 
assess their antiproliferative activities, and the most potent compound was further 
characterized (antiproliferative activity against a wider panel of cancer cells, histone 
H3 acetylation, clonogenic assay) as a valuable anticancer agent.
590
 
10.2. Chemistry 
The synthetic route followed for the preparation of 8-11 is reported in Scheme 1. 
Aldol condensation of commercially available ethyl 4-formyl-1-methyl-1H-pyrrole-
2-carboxylate 12a or ethyl 3-(4-formyl-1-methyl-1H-pyrrol-2-yl)acrylate 12b
591 
with 
3- or 4-tert-butoxycarbonylaminoacetophenones 13a,b was carried out in dry ethanol 
in the presence of sodium ethylate and afforded the pyrrole-containing ethyl esters 
14a-d (Scheme 1). The same reaction performed starting from ethyl 4-
formylbenzoate or ethyl-(4-formylphenyl)acrylate 15a,b furnished the ethyl 
benzoates/cinnamates 16a-d. The esters 14 and 16 were then hydrolyzed with lithium 
hydroxide in tetrahydrofuran/water to afford the corresponding carboxylic/acrylic 
acids 17 and 18, key intermediates for the synthesis of the related hydroxamates 
(reaction with ethyl chloroformate/triethylamine followed by addition of O-(2-
methoxy-2-propyl)hydroxylamine and final acidic treatment with the Amberlyst 15) 
8, 10 or 2’-aminoanilides [treatment with benzotriazole-1 
yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP reagent, Castro’s 
reagent), ortho-phenylendiamine, and (C2H5)3N in dry N,N-dimethylformamide] 9, 
11. Chemical and physical data of compounds 8-11 are listed in Table 10.1. 
Chemical and physical data of the intermediate compounds 14, 16-18 are listed in 
table 10.2. 
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Scheme 1 
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Reagents and conditions: a) C2H5ONa, anhyd. C2H5OH, RT, 2 h; b) LiOH, THF/H2O, overnight; c) 
1. ClCOOC2H5, (C2H5)3N, anhyd. THF, 0°C, 30 min, 2. CH3O(CH3)2ONH2, anhyd. THF, 0°C, 1 h, 3. 
Amberlyst 15, CH3OH, RT, 1.5 h; d) 1. (C2H5)3N, BOP reagent, anhyd. DMF, N2(g), RT, 2. o-
phenylendiamine, anhyd. DMF, N2(g), RT, 1 h. 
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Table 10.1. Chemical and physical properties of compounds 8-11. 
  
O
N
CONHOH
HN
O
O
n
8a-d
O
N
HN
O
O
n
O
H
N
H2N
9a-d
O
CONHOH
HN
O
O n
10a-d
O
HN
O
O n
H
N
O
NH2
11a-d  
Cpd NH-BOC n mp, °C 
recrystall. 
solvent 
Yield 
% 
8a 3 0 121-123 A 77 
8b 4 0 102-104 A 75 
8c 3 1 120-122 A 73 
8d 4 1 122-124 A 75 
9a 3 0 185-187 B 69 
9b 4 0 119-121 A 88 
9c 3 1 162-164 B 72 
9d 4 1 220-222 C 87 
10a 3 0 125-127 B 82 
10b 4 0 190-192 A 75 
10c 3 1 162-164 A 78 
10d 4 1 180-182 A 81 
11a 3 0 210-212 C 67 
11b 4 0 194-196 B 74 
11c 3 1 205-207 C 74 
11d 4 1 123-125 A 59 
A: toluene; B: acetonitrile; C: methanol 
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Table 10.2. Chemical and physical data of compounds 14, 16-18. 
O
N
COOEt
HN
O
O
n
14a-d
O
N
COOH
HN
O
O
n
17a-d
O
COOEt
HN
O
O n
16a-d
O
COOH
HN
O
O n
18a-d
3
4
 
Cpd NH-BOC N mp, °C 
recrystall. 
solvent 
Yield 
% 
14a 3 0 97-99 D 78 
14b 4 0 110-112 D 76 
14c 3 1 115-117 E 75 
14d 4 1 120-122 E 73 
16a 3 0 172-174 B 78 
16b 4 0 180-182 B 81 
16c 3 1 167-169 B 73 
16d 4 1 179-181 B 77 
17a 3 0 199-201 C 73 
17b 4 0 135-137 A 75 
17c 3 1 209-211 C 72 
17d 4 1 190-192 B 74 
18a 3 0 216-218 C 76 
18b 4 0 227-229 C 77 
18c 3 1 212-214 C 73 
18d 4 1 222-224 B 75 
A: toluene; B: acetonitrile; C: methanol; D: cyclohexane;  
E: cyclohexane/toluene 
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10.3. Experimental section 
Chemistry. Melting points were determined on a Büchi 530 melting point apparatus 
and are uncorrected. 
1
H NMR and 
13
C NMR spectra were recorded at 400 MHz on a 
Bruker AC 400 spectrometer; chemical shifts () are reported in ppm relative to the 
internal reference tetramethylsilane. EIMS data were recorded with a Fisons Trio 
1000 spectrometer; only molecular ions [M]
+
 and base peaks are given. All 
compounds were routinely checked by TLC, 
1
H NMR and 
13
C NMR spectra. TLC 
was performed on aluminum-backed silica gel plates (Merck DC, Alufolien 
Kieselgel 60 F254) with spots visualized by UV light. All solvents were reagent grade 
and, when necessary, were purified and dried by standard methods. Concentration of 
solutions after reactions and extractions involved the use of a rotary evaporator 
operating at reduced pressure of ~20 Torr. Organic solutions were dried over 
anhydrous Na2SO4. All chemicals were purchased from Aldrich Chimica, Milan 
(Italy) or from Alfa Aesar, Milan (Italy), and were of the highest purity. 
General procedure for the synthesis of the esters 14 and 16. Example: Synthesis 
of ethyl 3-(4-(3-(4-((tert-butoxycarbonyl)amino) phenyl)-3-oxoprop-1-
enyl)phenyl)acrylate (16 d): tert-Butyl 4-acetylphenylcarbamate 13b (2.12 mmol, 
0.5 g) and ethyl 3-(4-formylphenyl) acrylate 15b (2.12 mmol, 0.433 g) were added to 
a solution of Na
0
 (2.54 mmol, 0.05 g) in C2H5OH (5 mL). The resulting mixture was 
stirred at room temperature for 4 h. The reaction was quenched with H2O (30 mL) 
and extracted with EtOAc (3x50 mL). The combined organic extracts were washed 
with saturated NaCl solution (3x50 mL), dried with Na2SO4, and concentrated to 
obtain a residue that was purified by column chromatography (SiO2 eluting with 
EtOAc/n-hexane 1:2) to give the compound 16d as a pale-yellow solid. 
1
H NMR 
(CDCl3, 400 MHz): =1.33-1.37 (t, 3H,OCH2CH3), 1.54 (s, 9H, C(CH3)3), 4.25-4.31 
(q, 2H, OCH2CH3), 6.47-6.51 (d, 1H, CH=CHCOOEt), 6.76 (bs, 1H, (CH3)3CONH), 
7.50- 7.71 (m, 8H, benzene protons, CH=CHCOOEt and PhCOCH=CH), 7.77- 7.81 
(d, 1H, PhCOCH=CH), 8.00-8.02 ppm (d, 2H, benzene protons); 
13
C NMR (CDCl3): 
=28.5 (3C), 79.5, 118.9, 121.4, 122.1 (2C), 126.3 (4C), 130.1 (2C), 133.5, 134.4 
(2C), 141.7, 144.0, 145.2, 153.9, 161.6, 189.7 ppm; MS (EI) calcd for C25H27NO5 
m/z [M]
+
: 421.1889, found: 421.1885. 
General procedure for the synthesis of the acids 17 and 18. Example: Synthesis 
of 3-(4-(3-(4-((tert-butoxycarbonyl)amino)phenyl)- 3-oxoprop-1-enyl)-1-methyl-
1H-pyrrol-2-yl)acrylic acid (17 d): A solution of ethyl 3-(4-(3-(4-((tert-
butoxycarbonyl)amino)phenyl)-3- oxoprop-1-enyl)-1-methyl-1H-pyrrol-2-yl)acrylate 
14d (0.82 mmol, 0.35 g) and 2N KOH (1.64 mmol, 0.092 g) in C2H5OH (15 mL) 
was stirred overnight at room temperature. Then the solvent was evaporated and 2N 
HCl was slowly added till the aqueous phase reached pH 5.0. The colorless solid was 
filtered and washed first with H2O and then with a mixture of (C2H5)2O/petroleum 
ether 1:1 to afford pure 17d. 
1
H NMR ([D6]DMSO, 400 MHz): =1.46 (s, 9H, 
C(CH3)3), 3.87 (s, 3H, CH3), 6.34 (d, 1H, CH=CHCOOH), 7.11 (s, 1H, pyrrole- 
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proton), 7.26-7.37 (m, 3H, benzene protons and PhCOCH=CH), 7.57-7.63 (m, 4H, 
pyrrole-a proton, benzene protons, PhCOCH=CH and CH=CHCOOH), 8.08-8.09 (m, 
1H, benzene proton), 9.52 (bs, 1H, (CH3)3CONH), 13.0 ppm (bs, 1H, COOH); 
13
C 
NMR ([D6]DMSO, 400 MHz): =28.5 (3C), 34.0, 79.5, 104.8, 108.0, 121.6, 122.1 
(2C), 123.2, 127.4, 130.1 (2C), 130.6, 133.5, 138.8, 141.7, 145.2, 153.9, 170.6, 189.7 
ppm; MS (EI) calcd for C22H24N2O5 m/z [M]
+
: 396.1685, found: 396.1690. 
General procedure for the synthesis of the hydroxamic acids 8,10. Example: 
Synthesis of tert-butyl-(3-(3-(5-(hydroxycarbamoyl)-1-methyl-1H-pyrrol-3-
yl)acryloyl)phenyl)carbamate (8 a): (C2H5)3N (0.12 mmol, 0.017 mL) and 
ClCOOC2H5 (0.11 mmol, 0.015 mL) were slowly added to a cooled (0 °C) solution 
of 4-(3-(3- ((tert-butoxycarbonyl)amino)phenyl)-3-oxoprop-1-enyl)-1-methyl- 1H-
pyrrole-2-carboxylic acid 17a (0.092 mmol, 0.034 g) in anhydrous THF (5 mL), and 
the mixture was stirred for 45 min at room temperature under N2 atmosphere. 
Afterward, the solid was filtered, washed with anhydrous THF (3 x 5 mL) and then 
O-(2-methoxy-2-propyl)hydroxylamine (0.27 mmol, 0.02 mL) was added, and the 
resulting mixture was stirred for 15 min at room temperature. After this time the 
solvent was removed under vacuum, the residue was diluted in CH3OH (10 mL), and 
Amberlyst 15 ion-exchange resin (0.36 g) was added. The mixture was stirred at 
room temperature for 1 h. After that, the resin was filtered and the filtrate was 
concentrated under reduced pressure to give crude 8a, which was purified by 
recrystallization. 
1
H NMR ([D6]DMSO, 400 MHz): =1.50 (s, 9H, C(CH3)3), 3.94 (s, 
3H, CH3), 7.04 (s, 1H, pyrrole- proton), 7.26-7.67 (m, 6H, benzene proton, 
PhCOCH=CH and PhCOCH=CH), 8.09 (s, 1H, pyrrole- proton), 8.99 (bs, 1H, 
(CH3)3CONH), 9.56 (bs, 1H, CONHOH), 10.95 ppm (bs, 1H, CONHOH); 
13
C NMR 
([D6]DMSO, 400 MHz): =28.5 (3C), 32.9, 79.5, 111.0, 118.7, 122.1 (2C), 126.1, 
127.4, 130.1 (2C), 132.0, 133.5, 141.7, 145.2, 153.9, 163.0, 189.7 ppm; MS (EI) 
calcd for C20H23N3O5 m/z [M]
+
: 385.1638, found: 385.1632. 
General procedure for the synthesis of the 2’-aminoanilides 9,11. Example: 
Synthesis of tert-butyl-(3-(3-(5-((2-aminophenyl)carbamoyl)-1-methyl-1H-
pyrrol-3-yl)acryloyl)phenyl)carbamate (9 a): (C2H5)3N (1.6 mmol, 0.22 mL) and 
benzotriazole-1-yloxytris(dimethylamino) phosphonium hexafluorophosphate (BOP 
reagent) (0.48 mmol, 0.21 g) were added to a solution of 4-(3-(3-((tert-
butoxycarbonyl) amino)phenyl)-3-oxoprop-1-enyl)-1-methyl-1H-pyrrole-2- 
carboxylic acid 17a (0.4 mmol, 0.32 g) in anhydrous DMF (5 mL) under N2 
atmosphere. The resulting mixture was stirred for 30 min at room temperature; 
afterward 1,2-phenylenediamine (0.44 mmol, 0.05 g) was added under N2 
atmosphere and the reaction was stirred overnight. The reaction was quenched with 
H2O (50 mL) and extracted with EtOAc (3x30 mL). The combined organic extracts 
were dried and the residue obtained upon evaporation of solvent was purified by 
column chromatography (SiO2 eluting with EtOAc/n-hexane 1:1) to give pure 9a. 
1
H 
NMR ([D6]DMSO, 400 MHz): = 1.48 (s, 9H, C(CH3)3), 3.87 (s, 3H, CH3), 4.89 (bs, 
2H, NH2), 6.59-6.61 (m, 1H, benzene proton), 6.75-6.77 (d, 1H, benzene proton), 
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6.96-6.98 (m, 1H, benzene proton), 7.14-7.16 (d, 1H, benzene proton), 7.26-7.66 (m, 
7H, benzene protons, pyrrole  and - protons, PhCOCH=CH and PhCOCH=CH), 
8.09 (s, 1H, benzene proton), 9.35 (bs, 1H, (CH3)3CONH), 9.52 ppm (bs, 1H, 
CONH); 
13
C NMR ([D6]DMSO, 400 MHz): =28.5 (3C), 32.9, 79.5, 111.0, 116.5, 
118.7, 119.0, 119.6, 122.4, 122.9, 125.2, 125.5, 126.1, 127.4 (2C), 129.5, 132.0, 
136.4, 138.1, 141.8, 145.2, 153.9, 162.7, 189.7 ppm; MS (EI) calcd for C26H28N4O4 
m/z [M]
+
: 460.2111, found: 460.2118. 
tert-Butyl-(4-(3-(5-(hydroxycarbamoyl)-1-methyl-1H-pyrrol-3-yl)acryloyl) 
phenyl)carbamate (8 b): 
1
H NMR ([D6]DMSO, 400 MHz): = 1.50 (s, 9H, 
C(CH3)3), 3.94 (s, 3H, CH3), 7.04 (s, 1H, pyrrole-  proton), 7.26-7.67 (m, 6H, 
benzene protons, PhCOCH=CH and PhCOCH=CH), 8.09 (s, 1H, pyrrole- proton), 
8.99 (bs, 1H, (CH3)3CONH), 9.56 (bs, 1H, CONHOH), 10.95 ppm (bs, 1H, 
CONHOH); 
13
C NMR ([D6]DMSO, 400 MHz): =28.5 (3C), 32.9, 79.5, 111.0, 
118.7, 122.1 (2C), 126.1, 127.4, 130.1 (2C), 132.0, 133.5, 141.7, 145.2, 153.9, 163.0, 
189.7 ppm; MS (EI) calcd for C20H23N3O5 m/z [M]
+
: 385.1638, found: 385.1632. 
tert-Butyl-(3-(3-(5-(3-(hydroxyamino)-3-oxoprop-1-enyl)-1-methyl-1H-pyrrol-3-
yl)acryloyl)phenyl)carbamate (8 c): 
1
H NMR ([D6]DMSO, 400 MHz): =1.50 (s, 
9H, C(CH3)3), 3.94 (s, 3H, CH3), 7.04 (s, 1H, pyrrole- proton), 7.26-7.67 (m, 7H, 
benzene protons, PhCOCH=CH and PhCOCH=CH, CH=CHCONHOH), 8.09-8.3 
(m, 2H, pyrrole- proton, CH=CHCONHOH), 8.99 (bs, 1H, (CH3)3CONH), 9.56 
(bs, 1H, CONHOH), 10.95 ppm (bs, 1H, CONHOH); 
13
C NMR ([D6]DMSO, 400 
MHz): =28.5 (3C), 34.0, 79.5, 104.8, 108.0, 119.6, 123.2, 124.9, 125.5, 127.4 (2C), 
129.5, 130.6, 134.8, 136.4, 138.1, 145.2, 153.9, 161.6, 189.7 ppm; MS (EI) calcd for 
C22H25N3O5 m/z [M]
+
: 411.1794, found: 411.1788. 
tert-Butyl-(4-(3-(5-(3-(hydroxyamino)-3-oxoprop-1-enyl)-1-methyl-1H-pyrrol-3-
yl)acryloyl)phenyl)carbamate (8 d): 
1
H NMR ([D6]DMSO, 400 MHz): =1.48 (s, 
9H, C(CH3)3), 3.8 (s, 3H, CH3), 6.98 (s, 1H, pyrrole- proton), 7.16-7.7 (m, 7H, 
benzene protons, PhCOCH=CH and PhCOCH=CH, CH=CHCONHOH), 8.09–8.3 
(m, 2H, pyrrole- proton, CH=CHCONHOH), 9.02 (bs, 1H, (CH3)3CONH), 9.43 
(bs, 1H, CONHOH), 10.97 ppm (bs, 1H, CONHOH); 
13
C NMR ([D6]DMSO, 400 
MHz): =28.5 (3C), 34.0, 79.5, 104.8, 108.0, 122.1 (2C), 123.2, 124.9, 127.4, 130.1 
(2C), 130.6, 133.5, 134.8, 141.7, 145.2, 153.9, 161.6, 189.7 ppm; MS (EI) calcd for 
C22H25N3O5 m/z [M]
+
: 411.1794, found: 411.1788. 
tert-Butyl-(3-(3-(4-(hydroxycarbamoyl)phenyl)acryloyl) phenyl)-carbamate (10 
a): 
1
H NMR ([D6]DMSO, 400 MHz): =1.47 (s, 9H, C(CH3)3), 7.44-7.48 (m, 1H, 
COCH=CH), 7.50-8.03 (m, 8H, benzene protons, PhCOCH=CH), 8.10-8.14 (m, 1H, 
benzene proton), 9.09 (bs, 1H, (CH3)3CONH), 9.53 (bs, 1H, CONHOH), 11.30 ppm 
(bs, 1H, CONHOH); 
13
C NMR ([D6]DMSO, 400 MHz): =28.5 (3C), 79.5, 119.6, 
121.4, 125.5, 126.5 (2C), 127.4 (3C), 129.5, 133.4, 136.4, 138.1, 138.6, 145.2, 153.9, 
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163.0, 189.7 ppm; MS (EI) calcd for C21H22N2O5 m/z [M]
+
: 382.1529, found: 
382.1535. 
tert-Butyl-(4-(3-(4-(hydroxycarbamoyl)phenyl)acryloyl) phenyl)- carbamate (10 
b): 
1
H NMR ([D6]DMSO, 400 MHz): =1.49 (s, 9H, C(CH3)3), 6.65-8.11 (m, 10H, 
benzene protons, PhCOCH=CH and COCH=CH), 9.10 (bs, 1H, (CH3)3CONH), 9.84 
(bs, 1H, CONHOH), 11.39 ppm (bs, 1H, CONHOH); 
13
C NMR ([D6]DMSO, 400 
MHz): = 28.5 (3C), 79.5, 121.4, 122.1 (2C), 126.5 (2C), 127.4 (2C), 130.1 (2C), 
133.4, 133.5, 138.6, 141.7, 145.2, 153.9, 163.0, 189.7 ppm; MS (EI) calcd for 
C21H22N2O5 m/z [M]
+
: 382.1529, found: 382.1535. 
tert-Butyl-(3-(3-(4-(3-(hydroxyamino)-3-oxoprop-1-enyl)-phenyl)-acryloyl) 
phenyl) carbamate (10 c): 
1
H NMR ([D6]DMSO, 400 MHz): =1.48 (s, 9H, 
C(CH3)3), 6.52-6.56 (d, 1H, CH=CHCONH), 7.47-7.50 (d, 1H, PhCOCH=CH), 7.63-
7.96 (m, 10H, benzene protons, CH= CHCONH and PhCOCH=CH), 9.12 (bs, 1H, 
(CH3)3CONH), 9.55 (bs, 1H, CONHOH), 10.79 ppm (bs, 1H, CONHOH); 
13
C NMR 
([D6]DMSO, 400 MHz): =28.5 (3C), 79.5, 118.9, 119.6, 121.4, 125.5, 126.3 (4C), 
127.4, 129.5, 134.4 (2C), 136.4, 138.1, 144.0, 145.2, 153.9, 161.6, 189.7 ppm; MS 
(EI) calcd for C23H24N2O5 m/z [M]
+
: 408.1685, found: 408.1691. 
tert-Butyl-(4-(3-(4-(3-(hydroxyamino)-3-oxoprop-1-enyl)phenyl)acryloyl) 
phenyl)carbamate (10 d): 
1
H NMR ([D6]DMSO, 400 MHz): d=1.47 (s, 9H, 
C(CH3)3), 6.52-6.55 (d, 1H, CH=CHCONH), 7.45-7.47 (d, 1H, PhCOCH=CH), 7.49-
8.09 (m, 10H, benzene protons, CH=CHCONH and PhCOCH=CH), 9.10 (bs, 1H, 
(CH3)3CONH), 9.80 (bs, 1H, CONHOH), 10.78 ppm (bs, 1H, CONHOH); 
13
C NMR 
([D6]DMSO, 400 MHz): d=28.5 (3C), 79.5, 118.9, 121.4, 122.1 (2C), 126.3 (4C), 
130.1 (2C), 133.5, 134.4 (2C), 141.7, 144.0, 145.2, 153.9, 161.6, 189.7 ppm; MS 
(EI) calcd for C23H24N2O5 m/z [M]
+
: 408.1685, found: 408.1691. 
tert-Butyl-(4-(3-(5-((2-aminophenyl)carbamoyl)-1-methyl-1Hpyrrol-3-
yl)acryloyl)phenyl)carbamate (9 b): 
1
H NMR ([D6]DMSO, 400 MHz): =1.49 (s, 
9H, C(CH3)3), 3.91 (s, 3H, CH3), 4.89 (bs, 2H, NH2), 6.49-6.51 (m, 1H, benzene 
proton), 6.56-6.63 (d, 1H, benzene proton), 6.75-6.81 (m, 1H, benzene proton), 6.92-
6.94 (d, 1H, benzene proton), 7.31-7.64 (m, 7H, benzene protons, pyrrole  and  
protons, PhCOCH=CH and PhCOCH=CH), 8.08-8.09 (d, 1H, benzene proton), 9.35 
(bs, 1H, (CH3)3CONH), 9.52 ppm (bs, 1H, CONH); 
13
C NMR ([D6]DMSO, 400 
MHz): =28.5 (3C), 32.9, 79.5, 111.0, 116.5, 118.7, 119.0, 122.1 (2C), 122.4, 122.9, 
125.2, 126.1, 127.4, 130.1 (2C), 132.0, 133.5, 141.7, 141.8, 145.2, 153.9, 162.7, 
189.7 ppm; MS (EI) calcd for C26H28N4O4 m/z [M]
+
: 460.2111, found: 460.2118. 
tert-Butyl-(3-(3-(5-(3-(2-aminophenylamino)-3-oxoprop-1-enyl)-1-methyl-1H-
pyrrol-3-yl)acryloyl)phenyl)carbamate (9 c): 
1
H NMR ([D6]DMSO, 400 MHz): 
=1.48 (s, 9H, C(CH3)3), 3.79 (s, 3H, CH3), 4.89 (bs, 2H, NH2), 6.57-6.59 (m, 1H, 
benzene proton), 6.72-6.75 (d, 3H, CH=CHCONH, benzene protons), 6.88-6.90 (m, 
1H, benzene proton), 7.15 (s, 1H, pyrrole- proton), 7.33-7.35 (m, 1H, benzene 
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proton) 7.42-7.72 (m, 6H, benzene protons, pyrrole- proton, CH=CHCONH, 
PhCOCH=CH, PhCOCH=CH), 8.12 (s, 1H, benzene proton), 9.34 (bs, 1H, 
(CH3)3CONH), 9.52 ppm (bs, 1H, CONH); 
13
C NMR ([D6]DMSO, 400 MHz): 
=28.5 (3C), 34.0, 79.5, 104.8, 108.0, 116.5, 119.0, 119.6, 122.4, 122.9, 123.2, 
124.9, 125.2, 125.5, 127.4 (2C), 129.5, 130.6, 134.8, 136.4, 138.1, 141.8, 145.2, 
153.9, 166.7, 189.7 ppm; MS (EI) calcd for C28H30N4O4 m/z [M]
+
: 486.2267, found: 
486.2261. 
tert-Butyl-(4-(3-(5-(3-(2-aminophenylamino)-3-oxoprop-1-enyl)-1-methyl-1H-
pyrrol-3-yl)acryloyl)phenyl)carbamate (9 d): 
1
H NMR ([D6]DMSO, 400 MHz): 
=1.49 (s, 9H, C(CH3)3), 3.78 (s, 3H, CH3), 4.93 (bs, 2H, NH2), 6.55-6.59 (m, 1H, 
benzene proton), 6.71-6.75 (d, 3H, CH=CHCONH, benzene protons), 6.88-6.91 (m, 
1H, benzene proton), 7.17 (s, 1H, pyrrole- proton), 7.34-7.36 (m, 1H, benzene 
proton) 7.52-7.74 (m, 5H, benzene proton, pyrrole- proton, CH=CHCONH, 
PhCOCH=CH, PhCOCH=CH), 8.04-8.06 (d, 2H, benzene protons), 9.34 (bs, 1H, 
(CH3)3CONH), 9.52 ppm (bs, 1H, CONH); 
13
C NMR ([D6]DMSO, 400 MHz): 
=28.5 (3C), 34.0, 79.5, 104.8, 108.0, 116.5, 119.0, 122.1 (2C), 122.4, 122.9, 123.2, 
124.9, 125.2, 127.4, 130.1 (2C), 130.6, 133.5, 134.8, 141.7, 141.8, 145.2, 153.9, 
166.7, 189.7 ppm; MS (EI) calcd for C28H30N4O4 m/z [M]
+
: 486.2267, found: 
486.2261. 
tert-Butyl-(3-(3-(4-((2-aminophenyl)carbamoyl)phenyl)acryloyl)-
phenyl)carbamate (11a): 
1
H NMR ([D6]DMSO, 400 MHz): =1.49 (s, 9H, 
C(CH3)3), 4.93 (bs, 2H, NH2), 6.58-6.61 (m, 1H, benzene proton), 6.77-6.79 (d, 1H, 
benzene proton), 6.96-6.99 (m, 1H, benzene proton), 7.16-7.18 (d, 1H, benzene 
proton), 7.63-7.65 (d, 2H, benzene protons), 7.69-7.74 (d, 1H, PhCOCH=CH), 7.96-
8.23 (m, 5H, benzene protons and PhCOCH=CH), 8.15-8.23 (d, 2H, benzene 
protons), 9.75 (bs, 1H, (CH3)3CONH), 9.83 ppm (bs, 1H, CONH); 
13
C NMR 
([D6]DMSO, 400 MHz): =28.5 (3C), 79.5, 116.5, 119.0, 119.6, 121.4, 122.4, 122.9, 
125.2, 125.5, 126.5 (2C), 127.4 (3C), 129.5, 133.4, 136.4, 138.1, 138.6, 141.8, 145.2, 
153.9, 164.8, 189.7 ppm; MS (EI) calcd for C27H27N3O4 m/z [M]
+
: 457.2002, found: 
457.2008. 
tert-Butyl-(4-(3-(4-((2-aminophenyl)carbamoyl)phenyl)acryloyl)-
phenyl)carbamate (11b): 
1
H NMR ([D6]DMSO, 400 MHz): =1.49 (s, 9H, 
C(CH3)3), 4.93 (bs, 2H, NH2), 6.58-6.61 (m, 1H, benzene proton), 6.77-6.79 (m, 1H, 
benzene proton), 6.96-6.99 (m, 1H, benzene proton), 7.16-7.18 (m, 1H, benzene 
proton), 7.63-7.65 (d, 2H, benzene protons), 7.69-7.74 (d, 1H, PhCOCH=CH), 7.96-
8.23 (m, 5H, benzene protons and PhCOCH=CH), 8.15–8.23 (d, 2H, benzene 
protons), 9.75 (bs, 1H, (CH3)3CONH), 9.83 ppm (bs, 1H, CONH); 
13
C NMR 
([D6]DMSO, 400 MHz): =28.5 (3C), 79.5, 116.5, 119.0, 121.4, 122.1 (2C), 122.4, 
122.9, 125.2, 126.5 (2C), 127.4 (2C), 130.1 (2C), 133.4, 133.5, 138.6, 141.7, 141.8, 
145.2, 153.9, 164.8, 189.7 ppm; MS (EI) calcd for C27H27N3O4 m/z [M]
+
: 457.2002, 
found: 457.2008. 
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tert-Butyl-(3-(3-(4-(3-(2-aminophenylamino)-3-oxoprop-1-enyl)-
phenyl)acryloyl)phenyl)carbamate (11c): 
1
H NMR ([D6]DMSO, 400 MHz): 
d=1.49 (s, 9H, C(CH3)3), 4.95 (bs, 2H, NH2), 6.59-6.63 (m, 1H, benzene proton), 
6.73-6.75 (m, 1H, benzene proton), 6.83-6.85 (d, 1H, PhCOCH=CH), 6.97-6.99 (m, 
1H, benzene proton), 7.18-7.20 (m, 1H, benzene proton), 7.33-7.35 (d, 1H, 
PhCOCH=CH), 7.44-7.47 (t, 1H, benzene proton), 7.73-8.19 (m, 8H, benzene 
protons, PhCOCH=CH and PhCOCH=CH), 8.30-8.31 (m, 1H benzene proton), 9.57 
(bs, 1H, (CH3)3CONH), 9.75 ppm (bs, 1H, CONH); 
13
C NMR ([D6]DMSO, 400 
MHz): d=28.5 (3C), 79.5, 116.5, 118.9, 119.0, 119.6, 121.4, 122.4, 122.9, 125.2, 
125.5, 126.3 (4C), 127.4, 129.5, 134.4 (2C), 136.4, 138.1, 141.8, 144.0, 145.2, 153.9, 
166.7, 189.7 ppm; MS (EI) calcd for C29H29N3O4 m/z [M]
+
: 483.2158, found: 
483.2165. 
tert-Butyl-(4-(3-(4-(3-(2-aminophenylamino)-3-oxoprop-1-enyl)-
phenyl)acryloyl)phenyl)carbamate (11d): 
1
H NMR ([D6]DMSO, 400 MHz): 
d=1.47 (s, 9H, C(CH3)3), 4.55 (bs, 2H, NH2), 6.56-6.91 (m, 5H, CH=CHCONH, 
benzene protons), 7.33-8.10 (m, 11H, PhCOCH=CH, CH=CHCONH, PhCOCH=CH 
and benzene protons), 9.30 (bs, 1H, (CH3)3CONH), 9.80 ppm (bs, 1H, CONH); 
13
C 
NMR ([D6]DMSO, 400 MHz): d=28.5 (3C), 79.5, 116.5, 118.9, 119.0, 121.4, 122.1 
(2C), 122.4, 122.9, 125.2, 126.3 (4C), 130.1 (2C), 133.5, 134.4 (2C), 141.7, 141.8, 
144.0, 145.2, 153.9, 166.7, 189.7 ppm; MS (EI) calcd forC29H29N3O4 m/z [M]
+
: 
483.2158, found: 483.2165. 
10.4. Biological evaluation, results and discussion 
10.4.1. Human recombinant HDAC1 and HDAC4 assays 
Compounds 8-11 were tested at 5 M against hrHDAC1 (substrate: histone H3) and 
hrHDAC4 (substrate: the non-histone trifluoroacetyllysine derivative),
592
 and the 
results are summarized in Table 10.3. Among the hydroxamates 8 and 10, the 
benzene compounds 10 showed, in general, similar or better potency against HDAC1 
than the corresponding pyrrole analogues (with the exception of 10d) but lower than 
SAHA and, with some exceptions (10c and 8c), than MS-275, used as reference 
drugs. Typically, 3-NH-Boc-substituted compounds were more efficient than their 4-
NH-Boc counterparts, and the arylcarbonyl hydroxamates were less potent than the 
arylacrylic analogues, at least in the pyrrole series 8. However, 10a-c and the pyrrole 
8a displayed higher potency than SAHA against HDAC4. Regarding the 2’-
aminoanilides 9 and 11, both the pyrrole and benzene derivatives showed low 
inhibitory potency against HDAC1 if compared with the related hydroxamates, but 
against HDAC4 the pyrrole compounds 9 (with the exception of 9a) were more 
potent than the corresponding hydroxamates, thus being quite HDAC4-selective. 
Against HDAC4 the benzene anilides 11, despite a drop of potency when compared 
with the related hydroxamates, maintained 36- 41% inhibition at 5 M. In relation 
particularly to the pyrrole series 9, the introduction of the Boc-amino substituent at 
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the 3-position of the benzene ring seemed to be preferred, and the insertion of a 
double bond between the carbonyl function and the 2’-aminoanilide moiety led to 
more potent compounds (9c,d). 
Table 10.3. hrHDAC1 and hrHDAC4 inhibitory activity of compounds 8-11. 
Compound 
Inhibition (%)
a
 
HDAC1 HDAC4 
8a 37 ± 0.8 71 ± 4 
8b 24 ± 1 21 ±  2 
8c 65 ± 3 60 ±3 
8d 59 ± 2 51 ± 2 
9a 22 ± 2 43 ± 2 
9b 11 ± 1 32 ± 2 
9c 31 ± 1.2 64 ± 3 
9d 25 ± 2.1 6 ± 2.2 
10a 43 ± 1.8 83 ± 4.4 
10b 37 ± 1.1 8.3 ± 5.2 
10c 65 ± 2.4 76 ± 3.2 
10d 35 ± 1.8 63 ± 2.5 
11a 14 ± 0.9 38 ± 1.4 
11b 10 ± 0.3 36 ± 2.4 
11c 9 ± 0.2 41 ± 1.4 
11d 11 ± 0.9 40 ± 1.3 
SAHA 87 ± 2.2 63 ± 1.3 
MS-275 54 ± 2.1 10 ± 1.4 
a
Percent inhibition at 5M; data represent mean 
values ± SD of at least three separate experiments 
10.4.1.1.Methods 
The HDAC Fluorescent Activity Assay for HDAC1 and HDAC4 is based on the 
Fluor de Lys Substrate and Developer combination (BioMol), and has been carried 
out according to the supplier’s instructions and as previously reported.586e First, the 
inhibitors and purified recombinant HDAC1 or HDAC4 enzymes have been pre-
incubated at room temperature for 15 min before the addition of the substrate which 
is the Fluor de Lys substrate, which comprises an acetylated lysine side chain. For 
the HDAC4 assay, the HDAC4-selective, non-histone substrate reported by Lahm et 
al.
592
 was used. Full-length HDAC1 and HDAC4 with C-terminal His tags were 
expressed using baculovirus systems. Deacetylation sensitizes the substrates that, in 
the second step, treated with the developer produce a fluorophore. Fluorescence was 
detected with a TECAN Infinite M200 station. 
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10.4.2. Effect of compounds 8-11 on -tubulin acetylation in human leukemia U937 
cells as an indication of HDAC6 inhibition 
Western blot analyses in human leukemia U937 cells were performed on 8-11 (5 M, 
24h) to detect their effects on the acetylation level of -tubulin, a marker of HDAC6 
inhibition. MS-275 and SAHA (5 M, 24h) were used as reference drugs. Data 
depicted in Figure 10.2 show that both pyrrole (8) and benzene (10) hydroxamates 
were able to strongly increase -tubulin acetylation, with 10 more efficient than 8. In 
contrast, the 2’-aminoanilides 9 and 11 (including the reference MS-275) yielded a 
signal similar or slightly higher than the control (DMSO). 
 
Figure 10.2. Effects of compounds 8-11, MS-275 (MS), and SAHA (5 M, 24 h) on -tubulin 
acetylation (AcTub) in human U937 leukemia cells. Western blot analyses were performed with 
specific antibodies. ERK proteins were used for equal loading. Blots representative of two 
independent experiments with similar results are shown. 
10.4.2.1. Methods 
For determination of the acetylation levels of -tubulin in U937 cells and histone H3 
in HT29 cells, 25 g of total protein extracted from the cells were separated on 10 
and 13.5% polyacrylamide gels, respectively, and blotted as previously described.
586e
 
Immunodetection was performed using antibodies directed to acetylated -tubulin 
(Sigma-Aldrich), total ERKs (Santa Cruz Biotechnology), acetyl (Lys 9/14)-histone 
H3 (Ac-H3, Millipore), and -actin (Sigma-Aldrich). Anti-mouse or anti-rabbit 
immunoglobulin G (IgG)–horseradish peroxidase (HRP)-conjugated antibodies 
(Amersham Biosciences) were used as secondary antibodies at 1:10000 dilution. 
Antibody binding was visualized by enhanced chemiluminescence according to 
manufacturer’s specification and recorded on autoradiography film (Amersham 
Biosciences). 
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10.4.3. Profiling of selected compounds 8b and 10c on HDAC1-11 isoforms 
Two selected compounds, 8b and 10c, chosen because of their effect on tubulin 
acetylation and their high pro-apoptotic properties in U937 cells (See Sec. 10.4.5), 
were tested against all the HDAC1-11 isoforms in ten-dose IC50 mode with three fold 
serial dilution starting from 50 M solutions (Table 10.4). From these data, the tert-
butyl-(3-(3-(4-(3-(hydroxyamino)-3-oxoprop-1-en-1-yl)phenyl)acryloyl)phenyl) 
carbamate 10c was generally more potent than the tert-butyl (4-(3-(5-
(hydroxycarbamoyl)-1- methyl-1H-pyrrol-3-yl)acryloyl)phenyl)carbamate 8b against 
HDACs (with the exception of HDAC5), and was less efficient than SAHA, used as 
reference drug. Compound 10c displayed single-digit micromolar inhibition of 
HDAC1, -2, -4, -8, and -10, and nanomolar activity against HDAC6 (IC50=10.2 nM). 
Compound 8b was also highly potent against HDAC6, with an IC50 value similar to 
SAHA (IC50 8b= 27.9 nM; IC50 SAHA= 28.6 nM), confirming the western blot data 
on acetyl--tubulin, and because of its low activities against the other HDAC 
isoforms, it is extremely HDAC6-selective. 
Table 10.4. Inhibition of HDAC1-11 isoforms by compounds 8b and 10c and 
SAHA. 
HDACs 
IC50
 
(M) 
8 b 10 c SAHA 
1 54.8 2.9 0.26 
2 28% 
a 
2.1 0.92 
3 82.2 10.8 0.35 
4 74.4 3.2 0.49 
5 70.6 101.0 0.38 
6 0.03 0.01 0.03 
7 30% 
a 
34% 
a 
0.34 
8 19.8 1.2 0.24 
9 99.9 68.8 0.32 
10 NA 
b 
5.1 0.46 
11 16% 
a 
12.0 0.36 
a
 Percent inhibition at 50 M; b Not active. 
10.4.3.1. Methods 
Individual IC50 values for each HDAC isozyme were measured with the 
homogeneous fluorescence release HDAC assay. Purified recombinant enzymes 
were incubated with serial diluted inhibitors at the indicated concentration. The 
deacetylase activities of HDACs 1, 2, 3, 6, and 10 were measured by assaying 
enzyme activity using AMC-K(Ac)GL substrate and AMC-K(TFA)GL substrate for 
HDACs 4, 5, 7, 8, 9, and 11 as previously described.
592
 Deacetylated AMC-KGL was 
sensitive toward lysine peptidase, and free fluorogenic 4-methylcoumarin-7-amide 
(MCA) was generated, which can be excited at 355 nm and observed at 460 nm. The 
data was analyzed on a plate to plate basis in relationship to the control and imported 
into analytical software (GraphPad Prism).  
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10.4.4. Binding studies of 10c in the HDAC6 binding site 
To better rationalize the enhanced inhibitory activity against HDAC6 of the newly 
discovered compounds, molecular modeling studies were undertaken. As the X-ray 
structure of HDAC6 has not been solved, a homology-based model of its major 
functional domain (second catalytic subunit CDII, G482- G801)
593
 was constructed. 
In this step, multiple HDAC X-ray templates and subsequent multiple-threading 
alignments were employed following the I-TASSER methodology.
594
 Interestingly, 
the same methodology has been already applied by Kozikowski and co-workers to 
propose viable ligand-HDAC6 theoretical complexes.
595
 The resulting HDAC6 
model was then used to dock compound 10c, which is among the most active and 
selective HDAC6 inhibitors described herein. Analysis of the modeled enzyme 
binding cavity revealed that its outer portion is lined by five loops that could 
rearrange upon ligand binding. Therefore, to allow for a certain amount of protein 
plasticity during the docking calculation an induced-fit docking approach (IFD) was 
used. In the best ranking binding pose predicted by the IFD (Figure 10.3), 10c is well 
inserted in the enzyme binding cavity with its hydroxamate group coordinating the 
zinc ion. Moreover, the rigid aromatic spacer is embedded in an aromatic cage 
formed by H500, F620, and F680 engaging favorable charge-transfer interactions 
and hydrophobic contacts with P501. On the other hand, the tert-butylcarbamate 
group at position 3 of the terminal phenyl ring extends toward the outer portion of 
the binding gorge contacting one of the loops lining the rim of the catalytic tunnel 
(residues G677–G686). In this position the latter group hydrogen bonds with the 
F199 backbone CO group and engages in hydrophobic contacts with the M682 side 
chain.  
Figure 10.3. Predicted binding pose of 10c in the HDAC6 homology model. The ligand is represented 
as dark-gray sticks, whereas the enzyme is represented as white sticks. Hydrogen bonds are displayed 
as black dashed lines.  
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Analysis of the results obtained for 10d (Figure 10.4) revealed that the ligand is 
unable to form the aforementioned hydrogen bond interaction with the enzyme while 
the hydrophobic contacts with M682 are maintained. According to these calculations, 
the Boc-unsubstituted N-hydroxy- 3-(4-(3-oxo-3-phenylprop-1-en-1-
yl)phenyl)acrylamide would be unable to establish the same interaction pattern 
contacts with the outer portion of the enzyme. These data would explain why 10c 
(IC50= 0.01 M) is a more potent HDAC6i than its close analogue 10d or the Boc-
unsubstituted prototype (IC50=0.04 M and 0.5 M, respectively). 
Figure 10.4. Predicted binding pose of 10d in the HDAC6 homology model. The ligand is represented 
as brown sticks while the enzyme as cyan sticks and surface. 
10.4.4.1. Methods 
The human HDAC6 homology model was obtained using the I-TASSER 
approach.
594 
In particular
 
the sequence of the second catalytic subunit of HDAC6
 
(Q9UBN7), retrieved from the Uniprot server (http://www.uniprot.org), was used as 
the input for the ITASSER
 
method. The position of the zinc ion and the conformation
 
of the chelating residues were extracted from the resolved structure
 
of human 
HDAC7 complexed with SAHA (PDB ID: 3C0Z).
596 
The constructed model was 
then processed using the Protein Preparation
 
Wizard panel of the Schrödinger 2012 
molecular modeling
 
package. In particular, using the preprocess and analyze 
structure tool,
 
the bond orders were assigned, all the hydrogen atoms were
 
added, and 
the disulfide bonds were assigned. Using Epik 2.0 a prediction
 
of the heterogroups 
ionization and tautomeric states was
 
performed. An optimization of the hydrogen 
bonding network was
 
performed using the H-bond assignment tool. Finally, using the
 
impref utility, the positions of the hydrogen atoms were optimized
 
by keeping all the 
heavy atoms in place.
 
Ligand files (10c and 10d) were prepared employing the 
Builder
 
tool and generated with the Ligprep module within Schrödinger
 
2012 
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molecular modeling package. Partial ligand charges were calculated
 
by means of the 
Jaguar suite (Jaguar 4.1; Schrödinger, Inc.) within the same package. The 
electrostatic potential
 
was computed using 6-31G* basis set.
 
Ligands were submitted 
as starting geometries to IFD calculations (Schrödinger Suite 2012 )
 
using Glide 
(Glide 5.7; Schrödinger Suite 2012). In the first IFD stage, a softened-potential
 
docking was performed using GlideSP (Standard Precision) mode
 
generating 20 
initial poses. For each one, a full circle of protein refinement
 
was performed using 
Prime (Prime 3.0; Schrödinger Suite
 
2011). Residues of the protein
 
within 5.0 Å of 
ligand poses were refined, and side chains were
 
conformationally changed and 
subsequently minimized. Ligands
 
were re-docked with GlideXP included in IFD to 
generate poses. All
 
ligand–protein complex pictures were rendered employing the 
UCSF Chimera software. 
10.4.5. Effect of compounds 8-11 on cell-cycle distribution, apoptosis induction, and 
granulocytic differentiation in human U937 leukemia cells 
Compounds 8-11 were tested at 5 M for 30 h in U937 cells to determine their 
effects on cell cycle, apoptosis induction, and granulocytic differentiation (Figure 
10.5, 10.6a,b). SAHA and MS-275 (5 M) were used as reference drugs. Among the 
hydroxamates 8, 10, the compounds 8a, 8b, and 10c displayed an arrest in the G1 
phase similar to (10c) or higher than (8a, 8b) MS-275. Compound 8c blocked the 
cycle at the S phase, similar to SAHA. In relation to the 2’-aminoanilides, the 
benzene compounds 11a and 11b showed a block at the G1 phase similar to MS-275, 
whereas the remaining derivatives produced a weaker effect (Figure 10.5). 
Figure 10.5. Cell-cycle analysis in human U937 leukemia cells treated with compounds 8-11, SAHA, 
and MS-275 at 5 M for 30 h. 
Taking into account the pre-G1 peak as an index of pro-apoptotic properties of the 
compounds, Figure 10.6a shows that the hydroxamates 8a-c and 10c,d exhibited 15- 
21% apoptotic induction in this assay, with 8b and 10c being more potent than 
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SAHA (percent pre-G1 peak: 18.4 (8b), 21.4 (10c), and 16.9% (SAHA). The 
expression of the surface antigen CD11c was determined as a marker of granulocytic 
differentiation in U937 leukemia cells. The cells were treated with 8-11 at 5 M for 
30 h, and then the percentage values of CD11c-positive/propidium iodide (PI)-
negative cells were determined. In this assay, both the pyrrole hydroxamates (8c,d) 
and 2-aminoanilides (9c,d) were able to induce cytodifferentiation effects more 
potently than MS-275, one of the most efficient cytodifferentiating agents among the 
HDAC inhibitors described in literature.
588b,597
 In particular, 9c and 9d displayed 
respectively 90.9 and 76.1% of CD11c+/PI-cells (Figure 10.6b). 
Figure 10.6. a) apoptosis induction, b) granulocytic differentiation in human U937 leukemia cells 
treated with compounds 8-11, SAHA, and MS-275 at 5 M for 30 h. 
10.4.5.1. Methods 
Cell-cycle analysis of U937 cells. 2.5x10
5
 treated and untreated cells were collected, 
fixed, and resuspended in 500 L of a hypotonic buffer (0.1% Triton X-100, 0.1% 
sodium citrate, 50 g mL-1 propidium iodide (PI), RNase A). Cells were incubated in 
the dark for 30 min. Samples were acquired on a FACS-Calibur flow cytometer 
using Cell Quest software and analyzed with standard procedures using Cell Quest 
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software (Becton Dickinson) and ModFit LT version 3 Software (Verity) as 
previously reported.
598
 All the experiments were performed three times.  
Granulocytic differentiation on U937 cells. Granulocytic differentiation of U937 
cells was carried out as previously described.
598
 Briefly, treated and untreated cells 
were harvested and resuspended in 10 L phycoerythrin-conjugated CD11c (CD11c–
PE). Control samples were incubated with 10 L PE-conjugated mouse IgG1, 
incubated for 30 min at 4 °C in the dark, washed in PBS, and resuspended in 500 L 
PBS containing PI (0.25 g mL-1). Samples were analyzed by FACS with Cell Quest 
technology (Becton Dickinson). PI+ cells were excluded from the analysis. 
10.4.6. Antiproliferative activities of selected compounds in a panel of different 
cancer cell lines 
Selected pro-apoptotic compounds (8a, 8b, 10c and 10d) were first tested in three 
different human cancer cell lines (colon carcinoma HCT116, non-small-cell lung 
adenocarcinoma A549, and chronic myeloid leukemia K562), using the CellTiter- 
Glo luminescent cell viability assay, to determine their antiproliferative effects after 
72 h of treatment (Table 10.5). The benzene hydroxamates 10c and 10d showed the 
highest antiproliferative activities in these assays, with IC50 values ranging from 0.6 
to 4.1 M.  
Table 10.5. In vitro antiproliferative effects of selected compounds against cancer 
cell lines. 
Compound 
IC50
 
(M)a 
HTC116 A549 K562 
 8 a 3.6 12.2 1.5 
 8 b 9.7
 
18.8 3.1 
10 c 1.0 4.1 0.6 
10 d 1.3 3.1 1.6 
a
Concentration of test compound required for 50% 
inhibition of cell viability. Performed in replicate (n ≥ 2); 
values are the mean (SD < 30% of the mean). HTC116: 
human colon carcinoma, A549: human non small-cell 
lung adenocarcinoma, K562: chronic myeloid leukemia. 
Thus, we selected the tert-butyl-3-(3-(4-(3-(hydroxyamino)- 3-oxoprop-1-en-1-
yl)phenyl)acryloyl)phenylcarbamate 10c to extend the characterization against a 
panel of different cancer cells (colon carcinoma HT29, melanoma M14, nonsmall- 
cell lung adenocarcinoma H1299, breast adenocarcinoma MCF7, ovarian carcinoma 
HEY, glioblastoma U87, neuroblastoma LAN-5 and SH-SY5Y, pancreatic 
carcinoma PANC-1, prostate carcinoma PC3, and ovarian carcinoma SKOV3 cancer 
cells) after 48h treatment, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) method (Table 10.6). In these assays, the two 
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neuroblastoma LAN-5 and SH-SY5Y cell lines were the most sensitive, with 10c 
displaying sub-micromolar antiproliferative activities, followed by H1229 and HT29 
carcinoma cells (10c active at single-digit micromolar range), whereas the other 
screened cell lines were less susceptible to the treatment. 
Table 10.6. In vitro antiproliferative activity of 10c against a panel of cancer cell 
lines. 
Cell line IC50 (M)
a
 
Colon carcinoma HT29 3.2 
Melanoma M14 21 
Non-small-cell lung adenocarcinoma H1299 2.2 
Breast carcinoma MCF7 21 
Ovarian carcinoma HEY 20 
Ovarian carcinoma SKOV3 40 
Glioblastoma U87 13 
Neuroblastoma LAN- 5 0.4 
Neuroblastoma SH- SY5Y 0.6 
Pancreatic carcinoma PANC-1 28 
Prostate carcinoma PC3 24.5 
a
Concentration of 10c required for 50% inhibition of cell viability. Determined by 
MTT assay; cells were treated with 10c ranging from 0.1 to 100 M for 48h. The 
results are reported as the average of two or three independent experiment (SD < 30% 
of the mean). 
10.4.6.1. Effects of 10c in HT29 cells 
Choosing colon HT29 as a representative cancer cell line, the effect of 10c on 
acetylation level of histone H3 (10 M, 24 h) was detected by western blot analysis. 
SAHA was used at 50 M as reference drug. As depicted in Figure 10.7, an 
increased acetylation at Lys 9/14 of histone H3 was observed after exposure to 10c 
when compared with untreated cells. 
Figure 10.7. Western blot analysis of acetylated histone H3 on Lys 9/14 (Ac-H3) in protein extracts 
obtained after treatment of HT29 cells with 10c (10 M) and SAHA (50 M) for 24 h. -Actin is 
shown as loading and transferring control. A blot representative of two independent experiments with 
similar results is shown. 
To further characterize the antiproliferative effect of 10c in HT29 cells, experiments 
were performed by treating cells for 24 h with the compound (0.5, 1, and 5 M) and 
assessing cell proliferation both at the end of treatment and from 24 to 96 h after the 
end of treatment (Figure 10.8).   
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As reported in Figure 10.8, 10c induced a dose-dependent decrease of cell survival 
up to 16% (5 M, 96 h after the end of treatment). SAHA, tested at the same 
conditions, was less effective.  
Figure 10.8. Percentage of cell survival after treatment with 10c at doses ranging from 0.5 to 5 M 
for 24 h. Analysis was performed at the end of treatment (24 h), and 24 (24R), 48 (48R), 72 (72R), 
and 96 h (96R) after the end of treatment (R= recovery). The results are reported as (viability of 
treated cells)/(viability of control cells)×100, and represent the average ± SD of three independent 
experiments. 
Finally, we assessed the ability of HT29 cells to form colonies after treatment with 
10c (0.5, 1.0, and 5.0 mm, for 24 h). As reported in Figure 10.9, a dose-dependent 
decrease in colony-forming potential was evident in HT29 cells after 10c treatment. 
In particular, an approximate 60% reduction was observed after exposure to 5 M 
10c for 24 h as compared with control untreated cells. 
Figure 10.9. In vitro clonogenic ability of HT29 cells after treatment with 10c at doses ranging from 
0.5 to 5 M for 24 h. 
10.4.6.2. Methods 
Antiproliferative effects of compounds 8 and 10 on a wide panel of cancer cell 
lines.: The antiproliferative effect of selected 8 and 10 compounds was evaluated 
against K562, A549, and HCT116 cell lines using the CellTiter-Glo luminescent cell 
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viability assay (Promega) according to the manufacturer’s instructions. K562, A549, 
and HCT116 cells were incubated for 72 h with various inhibitor concentrations. An 
equivalent of the CellTiter-Glo reagent was then added, the solution was mixed for 2 
min in order to induce cell lysis, and the luminescence was recorded after a further 
10 min. IC50 values were calculated using GraphPad software.  
The antiproliferative effect of 10c on a wider panel of cancer cell lines was evaluated 
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 
mitochondrial respiration analysis, Sigma-Aldrich). Briefly, exponentially growing 
tumor cells were seeded (3×10
3
 cells per well) in sextuplicate in 96-well culture 
plates (Nunc), and 24 h later cells were treated with 10c at concentrations ranging 
from 0.1 to 100 M for 24 or 48 h. Cells were also treated with 1% DMSO, as 
control. Recovery experiments were performed by treating cells for 24 h with the 
compound and assessing cell proliferation both at the end of treatment and from 24 
to 96 h after the washout of the drug. Cell viability was evaluated by adding MTT to 
each well at a final concentration of 0.5 mg mL
-1
 and after 4 h of incubation at 37 °C, 
the formazan salt was dissolved with 200 L isopropyl alcohol. The absorbance of 
each well was measured with an ELISA reader (DASIT) at  570 nm and the 
viability was calculated for each concentration of 10c used as (ODtreated 
cells)/(ODcontrol cells)×100. The concentration of 10c that causes a 50% of cell viability 
inhibition (IC50) was also calculated. 
In vitro colony-forming assay. Suspensions from treated (0.5- 5 M 10c, 24 h) and 
untreated HT29 cells were seeded into 60 mm Petri dishes (Nunc, Mascia Brunelli) 
for 10 days. Colonies were stained with 2% methylene blue in 95% ethanol and 
counted (1 colony >50 cells). The surviving fractions were calculated as the ratio of 
number of colonies per number of plated cells ×100. 
10.4.7. Conclusion 
Using HDAC6-selective inhibitors 4-7, which bear the NH-Boc group at the CAP 
moiety and show growth inhibition of colon HCT116, estrogen-stimulated breast 
MCF7, and a panel of pancreatic carcinoma cell lines as a structural basis, we 
designed, new pyrrole- and benzene-containing hydroxamates (8, 10) and 2’-
aminoanilides (9, 11). These compounds (8, 10, 9, 11) are substituted with a NH-Boc 
group either at the 3- or 4-position of the benzoyl group and are therefore analogues 
of compounds 1, 2 previously described by us and endowed with anticancer 
properties. When tested against HDAC1 and -4, the 3-NH-Boc-substituted 
compounds seemed to be more potent than the corresponding 4-NH-Boc 
counterparts. The benzene hydroxamates 10 displayed higher inhibition than the 
related pyrrole analogues 8, and exhibited a great decrease in activity when changed 
into 2’-aminoanilides (11). In the pyrrole series a similar decrease of potency from 
hydroxamates 8 to anilides 9 was not registered. Both the pyrrole (8) and benzene 
(10) hydroxamates increased the acetylation level of -tubulin in human leukemia 
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U937 cells, a marker of HDAC6 inhibition, whereas both the anilides (9, 11) did not. 
Two compounds, 8b and 10c, were tested on all the HDAC1-11 isoforms, and in 
agreement with previous data, 10c was more potent than 8b in ten of the eleven 
tested isoforms, and both compounds showed HDAC6 inhibition at a nanomolar 
level, 8b being three fold less potent than 10c but extremely more selective because 
of its low potency against the other enzymes. In comparison with other known 
HDAC6-selective inhibitors, such as the Boc-containing compounds 4-7,
589
 the 
tetrahydropyrido[4,3-b]indole derivative tubastatin A,
595
 or the macrocyclic 
hydroxamates (S)-9, (S)-34, and (S)-35,
599
 compounds 8b and 10c displayed similar 
potency and/or selectivity, despite some chemical differences shown mainly at the 
CAP and HS level in the structures. In U937 cells, 8b and 10c (5 M, 30 h) induced 
greater apoptosis (18.4 and 21.4%) than SAHA (16.9 %), and the pyrrole 2’-
aminoanilides 9c and 9d (5 M, 30 h) showed the highest cytodifferentiating effect 
(76.1 and 90.9 %). When tested against a wide panel of different cancer cell lines, 
10c showed low or single-digit micromolar antiproliferative effect, probably related 
to its ability to inhibit HDAC1 and -2, largely overexpressed in cancer (see Sec. 
6.2.5.) Remarkably, against neuroblastoma LAN-5 and SH-SY5Y cell lines 10c 
exerted growth inhibition at nanomolar level, suggesting an additional role for 
HDAC6 inhibition in neurologic diseases.
600
 In colon HT29 cell line, chosen as a 
representative cell line, 10c increased the level of histone H3 acetylation (10 M, 24 
h), and decreased up to 60% the colony-forming potential in a dose-dependent 
manner. Further studies with 10c in vivo are required to assess its potential use as 
anticancer agent. 
*Adapted with the permission from Valente, S., Trisciuoglio, D., Tardugno, M., Benedetti, 
R., Labella, D., Secci, D., Mercurio, C., Boggio, R., Tomassi, S., Di Maro, S, Novellino, E., 
Altucci, L., Del Bufalo, D., Mai, A., Cosconati, S. tert‐Butylcarbamate‐containing histone 
deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative 
activities in cancer cells. ChemMedChem 2013, 8, 800-811.590 Copyright 2013 Wiley-VCH 
Verlag GmbH& Co. KGaA, Weinheim. 
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11. Pan-inhibitors simultaneously targeting Jumonji C and lysine 
specific demethylases
*
 
11.1. Research project 
In contrast to lysyl-acetylation, which normally correlates with transcriptional 
activation, lysyl-methylation correlates with both activation and repression 
depending on the context, including lysine residue location and the extent (me1, me2, 
or me3) of methylation. In general, methylation of histone H3 at Lys residues 9 or 27 
(H3K9 or H3K27) or histone H4 at Lys 20 (H4K20) is associated with repression, 
whereas H3K4, H3K36 and H3K79 methylation correlates with enhanced 
transcription.
444
 Lysine methylation was once thought to be irreversible, however, the 
identification, first, of the lysine specific demethylases (LSDs) followed by the 
Jumonji C (JmjC) demethylases has led to the proposal that it is dynamic. The human 
LSDs (LSD1 and LSD2) demethylate histone substrates using a flavin adenine 
dinucleotide (FAD)-dependent amine oxidase type mechanism. (See Sec. 7.2.1.2.). 
For mechanistic reasons, the LSDs demethylate only mono-and dimethylated lysines. 
LSD1 is specific for H3K4me1/me2 as a component of the CoREST co-repressor 
complex, but in presence of the androgen receptor (AR) its specificity changes from 
H3K4 to H3K9, thus, LSD1 can act either as a transcriptional corepressor or 
coactivator depending on its binding partners and substrates. Pathologically, LSD1 
was found to be oncogenic and/or overexpressed in several cancers ranging from 
leukemias to solid tumors.  
The JmjC enzymes belong to the cupin superfamily of oxygenases and contain an 
Fe
2+
 ion in their catalytic domain and use -ketoglutarate as co-substrate (See Sec. 
7.2.2.1). In contrast to the LSDs, the JmjC KDMs can demethylate all three lysine 
methylation states. JmjC demethylases are overexpressed in multiple types of cancer 
cells,and some JmjC demethylases have been involved in neural development and/or 
function and are associated with non-cancer diseases including X-linked mental 
retardation, autism and midline defects. 
In addition to histones, LSD1 and some JmjCs interact with non-histone proteins that 
also contribute to transcriptional and/or non-transcriptional related processes.  
In human prostate cancers, LSD1 and the JmjC KDM4A/C are co-expressed and co-
localize with androgen receptor (AR). Recently, KDM4A/C inhibitors were found 
not to inhibit prostate (LNCaP and PC3) and colon (HCT116) cancer cell growth in 
isolation, but displayed anti-proliferative effects in combination with NCL-2, an 
LSD1 inhibitor,
559
 suggesting a potential for synergy in LSD and JmjC KDM 
inhibition.
601
  
It is now clear that in multifactorial diseases such as cancer, central nervous system 
disorders, diabetes, or immunoinflammatory diseases, which involve multiple altered 
cellular pathways and signals, the use of single-target drugs (the “one drug, one 
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target” concept) can result in unsatisfactory treatment outcomes.602 Combination 
therapies employing two or more drugs, can be more efficient in controlling such 
complex disease systems and less prone to resistance.
603
 An alternative strategy to 
combination therapy is to develop a single chemical entity that is able to modulate 
multiple targets simultaneously (designed multiple ligands, DMLs).
604,605
 The overall 
goal of the DML approach is to enhance the efficacy and/or improve the safety of 
therapy respect to drug combination. Additional advantages of DMLs are the 
reduction of pill burden for patients, due to the administration of a single compound, 
a lower risk of drug-drug interactions, and improvement in medication adherence. 
Building on previous works,
544,573,576
 here are described pan-demethylase inhibitors 
1-6 (Figure 11.1) that simultaneously inhibit both LSD1 and JmjC KDMs. 
Compounds 1-6 were designed by coupling tranylcypromine (7),
544
 a known LSD1 
inhibitor, and 4-carboxy-4'-carbomethoxy-2,2'-bipyridine 8
553
or 5-carboxy-8-
hydroxyquinoline (9, 5-carboxy-8HQ),
606
 two 2OG competitive templates developed 
for JmjC inhibition (Figure 11.1). The molecular weight of these pan-demethylase 
inhibitors is acceptable because they result from combination of low molecular 
weight molecules.  
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Figure 11.1. Structures of the new pan-demethylase inhibitors 1-6 and of the single-family target 
inhibitors 7-9.  
The compounds were designed based on known inhibition results and 
crystallographic analyses of both the LSDs and JmjC KDMs. Based on manual 
docking studies (Figure 11.2), we proposed that conjugation of tranylcypromine to 
the carboxylate group of either 4-carboxy-4'-carbomethoxy-2,2'-bipyridine 8 
553
 or 5-
carboxy-8-hydroxyquinoline 9 
606
 (to form compounds 1, 2 and 3-6 respectively), 
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would give compounds that are capable of binding to both the LSD and KDM4 
active sites. 
Based on the LSD1 structure (PDB 2XAJ),
544 
 the bipyridyl (for 1) and 
hydroxyquinoline (for 3) rings are predicted to protrude into the LSD1 substrate 
binding pocket, with the tranylcypromine moiety conjugating to FAD, as occurs 
during inhibition by tranylcypromine 7 alone (Figure 11.2A). Analysis of the active 
site of KDM4A (PDB 3PDQ) leads to the proposal that both compounds 1 and 3 can 
chelate the protein-bound iron via their bipyridyl and hydroxyquinoline groups 
respectively, as observed for a known bipyridyl inhibitorand 5-carboxy-8HQ 9. 
Moreover, the primary amines of 1 and 3 may be involved in hydrogen bonding 
and/or electrostatic interactions with KDM4A (Figure 11.2B). 
Figure 11.2. Manual docking of compounds 1 and 3 in LSD1 and KDM4A active sites: (A) 1 (yellow, 
left) and 3 (cyan, right) docked into the active site of LSD1. (B) 1 (yellow, left) and 3 (cyan, right) 
docked into the active site of KDM4A. A known bipyridyl inhibitor is shown in pink (left) and the 5-
carboxy-8HQ 9 in orange (right). 
11.2. Chemistry 
Compounds 1 and 2 (Scheme 1A) were prepared by coupling 4-carboxy-4'-
carbomethoxy-2,2'-bipyridine 8
553
 with trans-N-Boc-2-(4-aminophenyl) 
cyclopropylamine 10
544
 using HOBt/EDCI to give amide 11; ester hydrolysis to give 
12 followed by N-Boc deprotection with CF3CO2H gave initial target 1 (Scheme 1, 
all hybrid compounds were prepared as trans racemates). Alternatively, 11 was 
directly cleaved in 4N HCl to give ester 2. To prepare 8-hydroxyquinoline 
compounds 3-6 (Scheme 1B), 5-carboxy-8HQ 9
606
 as its O-MOM-protected 
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derivative (13) was condensed with 10, and intermediate 14 was treated with 4N HCl 
to provide 3. Reaction of 13 with the requisite methyl-ω-aminoalkanoate 
hydrochlorides
607
 gave methyl esters 15-17, which after alkaline hydrolysis were 
condensed with 10 to give the intermediates 18-20. Subsequent acid deprotection of 
18-20 afforded final compounds 4-6. Alternatively, intermediates 15-17 were MOM 
group deprotected to give the 8HQ methyl esters 21-23, which were hydrolyzed to 
give acids 24-26.  
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15-17  R = MOM, R1 = CH3
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24-26  R = R1 = H
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  3  R = H, R1 = H 
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B
a f, a
dd
f
d
 
Reagents and conditions: a) racemic trans-N-Boc-2-(4-aminophenyl)cyclopropylamine 10, HOBt, 
EDCI, Et3N, DMF, room temperature; b) 0.2N NaOH, MeOH, RT; c) CF3COOH, 0 °C to room 
temperature; d) 4N HCl in 1,4-dioxane, THF/MeOH, room temperature; e) methyl ω-aminoalkanoate 
hydrochloride, HOBT, EDCI, Et3N, DCM, room temperature; f) 2N LiOH, THF, room temperature. 
The chemical and physical data of the intermediate 11-26 and final compounds 1-6 are 
reported in Table 11.1 and 11.2, respectively. 
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Table 11.1. Chemical and physical data of intermediates 11-26. 
Cpd mp, °C 
recrystall. 
Solvent 
Yield % 
11 196-199 A 80 
12 >250 A 89 
13 157-159 B 75 
14 188-191 C 67 
15 115-117 D 83 
16 96-98 D 52 
17 121-123 D 66 
18 184-186 D 88 
19 111-114 E 74 
20 69-72 E 74 
21 185-186 C 77 
22 175-177 C 95 
23 164-166 C 97 
24 217-218 A 86 
25 207-209 A 96 
26 187-189 C 66 
A: ethanol; B: acetonitrile/cyclohexane; C: acetonitrile; D: 
benzene/cyclohexane; E: cyclohexane 
Table 11.2. Chemical and physical data of intermediates 1-6. 
Cpd mp, °C 
recrystall. 
Solvent 
Yield % 
1 >250 A 90 
2 >250 A 61 
3 >250 A 71 
4 >250 A 85 
5 >250 A 65 
6 >250 A 89 
A: tetrahydrofuran/methanol 
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11.3. Experimental section 
Chemistry. Melting points were determined on a Buchi 530 melting point apparatus. 
1
H-NMR and 
13
C-NMR spectra were recorded at 400 MHz using a Bruker AC 400 
spectrometer; chemical shifts are reported in δ (ppm) units relative to the internal 
reference tetramethylsilane (Me4Si). Mass spectra were recorded on a API-TOF 
Mariner by Perspective Biosystem (Stratford, Texas, USA), samples were injected by 
an Harvard pump using a flow rate of 5-10 μL/min, infused in the Electrospray 
system. All compounds were routinely checked by TLC and 
1
H NMR. TLC was 
performed on aluminum-backed silica gel plates (Merck DC, Alufolien Kieselgel 60 
F254) with spots visualized by UV light or using a KMnO4 alkaline solution. All 
solvents were reagent grade and, when necessary, were purified and dried by 
standard methods. Concentration of solutions after reactions and extractions involved 
the use of a rotary evaporator operating at reduced pressure of ~ 20 Torr. Organic 
solutions were dried over anhydrous sodium sulfate. Elemental analysis has been 
used to determine purity of the described compounds, that is >95%. Analytical 
results are within 0.40% of the theoretical values. All chemicals were purchased 
from Sigma Aldrich, Milan (Italy) or from TCI Europe, Zwijndrecht (Belgium), and 
were of the highest purity. As a rule, samples prepared for physical and biological 
studies were dried in high vacuum over P2O5 for 20h at temperatures ranging from 
25 to 40 °C, depending on the sample melting point. 
trans-Methyl-4'-((4-(2-((tert-Butoxycarbonyl)amino)cyclopropyl)phenyl) 
carbamoyl) -[2,2'-bipyridine]-4-carboxylate (11). The reagents HOBT (62 mg, 
0.39 mmol), EDCI (75 mg, 0.39 mmol) and Et3N (0.15 mL, 1.11 mmol) were added 
in sequence to a mixture of compound 8
553
 (101 mg, 0.39 mmol) and trans-tert-butyl 
2-(4-aminophenyl)cyclopropylcarbamate 10
546
 (81 mg, 0.33 mmol) in dry DMF (2.1 
mL), and the resulting solution was stirred at room temperature overnight. The 
reaction was quenched with brine (5 mL) and concentrated under reduced pressure, 
and the aqueous phase was extracted with AcOEt (4×30 mL). The combined organic 
phases were washed with NaHCO3 saturated solution (2×7 mL) and brine (5 mL). 
The organic phases were collected, dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo to give a crude product that was purified by column 
chromatography on silica gel (eluent: CHCl3/MeOH 100/1) to give compound 11. 
1
H-NMR (DMSO-d6) δH/ppm: 1.10 (m, 2H, -CH2- cyclopropane ring), 1.43 (s, 9H, 
NHCO2C(CH3)3), 1.91 (m, 1H, -CH- cyclopropane ring), 2.62 (m, 1H, -CH- 
cyclopropane ring), 3.98 (s, 3H, CO2CH3), 7.12 (d, 2H, benzene ring), 7.24 (bs, 1H, 
CHNHCO2tBu), 7.70 (d, 2H, benzene ring), 7.97 (m, 2H, bipyridine rings), 8.89 (s, 
2H, bipyridine rings), 8.93 (m, 1H, bipyridine ring), 8.98 (m, 1H, bipyridine ring), 
10.64 (bs, 1H, ArNHCO). 
13
C-NMR (DMSO-d6) δC/ppm: 15.6, 22.4, 29.3, 31.3, 
49.7, 81.2, 117.8, 118.2, 121.1, 121.8, 122.6, 126.5, 132.4, 137.6, 142.8, 149.2, 
150.0, 154.8, 155.3, 156.0, 159.2, 166.7, 168.8. MS, m/z: 489 [M+H]
+
. 
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General Procedure for the Synthesis of trans-Methyl 4'-((4-(2-
Aminocyclopropyl)phenyl)carbamoyl)-[2,2'-bipyridine]-4-carboxylate 
hydrochloride (2), trans-N-(4-(2-Aminocyclopropyl)phenyl)-8-
hydroxyquinoline-5-carboxamide hydrochloride (3) and trans-N-(ω-((4-(2-
Aminocyclopropyl)phenyl)amino)-ω-oxoalkyl)-8-hydroxyquinoline-5-
carboxamide hydrochlorides (4-6). Example: trans-N-(4-((4-(2-
Aminocyclopropyl)phenyl)amino)-4-oxobutyl)-8-hydroxyquinoline-5-
carboxamide hydrochloride (4). Compound 18 (100 mg, 0.18 mmol, 1.0 eq) was 
dissolved in a mixture of dry THF/MeOH (1.4 mL/1.4 mL) and the solution stirred at 
0 °C, then 4N HCl in 1,4-dioxane (3.65 mL, 14.58 mmol) was added dropwise and 
the mixture was allowed to warm at room temperature. After 3 hours, the suspension 
was cooled at 0 °C, and 4N HCl in 1,4-dioxane (1.82 mL, 7.29 mmol) was added 
dropwise again. After 8 hours, when conversion was complete, the suspension was 
filtered and washed with dry THF and then with dry Et2O to afford compound 4 as a 
yellow hygroscopic solid. 
1
H-NMR (DMSO-d6) δH/ppm: 1.15 (m, 1H, -CHH- 
cyclopropane ring), 1.35 (m, 1H, -CHH- cyclopropane ring), 1.90 (m, 2H, 
CH2CH2CH2), 2.28 (m, 1H, -CH- cyclopropane ring), 2.42 (m, 2H, CH2CH2CO), 
2.74 (m, 1H, -CH- cyclopropane ring), 7.06 (d, 2H, benzene ring), 7.30 (d, 1H, 
quinoline ring), 7.52 (d, 2H, benzene ring), 7.87 (m, 2H, quinoline ring), 8.47 (bs, 
3H, CHNH2
.
HCl), 8.65 (bs, 1H, CONHCH2), 9.02 (d, 1H, quinoline ring), 9.24 (d, 
1H, quinoline ring), 10.01 (s, 1H, ArNHCO), 11.40 (bs, 1H, quinoline OH). 
13
C-
NMR (DMSO-d6) δC/ppm: 14.9, 22.8, 26.2, 28.5, 34.1, 40.1, 112.4, 119.7, 124.5, 
126.7, 128.2, 128.5, 130.5, 131.1, 133.6, 135.3, 138.9, 150.3, 157.7, 162.1, 180.6. 
MS (relative to free amine), m/z: 405 [M+H]
+
. 
trans-Methyl 4'-((4-(2-Aminocyclopropyl)phenyl)carbamoyl)-[2,2'-bipyridine]-
4-carboxylate hydrochloride (2). 
1
H-NMR (DMSO-d6) δH/ppm: 1.22 (m, 1H, -
CHH- cyclopropane ring), 1.39 (m, 1H, -CHH- cyclopropane ring), 2.34 (m, 1H, -
CH- cyclopropane ring), 2.81 (m, 1H, -CH- cyclopropane ring), 3.97 (s, 3H, 
CO2CH3), 7.19 (d, 2H, benzene ring), 7.76 (d, 2H, benzene ring), 7.99 (m, 2H, 
bipyridine rings), 8.43 (bs, 3H, CHNH2
.
HCl), 8.89 (s, 2H, bipyridine rings), 8.94 (d, 
1H, bipyridine ring), 8.98 (d, 1H, bipyridine ring), 10.71 (bs, 1H, ArNHCO). 
13
C-
NMR (DMSO-d6) δC/ppm: 14.5, 22.4, 28.3, 52.0, 117.6, 118.1, 120.8, 122.1, 123.0, 
125.8, 133.4, 137.5, 144.1, 149.9, 150.5, 155.2, 156.8, 158.2, 165.3, 166.4. MS 
(relative to free amine), m/z: 389 [M+H]
+
. 
trans-N-(4-(2-Aminocyclopropyl)phenyl)-8-hydroxyquinoline-5-carboxamide 
hydrochloride (3). 
1
H-NMR (DMSO-d6) δH/ppm: 1.23 (m, 1H, -CHH- cyclopropane 
ring), 1.38 (m, 1H, -CHH- cyclopropane ring), 2.32 (m, 1H, -CH- cyclopropane 
ring), 2.80 (m, 1H, -CH- cyclopropane ring), 7.17 (d, 2H, benzene ring), 7.28 (d, 1H, 
quinoline ring), 7.72 (d, 2H, benzene ring), 7.79 (m, 1H, quinoline ring), 7.94 (d, 1H, 
quinoline ring), 8.38 (bs, 3H, CHNH2
.
HCl), 9.00 (m, 2H, quinoline ring), 10.47 (s, 
1H, ArNHCO). 
13
C-NMR (DMSO-d6) δC/ppm: 14.8, 22.6, 28.2, 113.8, 121.7, 125.7, 
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126.8, 128.0, 129.1, 130.2, 130.9, 134.1, 135.8, 137.9, 152.1, 159.3, 165.1. MS 
(relative to free amine), m/z: 320 [M+H]
+
. 
trans-N-(5-((4-(2-Aminocyclopropyl)phenyl)amino)-5-oxopentyl)-8-
hydroxyquinoline-5-carboxamide hydrochloride (5). 
1
H-NMR (DMSO-d6) 
δH/ppm: 1.17 (m, 1H, -CHH- cyclopropane ring), 1.33 (m, 1H, -CHH- cyclopropane 
ring), 1.64 (m, 4H, CH2CH2CH2CH2), 2.26 (m, 1H, -CH- cyclopropane ring), 2.36 (t, 
2H, CH2CH2CO), 2.75 (m, 1H, -CH- cyclopropane ring), 7.07 (d, 2H, benzene ring), 
7.21 (d, 1H, quinoline ring), 7.53 (d, 2H, benzene ring), 7.78 (m, 2H, quinoline ring), 
8.35 (bs, 3H, CHNH2
.
HCl), 8.57 (bs, 1H, CONHCH2), 8.97 (d, 1H, quinoline ring), 
9.06 (d, 1H, quinoline ring), 9.92 (s, 1H, ArNHCO), 11.10 (bs, 1H, quinoline OH). 
13
C-NMR (DMSO-d6) δC/ppm: 14.5, 22.3, 23.1, 28.0, 29.4, 38.3, 39.0, 114.4, 121.9, 
125.4, 126.6, 127.9, 128.8, 130.5, 131.1, 134.7, 135.4, 138.9, 151.7, 159.3, 162.4, 
179.7. MS (relative to free amine), m/z: 419 [M+H]
+
.  
trans-N-(6-((4-(2-Aminocyclopropyl)phenyl)amino)-6-oxohexyl)-8-
hydroxyquinoline-5-carboxamide hydrochloride (6). 
1
H-NMR (DMSO-d6) 
δH/ppm: 1.18 (m, 1H, -CHH- cyclopropane ring), 1.38 (m, 3H, -CHH- cyclopropane 
ring and –CH2- aliphatic chain), 1.61 (m, 4H, aliphatic chain), 2.32 (m, 3H, -CH- 
cyclopropane ring and CH2CH2CO), 2.75 (m, 1H, -CH- cyclopropane ring), 3.33 (t, 
2H, NHCH2CH2), 7.06 (d, 2H, benzene ring), 7.33 (d, 1H, quinoline ring), 7.52 (d, 
2H, benzene ring), 7.85 (d, 1H, quinoline ring), 7.89 (m, 1H, quinoline ring), 8.43 
(bs, 3H, CHNH2
.
HCl), 8.62 (bs, 1H, CONHCH2), 9.03 (d, 1H, quinoline ring), 9.24 
(d, 1H, quinoline ring), 9.92 (s, 1H, ArNHCO). 
13
C-NMR (DMSO-d6) δC/ppm: 14.3, 
22.2, 25.2, 25.7, 28.1, 29.5, 38.4, 39.5, 114.3, 121.5, 125.8, 126.9, 127.7, 128.7, 
130.4, 131.3, 134.5, 135.3, 138.8, 151.7, 159.5, 162.7, 179.8. MS (relative to free 
amine), m/z: 433 [M+H]
+
. 
4'-((4-(2-((tert-Butoxycarbonyl)amino)cyclopropyl)phenyl)carbamoyl)-[2,2'-
bipyridine]-4-carboxylic acid (12). Compound 11 (111 mg, 0.227 mmol, 1.0 eq) 
was suspended in 4 mL of MeOH and cooled in an ice bath, then NaOH (27.3 mg, 
0.682 mmol, 3.0 eq) in water (0.7 mL) was added dropwise and the mixture was 
allowed to stir at room temperature. After 9 hours the organic solvent was removed 
in vacuo and the aqueous phase, cooled at 0 °C, was acidified to pH 2 with a solution 
of 0.5N KHSO4. The obtained suspension was filtered to afford the desired 
compound 12 (89%) as a yellow solid. 
1
H-NMR (DMSO-d6) δH/ppm: 1.11 (m, 2H, -
CH2- cyclopropane ring), 1.39 (s, 9H, NHCO2C(CH3)3), 1.90 (m, 1H, -CH- 
cyclopropane ring), 2.62 (m, 1H, -CH- cyclopropane ring), 7.12 (d, 2H, benzene 
ring), 7.24 (bs, 1H, CHNHCO2tBu), 7.70 (d, 2H, benzene ring), 7.95 (m, 2H, 
bipyridine rings), 8.88 (s, 2H, bipyridine rings), 8.94 (m, 2H, bipyridine ring), 10.64 
(bs, 1H, ArNHCO), 13.89 (bs, 1H, COOH). 
13
C-NMR (DMSO-d6) δC/ppm: 14.1, 
21.9, 27.8, 32.7, 80.3, 117.6, 118.2, 118.4, 120.1, 121.5, 124.4, 125.3, 134.0, 137.4, 
144.9, 149.1, 149.9, 154.9, 155.4, 155.9, 159.5, 164.8, 170.1. MS, m/z: 475 [M+H]
+
. 
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trans-4'-((4-(2-Aminocyclopropyl)phenyl)carbamoyl)-[2,2'-bipyridine]-4-
carboxylic acid trifluoroacetate (1). Trifluoroacetic acid (1.04 mL, 13.54 mmol, 
230 eq) was added to 12 (28.2 mg, 0.059 mmol, 1.0 eq) placed in an ice bath, and the 
mixture was allowed to stir at room temperature. After 5 hours the solvent was 
removed at low temperature under reduced pressure, then the solid was stirred as 
suspension in dry Et2O for 1 hour and filtered to provide the desired compound 1 
(90%) as a dark red solid. 
1
H-NMR (DMSO-d6) δH/ppm: 1.23 (m, 1H, -CHH- 
cyclopropane ring), 1.33 (m, 1H, -CHH- cyclopropane ring), 2.28 (m, 1H, -CH- 
cyclopropane ring), 2.84 (m, 1H, -CH- cyclopropane ring), 7.20 (d, 2H, benzene 
ring), 7.74 (d, 2H, benzene ring), 7.96 (m, 2H, bipyridine rings), 8.26 (bs, 3H, 
NH2
.
CF3COOH ), 8.88 (s, 2H, bipyridine rings), 8.94 (m, 2H, bipyridine ring), 10.69 
(bs, 1H, ArNHCO). 
13
C-NMR (DMSO-d6) δC/ppm: 14.9, 22.6, 28.2, 117.3, 117.9, 
118.7, 120.7, 121.2, 124.1, 125.5, 134.5, 138.7, 144.9, 149.2, 149.8, 155.2, 156.1, 
159.8, 162.2, 164.9, 170.4. MS (relative to free amine), m/z: 375 [M+H]
+
. 
8-(Methoxymethoxy)quinoline-5-carboxylic acid (13). 8-Hydroxyquinoline-5-
carboxylic acid (2.41 g, 12.8 mmol, 1 eq) was added portion wise to a stirring 
suspension of 60% NaH (1.28 g, 31.9 mmol, 2.5 eq) in dry THF (30 mL) at 0 °C, and 
the resulting mixture was stirred under inert atmosphere (N2) for 30 min. Then 
MOM-Br (2.5 mL, 30.6 mmol, 2.4 eq) dissolved in dry THF (20 mL) was added 
dropwise, and the suspension was allowed to warm to room temperature under inert 
atmosphere (N2). After 4 hours, a solution of LiOH (1.22 g, 51.0 mmol, 4.0 eq) in 
water (25.5 mL) was added at 0 °C, and the resulting mixture was stirred at room 
temperature overnight. The reaction mixture was acidified with glacial acetic acid to 
pH 4 and then extracted with DCM (5×90 mL); the organic phases were collected, 
dried over anhydrous Na2SO4, filtered and the solvent removed under reduced 
pressure to give compound 13 (98%) as a white solid. 
1
H-NMR (CD3OD) δH/ppm: 
2.09 (s, 3H, CH2OCH3), 4.08 (s, 2H, OCH2OCH3), 5.97 (d, 1H, quinoline ring), 6.18 
(m, 1H, quinoline ring), 6.83 (d, 1H, quinoline ring), 7.39 (d, 1H, quinoline ring), 
8.06 (d, 1H, quinoline ring). 
13
C-NMR (CD3OD) δC/ppm: 55.1, 95.3, 104.5, 119.0, 
122.7, 126.5, 131.3, 133.1, 140.0, 148.1, 159.7, 167.5. MS, m/z: 234 [M+H]
+
.  
trans-tert-Butyl(2-(4-(8-(Methoxymethoxy)quinoline-5-carboxamido)phenyl) 
cyclopropyl) carbamate (14). Compound 14 was prepared following the same 
procedure used for 11, starting from 13 and 10. 
1
H-NMR (CDCl3) δH/ppm: 1.19 (m, 
2H, -CH2- cyclopropane ring), 1.49 (s, 9H, NHCO2C(CH3)3), 2.07 (m, 1H, -CH- 
cyclopropane ring), 2.74 (m, 1H, -CH- cyclopropane ring), 3.61 (s, 3H, CH2OCH3), 
5.58 (s, 2H, OCH2OCH3), 7.21 (d, 2H, benzene ring), 7.44 (d, 1H, quinoline ring), 
7.56 (m, 3H, quinoline ring and benzene ring), 7.67 (s, 1H, CONHAr), 7.80 (d, 1H, 
quinoline ring), 8.93 (d, 1H, quinoline ring), 9.04 (d, 1H, quinoline ring). 
13
C-NMR 
(CDCl3) δC/ppm: 15.2, 23.3, 29.0, 32.8, 55.4, 80.5, 95.1, 107.8, 121.8, 125.3, 126.0, 
127.7, 128.3, 130.0, 131.4, 133.8, 136.5, 138.1, 151.5, 156.4, 161.2, 164.4. MS, m/z: 
464 [M+H]
+
. 
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General Procedure for the Synthesis of 8-(Methoxymethoxy)quinoline-5-
carboxyamidoalkyl Methyl Esters (15-17). Example: Methyl 4-({[8-
(Methoxymethoxy)quinolin-5-yl]carbonyl}amino)butanoate (15). The reagents 
HOBT (382 mg, 2.40 mmol), EDCI (460 mg, 2.40 mmol) and Et3N (1.12 mL, 8 
mmol) were added in sequence to a mixture of 13 (560 mg, 2.40 mmol) and methyl 
4-aminobutanoate hydrochloride (306 mg, 2 mmol) in dry DCM (12 mL), and the 
solution was stirred at room temperature. After overnight stirring, the reaction 
mixture was diluted with DCM (90 mL) and the organic phase washed with Na2CO3 
(2×50 mL) and brine (2×50 mL), dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo to give a residue that was purified by column chromatography 
on silica gel (eluent: DCM/MeOH 35/1). The collected fractions were evaporated 
and the resulting crude was finally recrystallized from benzene/cyclohexane to afford 
compound 15 (83%) as a white solid. 
1
H-NMR (CDCl3) δH/ppm: 2.04 (m, 2H, 
NCH2CH2CH2), 2.52 (t, 2H, CH2CH2CO2Me), 3.61 (m, 5H, NHCH2CH2 and 
CO2CH3), 3.70 (s, 3H, OCH2OCH3), 5.56 (s, 2H, OCH2OCH3), 6.32 (bs, 1H, 
CONHCH2), 7.39 (d, 1H, quinoline ring), 7.53 (m, 1H, quinoline ring), 7.66 (d, 1H, 
quinoline ring), 8.91 (d, 1H, quinoline ring), 9.01 (d, 1H, quinoline ring). 
13
C-NMR 
(CDCl3) δC/ppm: 22.8, 29.5, 40.3, 50.7, 55.4, 92.7, 107.8, 126.3, 129.7, 130.1, 131.3, 
131.9, 137.5, 151.3, 163.4, 165.0, 176.1. MS, m/z: 333 [M+H]
+
.  
Methyl 5-({[8-(Methoxymethoxy)quinolin-5-yl]carbonyl}amino)pentanoate (16). 
1
H-NMR (CDCl3) δH/ppm: 1.77 (m, 4H, CH2CH2CH2CH2), 2.44 (t, 2H, 
CH2CH2CO2Me), 3.53 (m, 2H, NHCH2CH2), 3.60 (s, 3H, CO2CH3), 3.71 (s, 3H, 
OCH2OCH3), 5.56 (s, 2H, OCH2OCH3), 6.16 (bs, 1H, CONHCH2), 7.39 (d, 1H, 
quinoline ring), 7.53 (m, 1H, quinoline ring), 7.67 (d, 1H, quinoline ring), 8.89 (d, 
1H, quinoline ring), 9.00 (d, 1H, quinoline ring). 
13
C-NMR (CDCl3) δC/ppm: 22.3, 
30.1, 32.4, 39.7, 52.6, 56.6, 92.7, 111.2, 128.1, 128.7, 130.2, 132.1, 133.7, 137.9, 
155.3, 163.4, 164.1, 176.7. MS, m/z: 347 [M+H]
+
.  
Methyl 6-({[8-(Methoxymethoxy)quinolin-5-yl]carbonyl}amino)hexanoate (17). 
1
H-NMR (CDCl3) δH/ppm: 1.50 (m, 2H, aliphatic chain), 1.72 (m, 4H, aliphatic 
chain), 2.38 (t, 2H, CH2CH2CO2Me), 3.55 (m, 2H, NHCH2CH2), 3.60 (s, 3H, 
CH2OCH3), 3.69 (s, 3H, CO2CH3), 5.56 (s, 2H, OCH2OCH3), 6.06 (bs, 1H, 
CONHCH2), 7.39 (d, 1H, quinoline ring), 7.53 (m, 1H, quinoline ring), 7.65 (d, 1H, 
quinoline ring), 8.87 (d, 1H, quinoline ring), 9.01 (d, 1H, quinoline ring).
13
C-NMR 
(CDCl3) δC/ppm: 24.3, 25.2, 30.1, 32.9, 41.6, 51.7, 57.6, 93.2, 109.8, 123.2, 128.9, 
129.6, 131.2, 132.3, 135.2, 153.8, 161.1, 162.8, 175.8. MS, m/z: 361 [M+H]
+
. 
General Procedure for the Synthesis of trans-tert-Butyl (2-(4-(ω-(8-
(Methoxymethoxy)quinoline-5-carboxamido)alkylamido)phenyl)cyclopropyl) 
carbamate (18-20). Example: trans-tert-Butyl (2-(4-(6-(8-
(Methoxymethoxy)quinoline-5-
carboxamido)hexanamido)phenyl)cyclopropyl)carbamate (20). LiOH (102 mg, 
4.26 mmol) dissolved in water (3 mL) was added to a stirred solution of 17 (360 mg, 
1.07 mmol) in THF (4 mL) placed on an ice bath, and the resulting mixture was 
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stirred at room temperature overnight. The reaction was acidified with glacial acetic 
acid to pH 4-5, then diluted with DCM (50 mL) and extracted; the aqueous phase 
was further extracted with DCM (9×50 mL). The organic phases were collected, 
dried over anhydrous Na2SO4, filtered and concentrated in vacuo to afford the 5-({[8-
(methoxymethoxy)quinolin-5-yl]carbonyl}amino)hexanoic acid (300 mg, 85%) as a 
white solid that was used in the next step without further purification. HOBT (92 mg, 
0.58 mmol), EDCI (110 mg, 0.58 mmol) and Et3N (0.24 mL, 1.70 mmol) were added 
in sequence to a mixture of 5-({[8-(methoxymethoxy)quinolin-5-
yl]carbonyl}amino)hexanoic acid (190 mg, 0.58 mmol) and trans-tert-butyl 2-(4-
aminophenyl)cyclopropylcarbamate 10
544
 (132 mg, 0.53 mmol) in dry DMF (4.2 
mL) and the resulting solution was stirred at room temperature. After 18 h the 
solvent was evaporated under reduced pressure and the residue partitioned between 
AcOEt (100 mL) and brine (20 mL). The organic phase was further washed with 
NaHCO3 saturated solution (2 × 40 mL) and the aqueous phases back-extracted with 
AcOEt (40 mL). The organic phases were collected, dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo to give a crude product that was purified by 
column chromatography on silica gel (eluent: CHCl3/MeOH 30/1) to give compound 
20 (74%) as a yellow foam. 
1
H-NMR (CDCl3) δH/ppm: 1.15 (m, 2H, -CH2- 
cyclopropane ring), 1.47 (s, 9H, NCO2C(CH3)3), 1.53 (m, 2H, aliphatic chain), 1.72 
(m, 2H, aliphatic chain), 1.81 (m, 2H, aliphatic chain), 2.02 (m, 1H, -CH- 
cyclopropane ring), 2.40 (t, 2H, CH2CH2CO), 2.68 (m, 1H, -CH- cyclopropane ring), 
3.57 (m, 5H, NHCH2CH2 and CH2OCH3), 4.88 (bs, 1H, CHNHCO2tBu), 5.55 (s, 2H, 
OCH2OCH3), 6.28 (bs, 1H, CONHCH2), 7.07 (d, 2H, benzene ring), 7.35 (m, 2H, 
quinoline ring and ArNHCO), 7.40 (d, 2H, benzene ring), 7.50 (m, 1H, quinoline 
ring), 7.65 (d, 1H, quinoline ring), 8.87 (d, 1H, quinoline ring), 9.00 (d, 1H, 
quinoline ring). 
13
C-NMR (CDCl3) δC/ppm: 16.3, 21.7, 24.6, 26.7, 29.1, 29.7, 32.5, 
37.6, 39.3, 53.8, 79.1, 89.4, 107.5, 124.6, 127.3, 127.8, 128.2, 129.3, 132,5, 133.6, 
135.0, 139.2, 140.6, 151.0, 153.3, 159.8, 162.7, 182.9. MS, m/z: 577 [M+H]
+
. 
trans-tert-Butyl (2-(4-(4-(8-(Methoxymethoxy)quinoline-5-
carboxamido)butanamido)phenyl)cyclopropyl)carbamate (18). 
1
H-NMR (CDCl3) 
δH/ppm: 1.14 (m, 2H, -CH2- cyclopropane ring), 1.47 (s, 9H, NCO2C(CH3)3), 2.02 
(m, 1H, -CH- cyclopropane ring), 2.09 (m, 2H, CH2CH2CH2), 2.53 (t, 2H, 
CH2CH2CONH), 2.69 (m, 1H, -CH- cyclopropane ring), 3.59 (s, 3H, CH2OCH3), 
3.66 (m, 2H, NHCH2CH2), 4.89 (bs, 1H, CHNHCO2tBu), 5.54 (s, 2H, OCH2OCH3), 
6.65 (bs, 1H, CONHCH2), 7.08 (d, 2H, benzene ring), 7.32 (d, 1H, quinoline ring), 
7.50 (m, 3H, benzene ring and quinoline ring), 7.65 (d, 1H, quinoline ring), 8.46 (bs, 
1H, ArNHCO), 8.89 (d, 1H, quinoline ring), 9.00 (d, 1H, quinoline ring). 
13
C-NMR 
(CDCl3) δC/ppm: 16.0, 22.1, 26.8, 27.5, 32.3, 35.8, 39.0, 53.5, 80.2, 95.5, 107.4, 
119.6, 126.6, 126.9, 128.3, 129.3, 131.5, 133.9, 135.1, 137.7, 141.8, 148.8, 155.9, 
159.5, 165.6, 184.4. MS, m/z: 549 [M+H]
+
. 
trans-tert-Butyl (2-(4-(5-(8-(Methoxymethoxy)quinoline-5-
carboxamido)pentanamido)phenyl)cyclopropyl)carbamate (19). 
1
H-NMR 
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(CDCl3) δH/ppm: 1.15 (m, 2H, -CH2- cyclopropane ring), 1.47 (s, 9H, 
NHCO2C(CH3)3), 1.78 (m, 2H, aliphatic chain) 1.87 (m, 2H, aliphatic chain), 2.02 
(m, 1H, -CH- cyclopropane ring), 2.09 (m, 2H, CH2CH2CH2), 2.49 (t, 2H, 
CH2CH2CO), 2.68 (m, 1H, -CH- cyclopropane ring), 3.58 (m, 5H, NHCH2CH2 and 
CH2OCH3), 4.87 (bs, 1H, NHCO2tBu), 5.56 (s, 2H, OCH2OCH3), 6.41 (bs, 1H, 
CONHCH2), 7.07 (d, 2H, benzene ring), 7.38 (d, 1H, quinoline ring), 7.45 (m, 3H, 
benzene ring and quinoline ring), 7.64 (bs, 1H, ArNHCO), 7.68 (d, 1H, quinoline 
ring), 8.85 (d, 1H, quinoline ring), 9.00 (d, 1H, quinoline ring). 
13
C-NMR (CDCl3) 
δC/ppm: 15.8, 21.7, 21.9, 27.8, 29.1, 29.8, 37.7, 39.4, 53.0, 80.1, 93.8, 106.9, 123.4, 
126.6, 127.0, 127.5, 128.4, 130.0, 131.8, 136.1, 137.7, 138.1, 149.7, 156.5, 161.2, 
164.4, 182.2. MS, m/z: 563 [M+H]
+
. 
General Procedure for the Synthesis of ω-(8-Hydroxyquinoline-5-
carboxamido)alkyl Methyl Esters (21-23). Example: Methyl 5-(8-
Hydroxyquinoline-5-carboxamido)pentanoate (22). Compound 16 (150 mg, 0.43 
mmol, 1.0 eq) was dissolved in a mixture of dry THF/MeOH (2 mL/2 mL) and the 
solution was stirred at 0 °C, then 4N HCl in 1,4-dioxane (6.5 mL, 25.98 mmol, 60 
eq) was added dropwise, and the mixture was allowed to warm to room temperature. 
After 6 hours, when conversion was complete, the suspension was filtered and 
washed with dry Et2O to give compound 22 (95%) as a yellow solid. 
1
H-NMR 
(DMSO-d6) δH/ppm: 1.60 (m, 4H, CH2CH2CH2CH2), 2.38 (t, 2H, CH2CH2CO2Me), 
3.32 (m, 2H, NHCH2CH2), 3.60 (s, 3H, CO2CH3), 7.44 (d,1H, quinoline ring), 7.92 
(d, 1H, quinoline ring), 8.00 (m, 1H, quinoline ring), 8.70 (bs, 1H, CONHCH2), 9.08 
(d, 1H, quinoline ring), 9.39 (m, 1H, quinoline ring), 12.17 (bs, 1H, ArOH). 
13
C-
NMR (DMSO-d6) δC/ppm: 22.9, 29.7, 32.8, 40.1, 50.8, 111.6, 126.5, 128.5, 131.6, 
132.0, 134.9, 140.2, 153.0, 161.2, 163.8, 175.9. MS, m/z: 303 [M+H]
+
.  
Methyl 6-(8-Hydroxyquinoline-5-carboxamido)hexanoate (23). 
1
H-NMR 
(DMSO-d6) δH/ppm: 1.37 (m, 2H, aliphatic chain), 1.59 (m, 4H, aliphatic chain), 
2.33 (t, 2H, CH2CH2CO2Me), 3.30 (m,  2H, NHCH2CH2), 7.28 (d, 1H, quinoline 
ring), 7.82 (d, 1H, quinoline ring), 7.87 (m, 1H, quinoline ring), 8.57 (bs, 1H, 
CONHCH2), 9.02 (d, 1H, quinoline ring), 9.18 (d, 1H, quinoline ring), 11.35 (bs, 1H, 
ArOH). 
13
C-NMR (DMSO-d6) δC/ppm: 24.5, 26.4, 30.0, 32.7, 40.4, 51.5, 109.5, 
122.6, 130.4, 130.8, 133.0, 133.7, 134.0, 152.5, 160.8, 163.0, 174.1. MS, m/z: 317 
[M+H]
+
.  
Methyl 4-(8-Hydroxyquinoline-5-carboxamido)butanoate (21). 
1
H-NMR 
(DMSO-d6) δH/ppm: 1.84 (m, 2H, CH2CH2CH2), 2.42 (t, 2H, CH2CH2CO2Me), 3.61 
(s, 3H, CO2CH3), 7.09 (d, 1H, quinoline ring), 7.62 (m, 1H, quinoline ring), 7.69 (d, 
1H, quinoline ring), 8.43 (bs, 1H, CONHCH2), 8.87 (m, 2H, quinoline ring), 10.21 
(bs, 1H, ArOH). 
13
C-NMR (DMSO-d6) δC/ppm: 23.6, 30.0, 39.7, 50.2, 107.7, 126.8, 
129.8, 130.0, 133.1, 133.8, 136.8, 151.2, 162.7, 164.9, 176.0. MS, m/z: 289 [M+H]
+
.  
General Procedure for the Synthesis of ω-(8-Hydroxyquinoline-5-
carboxamido)alkanoic acids (24-26). Example: 5-(8-Hydroxyquinoline-5-
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carboxamido)pentanoic acid (25). A solution of LiOH (47 mg, 1.11 mmol, 3.0 eq) 
in water (0.6 mL) was added to a stirred solution of compound 22 (112 mg, 0.37 
mmol, 1.0 eq) in THF (1.3 mL) placed on an ice bath, and the resulting mixture was 
stirred at room temperature overnight. The solvent was removed, NaHCO3 saturated 
solution (10 mL) was added and the aqueous phase was washed with AcOEt (3 × 10 
mL). The aqueous solution was acidified with glacial acetic acid to pH 4, then 
extracted with AcOEt (5×20 mL). The organic phases were collected, dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo to afford compound 25 (96%) 
as an off yellow solid. 
1
H-NMR (DMSO-d6) δH/ppm: 1.58 (m, 4H, aliphatic chain), 
2.30 (t, 2H, CH2CH2CO2H), 7.08 (d, 1H, quinoline ring), 7.62 (m, 1H, quinoline 
ring), 7.68 (d, 1H, quinoline ring), 8.41 (bs, 1H, CONHCH2), 8.84 (d, 1H, quinoline 
ring), 8.88 (d, 1H, quinoline ring), 10.17 (bs, 1H, ArOH), 11.98 (bs, 1H, CH2CO2H). 
13
C-NMR (DMSO-d6) δC/ppm: 22.6, 29.8, 33.3, 39.9, 111.1, 126.3, 128.4, 128.7, 
131.8, 132.7, 136.0, 151.0, 160.1, 162.9, 177.9. MS, m/z: 289 [M+H]
+
.  
5-(8-Hydroxyquinoline-5-carboxamido)hexanoic acid (26). 
1
H-NMR (DMSO-d6) 
δH/ppm: 1.38 (m, 2H, aliphatic chain), 1.57 (m, 4H, aliphatic chain), 2.23 (t, 2H, 
CH2CH2CO2H), 7.08 (d, 1H, quinoline ring), 7.62 (m, 1H, quinoline ring), 7.69 (d, 
1H, quinoline ring), 8.41 (bs, 1H, CONHCH2), 8.83 (d, 1H, quinoline ring), 8.88 (d, 
1H, quinoline ring), 10.16 (bs, 1H, ArOH), 12.00 (bs, 1H, CH2CO2H). 
13
C-NMR 
(DMSO-d6) δC/ppm: 24.3, 27.2, 29.0, 34.5, 40.1, 110.4, 125.8, 128.8, 129.1, 131.9, 
132.5, 133.9, 153.4, 158.5, 162.3, 175.5. MS, m/z: 303 [M+H]
+
.  
5-(8-Hydroxyquinoline-5-carboxamido)butanoic acid (24). 
1
H-NMR (DMSO-d6) 
δH/ppm: 1.79 (m, 2H, CH2CH2CH2), 2.32 (m, 2H, CH2CH2CO2H), 7.08 (d, 1H, 
quinoline ring), 7.62 (m, 1H, quinoline ring), 7.69 (d, 1H, quinoline ring), 8.44 (bs, 
1H, CONHCH2), 8.84 (d, 1H, quinoline ring), 8.89 (d, 1H, quinoline ring), 10.20 (bs, 
1H, ArOH), 12.05 (bs, 1H, CH2CO2H). 
13
C-NMR (DMSO-d6) δC/ppm: 23.2, 33.2, 
39.5, 110.8, 126.0, 128.5, 128.7, 131.9, 132.2, 135.5, 151.0, 159.7, 162.9, 178.8. MS, 
m/z: 275 [M+H]
+
. 
11.4. Biological evaluation, results and discussion 
11.4.1. KDM inhibitory assays 
Compounds 1-6 were tested against LSD1 and a subfamily representative panel of 
JmjC KDMs including KDM4. In LSD1 inhibition assays, the tested compounds all 
showed single-digit (1, 5, 6) or submicromolar (2-4) IC50 values, with similar or 
increased potencies respect to the reference 7 (Table 11.3, 11.4). Compounds 1-3 were 
also tested against MAO-A and MAO-B to assess their selectivity towards LSD1: at 
the tested conditions, 1 and 3 were definitively more effective in inhibiting LSD1 than 
MAOs, while 2 was less potent against MAO-B but showed similar inhibitory potency 
against MAO-A respect to LSD1, analogously to what observed with other 
tranylcypromine- based compounds (Table 11.3).
544
 Inhibition of the JmjC KDMs by 
the hybrid compounds 1-6 (Table 11.4) was then investigated, using 8 and 9 as 
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references. Interestingly, both 8HQ (compounds 3-6) and bipyridine (compound 1) 
hybrid inhibitors showed similar potencies against JmjC KDMs as the reference 
compounds 8 and 9, demonstrating that the conjugation of tranylcypromine does not 
adversely affect activity. Compound 1 displayed low-or sub-micromolar activity 
against all the tested JmjCs, thus being the most potent of the series. Importantly, 
when tested against the hypoxia inducible factor hydroxylases FIH and PHD2, the 
former of which is closely related to the JmjC KDMs, 1 showed no/weak inhibition, 
revealing high KDM-selectivity. Consistent with previous SAR for the bipyridine 
derivatives, the free acid is required for high potency against JmjC KDMs as the ester 
“pro-drug” form (2) weakens the potency. Single digit (9 out of 10) values were 
obtained for 2-6 against KDM4, the KDM subfamily that has been shown to work 
synergistically with LSD1 (Table 11.3, 11.4).
559
 
Table 11.3. Inhibition of both LSD1 enzyme by pan-demethylase inhibitors 1-6. 
Compound 7-9 are used as refence 
cpd 
IC50, µM 
LSD1 
(KDM1) 
MAO A MAO B 
1 2.2 35.4 47.0 
2 <1 <1 43.3 
3 <1 8.9 81.0 
4 <1   
5 1.6   
6 1.0   
7 2.1 4.5 2.5 
8 >100   
9 ND
a 
  
Inhibition assays were performed in duplicate. The errors in 
determinations of IC50s are within ±10% of their values. 
a
ND, Not 
Detectable. Compound 9 interferes with the peroxidase used in the 
coupled enzymatic assay and the inhibition could not be reliably 
measured. 
 
  
 173 |Pan-KDM inhibitors 
Table 11.4. Inhibition of JmjC enzymes by pan-demethylase inhibitors 1-6. The KDM 
subfamily of each enzyme is reported among brackets. Single family-specific target 
inhibitors 7-9 were used as references. 
cpd 
 
IC50, µM 
FBXL11 
(KDM2/7) 
JMJD1A 
(KDM3) 
JMJD2C 
(KDM4) 
JMJD2E 
(KDM4) 
JARID1C 
(KDM5) 
JMJD3 
(KDM6) 
FIH PHD2 
1 0.22 0.14 0.07 0.42 0.19 2.7 >100 278 
2 12.2 37 2.7 16 8.5 76   
3 7.8 31 1.2 3.9 26 27 25 8.5 
4 12 12 4.5 5.5 35 18   
5 8.2 9.7 3.1 3.5 21 14   
6 12 9.1 2.5 5.1 37 16   
7 >100 >100 >100 >100 >100 >100   
8 4.8 1.1 3.5 5.0 0.03 11.2   
9 15 0.17 0.6 0.3 25 0.14   
Inhibition assays were performed in duplicate. The errors in determinations of IC50s are 
within ±10% of their values. 
 
11.4.1.1. Methods 
LSD1 assay. His-tagged recombinant form of human LSD1 comprising residues 
171-836 was copurified with a glutathione transferase-tagged CoREST protein 
(residues 308-440) as described.
544 
The potency of the inhibitors was evaluated by 
measuring their IC50 using a coupled enzymatic assay monitoring hydrogen peroxide 
formation. A peptide corresponding to the N-terminal 21 amino acids of H3 
monomethylated on Lysine 4 was used as substrate at the fixed concentration of 29 
M (five-fold the Km). The reaction mixture contained 50 mM Hepes pH 7.5, 0.1 
mM 4-aminoantipyrine, 1 mM 3,5- dichloro-2-hydroxybenzenesulfonic acid, 2.8 μM 
horseradish peroxidase, 1 μM LSD1/CoREST. The enzyme was incubated for five 
minutes at room temperature before measuring the enzymatic activity. 
MAO-A and MAO-B assays. Recombinant human MAO-A and -B were expressed 
in P. pastoris and purified as described.
544
 IC50 values were measured with the 
peroxidase-coupled assay using benzylamine (MAO-B) and kynuramine (MAO-A) 
as substrates, at the fixed concentration of 333 M (1.5 fold the Km). The protein 
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(16.7 nM) was titrated with increasing concentrations of inhibitor (5 minute 
incubation at room temperature). The reaction mixture contained 50 mM Hepes pH 
7.5, 0.025% (w/v) reduced Triton-X100, 0.1 mM Amplex Red, 2.8 μM horseradish 
peroxidase, 16 nM enzyme. 
JmjC inhibitory assays. Materials. Anti-histone H3 (dimethyl K9) (Abcam), 
antihistone H3 (trimethyl K9) (Abcam), anti-histone H3 (dimethyl K4) (Abcam), 
anti-histone H3 (trimethyl K4) (Diagenode) goat anti-mouse Alexafluor 488 
(Invitrogen) or goat anti-rabbit Alexafluor 488 (Invitrogen). 
2OG oxygenase enzyme assay. All recombinant 2OG oxygenase enzymes were 
produced as described.
628
 The IC50 values of inhibitors against JmjC containing 
KDMs were determined using AlphaScreen as described.
608
 RapidFire mass 
spectrometry based assay methods were used for PHD2 and FIH. 
11.4.2. Effects of 2 and 3 on histone methylation in HeLa cells 
We then investigated whether the pan-demethylase inhibitors 1, 2 and 3 affect 
selected global histone methylation states in HeLa cells, using immunofluorescence 
based methods (Figure 11.3). 
 
Figure 11.3. Detection of changes in the global histone methylation levels in HeLa cells after 
treatment with 1, 2, 3, 7, 8a and 9 over 72 h using an immunofluorescence-based assay (A-H). 
Cytotoxicity of compounds 2, 3 and 8a at high doses is shown as number of cells per fixed field of 
view (I). 
Compounds 7 for LSD1, and 8a
558
 (a pro-drug form of 8,
490
 Figure 11.1) and 9 for 
JmjC enzymes, were used as references. The hybrid inhibitors 2 and 3 caused 
substantial, dose-dependent increases of methyl marks at lower concentrations than 
9, whereas 7 caused essentially no changes in the overall methylation levels 
(including H3K4 methylations), in agreement with previous studies.
479,609,610
 The 
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lack of effects on H3K4me3 may reflect the weaker inhibition of H3K4 
demethylases (JARID/KDM5) over H3K9me3 KDMs (KDM4), coupled to the 
simultaneous effect of inhibiting the H3K4me2 selective demethylase LSD1 (Table 
11.3, 11.4) or more complex effects due to inhibition of multiple targets. The 2,2'-
bipyridine derivative 2 caused a H3K9me2/3-specific dose-dependent 
hypermethylation effect, whereas 8a and 7 alone had no effect. This observation 
suggests that the “hybridization” of the bipyridyl and tranylcypromine motif has a 
synergistic effect, with respect to inhibition of LSD1 and KDM4/3 families. There 
was a general decrease in the immunofluorescence signal at higher doses where 
toxicity was observed (Figure 11.3I). 
11.4.2.1.Methods 
Cell culturing. HeLa cells were maintained in OptiMEM media supplemented with 
0.5% foetal calf serum and 1% penicillin-streptomycin. Cells (1500 cells per well) 
were seeded into 96-well optical grade plate (Becton Dickinson) and left overnight to 
adhere. Test compounds were diluted in culture medium at a concentration of 100 
μM, further serially diluted at a ratio of 1:2 (1% DMSO final), and incubated on the 
adhered HeLa cells. Media containing inhibitors was replaced every 24 h for 3 day 
period. 
Immunostaining. Cells were rinsed with phosphate buffered saline (PBS) and fixed 
in 4% paraformaldehyde (20 min) and permeabilised with 0.5% TritonX-100 (10 
min), followed by another PBS rinse. The cells were blocked (30 min) with 3% 
foetal calf serum diluted in PBS and further incubated overnight in primary antibody 
(1:500) diluted in blocking solution. Cells were rinsed three times with PBS, 
followed by incubation with the secondary antibody for 1 hour. After PBS rinses 
(×3), cells were stained with DAPI. 
Image acquisition and analysis. The Pathway (Beckton Dickinson), an automated 
high-content imaging platform, was used to image the immunostained cells in the 96-
well plate configuration. For each well, the system acquired a 3-by-3 tile-scanned 
image for Alexafluor 488 and DAPI. During analysis, the Pathway’s software used 
the DAPI staining to identify nuclei as regions-of-interests (ROI). For each nucleus, 
the software extracted the average intensity of the histone staining, followed by the 
average intensity of all the nuclei in that particular well. The number of remaining 
cells and average nuclear size of each well was also calculated from the DAPI image. 
These three parameters from each well were then plotted against the corresponding 
concentration to obtain a dose response curve, which was plotted in GraphPad Prism 
5. 
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11.4.3. Effects of pan-KDM inhibitors in human prostate LNCaP and colon HCT116 
cancer cells 
Compounds 1-6 (50 μM) were tested in human prostate LNCaP and colon HCT116 
cancer cells to investigate their effects on cell cycle (after 30 h), apoptosis (after 30 
h) and differentiation (after 48 h), using 7-9 as references. In LNCaP cells, 2, 3 and 6 
caused a strong G1 phase arrest (≥ 90%) with a substantial fraction of the cells in 
pre-G1 stage consistent with apoptosis induction, especially for 2 and 3 (Figure 
11.4A). In HCT116 cells, the pan-inhibitors 3 and 5 and the JmjC selective inhibitor 
9 displayed cell cycle alteration when compared to controls; however, as with the 
LNCaP cells, only compounds 2 and 3 induced the pre-G1 phase accumulation 
(Figure 11.4B). Dose-response curves for apoptosis in LNCaP and HCT116 cells 
were detected after treatment of cells for 48 h with 2 and 3 at doses from 10 to 100 
M (Figure 11.4C). When compared in independent experiments to a combination of 
the single-family target inhibitors 7 and 8, 2 and 3 showed much more efficacy in 
inducing apoptosis both in LNCaP and HCT116 cells (at 50 μM for 24 h; Figure 
11.5). To assess their differential toxicity, compounds 2 and 3 were also tested (50 
μM, 24 h) in mesenchymal progenitor (MePR) cells 611: in this non-cancer cell line 2 
increased the pre-G1 peak percentage from 8.4 to 12.8% respect to the control, while 
with 3 the same value was under the control value (4.2%), suggesting a cancer cell-
selective apoptotic induction for the two pan-KDM inhibitors (Figure 11.5). 
A) 
B) 
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C) 
 
Figure 11.4. Effects of pan-demethylase inhibitors 1-6 in LNCaP and in HCT116 cells. Cell cycle 
effect (left) and percentage of cells at pre-G1 peak (right) of 1-9 (50 μM, 30 h) in LNCaP (A) and 
HCT116 (B) cells. (C) dose-response curves with 2 and 3 for apoptosis (48h) in LNCaP (left) and 
HCT116 (right) cells. 
 
Figure 11.5. Comparison of effects on pre-G1 peak accumulation for 2, 3, 7, 8 and combination of 7 
plus 8 (50 μM, 24 h) in LNCaP, HCT116, and MePR cells. 
Despite differences in number of cells in pre-G1 phase, among Figure 11.4 and 11.5, 
compounds 2 and 3 induced cell death in cancer specific manner. These differences, 
however, could be due to cell populations (ie, the value of percentage of pre-G1 for 
the untreated HCT116 cells was around 2% in Figure 11.4 and around 8% in Figure 
11.5). Also times of induction (30 h in Figure 11.4 and 24 h in Figure 11.5) could 
justify the differences among percentages in data. 
Effects on cell proliferation and migration were detected by treating LNCaP and 
HCT116 cells with 50μM 2 and 3 up to 72 h, using the HDAC inhibitor SAHA as a 
positive control. In LNCaP cells, 2 showed similar growth arrest as SAHA, while 3 
was less effective (Figure 11.6A, left). Differently from SAHA, neither 2 or 3 was 
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able to stop migration in this cell line (Figure 11.6A, right). In HCT116 cells, strong 
antiproliferative effects for 2 and 3 were detected even after 6 h (Figure 11.6B, left), 
while the corresponding SAHA effect appeared only at 72 h. In this cell line, 2 and 
SAHA strongly hampered migration, while 3 had no effect (Figure 11.6B, right). 
A) 
B) 
Figure 11.6. Proliferation curves and cell migration relative to LNCaP (A) and HCT116 (B) cell lines 
after 24h. The HDAC inhibitor SAHA is used as a reference drug. Left: proliferation curves after 24h. 
Control (untreated cells) in red, cells treated with SAHA (5 μM) in green, cells treated with 2 (50μM) 
in blue, cells treated with 3 (50 μM) in violet, in blue (LNCaP, A) or yellow-green (HCT116, B) the 
base lines. Right: cell migration after 24 h. Histograms have been represented by slope relative to the 
control (untreated cells), cells treated SAHA (5 μM), cells treated with 2 (50 μM) and cells treated 
with 3 (50 μM). Data show the mean value from three parallel experiments with error bars showing 
the standard deviations on top of each column. 
Western blot analysis using mark-specific antibodies supported the proposal that the 
effects of 2 and 3 in LNCaP and HCT116 cells are due to both LSD1 and JmjC 
inhibition. Figure 11.7 shows increased H3K4me2/3 and H3K9me3 methylation after 
treatment with 50 M 2 and 3. 
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A) LNCaP cells 
 
 
B) HCT116 cells 
Figure 11.7. Western blot analyses of H3K4me2/3 and H3K9me2/3 methylation after treatment of 
LNCaP (A) and HCT116 (B) cells with 2, 3 and the references 7-9. 
11.4.3.1. Methods 
Cell lines. HCT116 (human colorectal carcinoma cell line-ATCC) were grown at 37 
°C in air and 5% CO2 in DMEM medium (Euroclone) and LNCaP (human prostate 
cancer cell line-ATCC) in RPMI medium (Euroclone). Both media were 
supplemented with 10% heat-inactivated FBS (Euroclone), 1% glutamine (Lonza), 
1% penicillin/streptomycin (Euroclone) and 0.1% gentamycin (Lonza). 
Cell cycle analysis. 2.5×10
5 
cells (HCT116 and LNCaP) were collected by 
centrifugation after 48 h of stimulation with reference or testing compounds at 50 
μM. The cells were resuspended in 500 µL of hypotonic buffer (0.1% NP-40, 0.1% 
sodium citrate, 50 µg/mL PI, RNAse A) and incubated in the dark for 30 min. The 
analysis was performed by FACS-Calibur (Becton Dickinson) using the Cell Quest 
Pro software (Becton Dickinson) and ModFit LT version 3 software (Verity). Pre-G1 
picks were analyzed as indicative of sub-G1 apoptotic population. The experiments 
were performed in triplicate and shown data represent independent media values. 
Dose-dependent apoptosis evaluation. 2.5×10
5 
HCT116 and LNCaP cells were 
treated for 48 h with increasing doses (10, 25, 50, 100 μM) of 2 and 3. Cell cycle 
distribution of 10,000 cells was analyzed with a FACS-Calibur flow cytometer 
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(Becton Dickinson) by ModFit version 3 Technology (Verity). Pre-G1 picks were 
analyzed as indicative of sub-G1 apoptotic population. All the experiments were 
performed at least 3 times and values were expressed in mean ± SD. 
 
Histone Extraction. After stimulation with compounds, cells (HCT116 and LNCaP) 
were collected by centrifugation and washed two times with PBS. Then the samples 
were resuspended in Triton extraction buffer (PBS containing 0.5% Triton X 100 
(v/v), 2 mM PMSF, 0.02% (w/v) NaN3), and the lysis was performed for 10 min at 4 
°C. Next, samples were centrifugated at 2000 rpm for 10 min at 4 °C, and the pellets 
were washed in TEB (half the volume). After a new centrifugation under the same 
conditions, the samples were re-suspended in 0.2 N HCl and the acidic histone 
extraction was carried out overnight at 4 °C. The supernatant was recovered by 
centrifugation and the protein content was quantified with BCA
™
 Protein Assay 
(Pierce). 
 
Western blot analysis. Histone extracts (10 μg) were denatured and boiled in buffer 
(0.25 M Tris-HCl pH 6.8, 8% SDS, 40% glycerol, 5% 2-mercaptoethanol, 
bromophenol blue 0.05%) for 3 min before electrophoresis. Proteins were subjected 
to SDS-PAGE (15% polyacrylamide gels) in Tris-glycine-SDS (25 mM Tris, 192 
mM glycine, 0.1% SDS). After electrophoresis, proteins were transferred to 
nitrocellulose membranes (Biorad Mini-protean gel and Transblot Turbo, Transfer 
System Biorad). The membranes were stained with Ponceau red, before to start with 
blocking (5% non-fat dry milk in TBS 1x/Tween 0.1%), and then incubated with the 
primary antibodies overnight at 4 °C. The employed antibodies were H3K4me2 and 
H3K4me3, H3K9me2 and H3K9me 3 (Abcam); total H4 (Cell Signalling) was used 
to normalize for equal loading of histone extracts.  
 
Determining cell proliferation with the xCELLigence system. Tumour cell 
proliferation was monitored with the xCELLigence system (Roche). LNCaP and 
HCT116 cells were suspended in DMEM and RPMI media respectively and added 
into a 96 well microtiter plate that is specifically designed to measure cellular 
impedance (E-Plate, Roche). The measured impedance, which is dependent on the 
level of confluence, was expressed as an arbitrary unit called Cell Index. The Cell 
Index at each time point is defined as (Rn-Rb)/(15X), where Rn is the cell-electrode 
impedance of the well when it contains cells and Rb is the background impedance of 
the well with the media alone. xCELLigence monitors cellular events in real time 
measuring electrical impedance across interdigitated micro-electrode integrated on 
the bottom of tissue culture E-Plates. The impedance measurement provides 
quantitative information about the biological status of the cells, including cell 
number, viability, and morphology. For experiments, LNCaP and HCT116 cell lines 
were starved in DMEM/10% FBS and RPMI/10% FBS, respectively, overnight 
before being seeded on an EPlate 96. Two hours after seeding, scalar cell 
concentrations were added in triplicate. Dynamic CI values were monitored in 30-
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minute intervals from the time of plating until the end of the experiment. CI values 
were calculated and plotted on the graph. Standard deviation of tetraplicates of wells 
for the two types cells with different treatments were analysed with the RTCA 
Software. 
 
Cell migration assay. The kinetic information about cell migration by dynamically 
recording the whole cell migration process in real time without labelling cells, has 
been performed with the Roche xCELLigence Real-Time Cell Analyzer (RTCA) DP 
instrument. The RTCA DP instrument uses the CIM (cellular invasion/migration)-
Plate 16 featuring microelectronic sensors integrated into the underside of the 
microporous polyethylene terephthalate (PET) membrane of a Boyden-like chamber. 
In this way cells migrate from the upper chamber through the membrane into the 
bottom chamber in response to the chemoattractant (foetal bovine serum) so 
contacting and adhering to the electronic sensors on the underside of the membrane, 
resulting in an increase of the impedance. The impedance increase is proportional to 
increasing numbers of migrated cells on the underside of the membrane. Moreover 
cell-index values reflecting impedance changes are recorded by RTCA DP 
instrument. The CIM-Plate has been assembled by placing the top chamber into the 
bottom chamber and snapping the two together. Serum-free medium has been placed 
in the top chamber to hydrate and pre-incubate the membrane for 1 h in the CO2 
incubator at 37 °C before obtaining a background measurement. LNCaP and 
HCT116 cells were resuspended at the indicated concentration in serum-free 
medium. Once the CIM-Plate has equilibrated, it has been placed in the RTCA DP 
station and the background cell index values have been measured. The CIM-Plate 
was then removed from the RTCA DP station and then cells have been added to the 
top chamber at the desired concentration. The CIM-Plate was placed in the RTCA 
DP station and migration has been monitored every 2 minutes for several hours. 
Cells have been analysed in absence or presence of 10% FBS in the bottom chamber. 
Cell migration was detected by automated real time monitoring and the low and high 
seeding densities were quantitatively monitored and reflected by the cell index 
values. 
11.4.4. Conclusion 
In conclusion, we have shown that “pan-KDM” inhibitors can be obtained by 
coupling the chemical features of tranylcypromine, a known LSD1 inhibitor, with the 
2,2'-bipyridine or 5-carboxy-8HQ scaffolds, two 2OG competitive moieties 
developed for JmjC inhibition. Such compounds are able to inhibit LSD1 as well as 
JmjC enzymes while have little or no effect against other tested 2OG enzymes 
lacking KDM activity. It is also interesting that the tranylcypromine-moieties act as 
covalently binding inhibitors, whereas the JmjC inhibitor scaffolds bind reversibly. 
The application of such LSD/JmjC hybrid inhibitors to cells enables simultaneous 
increases in levels of H3K4me2/3 and H3K9me2/3 as well as high growth arrest and 
apoptosis (2 and 3) in LNCaP prostate and HCT116 colon cancer cells, whereas the 
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related family-specific single-target inhibitors 7-9 as well as a combination of 7 plus 
8 were inactive. When tested in MePR non-cancer cells to assess their differential 
toxicity, 2 and 3 showed very low (2) or no (3) ability to increase the pre-G1 
accumulation. It should be noted that since a single KDM may target multiple 
substrates, different biological effects depending on the context could manifest. More 
generally, the results demonstrate that hybrid molecules inhibiting different classes 
of histone modifying enzymes have substantial potential as functional probes or 
histone methylation, and we suggest that combining other types of inhibitors 
targeting histone modifying enzymes may be productive with respect to regulating 
the expression of specific sets of genes. Our pan-demethylase inhibitors may also be 
useful for medicinal chemistry efforts relating to cancer, in line with SAHA, which 
likely owes its anticancer activity to its pan-HDAC inhibitor profile.
612 
 
*Adapted with the permission from Rotili, D., Tomassi, S., Conte, M., Benedetti, R., 
Tortorici, M., Ciossani, G., Valente, S., Marrocco, B., Labella, D., Novellino, E., Mattevi, 
A., Altucci, L., Tumber, A., Yapp, C., King, O. N. F., Hopkinson, R. J., Kawamura, A., 
Schofield, C. J., Mai. A. Pan-histone demethylase inhibitors simultaneously targeting 
Jumonji C and lysine specific demethylases display high anticancer activities. J. Med. 
Chem., accepted.612 
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12. From BIX-01294 to a selective inhibitor of Jumonji 
demethylases
*
 
12.1. Research project 
Figure 12.1. BIX-01294 and its analogs. 
BIX-01294 (a diazepin-quinazolin-amine derivative; Figure 12.1) inhibits activities 
of G9a
613
 and G9a-like protein (GLP) lysine methyltransferase by mimicking the 
bound conformation of histone H3 Lys4 to Arg8, residues N-terminal to the target 
lysine 9 of histone H3, in the substrate peptide-binding groove.
565
 Addition of a 
lysine or methyl-lysine mimic to BIX-01294 enhances its potency of inhibition of 
G9a and GLP due to the insertion of the mimics into the target lysine-binding 
channel.
575,577,614,615
 It is interesting to note that both lysine methyltransferases and 
demethylases recognize lysines in methylated and unmethylated states, whether they 
are substrates or reaction products. We therefore explore whether BIX analogs can 
function as selective inhibitors of human KIAA1718 (a H3K9me2 demethylase, also 
known as JHDM1D), in comparison with their inhibitions of human GLP (a H3K9 
methyltransferase, also known as EHMT1) whose loss-of-function mutations cause 
the 9q34 subtelomeric deletion syndrome
616
 and human JARID1C (a H3K4me3 
demethylase, also known as SMCX) mutations of which affect its demethylase 
activity are found in X-linked mental retardation patients.
528,617
 KIAA1718 belongs 
to a small family of Jumonji proteins with three members (PHF2, PHF8 and 
KIAA1718) (See Sec. 7.2.2.7). Each of these proteins harbors two domains in its 
respective N-terminal half: a PHD domain that binds tri-methylated histone H3 
lysine 4 (H3K4me3), a modification associated with transcriptional activation, and 
their linked Jumonji domains which remove methyl marks (H3K9me2, H3K27me2, 
or H4K20me1) that are associated with transcriptional repression.
497 
KIAA1718 
removes methyl marks from dimethylated H3 lysine 9 (H3K9me2) and/or lysine 27 
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(H3K27me2),
497,534,539
 which shares an ARKS sequence. By using a structure activity 
relationship (SAR) approach we have designed a new set of inhibitor, starting from 
the BIX-01294 structure, which selectively inhibited KIAA1718 but not GLP (Figure 
12.1). 
12.2. Chemistry 
The derivatives 1-5 have been prepared as reported in Scheme 1. The 
dichloroquinazoline derivative 11, prepared as reported previously,
618
 was treated 
with dimethylamine at room temperature providing the 4-substituted intermediate 12. 
This latter was converted into 13 by the mean of a further treatment with 
dimethylamine at 110 °C in a sealed tube. The intermediate 13 was then converted 
into the phenol derivative 14 by debenzylation with trifluoroacetic acid under reflux 
conditions. The same reaction has been performed to convert 12 into its debenzylated 
derivative 19. The two phenol compounds 14 and 19 undergo to a Mitsunobu 
reaction with the Boc-protected 5-aminopentan-1-ol to provide the derivatives 16 and 
20, respectively, that were finally converted into the final derivatives 3 and 4, 
respectively, by deprotection and salification with HCl. Compound 20 has also been 
treated with the commercially available N
1
,N
1
-dimethylpropane-1,3-diamine at 110 
°C in a sealed tube to give the intermediate 21, that was finally deprotected with HCl 
to give 5. By the means of a Mitsunobu reaction with the 4-bromobutanol the 
intermediate 14 was also converted into the corresponding bromoalkyl ether 15 that 
was finally transformed into the final compound 2 by treatment with dimethylamine 
at 110 °C in a sealed tube and subsequent salification with HCl. By a catalytic 
hydrogenation 12 was also converted into its debenzylated and dechlorinated 
intermediate 17 that, after alkylation under Mitsunobu conditions with the Boc-
protected 5-aminopentan-1-ol and subsequent deprotection/salification with HCl, 
gave the final compound 1. The derivatives 6-10 have been prepared as reported in 
Scheme 2. The intermediates 28-30 were obtained after treatment of the 
dichloroquinazoline 11 with the proper amines, followed by trifluoroacetic acid 
mediated deprotection and subsequent Mitsunobu reaction with the Boc-protected 5-
aminopentan-1-ol. The final compounds 8-10 were then obtained by 
deprotection/salification with HCl of the intermediates 28-30. The compound 6 was 
obtained by treatment of 30 with N
1
,N
1
-dimethylpropane-1,3-diamine at 110 °C in a 
sealed tube to give the intermediate 31 and final deprotection with HCl. By reaction 
at room temperature with iodomethane, starting from 29, was obtained the 
ammonium salt 32 that was finally converted into the compound 7 by HCl-mediated 
deprotection/salification. 
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Scheme 1
 
 
Reagents and conditions: (a) Dimethylamine 2M in THF, dry THF, rt; (b) dimethylamine 2M in 
THF, dry THF, 110 °C, sealed tube; (c) TFA, reflux; (d) 4-bromo-1-butanol, PPh3, DIAD, dry THF, 
N2, rt; (e) dimethylamine 2M in THF, dry THF, 110 °C sealed tube; (f) HCl 2N in diethyl ether, dry 
THF, rt; (g) 5-(Boc-amino)-1-pentanol, PPh3, DIAD, dry THF, N2, rt; (h) HCl 4N in dioxane, dry THF 
or dry THF-MeOH (1:1), rt; (i) H2, Pd-C, dry THF-MeOH (2:1), 1 atm, rt; (j) 3-(dimethylamino)-1-
propylamine, 110 °C, sealed tube. 
Scheme 2
 
 
Reagents and conditions: (a) Various amines, dry THF, rt; (b) TFA, reflux; (c) 5-(Boc-amino)-1-
pentanol, PPh3, DIAD, dry THF, N2, rt; (d) HCl 4N in dioxane, dry THF or dry THF-MeOH (1:1), rt; 
(e) 3-(dimethylamino)-1-propylamine, 110 °C, sealed tube; (f) MeI, dry THF, rt. 
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The chemical and physical data of the intermediate 11-32 and final compounds 1-10 
are reported in Table 12.1 and 12.2, respectively. 
Table 12.1. Chemical and physical data of compounds 11-32. 
 
Cpd R1 R2 R3 mp, °C 
recrystall. 
solvent 
Yield 
% 
12 Cl 
 
Bn 151-153 A  89 
13 
  
Bn 112-113 B 88 
14 
  
H 149-151 A 80 
15 
   
oil - 70 
16 
   
oil - 67 
17 H 
 
H 210-213 C 75 
18 H 
  
oil - 70 
19 Cl 
 
H 219-221 C 80 
20 Cl 
  
oil - 65 
21    
87-90 D 75 
22 Cl 
 
Bn 132-134 B 89 
23 Cl  Bn 135-138 B 91 
24 Cl 
 
Bn 155-158 A 90 
25 Cl 
 
H 160-163 A 80 
26 Cl  H 95-99 E 81 
27 Cl 
 
H 189-191 F 78 
28 Cl 
  
130-132 B 66 
29 Cl   
oil - 67 
30 Cl 
  
88-90 D 68 
31    
44-47 D 71 
32 Cl 
  
159-162 A 83 
A: acetonitrile; B: benzene; C: methanol; D: cyclohexane; E: cyclohexane/benzene; F: 
acetonitrile/methanol . 
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Table 12.2. Chemical and physical data of final compounds 1-10. 
 
Cpd R1 R2 R3 mp, °C 
recrystal. 
solvent 
Yield 
% 
1 H 
  
>250 C 93 
2 
   
>250 C 94 
3 
   
>250 C 95 
4 Cl 
  
>250 C 94 
5 
  
 >250 C 92 
6 
  
 >250 C 96 
7 Cl N
H
N
I
  
>250 C 93 
8 Cl N
H
N
HCl
  
>250 C 97 
9 Cl 
  
>250 C 95 
10 Cl 
 
 >250 C 96 
A: acetonitrile; B: benzene; C: methanol; D: cyclohexane; E: cyclohexane/benzene; F: 
acetonitrile/methanol . 
 
12.3. Experimental section 
Chemistry. Melting points were determined on a Buchi 530 melting point apparatus 
and are uncorrected. 
1
H-NMR and 
13
C-NMR spectra were recorded at 400 MHz on a 
Bruker AC 400 spectrometer; chemical shifts are reported in δ (ppm) units relative to 
the internal reference tetramethylsilane (Me4Si). EIMS spectra were recorded with a 
Fisons Trio 1000 spectrometer; only molecular ions (M
+
) and base peaks are given. 
All compounds were routinely checked by TLC and 
1
H NMR. TLC was performed 
on aluminum-backed silica gel plates (Merck DC, Alufolien Kieselgel 60 F254) with 
spots visualized by UV light. All solvents were reagent grade and, when necessary, 
were purified and dried by standard methods. Concentration of solutions after 
reactions and extractions involved the use of a rotary evaporator operating at reduced 
pressure of ca. 20 Torr. Organic solutions were dried over anhydrous sodium sulfate. 
Analytical results are within ± 0.40% of the theoretical values. All chemicals were 
purchased from Aldrich Chimica, Milan (Italy), or from Alfa Aesar, Milan (Italy), 
and were of the highest purity. 
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General procedure for the synthesis of the 4-Amino-quinazoline derivatives (12, 
22-24). Example: 7-(Benzyloxy)-2-chloro-6-methoxy-N,N-dimethylquinazolin-4-
amine (12).To 7-(benzyloxy)-2,4-dichloro-6-methoxyquinazoline 11 (650 mg, 1.939 
mmol) dissolved in dry THF (12.5 mL) was added a solution of dimethylamine 2M 
in THF (2.90 mL, 5.817 mmol); the mixture was stirred at room temperature and the 
reaction was completed after 1h and 10 min. The resulting solid in suspension was 
filtered off and washed with THF. The filtrate and washings were concentrated in 
vacuum and the residual solid triturated from petroleum ether, collected by filtration, 
washed with petroleum ether and dried to give pure 3 as a white solid (75%). 
1
H-
NMR (CDCl3, 400 MHz, δ; ppm) 3.36 (s, 6H, N-(CH3)2), 4.01 (s, 3H, OCH3), 5.27 
(s, 2H, CH2-benzyl protons), 7.21 (s, 1H, H quinazoline ring), 7.29 (s, 1H, H 
quinazoline ring), 7.34-7.36 (m, 1H, H phenyl ring), 7.40-7.42 (d, 2H, H phenyl 
ring), 7.47-7.49 (d, 2H, H phenyl ring). 
13
C-NMR (CDCl3) δ 40.7 (2C), 56.2, 71.2, 
103.3, 107.8, 117.3, 127.2 (2), 127.7, 129.0 (2), 141.2, 148.9, 152.5, 156.1, 160.3, 
179.6. MS (EI): m/z [M]
+
: 343.11. 
Procedure for the preparation of the 7-(Benzyloxy)-6-methoxy-N
2
,N
2
,N
4
,N
4
-
tetramethylquinazoline-2,4-diamine (13).A solution of dimethylamine 2M in THF 
(2.25 mL) was added to 7-(benzyloxy)-2-chloro-6-methoxy-N,N-dimethylquinazolin-
4-amine 12 (200 mg, 0.582 mmol) in a sealed tube and the resulting mixture was 
stirred at 110 °C for 26h. After cooling to room temperature the reaction was 
quenched with 10 mL of water, then extracted with ethyl acetate (3 x 10 mL). The 
collected organic phases were washed with brine (1 x 5 mL), dried over sodium 
sulfate and concentrated to give pure 13 which was directly used in the following 
step without further purification. 
1
H-NMR (DMSO-d6, 400 MHz, δ; ppm) 3.11 (s, 
6H, N-(CH3)2),  3.18 (s, 6H, N-(CH3)2), 3.82 (s, 3H, OCH3), 5.20 (s, 2H, CH2-benzyl 
protons), 6.90 (s, 1H, H quinazoline ring), 7.20 (s, 1H, H quinazoline ring), 7.36-7.38 
(m, 1H, H phenyl ring), 7.42-7.44 (d, 2H, H phenyl ring), 7.47-7.49 (d, 2H, H phenyl 
ring). 
13
C-NMR (DMSO) δ 40.3 (2C), 40.7 (2C), 56.2, 71.2, 103.5, 107.8, 113.3, 
127.2(2C), 127.7, 129.0 (2C), 141.2, 148.9, 150.6, 159.9¸179.3, 183.2 MS (EI): m/z 
[M]
+
: 352.19. 
General procedure for the synthesis of the Tert-butyl-(5-((4-(amino substituted)-
2-((3-(dimethylamino)propyl)amino)-6-methoxyquinazolin-7-
yl)oxy)pentyl)carbamates (21, 31).Example: Tert-butyl-(5-((4-(dimethylamino)-
2-((3-(dimethylamino)propyl)amino)-6-methoxyquinazolin-7-
yl)oxy)pentyl)carbamate (21). A mixture of tert-butyl (5-((2-chloro-4-
(dimethylamino)-6-methoxyquinazolin-7-yl)oxy)pentyl)carbamate 20 (180 mg, 
0.410 mmol) and 3-dimethylaminopropylamine (0.36 mL) was placed in a sealed 
tube and stirred at 110 °C for 7 h. After cooling to room temperature, 10 mL of water 
were added and the aqueous phase was extracted with ethyl acetate (3 x 10 mL), the 
combined organic phases were then washed with brine (1 x 5 mL) and dried over 
sodium sulfate. After evaporation in vacuum the crude was purified by aluminum 
oxide chromatographic column eluting with AcOEt: MeOH 25:1 to provide the 
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desired compound 21. 
1
H-NMR (DMSO-d6, 400 MHz, δ; ppm) 1.64-1.77 (m, 2H, -
NHCH2CH2CH2N(CH3)2, 2.15 (s, 6H, -NHCH2CH2CH2N(CH3)2), 2.28 (t, 2H, -
NHCH2CH2CH2N(CH3)2), 2.93 (q, 2H, -CH2NH-Boc), 3.13 (s, 6H, -N(CH2)3), 3.27-
3.29 (t, 2H, -NHCH2CH2CH2N(CH3)2), 3.80 (s, 3H, -OCH3), 4.02 (t, 2H, -OCH2), 
6.33 (t, 1H, -NHCH2CH2CH2N(CH3)2), 6.74 (s, 1H, H quinazoline ring) 6.79 (s, 1H, 
-NH-Boc), 7.15 (s, 1H, H quinazoline ring). 
General procedure for the synthesis of the 7-Hydroxy quinazoline derivatives 
(14, 19, 25-27). Example: 2-Chloro-4-(3-(dimethylamino)propylamino)-6-
methoxyquinazolin-7-ol (26). A solution of 7-(benzyloxy)-2-chloro-N-(3-
(dimethylamino)propyl)-6-methoxyquinazolin-4-amine 23 (400 mg, 0.996 mmol) in 
trifluoroacetic acid (5.5 mL) was refluxed at 115°C for 1.5 h. The trifluoroacetic acid 
was removed by evaporation, the reaction was left to reach 0 °C, quenched with 
water (6 mL) and a saturated solution of Na2CO3 was then slowly added until pH 
9.5-10 to give a white suspension. The resulting precipitate was collected, the 
aqueous layer was extracted with a mixture of CHCl3: i-PrOH 4:1 (3 x 20 mL) and 
the combined organic phases were dried over sodium sulfate. After evaporation in 
vacuum the obtained solid was reunited with the first one, triturated from petroleum 
ether/diethyl ether (1:1) and then filtered to give the pure compound 26 (80%). 
1
H-
NMR (DMSO-d6, 400 MHz, δ; ppm) 1.74-1.80 (m, 2H, NHCH2CH2CH2), 2.17 (s, 
6H, N-(CH3)2), 2.30-2.34 (t, 2H, NHCH2CH2CH2), 3.46-3.51 (m, 2H, 
NHCH2CH2CH2), 3.89 (s, 3H, OCH3), 6.89 (s, 1H, H quinazoline ring), 7.57 (s, 1H, 
H quinazoline ring), 8.36 (s, 1H, NH), 10.32 (bs, 1H, OH). 
13
C-NMR (DMSO) δ 
26.6, 43.2, 45.9 (2C), 56.2, 56.5, 99.5, 110.6, 110.7, 147.3¸150.3, 155.1¸155.8, 158.9.   
MS (EI): m/z [M]
+
: 310.12. 
General procedure for the preparation of the 4-(dimethylamino)-6-
methoxyquinazolin-7-ol (17). To a solution of the compound 12 (545 mg, 1.585 
mmol) in a mixture of dry THF: dry MeOH (2:1) (38 mL: 19 mL) was added Pd-C 
10% wt (0.168 g) at room temperature and 1 atm H2 till the reaction was completed 
(3h). The reaction was then filtered to remove palladium, the solvent was distilled to 
give a crude yellow solid that was triturated from a mixture THF: MeOH (2:1), 
collected by filtration, washed with diethyl ether and dried to give the desired 
compound 17. 
1
H-NMR (DMSO-d6, 400 MHz, δ; ppm) 3.56 (s, 6H, N-(CH3)2), 3.94 
(s, 3H, OCH3), 7.29 (s, 1H, H quinazoline ring), 7.57 (s, 1H, H quinazoline ring), 
8.65 (s, 1H, H quinazoline ring), 11.51-11.67 (bs, 1H, OH). 
13
C-NMR (DMSO) δ 
40.7 (2C), 56.2, 103.8, 112.5, 118.8, 148.1, 151.1¸ 154.7, 155.0, 178.1. MS (EI): m/z 
[M]
+
: 219.10. 
General procedure for the synthesis of NH-Boc quinazoline derivatives 
(16,18,20,28-30). Example: Tert-butyl 5-(4-(1-benzylpiperidin-4-ylamino)-2-
chloro-6-methoxyquinazolin-7-yloxy)pentylcarbamate (30). Triphenylphosphine 
(1.845 g, 7.04 mmol) and 5-(Boc-amino)-1-pentanol (1.040 g, 5.12 mmol) were 
added to a solution of 4-(1-benzylpiperidin-4-ylamino)-2-chloro-6-
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methoxyquinazolin-7-ol 27 (0.510 g, 1.28 mmol) in dry THF (22mL) under nitrogen 
atmosphere; afterwards DIAD (1.293 g, 6.4 mmol) was added dropwise at 0 °C. 
Then the reaction was left to reach room temperature and stirred for 2h. The solvent 
was removed to give a residue that was purified by chromatographic column on silica 
gel eluting with CHCl3:MeOH 30:1 to provide pure 30. 
1
H-NMR (CDCl3, 400 MHz, 
δ; ppm) 1.54 (s, 9H, C(CH3)3), 1.57-1.61 (m, 4H, OCH2CH2CH2CH2), 1.72-1.73 (m, 
4H, OCH2CH2CH2CH2CH2), 2.15-2.16 (m, 2H, CH2 piperidine ring), 2.34-2.37 (m, 
2H, CH2 piperidine ring), 2.99-3.02 (m, 2H, CH2 piperidine ring), 3.17-3.18 (m, 2H, 
CH2 piperidine ring), 3.65 (s, 2H, CH2-benzyl protons), 4.00 (s, 3H, OCH3), 4.11-
4.14 (t, 2H, OCH2), 4.33-4.35 (bs, 1H, NHCOOC(CH3)3), 4.57-4.59 (bs, 1H, NH), 
5.38-5.40 (m, 1H, H piperidine ring), 6.79 (s, 1H, H quinazoline ring), 7.11 (s, 1H, H 
quinazoline ring), 7.28 (d, 2H, H phenyl ring), 7.32 (m, 1H, H phenyl ring), 7.37-
7.39 (d, 2H, H phenyl ring). 
13
C-NMR (CDCl3) δ 23.1, 28.5 (3C), 29.4, 30.0, 30.4 
(2C), 41.9, 49.4 (2C), 53.1, 56.2, 60.4, 69.2 , 79.5, 99.2, 107.1 , 111.0, 127.3, 128.5 
(2C), 128.9 (2C), 135.6, 147.4, 151.5 ,155.8, 156.0, 158.9, 159.6.  MS (EI): m/z 
[M]
+
: 583.29. 
Preparation of 3-(7-(5-(tert-butoxycarbonyl)pentyloxy)-2-chloro-6-
methoxyquinazolin-4-ylamino)-N,N,N-trimethylpropan-1-aminium iodide (32). 
To a solution of the NH-Boc intermediate 28 (0.400 g, 0.808 mmol) in dry THF (5 
mL) was slowly added iodomethane (4.04 mmol, 0.573 g), then the reaction was 
stirred at room temperature for 1 hour. The solvent was distilled and the crude 
product was purified by aluminum oxide chromatographic column eluting with 
CHCl3: MeOH: TEA ,30: 1: 0.1, to provide pure 32. 
1
H-NMR (CDCl3, 400 MHz, δ; 
ppm) 1.45 (s, 9H, C(CH3)3), 1.52-1.55 (m, 4H, OCH2CH2CH2CH2), 1.90-1.92 (m, 
4H, NHCH2CH2CH2 and OCH2CH2CH2CH2CH2), 2.40 (m, 2H, NHCH2CH2CH2), 
3.35 (s, 9H, N(CH3)3), 3.71-3.73 (m, 2H, NHCH2CH2CH2), 3.85-3.86 (m, 2H, 
NHCH2CH2CH2), 3.99-4.01 (t, 2H, OCH2), 4.12 (s, 3H, OCH3), 4.61 (bs, 1H, 
NHCOOC(CH3)3), 7.05 (s, 1H, H quinazoline ring), 7.86 (s, 1H, H quinazoline ring), 
8.22 (bs, 1H, NH). 
13
C-NMR (CDCl3) δ 22.3, 23.1, 28.5 (3C), 29.4, 30.0, 41.9, 44.0, 
54.7 (3C), 56.2, 64.4, 69.2, 79.5, 99.2, 107.1, 111.0, 147.4, 151.5, 155.8, 156.0, 
158.9, 159.6. MS (EI): m/z [M]
+
: 637.19. 
Preparation of the derivative 7-(4-Bromobutoxy)-6-methoxy-N
2
,N
2
,N
4
,N
4
-
tetramethylquinazoline-2,4-diamine (15). Triphenylphosphine (770 mg, 2.93 
mmol) and 4-bromo-1-butanol (327 mg, 2.13 mmol) were added to a solution of 2,4-
dimethylammino-2-chloro-6-methoxyquinazolin-7-ol 14 (140 mg, 0.533 mmol) in 
dry THF (6.5 mL) under nitrogen atmosphere; afterwards DIAD (539.6 mg, 0.525 
mL, 2.67 mmol) was added dropwise at 0 °C. Then the reaction was left to reach 
room temperature and stirred for 36 h. The solvent was removed to give a residue 
that was purified by chromatographic column on silica gel eluting with 
CHCl3:MeOH 60:1 to give pure 15. 
1
H-NMR (CDCl3, 400 MHz, δ; ppm) 2.09 (m, 
4H, OCH2CH2CH2CH2Br), 3.20 (s, 12H, N(CH3)2), 3.51-3.58 (t, 2H, 
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OCH2CH2CH2CH2Br), 3.91 (s, 3H, OCH3), 4.23 (m, 2H, OCH2CH2CH2CH2Br), 7.17 
(s, 1H, H quinazoline ring), 7.28 (s, 1H, H quinazoline ring). 
Preparation of the derivative 7-(4-(dimethylamino)butoxy)-6-methoxy-
N
2
,N
2
,N
4
,N
4
-tetramethylquinazoline-2,4-diamine dihydrochloride (2). To the 
intermediate 7-(4-bromobutoxy)-6-methoxy-N
2
,N
2
,N
4
,N
4
-tetramethylquinazoline-2,4-
diamine 15 (108 mg, 0.271 mmol) in dry DMF (1 mL) was added a 2.0 M 
dimethylamine solution in THF (2 mL), then the mixture was heated in a sealed tube 
under stirring at 110 °C for 4 hour. The reaction was quenched with water (15 mL), 
then extracted with ethyl acetate (3 x 15 mL). The collected organic phases were 
washed with saturated sodium chloride solution (2 x 5 mL) and dried over sodium 
sulfate. The solvent was removed to give a crude residue that was purified by 
aluminum oxide chromatographic column eluting with AcOEt:MeOH 25:1 to 
provide the pure 7-(4-(dimethylamino)butoxy)-6-methoxy-N
2
,N
2
,N
4
,N
4
-
tetramethylquinazoline-2,4-diamine. The 7-(4-(dimethylamino)butoxy)-6-methoxy-
N
2
,N
2
,N
4
,N
4
-tetramethylquinazoline-2,4-diamine (0.14 mmol, 50 mg) was then 
dissolved in  dry THF (1 mL) and to the solution was added HCl 2M in diethyl ether  
(1 mL). After 2 hours of stirring at room temperature the solid in suspension  was 
filtered, washed with dry diethyl ether to give the desired dihydrochloride salt 2. 
1
H-
NMR (DMSO-d6, 400 MHz, δ; ppm) 1.84 (m, 4H, CH2CH2CH2CH2O), 2.72 (s, 6H, 
CH2N(CH3)2), 3.12 ( m, 2H, CH2N(CH3)2), 3.25 (s, 6H, N(CH3)2), 3.44 (s, 6H, 
N(CH3)2), 3.85 (s, 3H, OCH3), 4.10 (m, 2H, OCH2), 7.44 (s, 1H, H quinazoline ring), 
7.81 (s, 1H, H quinazoline ring), 10.57 (bs, 1H, CH2
+
HN(CH3)2), 12.20 (bs, 1H, 
+
HN(CH3)2). 
13
C-NMR (DMSO-d6) δ 24.1, 27.4, 40.3 (2C), 40.7 (2C), 45.9 (2C), 
56.2, 59.1, 68.9, 103.5, 107.8, 113.3, 148.9, 150.6, 159.9, 179.3, 183.2. MS (EI): m/z 
[M]
+
: 433.20. 
General procedure for the synthesis of hydrochlorides derivatives (1-10). 
Example: 7-(5-Aminopentyloxy)-2-chloro-N-(2-(dimethylamino)ethyl)-6-
methoxyquinazolin-4-amine dihydrochloride (8). The compound 28 (50 mg, 0.104 
mmol) was dissolved in a mixture dry THF: dry MeOH (1:1) and to the solution was 
added HCl 4N in dioxane (1.55 mL, 6.23 mmol). After stirring at room temperature 
for 1 day the reaction mixture was filtered and the solid was washed with dry diethyl 
ether to give the desired hydrochloride salt 8. 
1
H-NMR (DMSO-d6, 400 MHz, δ; 
ppm) 1.49-1.51 (m, 2H, CH2CH2CH2O), 1.63-1.66 (m, 2H, CH2CH2CH2CH2O), 
1.79-1.83 (m, 2H, CH2CH2O), 2.80-2.82 (m, 2H, H3N
+
CH2CH2), 2.87-2.88 (ss, 6H, 
+
HN(CH3)2), 3.40-3.41 (m, 2H, NHCH2CH2), 3.87-3.89 (m, 2H, NHCH2CH2), 3.94 
(s, 3H, OCH3), 4.10-4.13 (m, 2H, CH2CH2CH2O), 7.11 (s, 1H, H quinazoline ring), 
7.88-7.95 (s, m, 4H, H3N
+
, H quinazoline ring), 9.04 (t, 1H, HNCH2), 10.38 (bs, 1H, 
+
HN(CH3)2). 
13
C-NMR (DMSO-d6) δ 23.1, 29.4, 32.8, 42.1, 45.6 (2C), 47.1, 56.2, 
58.1, 69.2, 99.2, 107.1, 111.0, 147.4, 151.5, 155.8, 158.9, 159.6. MS (EI): m/z [M]
+
: 
453.15. 
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7-(5-aminopentyloxy)-6-methoxy-N,N-dimethylquinazolin-4-amine 
hydrochloride (1). 
1
H-NMR (DMSO-d6, 400 MHz, δ; ppm) 1.50-1.52 (m, 2H, 
CH2CH2CH2O), 1.61-1.67 (m, 2H, CH2CH2CH2CH2O), 1.82-1.86 (m, 2H, 
CH2CH2O), 2.80-2.82 (m, 2H, H3N
+
CH2CH2), 3.56 (s, 6H, N(CH3)2), 3.95 (s, 3H, 
OCH3), 4.14-4.18 (t, 2H, CH2CH2CH2O), 7.41 (s, 1H, H quinazoline ring), 7.60 (s, 
1H, H quinazoline ring), 7.87-7.94 (m, 3H, H3N
+
), 8.72 (s, 1H, H quinazoline ring). 
13
C NMR (DMSO-d6) δ 23.1, 29.4, 32.8, 40.7 (2C), 42.1, 56.2, 69.2, 103.5, 
108.9¸119.2, 148.2, 152.3, 155.0, 159.2, 178.1.  (EI): m/z [M]
+
: 340.17. 
7-(5-Aminopentyloxy)-6-methoxy-N
2
,N
2
,N
4
,N
4
-tetramethylquinazoline-2,4-
diamine dihydrochloride (3).
1
H-NMR (DMSO-d6, 400 MHz, δ; ppm) 1.50 (m, 2H, 
CH2CH2CH2O), 1.64 (m, 2H, CH2CH2CH2CH2O), 1.81 (m, 2H, CH2CH2O), 1.99 (m, 
2H, NHCH2CH2), 2.74 (s, 6H, 
+
HN(CH3)2), 2.80 (m, 2H, H3N
+
CH2CH2), 3.11 (m, 
2H, CH2CH2N(CH3)2H
+
), 3.47 (s, 6H, N(CH3)2), 3.49 (m, 2H, NHCH2CH2CH2), 
3.86 (s, 3H, OCH3), 4.09 (m, 2H, CH2CH2CH2O), 7.15 (s, br, 1H NHCH2CH2CH2), 
7.45 (s, 1H, H quinazoline ring), 7.93 (m, 4H, H quinazoline ring and H3N
+
), 10.6 (s, 
br, 
+
HN(CH3)2), 12,8 (s br, 1H, HN
+
 quinazoline ring). 
13
C-NMR (DMSO-d6) δ 23.1, 
29.4, 32.8, 40.3 (2C), 40.7 (2C), 42.1, 56.2, 69.2, 103.5, 107.8, 113.3, 148.9, 150.6, 
159.9, 179.3, 183.2. (EI): m/z [M]
+
: 419.19. 
7-(5-Aminopentyloxy)-2-chloro-6-methoxy-N,N-dimethylquinazolin-4-amine 
hydrochloride (4). 
1
H-NMR (DMSO-d6, 400 MHz, δ; ppm) 1.47-1.51 (m, 2H, 
CH2CH2CH2O), 1.62-1.66 (m, 2H, CH2CH2CH2CH2O), 1.80-1.83 (m, 2H, 
CH2CH2O), 2.79-2.83 (m, 2H, H3N
+
CH2CH2), 3.34 (s, 6H, N(CH3)2), 3.90 (s, 3H, 
OCH3), 4.11-4.15 (t, 2H, CH2CH2CH2O), 7.15 (s, 1H, quinazoline ring), 7.43 (s, 1H, 
quinazoline ring), 7.87-7.95 (m, 3H, H3N
+
). 
13
C-NMR (DMSO-d6) δ 23.1, 29.4, 32.8, 
40.7 (2C), 42.1, 56.2 , 69.2, 103.3, 107.8, 117.3, 148.9, 152.5, 156.1, 160.3, 179.6. 
(EI): m/z [M]
+
: 374.13. 
7-(5-Aminopentyloxy)-N
2
-(3-(dimethylamino)propyl)-6-methoxy-N
4
,N
4
-
dimethylquinazoline-2,4-diamine trihydrochloride (5). 
1
H-NMR (DMSO-d6, 400 
MHz, δ; ppm) 1.50 (m, 2H, CH2CH2CH2O), 1.65 (m, 2H, CH2CH2CH2CH2O), 1.81 
(m, 2H, CH2CH2O), 2.80 (m, 2H, H3N
+
CH2CH2), 3.26 (s, 6H, N(CH3)2), 3.45 (s, 6H, 
N(CH3)2), 3.87 (s, 3H, OCH3), 4.08 (m, 2H, CH2CH2CH2O), 7.15 (s, 1H, NHCH2), 
7.45 (s, 1H, quinazoline ring), 7.76 (s, 1H, quinazoline ring), 7.99 (s br, 3H, H3N
+
), 
12,1 (s br, 1H, HN
+
 quinazoline ring). 
13
C-NMR (DMSO-d6) δ 23.1, 26.6 , 29.4, 
32.8, 40.7 (2C), 42.1, 42.8, 45.9 (2C), 56.2, 56.5, 69.2, 101.9, 105.4, 112.2, 147.5, 
148.1, 158.3, 176.3, 177.9. (EI): m/z [M]
+
: 476.24.  
7-(5-Aminopentyloxy)-N
4
-(1-benzylpiperidin-4-yl)-N
2
-(3-
(dimethylamino)propyl)-6-methoxyquinazoline-2,4-diamine trihydrochloride 
(6).
1
H-NMR (DMSO-d6, 400 MHz, δ; ppm) 1.47-1.52 (m, 2H, CH2CH2CH2O), 1.62-
1.66 (m, 2H, CH2CH2CH2CH2O), 1.80-1.82 (m, 2H, H3N
+
CH2CH2), 2.00 (m, 2H, 
piperidine ring), 2.00-2.03 ( m, 4H, CH2CH2O and CH2 piperidine ring), 2.77-2.85 
 193 |BIX-01294 analogs 
(m, 8H, N(CH3)2 and propyl protons), 3.15-3.18 (m, 2H, CH2N(CH3)2), 3.32-3.40 (m, 
4H, piperidine ring), 3.50-3.65 (m, 2H, NHCH2), 3.89 (s, 3H, OCH3), 4.07-4.09 (t, 
2H, CH2CH2CH2O), 4.34 (s, 2H, CH2-benzyl protons), 4.51-4.52 ( m, 1H, piperidine 
ring), 7.03 (s, 1H, NHCH2), 7.48 ( s, 1H, quinazoline ring), 7.69  (s, 1H, quinazoline 
ring), 7.93-8.00 (m, 2H, phenyl ring), 8.12-8.35 (m, 5H, benzenic protons and NH2), 
9.33-9.37 (s, 1H, NH-piperidine), 10.89-10.96 (bs, 1H, H3N
+
), 11.23-11.34 (bs, 1H, 
+
HNbn), 12.78-12.90 (bs, 1H, 
+
HN(CH3)2). 
13
C-NMR (DMSO-d6) δ 23.1, 26.6, 29.4, 
30.4 (2C), 32.8, 42.1, 42.8, 45.9 (2C), 49.4 (2C), 53.1, 56.2, 56.5, 60.4, 69.2, 97.8, 
104.7 , 105.9, 127.3, 128.5 (2C), 128.9 (2C), 135.6, 146.5, 146.6, 157.2, 157.6. 
176.0. (EI): m/z [M]
+
: 657.31. 
3-(7-(5-aminopentyloxy)-2-chloro-6-methoxyquinazolin-4-ylamino)-N,N,N-
trimethylpropan-1-aminium iodide hydrochloride (7). 
1
H-NMR (DMSO-d6, 400 
MHz, δ; ppm) 1.48-1.50 (m, 2H, CH2CH2CH2O), 1.62-1.66 (m, 2H, 
CH2CH2CH2CH2O), 1.78-1.82 (m, 2H, CH2CH2O), 2.12-2.13 (m, 2H, NHCH2CH2), 
3.09(s, 9H, N(CH3)3),  3.45-3.49 (m, 2H, NHCH2CH2CH2), 3.58-3.60 (m, 2H, 
H3N
+
CH2CH2), 3.79 -3.82 (m, 2H, NHCH2CH2CH2), 3.93 (s, 3H, OCH3), 4.09-4.11 
(m, 2H, CH2CH2CH2O), 7.10 (s, 1H, quinazoline ring), 7.87-7.95 (m, 3H, 
quinazoline ring and  NH2), 9.13 (s, 1H, NH-CH2), 10.12-10.16 (bs, 1H, 
+
H3N). 
13
C-
NMR (DMSO-d6) δ 22.3 , 23.1, 29.4, 32.8, 42.1, 44.0, 54.7 (3C), 56.2, 64.4, 69.2, 
99.2, 107.1, 111.0, 147.4, 151.5, 155.8, 158.9, 159.6. (EI): m/z [M]
+
: 573.11. 
7-(5-aminopentyloxy)-2-chloro-N-(3-(dimethylamino)propyl)-6-
methoxyquinazolin-4-amine dihydrochloride (9). 
1
H-NMR (DMSO-d6, 400 MHz, 
δ; ppm) 1.49-1.50 (m, 2H, CH2CH2CH2O), 1.62-1.65 (m, 2H, CH2CH2CH2CH2O), 
1.78-1.82 (m, 2H, CH2CH2O), 2.03-2.07 ( m, 2H, m, 2H, NHCH2CH2), 2.77-2.83 (m, 
8H, CH2N(CH3)2 and CH2N(CH3)2), 3.15-3.17 (m, 2H, H3N
+
CH2CH2), 3.56-3.58 (m, 
2H, NHCH2CH2), 3.91 (s, 3H, OCH3), 4.09-4.12 (m, 2H, CH2CH2CH2O), 7.46 (s, 
1H, quinazoline ring), 7.84-7.88 (m, 4H, quinazoline ring and  H3N
+
), 8.88 (s, 1H, 
NH-CH2), 10.21-10.23 (bs, 1H, 
+
HN(CH3)2). 
13
C NMR (DMSO-d6) δ 23.1, 26.6, 
29.4¸32.8, 42.1, 43.2, 45.9 (2C), 56.2, 56.5, 69.2, 99.2, 107.1, 111.0, 147.4, 151.5, 
155.8, 158.9, 159.6. (EI): m/z [M]
+
: 467.16. 
7-(5-aminopentyloxy)-N-(1-benzylpiperidin-4-yl)-2-chloro-6-
methoxyquinazolin-4-amine dihydrochloride (10). 
1
H-NMR (DMSO-d6, 400 
MHz, δ; ppm) 1.47-1.49 ( m, 2H, CH2CH2CH2O), 1.61-1.63 (m, 2H, 
CH2CH2CH2CH2O), 1.78-1.80 (m, 2H, CH2CH2O), 2.11 (m, 4H, CH2 piperidine 
ring), 2.80-2.82 (m, 2H, H3N
+
CH2CH2), 3.14 (m, 2H, CH2 piperidine ring), 3.37-3.39 
(m, 2H, CH2 piperidine ring), 3.91 (s, 3H, OCH3), 4.09-4.11 (m, 2H, CH2CH2CH2O), 
4.28-4.30 (m, 3H, CH2-benzyl ring and CH  piperidine ring), 7.07 ( s, 1H, 
quinazoline ring), 7.47-7.48 (m, 3H, quinazoline ring and phenyl ring), 7.65-7.66 (m, 
2H, phenyl ring), 7.83 (m, 3H, H phenyl ring and NH2), 8.45-8.46 (s, 1H, NH-
piperidine), 10.89-11.12 (bs, 1H, H3N
+
), 11.34 (bs, 1H, 
+
HN piperidine ring). 
13
C-
NMR (DMSO-d6) δ 23.1, 29.4, 30.4 (2C), 32.8, 42.1, 49.4 (2C), 53.1, 56.2, 60.4, 
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69.2, 99.2, 107.1, 111.0, 127.3, 128.5 (2C), 128.9 (2C), 135.6, 147.4, 151.5, 155.8, 
158.9, 159.6. (EI): m/z [M]
+
: 555.19. 
12.4. Biological evaluation, results and discussion 
12.4.1. Inhibition of KIAA1718 by BIX and its analog 6 
First, we found that BIX-01294 inhibits the demethylation activity of KIAA1718 
Jumonji domain (residues 92-488) with an IC50 (half-maximal inhibitory 
concentration) value of approximately 16.5 μM, using a histone H3K9me2 peptide 
(residues 1-24) as substrate, by a mass spectrometry-based demethylation assay
497
 
(Figure 12.2, right). Next, we tested the BIX analog 6 (Figure 12.2, left), which was 
originally generated with improved inhibition for GLP,
575
 with the replacement of 
the O6-methoxy group with a 5-aminopentyloxy substituent at position 7 of the 
quinazoline ring and the diazepane ring with a 3-dimethylaminopropyl group at 
position 2. The cumulative effect of these changes in 6 decreases its IC50 by a factor 
of approximately 4.5 in comparison to that of BIX. 
 
Figure 12.2. The inhibition (IC50 values) of compounds BIX-01294 and 6 against demethylation 
reaction by KIAA1718 (Jumonji domain) is plotted against various concentrations of inhibitor. 
12.4.1.1. Methods 
Protein purification and expression. KIAA1718 and PHF8 proteins, used in this 
study, were expressed and purified as described.
497
 Briefly, the plasmid encoding the 
GST tagged fusion proteins were transformed into E. coli BL21 DE3 codon plus 
cells and grown in auto induction media
619 
at 37C. The proteins were purified by 
three-column chromatography (GST, Hi-TrapSP and S200). The GST tag was 
removed by thrombin cleavage. The purified KIAA1718 (residues 92-488) was 
concentrated to approximately 10-15 mg ml
-1
 in 20 mM BisTris pH 5.5, 5% glycerol, 
200 mMNaCl and 1 mMdithiothreitol. 
KIAA1718 assay. We tested the compounds BIX-01294 and 6 under the conditions 
of 2.5 μM enzyme and 5 μM H3(1-24)K9me2 peptide substrate in 50 mM HEPES 
pH 7.0, 1 mM α-KG, 50 μM Fe(NH4)2(SO4)2 and 2 mM ascorbic acid. The enzyme 
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and the respective inhibitor were preincubated for 10 min at room temperature 
(approximately 21 °C). Adding substrate H3 peptide initiated reaction for 10 min at 
37 °C and subjected to mass spectrometry-based inhibition assay as previously 
described.
566
 
12.4.2. Structure of KIAA1718 Jumonji domain bound with 6 
We co-crystallized KIAA1718 Jumonji domain with 6, which was dissolved in 
aqueous buffer, in the presence of α-ketoglutarate and Ni2+ ion. The structure was 
solved at a resolution of 2.8 Å. The first 22 residues (amino acids 92-113) and the 
last 9 residues (amino acids 480-488) of KIAA1718 were not observed.  
Figure 12.3. Structure of KIAA1718-6 complex. 
(a) Superimposition of KIAA1718 Jumonji domain structures with bound 6 (colored in green) and in 
the absence of bound substrate (cyan; PDB 3KVA). (b, c) Surface representation of the KIAA1718 
Jumonji domain with 6 bound in the acidic substrate peptide binding groove (b), which is occupied by 
a histone peptide in the closely related PHF8 structure (c; PDB 3KV4). The surface charge at neutral 
pH is displayed as red for negative, blue for positive, and white for neutral. (d) Superimposition of H3 
peptide (grey; taken from PDB 3KV4) and 6 (yellow). The inhibitor occupies the space of bound 
histone H3 peptide from Lys4 (main chain) to Lys9 (main chain). The corresponding tyrosine (Tyr292 
in KIAA1718 and Tyr257 in PHF8) adopts different rotamer conformation resulting in a different 
mode of binding of α-ketoglutarate (αKG). (e) Enlarged view of 6 binding site with α-ketoglutarate 
(green) in the bottom of the pocket. (f) Network of interactions centered on the amino group of 5-
aminopentyloxy moiety at position 7 of 6. The metal ion (in small ball) is coordinated by side chains 
of His282, Asp284, His354 and two oxygen atoms of α-ketoglutarate. (g) The methyl group of the 
methoxy at site 6 of compound 6, mimics the side chain of histone H3 Ala7 (see panel d), is bound in 
a shallow surface pocket of KIAA1718. 
  
 196 |BIX-01294 analogs 
The protein component of the structure is highly similar to that of KIAA1718 in the 
absence of bound peptide substrate (Figure 12.3a; PDB 3KVA) and that of PHF8 in 
the presence of bound H3 peptide substrate (Figure 12.3c; PDB 3KV4), with a root 
mean squared deviation (rmsd) of approximately 0.3 Å and 1.3 Å, respectively, when 
comparing 366 pairs of Cα atoms (residues 114-479). 
Compound 6 lies in a location occupied by the histone H3 peptide in the PHF8-
peptide complex and occupies approximately the same space as that by histone H3 
lysine 4 (main chain) to lysine 9 (Figure 12.3d), with a total of buried interface area 
of 422 Å
2
. The acidic binding pocket is wide open and the α-ketoglutarate can be 
seen at the bottom of the pocket (Figure 12.3e). The 5-aminopentyloxy moiety at 
position 7 of the quinazoline ring is extended near the metal cofactor in the active 
site, with the aliphatic chain stacking with the planar surface of His282 and the 
terminal amino group forming a weak hydrogen bond with one of the carboxyl 
oxygen atoms of Asp284 (3.4 Å) (Figure 12.3f). The side chains of His282 and 
Asp284, together with His354, coordinate the binding of the metal ion. The N,N-
dimethylpropylamine side chain at position 2 is near the acidic entrance of the 
substrate binding groove on the protein surface (Figure 12.3e) and the terminal 
dimethylated amino group folds back and stacks with the planar surface of the 
quinazoline ring (Figure 12.3f). The methyl group of the methoxy at position 6 is 
inserted into a shallow surface pocket of an inner wall formed by Gln200 and Thr279 
(Figure 12.3g), mimicking the side chain of histone H3Ala7 (H3A7; Figure 12.3d). 
The O6 methyoxy-H3A7 mimic has also been observed in the interactions of 6 as 
well as BIX with GLP methyltransferase.
566,574
 Thus, we suggest the O6 methyoxy at 
position 6 is an important discriminator of H3K9 enzymes (methylase and 
demethylases) vs. H3K4 enzyme(s) (see below). The N-benzyl-4-amino-piperidine 
moiety at position 4 is not observed in the structure. We could however model the 
moiety in the current structure without steric clashes with the protein by pointing the 
moiety to the solvent (Figure 12.4). 
Figure 12.4. A model of the complete molecule 6 inside KIAA1718, in yellow it is show the suppose 
binding mode of the N-benzyl-4-amino-piperidine moiety. 
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12.4.2.1. Methods 
The crystals were grown at 16 C by hanging drop vapor diffusion method. The 
concentrated KIAA1718 (92-488) protein solution (~10 mg ml
-1
) was mixed with 5 
mM -ketoglutarate, 4 mM NiCl2 and 1 mM compound 6 (dissolved in aqueous 
buffer) prior to the setting up for crystallization. The well solution contained 15-20% 
(v/v) polyethylene glycol 5KMME, 0.2M CaCl2, 0.1M BisTris pH 6.4. 
The X-ray diffraction data
576
 were collected at the Advanced Photon Source, 
Argonne National Laboratory, SERCAT beamline (22-BM). Diffraction data were 
processed scaled by HKL2000. We used PHENIX  for molecular replacement, using 
a previously solved KIAA1718 (residues 92-488) structure (PDB 3KVA) as the 
initial model, and refinement. Coot was used for graphic model building. PRODRG 
server generated the initial model of compound 6. The ReadySet software integrated 
in PHENIX generated the structural restraints for the inhibitor molecule. PyMOL 
(DeLano Scientific) was used to prepare the structural figures. 
12.4.3. Generation of selective KIAA1718 inhibitors 
In order to draw preliminary structure activity relationships keeping intact the 6 
methoxy group we modified the positions 2, 4 and 7 of the quinazoline ring. As we 
can see from Table 12.3, in position 7 the 5-aminopentyloxy moiety is always better 
in terms of inhibitory potency than its closer homologues and than its methylated 
counterparts. As suggested by X-ray and docking inspections, the removal of the N-
benzylpiperidine at position 4 didn’t lead to any loss of activity. Indeed, the 
derivative 5 showed almost the same % of KIAA1718 inhibition of the prototype 6. 
The same inhibitory potency was also observed by removing the dimethylammino-
propylamino side chain at position 2 as exemplified by the derivative 10. On the 
other hand, the double removal of the substituents at both positions 2 and 4 always 
led to a decrease of potency. 
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Table 12.3. Percent of inhibition of 1-10 against KIAA1718. 
 
Cpd R1 R2 R3 
% KIAA1718 
Inhibition 
@ 10 µM 
1 H 
  
22 
2 
   
17.4 
3 
   
23 
4 Cl 
  
21 
5 
  
 77 
6 
  
 79 
7 Cl N
H
N
I
 
 58 
8 Cl N
H
N
HCl
  
69 
9 Cl 
  
73 
10 Cl 
 
 76 
 
The IC50 values determinations confirmed the results obtained at fixed doses. Indeed, 
the removal of the substituent at either positions 2 or 4 led to two derivatives 10 and 
5 with IC50 values 2.4 and 3.4 M, respectively, equal or even slightly better than 
that of the prototype 6 (IC50= 3.7 M). Only the removal of both branches at the 
same time led to a drop of inhibitory potency of about 5-fold as proved by the 
compound 3 which has an IC50 19 M (Figure 12.5). 
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Figure 12.5. IC50 values of compounds 3, 5, 6, 10 against demethylation reaction by KIAA1718. 
We then decided to evaluate the effects of the removal of the substituents at positions 
2 and 4 on the inhibition of GLP methyltransferase, considering that compound 6 
was originally designed to improve the potency against H3K9 methyltransferase 
activities of G9a and GLP (with an IC50 value of 50 nM).
575 
Surprisingly, as shown in 
Figure 12.6 both derivatives with only one branch missing (5, 10) and the derivative 
without the two branches (3) were completely inactive against GLP at least at 10 M 
concentration and more importantly in this way they revealed to be selective 
inhibitors of KIAA1718. 
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Figure 12.6. Effect of compounds 10, 5, 3, 6 on methylation reaction by GLP (SET domain) at fixed 
dose of 10 M. 
After the finding that simplified analogues of 6 were able to discriminate between 
histone lysine 9 methyltransferases such as GLP and histone lysine 9 demethylases 
such as KIAA1718, we decided to test the new analogs against other two jumonji 
demethylases. One, PHF8, that belongs to the same subfamily of KIAA (KDM7) and 
works on the same substrate, the dimethylated lysine 9 of the histone H3, and another 
one JARID1C that belongs to another subfamily (KDM5) and demethylates the tri-
methylated lysine 4 of the histone H3. All the derivatives displayed about an 80% 
inhibition of PHF8 (Figure 12.7, left). As evident from the activity data (Figure 12.7, 
right), neither BIX nor its analogs (6, 5) can significantly inhibit JARID1C 
demethylation activity on the H3K4me3 peptide substrates. This is consistent with 
the fact that recognition of H3K4 and H3K9 methylation marks involves different 
sets of backbone and side chain interactions, the BIX analogs tested in this work 
were originally designed to mimic H3K9 binding. Both graphs demonstrate a 
subfamily selectivity in the inhibition of jumonji histone demethylases by our 
compounds.  
Figure 12.7. Percentage of inhibition of the H3K9me2 demethylation activities of PHF8 Jumonji 
domain (residues 65-447) on H3(1-24)K9me2. H3K4me3 demethylation activity of JARID1C(1-839) 
on H3(1-24)K4me3K9me2 substrate.In both assays are used 10 μM inhibitors. 
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12.4.3.1. Methods 
Percentage of inhibition of the H3K9me2 demethylation activities of KIAA1718 
Jumonji domain and PHF8 Jumonji domain was determined under the conditions of 
2.5 μM enzyme, 5 μM substrate H3 ((1-24) K9me2) and 10 μM inhibitors. Enzymes 
were pre-incubated with the inhibitors for 10 min at room temperature 
(approximately 21 °C) prior to the addition of substrate peptide. The reactions were 
then incubated at 37 °C for 10 min (KIAA1718) or 60 min (PHF8). 
To determinate the inhibition of 3, 5, 6 and 10 against methylation reaction by GLP 
we used the following conditions:0.1 μM enzyme and 5 μM H3 peptide (residues 1-
15) in 20 mM Tris 8.0, 5 mM dithiothreitol (DTT) and 100 μM S-adenosyl-L-
methionine (AdoMet). GLP was pre-incubated with varying 10 μM of inhibitors for 
5 min at room temperature (approximately 21 °C). Adding substrate H3 peptide 
initiated reaction for 5 min at 30° C. 
H3K4me3 demethylation activity of JARID1C (1-839) on H3(1-24)K4me3, K9me2 
substrate was determined, under these conditions: 0.25 μM enzyme, 10 μM peptide 
substrate and 10 μM inhibitor in 50 mM MES pH 6.8. Enzyme was pre-incubated 
with inhibitor at room temperature (~ 21 °C) prior to the addition of substrate peptide 
and the reactions were lasted for 10 min at 37 °C. 
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12.4.4. Conclusion 
Here we show that BIX-01294, a H3K9 peptide mimic small molecule compound, 
can inhibit both H3K9 methyltransferase (GLP: IC50= 0.25 μM) and demethylase 
(KIAA1718: IC50=16.5 μM). Supported by crystallographic and docking studies we 
have increased the inhibitory potency against the lysine 9 methyltransferase GLP of 
about 13-fold developing the derivative 6. By deleting the benzylated six-membered 
piperidine ring moiety, as suggested by the co-crystal structure of KIAA1718-6 
complex, we have obtained some simplified analogues such as the compound 5 that is 
more selective against KIAA1718 ( and his subfamily PHF8) than GLP of almost 13 
fold (GLP: IC50= 75 μM, KIAA1718: IC50= 3.4 μM). This reversal of selectivity is 
only due to the severe loss in activity against GLP without affecting inhibition 
against KIAA1718. Therefore, the current structure of KIAA1718-6 complex 
provides new avenues for further improving the potency and selectivity of the 
inhibitor by strengthening KIAA1718-6 interactions. For example, the N,N-
dimethylpropylamine side chain at position 2 has little contact with the protein and 
replacement with group(s) that maximize the interaction near the entrance of the 
substrate binding groove may increase the potency against KIAA1718.  
To best of our knowledge, compound 5 is the first examples of subfamily-selective 
small molecule inhibitors of jumonji demethylases which don’t chelate the Fe2+ 
cofactor of these enzymes. Iterative cycles of crystallography, synthesis, and 
bioassay will ultimately aid successful design of selective and potent epigenetic 
inhibitors of histone lysine demethylases. 
*Adapted with the permission from Upadhyay, A. K., Rotili, D., Han, J. W., Hu, R., Chang, 
Y., Labella, D., Zhang, X., Yoon, Y. S., Mai, A., Cheng, X. An analog of BIX-01294 
selectively inhibits a family of histone H3 lysine 9 Jumonji demethylases. J. Mol. Biol. 2012, 
416, 319-327.
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13. In vitro assays to determine Sirtuin deacylation activity 
Consistent with the diverse cellular functions of sirtuins, different peptide substrates 
have been identified as targets for deacylation by the various sirtuin enzymes. 
Activation of these enzymes has been thought to provide protection from certain 
neurodegenerative diseases and metabolic disorders, and the inhibition of the 
enzymes may inhibit progression of cancer.
224 
Identification of small-molecule 
modulators (activators or inhibitors) of this class of enzymes could lead to the 
development of novel therapeutic agents. Therefore, it is important to develop 
powerful screening methods to investigate activities, substrate specificities or the 
effectiveness of potential activators and inhibitors. In the literature several assays for 
sirtuin enzymes have been reported. Early approaches monitored the release of 
radioactive products derived from either 
3
[H]-acetylated substrates or 
14
[C]-NAD
+
 
and 
32
[P]-NAD
+
, respectively.
620-623
 Later developments mainly utilized fluorescence 
detection, for example the commercially available Fluor de Lys
TM
-assay. It is based 
on the deacetylation of acetylated tetrapeptides labeled with 7-amino-4-
methylcoumarin at the C-terminus. An alternative method using Z-Mal as a substrate 
was shown by Heltweg et al..
624 
Other approaches include the separation of 
acetylated peptides and their respective deacetylated products by high performance 
liquid chromatography (HPLC) or mass spectrometry (MS) after enzymatic 
reaction.
625
 Furthermore, Marcotte et al. reported on a fluorescence resonance energy 
transfer (FRET)-based assay using peptides modified with a quencher at the N-
terminus and a fluorophore at the C-terminus.
626 
Liu and coworkers used Caliper´s 
sipper chips to realize a microfluidic mobility shift assay for the determination of Km 
and IC50 values. They also employed luciferase in a bioluminescence assay based 
upon quantitation of remaining NAD
+
.
627
 Moreover, the deacetylation of proteins has 
been studied by means of an enzyme-linked immunosorbent assay (ELISA).
628 
Scriba´s group demonstrated the determination of kinetic and inhibition parameters 
of hSIRT1 and hSIRT2 establishing a validated capillary electrophoresis (CE) 
method. As substrates 9-fluorenylmethoxycarbonyl (Fmoc)-labeled peptides were 
synthesized and evaluated.
629
 More recently, Denu´s group developed a 
spectroscopic assay capable of determining steady-state kinetic parameters and 
continuous product monitoring. Formed nicotinamide is converted on a microplate 
by additional enzymatic and oxidative steps yielding NAD(P)
+
.
630
 Moreover, a 
fluorogenic assay based on the quantification of remaining NAD
+
 was published. In 
this approach the remaining cofactor is converted to a highly fluorescent compound 
with a two-step fluorogenic reaction.
631
  
During my stay at the University of Bayreuth, laboratory of Prof. Steegborn, my goal 
was to learn and apply the FdL assay, continuous microplate assay and a MS-based 
assay to investigate the potential effect of small molecules that can regulate Sirtuin 
activity.  
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13.1. Fluorescence assay of SIRT protein deacetylases 
One of the traditional assays for the in vitro measurement of histone 
deacetylase/deacylase activity is the widely used “Fluor-de-Lys” assay. The assay is 
based on peptidic substrates that contain an -acylated lysine residue followed by a 
4-methylcoumarin-7-amide (MCA) moiety at their carboxytermini. The assay is a 
two-step enzymatic reaction (Figure 13.1).
632
 In the first reaction catalyzed by 
histone deacetylases, acetate is released from -acetylated lysine moieties. In the 
second reaction, the deacetylated peptides are recognized as substrates by trypsin, 
which cleaves only after deacetylation and then after lysine residues. The assay is 
highly sensitive and does not demand the consumption of expensive material such as 
histones. However, since the peptidic substrates used so far are only poor substrates 
to trypsin, relatively high concentrations of the latter are required to drive the 
(second) reaction to completion within a short period of time. 
Figure 13.1. Principle of the fluorescence deacetylase assay. The assay comprises two steps. In step 
I the ε-acetylated lysyl moieties of the peptidic substrate is deacetylated. In step II deacetylated 
substrate molecules are cleaved by trypsin which at the same time releases fluorescent 7-amino-4-
methylcoumarin. Fluorescence measurement is done at λex=390 nm and λem=460 nm. 
This assay can be easily used for high-throughput-screening but can cause artifact. 
For example Sirt1 activation by some compounds in Fluor de Lys assays does not 
correlate with activity measured using nonfluorescent peptides or full-length 
proteins. Indeed, the putative Sirt1 activator resveratrol requires the AMC portion of 
the Fluor de Lys substrate to observe activation.
223  
We use this assay to test a series of EX-527 analogs against human SIRT1. The 
protein was already provided in lab, but the compounds didn´t show any effect. 
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13.1.1. Materials and methods 
The SIRT inhibition assay was performed using human recombinant SIRT1 
produced in E. coli. Compounds were tested using a SIRT1 Fluorescent Activity 
Assay Kit (Enzo Life Science, Plymouth Meeting, PA). The procedure includes two 
steps: in the first part 0.1 mM SIRT1 substrate, a p53-derived fluorophore-labeled 
peptide (FdL-1 substrate peptide, Enzo), was incubated with 0.3 μg of protein, 0.5 
mM NAD
+
 in the presence of 10/50 μM compounds and 1% (v/v) DMSO or DMSO 
without compound as a control, for 30 minutes at 37 °C, in a total volume of 50 L. 
In the second stage samples were incubated with Developer II for 45 minutes at room 
temperature. Developer II includes nicotinamide (NAM), a sirtuin inhibitor that stops 
the SIRT1 activity, and trypsin, which releases the fluorophor, thus producing the 
fluorescent signal. The fluorescence was measured on a FluoDia T70 (Photal) 
microplate reader, with excitation set at 360 nm and emission detection set at 460 
nm. 
13.2. Continuous microplate assay 
In 2009, Smith and colleagues reported another spectroscopic assay, the continuous 
microplate assay, that is using an enzyme-coupled system in which NAM is 
converted to nicotinic acid and ammonia by nicotinamidase (Figure 13.2).
629 
 Almost 
all of the assays, known until this study, required unnatural fluorescent or radioactive 
substrates, additional enzymatic steps for detection of the deacetylation reaction, and 
specialized equipment. Furthermore, all previously reported sirtuin assays were 
endpoint assays. The continuos microplate assay allows to measure sirtuin activity 
with native substrates, does not use radioactive or fluorescent labels, requires no 
special instrumentation other than a common spectrophotometer, and measures 
sirtuin activity continuously. This assay is also a rapid method because it doesn’t 
need any additional workup steps to detect enzymatic activity.
629  
This assay is based on the reaction shown in Figure 13.2.
629
 Sirtuins catalyze protein 
deacetylation using NAD
+
 as a cosubstrate forming deacetylated peptide/protein, O-
acetyl-ADP-ribose (OAADPr), and NAM. Sirtuins stoichiometrically use NAD
+
 
such that one molecule of NAM is formed from NAD
+
 for every lysine residue 
deacetylated. Nicotinamidase hydrolyzes NAM in nicotinic acid and ammonia. The 
ammonia is transferred to -ketoglutarate via glutamate dehydrogenase, yielding to 
glutamate and the oxidation of NAD(P)H to NAD(P)
+
. NAD(P)H consumption 
oxidation is measured spectrophotometrically at 340 nm.  
This test still has disadvantages: it suffers from interference of absorbing and/or 
fluorescent compounds, furthermore compounds intended to modulate sirtuin activity 
could interfere with coupled enzymes (e.g. GW5074 is a GDH inhibitor) and, more 
importantly, this assay is not very sensitive. 
The continuous microplate assay was used to test the potential activity of some 
SRT1720 analogs on human SIRT3, but no significant result were found.  
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Figure 13.2. Scheme of the nicotinamidase/ glutamate dehydrogenase enzyme couple assay. 
13.2.2. Materials and methods 
Materials. Chemicals were purchased from Sigma-Aldrich, Roth and Applichem. 
Buffers were prepared with ddH2O. The peptide (ACS2_2, TRSG-acetylK- VMRRL) 
was synthesized by GL Biochem. Human Sirt3 (aa 114- 380) was available in lab and 
at least affinity purified and gelfiltrated. The protein possessed an N-terminal hexa-
histidine tag and a TEV protease cleavage site for tag removal.  
Continuous Deacetylation Assay. Reaction mixture, total volume 100 L, consisted 
of 2 μM hSirt3, 200 μM substrate peptide (ACS2_2), 0.5 mM NAD+, 3.5 mM α-
ketoglutarate, 2 μM nicotinamidase, 2 U/mL GDH and 0.5 mM NADPH, in 20 mM 
sodium phosphate buffer pH 7.7, in the presence of 10/100 μM compounds in 2% 
DMSO. All assay components except compound and NAD
+
 where preincubated for 
5 minutes and the reaction was initiated by addition of NAD
+
. The consumption of 
NADPH was followed as a decrease in absorption at a wavelength of 340 nm, in a 
96-well plate and monitored using a LAMBDA-Scan spectrophotometer (MWG 
Biotech). The assays were performed for 1 hour at room temperature with 
measurement intervals of 1 min. Activity was determined by linear fitting of the 
initial rate of the reaction.  
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13.3. Identification of small molecules as SIRT5 inhibitors through MS-Based 
Deacylation Assay 
Recently, Sirt5 was found to possess potent and unique demalonylase and 
desuccinylase activities and CPS1 is the most important substrate.
223 
Du et al. show 
that while CPS1 is both acetylated and succinylated at three lysine residues (K44, 
K287, and K1291), in the absence of SIRT5 succinylation of K1291 increases, 
whereas succinylation of K44 and K287 or acetylation of K44, K287, and K1291 
remain unchanged. These new succinylation data suggests that SIRT5 regulates the 
enzymatic activity of CPS1 by desuccinylating K1291. Because acetylation and 
succinylation can occur on the same CPS1 lysine residues, further studies are needed 
to resolve which modification is regulatory. The preference for succinyl and malonyl 
groups is due to the presence of an arginine residue (Arg
105
) and tyrosine residue 
(Tyr
102
) in the acyl pocket of Sirt5 (Figure 13.3).
623  
Figure 13.3. Sirt5-succinyl peptide-NAD ternary structure showing that the succinyl group interact 
with Tyr
102
 and Arg
105
. 
Sirt5 deficiency in mice leads to hyperammonemia after a period of caloric 
restriction. This effect is due to the lack of Sirt5-dependent deacylation and thereby 
activation of its first identified physiological substrate carbamoyl phosphate 
synthetase 1 (CPS1). Sirt5 activity is triggered by higher NAD
+
 availability in times 
of nutrient deprivation, when amino acids are catabolized as an alternative energy 
source and CPS1 is needed to detoxicate the by-product ammonia through catalyzing 
the first step of the urea cycle.
230,259  
Inhibitors that are specific for a particular Sirtuin isoform will be very useful for 
investigating the therapeutic potential of the specific Sirtuin and their biological 
function. The major obstacle in the development of small molecules that can regulate 
Sirtuin activity is the fact that some human Sirtuins have very weak enzymatic 
activity, not always the proper Sirtuin substrate is known, and suitable assays are 
either not available or difficult to perform.  
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In order to overcome the limitations of the in vitro assays described above, it is 
possible to use a deacylation assay based on the direct and label-free relative 
quantification of substrate and product using LC-MS.
257  
Figure 13.4. Novel 3-Arylidenindolin-2-ones. 
The aim of this project was to identify a potent and selective inhibitor for the human 
isoform Sirt5. Until now just few modulators have been reported for Sirt5. 
Thiosuccinyl peptides are the only know selective and potent Sirt5 inhibitors. The 
thioacetylated peptides can undergo the first step of the sirtuin-catalyzed deacylation 
reaction, forming the covalent thioalkyl-imidate intermediate that stops any futher 
reaction. Despite this first success, peptide derivative inhibitors are generally 
pharmacologically limited due to their size, biostability and poor membrane 
permeability.
634
 
In a recent study, carried out by our collaborators Suenkel et al., it has been found 
that GW5074 (Figure 13.4), an indole derivative, is able to inhibit Sirt5 
desuccinylation activity with an IC50 of 20 M; so a first pharmacological scaffold 
has been identified in order to develop Sirt5 specific inhibitors.
404 
 
In 2010, Prof. Bracher and his team from Ludwidg-Maximilians-Universität 
München, presented novel Sirt inhibitors based on a 6,7-dichloro-2-oxindole scaffold 
with low micromolar activity. To prepare this series of derivatives, they combined 
structural elements of the alkaloid -Carboline (with antiproliferative and antiviral 
activity) with those of the Sirtuin inhibitor GW5074 (Figure 13.4).
635 
Due to the 
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structure similarity with GW5074, we decided to test these series of analogs (Figure 
13.4) in order to find a more selective and potent inhibitor of human Sirt5.  
GW5074 disturbs signal in FdL assay and it is known to inhibit the glutamate 
dehydrogenase (GDH), which makes this compound incompatible with the 
continuous assays, so we tested this series of analogs on hSirt5 in a MS-based assay 
using, as substrate, the succinylated peptide Peroxiredoxin 1 (succPRX1: SKEYFS-
succinylLys-QK). 
13.3.1. Materials and methods 
13.3.1.1. Expression and purification of human Sirt5 (34-302) 
Heterologous overexpression of protein. The human Sirt5 construct used in this 
study (already provided by the lab of Prof. Clemens Steegborn) comprises amino 
acids 34-302 cloned in pET151/D-TOPO vector harboring a N-terminal 6x His tag 
and a TEV protease cleavage site. Sirt5 protein was expressed in E. coli BL21DE3 
Rosetta 2 cells. Cells were cultured at 37 °C to an OD600 of 0.6, in LB media 
(containing 100 μg/ml Ampicillin and 34 μg/ml Chloramphenicol). Expression was 
induced by adding 0.5 mM isopropylthiogalactopyranoside (IPTG), and culturing 
continued overnight at 20 °C/140 RPM in a shaker (Infors HT, Switzerland). After 
overnight protein expression, the cells were harvested by centrifugation at 5.000 
RPM at 4 °C for 20 minutes, cell pellets were resuspended in lysis buffer (50 mM 
Tris/HCl pH 7.8, 200 mM NaCl) supplemented with 0.5 mM 
phenylmethylsulfonylfluorid (PMSF) and stored at – 80 °C until required. 
Cell lysis. Frozen cells were thawed and resuspended on ice in lysis buffer. During 
resuspension, 0.04 mg lyzosyme were added to 1 g cells and incubated for 20 minute. 
Cells lysis was further performed mechanically using a a Microfluidizer 
(Microfluidics, USA) maintained at 4 C. The lysed cells were centrifuged at 18.000 
RPM for 45 minutes in a refrigerated Beckman Coulter Avanti J-26XP centrifuge 
fitted with a JA-30.50 Ti rotor (Beckman Coulter, USA) to remove cell debris. 
Purification of protein 
Affinity chromatography. Purification of recombinant protein containing His-tag 
was performed using TALON resin (Clontech, USA). For every liter of E. coli 
culture, 1 ml bed volume of resin was used. Prior to usage, the resin was washed and 
equilibrated twice with 10 bed volumes of lysis buffer. The cleared E. coli 
supernatant containing the recombinant protein in lysis buffer was incubated with the 
resin at 4 C for 1 hour by stirring for efficient binding of the protein to the resin. 
After the incubation, the flowthrough was collected by gravity flow using a glass 
column (Bio-Rad, USA) and the column washed with 10 bed volumes of wash buffer 
A and 10 bed volumes of buffer B, then eluted with elution buffer (buffer 
compositions see below). The samples were run on SDS-PAGE to access the size 
and purity of the protein before performing additional purification steps.  
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Buffer compositions. Lysis buffer: 50 mM Tris, pH 7.5, 300 mM NaCl, 0.2 mM 
PMSF, protease inhibitor (Roche cOmplete EDTA free). Wash buffer: buffer A) 50 
mM Tris/HCl pH 7.8, 500 mM NaCl; buffer B) 50 mM Tris/HCl pH 7.8, 200 mM 
NaCl, 5 mM imidazole. Elution buffer: 50 mM Tris/HCl pH 7.8, 200 mM NaCl, 250 
mM imidazole.  
Size exclusion chromatography. Elution samples from the affinity chromatography 
were pooled, concentrated using an Amicon centrifugal concentrator (Millipore, 
USA) to 5 ml and applied on to a preequilibrated Superose 12 size exclusion column 
(GE Healthcare, USA) and eluted with 20 mM Tris/HCl pH 7.8, 150 mM NaCl 
Following chromatography, the samples were run on SDS-PAGE to access their 
purity; appropriate fractions were pooled and concentrated. 
Determination of protein concentration 
Protein concentrations were either determined by Bradford-assay or based on 
Lambert-Beer’s law. For those purposes, absorptions were measured using a Cary® 
50 UV-Vis spectrophotometer (Varian). Bradford-assay was performed by mixing 
200 μL Bradford-reagent (Bio-rad), 790 μL ddH2O with 10 μL protein solution and 
determination of absorption at 595 nm to calculate protein concentration via 
equation 1, which is based on experimental data with standard proteins.
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Equation 1. C:concentration A595: Absorption at 595 nm Vprotein: Volume of protein solution used for 
measurement 
Determination of protein concentration based on Lambert-Beer’s law was done by 
measuring absorption at 280 nm and calculating protein concentration using 
equation 2, including the protein’s theoretical absorption coefficient at 280 nm.  
      
    
   
      
Equation 2. C: concentration [mM] A280: absorption at a wavelength of 280 nm ε280: absorption 
coefficient at a wavelength of 280 nm [M
-1
cm
-1
] d: thickness of cuvette (1 cm) 
Absorption coefficients at 280 nm were calculated from the amino acid sequence 
using Protparam 67. 
13.3.1.2. Mass-spectrometry based deacylation assay 
Direct measurement of desuccinylation by Sirt5 was done by a MS-based deacylation 
assay already established in Prof. Steegborn lab.
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 We decided to test the series of 
3-Arylidenindolin-2-ones (Figure 13.4) at two concentration, 10 and 100 M. The 
reaction mixture, containing 0.05 mM succPRX1 and hSirt5 0.01 mg/ml, was 
incubated at 37 °C and reaction was started by adding 2.5 mM NAD
+
 and different 
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compound concentrations in 20mM Tris/HCl pH 7.8 and 150mM NaCl. The reaction 
was stopped with trifluoroacetic acid (0.25% final concentration) at four time points 
within 20 min incubation. Samples were diluted with 0.1 % formic acid, to achieve 
the final peptide concentration of 1M, and were filtered by using a AcroPrep™ 
Advance 96-well Filter Plates. After filtration samples were analyzed to detect the 
ratio of the succinylated and desuccinylated peptide species, with a LC-MS system 
by using a linear gradient from 0% to 45% buffer B in 20 min (buffer A: 0.1%TFA, 
buffer B: Acetonitrile, 0.1%TFA). To determine the peak areas Skyline software was 
used (MacCoss lab, Seattle). Skyline determined two transitions for the peptide that 
contained the succinylated lysine (succPRX1: SKEYFS-succinylLys-QK) and one 
for the desuccinylated peptide (PRX1: SKEYFSKQ). Sirt5 activity was calculated by 
linear regression analysis of time series using Excel 2010. In all MS based assays the 
relative amount of deacylated peptide in percent (= Deacetylation [%]) was 
calculated according to equation 3. For the analysis the value for deacylation [%] of 
the sample, where the putative inhibitor was absent, was set as 100 % to get relative 
values for deacylation. 
                
                      
                                           
                 Equation 3 
 
13.3.2. Results 
Testing Sirt5 activity was initially performed with a MS-based assay using a 
succCPS1 substrate, but no good signals for the peptides were detectable in MS-
spectra, possibly due to the high hydrophobicity of the CPS1-peptide. We then 
decided to use as substrate a succylated peptide derived from peroxiredoin1 
(succPRX1). In Figure 13.5 the effect of GW5074 derivates on Sirt5 is shown. The 
best compounds that show a relative Sirt5 dessucinylation activity similar to 
GW5074, are the following: UBCS_164, bearing the same aromatic substitution of 
the parent compound, UBCS_165 characterized by the 2,4-dimethylpyrrole and 
UBCS_167 having the p-Fluor on the aromatic ring (Figure 13.4). To evaluate the 
selectivity of these promising analogs, we decided to test UBCS_164, 165,167 and 
the parent compound GW5074 (at 10 and 100 M) on the human Sirtuin 1, 2 and 3 
(Figure 13.6). In the assay, for better comparison, we kept NAD
+
 and substrate 
concentration constant (See Sec. 13.3.1.2.), and we used 0.02 mg/ml of each enzyme. 
For the different isoform Sirt1, 2 and 3, we used the in vitro substrates p53short 
(RHK-acetylK-LMFK), α-Tubulin (MPSD-acetylK-TIG) and ACS2_2 (TRSG-
acetylK- VMRRL) respectively.  
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Figure 13.5. Relative Sirt5 desuccinylation activity in presence of 10 and 100 M compound. 
Relative activities were calculated by determining the linear slope of each assay at four time points 
within 20 min incubation. Error bars are the variation of three independent assays. 
Figure 13.6. Relative deacylation activity on different Sirtuin isoforms. 
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13.3.3. Conclusion 
As shown in Figure 13.5, the compound UBCS_164 exhibits an activity against Sirt5 
comparable to the lead compound GW5074. From this first comparison we can 
conclude that by changing the halogen substitution of the oxindole scaffold from 
position 5 to both position 6 and 7 no gain in the inhibition is observed. No Sirt5 
inhibition is shown when the two bromide are removed from the aromatic ring as for 
UBCS_159 and when a steric hindrance at position 3, 4, 5 of the phenyl group is 
present, as in UBCS_169. Particularly interesting are the results obtained by testing 
the GW5074 analogs on the different Sirtuin isoform (Figure 13.6). The parent 
compound GW5074 show at 100 M a strong inhibition of Sirt1 that decrease in 
order against Sirt2, 3 and 5; we can observe the same trends for UBCS_164. The 
compounds UBCS_165 and 167, bearing the 2, 4-dimethylpyrrole and the p-Fluor on 
the aromatic ring, respectively, show almost the same inhibition for all four Sirtuin 
isoform. In conclusion we cannot gain selectivity just by changing the halogen 
substitution on the oxindole scaffold, but we can modulate the potency and 
selectivity of the compounds in particularly by changing the benzyliden substitution. 
For a better potency it seems that the benzylidene ring needs to have a 4-phenol or a 
good hydrogen bond donator, flanked by a halogen substitute.  
 214 |References  
14. References 
1. Waddington, C.H. The epigenotype. Endeavour 1942, 1, 18-20. 
2. Goldberg A.D., Allis C.D., Bernstein E. Epigenetics: a landscape takes shape. 
Cell. 2007, 128, 635-8. 
3. Jones, P.A., Baylin, S.B. The fundamental role of epigenetic events in cancer. 
Nat. Rev. Genet. 2002, 3, 415-428. 
4. Jones, P.A., Martienssen, R.. A blueprint for a human epigenome project: the 
AACR human epigenome workshop. Cancer Res. 2005, 65, 11241-11246. 
5. Yoo, C.B., Jones, P.A. Epigenetic therapy of cancer: past, present and future. 
Nat. Rev. Drug Discov. 2006, 5, 37-50. 
6. Jones, P.A., Baylin, S. B. A decade of exploring the cancer epigenome -
biological and translational implications. Nature Reviews Cancer 2011, 11, 726-
734. 
7. Kouzarides, T. Chromatin Modifications and Their Function. Cell 2007, 128, 
693-705. 
8. Bird A. Perceptions of epigenetics Nature 2007,447.  
9. Dennis C. Altered states. Nature 2003, 421, 686-688. 
10. Maier S., Olek A. Diabetes: A candidate disease for efficient DNA methylation 
profiling. J Nutr Sci 2002, 132, 2440-2443. 
11. Lister, R., Pelizzola, M., Dowen, R. H., Hawkins, R.D., Hon, G., Tonti-Filippini, 
J., Nery, J.R., Lee, L., Ye, Z., Ngo, Q. M., Edsall, L., Antosiewicz-Bourget, J., 
Stewart, R., Ruotti, V., Millar, A. H., Thomson, J.A., Ren,B., Ecker, J.R. Human 
DNA methylomes at base resolution show widespread epigenomic differences. 
Nature 2009, 462, 315-322. 
12. Laurent, L., Wong, E., Li, G., Huynh, T., Tsirigos, A., Ong, C. T., Low, H. M., 
Kin Sung, K. W., Rigoutsos, I., Loring, J., Wei, C.L. Dynamic changes in the 
human methylome during differentiation. Genome Res. 2010, 20, 320-321. 
13. Portela, A., Esteller, M. Epigenetic modifications and human disease. Nat. 
Biotechnol. 2010, 28, 1057-1068. 
14. Doi, A., Park, I.-H., Wen, B., Murakami, P., Aryee, M. J., Irizarry, R., Herb, B., 
Ladd-Acosta, C., Rho, J., Loewer, S., Miller, J., Schlaeger, T., Daley, G.Q., 
Feinberg, A.P. Differential methylation of tissue- and cancer-specific CpG 
island shores distinguishes human induced pluripotent stem cells, embryonic 
stem cells and fibroblasts. Nat. Genet. 2009, 41, 1350-1353. 
15. Irizarry, R. A., Ladd-Acosta, C., Wen, B., Wu, Z., Montano, C., Onyango, P., 
Cui, H., Gabo, K., Rongione, M., Webster, M., Ji, H., Potash, J. B., Sabunciyan, 
S., Feinberg, A. P. The human colon cancer methylome shows similar hypo- and 
hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 
2009, 41, 178-186. 
16. Razin, A., Riggs, A.D. DNA methylation and gene function. Science 1980, 210, 
604-610. 
 215 |References  
17. Comb, M., Goodman, H.M. CpG methylation inhibits proenkephalin gene 
expression and binding of the transcription factor AP-2. Nucleic Acids Res. 
1990, 18, 3975-3982. 
18. Inamdar, N.M.; Ehrlich, K.C.; Ehrlich, M. CpG methylation inhibits binding of 
several sequence specific DNA-binding proteins from pea, wheat, soybean and 
cauliflower. Plant Mol. Biol. 1991, 17, 111-123. 
19. Ehrlich, M. DNA methylation in cancer: too much, but also too little. Oncogene 
2002, 21, 5400-5413. 
20. Robertson, K.D., Jones, P.A. DNA methylation: past, present and future 
directions. Carcinogenesis 2000, 21, 461-467. 
21. Yan, J.; Zierath, J. R.; Barres, R. Evidence for non-CpG methylation in 
mammals. Exp. Cell Res. 2011, 317, 2555–2561. 
22. Klimasauskas, S., Kumar, S., Roberts, R. J., Cheng, X. HhaI methyltransferase 
flips its target base out of the DNA helix. Cell 1994, 76, 357-369. 
23. Svedruzic, Z.M., Reich, N.O. Mechanism of allosteric regulation of DNMT1’s 
processivity. Biochemistry 2005, 44, 14977-14988. 
24. Okano, M., Bell, D. W., Haber, D. A., Li, E. DNA methyltransferases DNMT3A 
and DNMT3B are essential for de novo methylation and mammalian 
development. Cell 1999, 99, 247-257. 
25. Leonhardt, H., Page, A.W., Weier, H.U., Bestor, T.H. A targeting sequence 
directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. 
Cell 1992, 71, 865-873. 
26. Okano, M., Xie, S., Li, E. Cloning and characterization of a family of novel 
mammalian DNA (cytosine-5) methyltransferases. Nat. Genet. 1998, 19, 219-
220. 
27. Lauster, R., Trautner, T.A., Noyer-Weidner, M. Cytosine-specific type II DNA 
methyltransferases. A conserved enzyme core with variable target recognizing 
domains. J. Mol. Biol. 1989, 206, 305-312. 
28. Robertson, K.D. DNA methylation, methyltransferases, and cancer. Oncogene 
2001, 20, 3139-3155. 
29. Bestor, T.H., Verdine, G.L. DNA methyltransferases. Curr. Opin. Cell Biol. 
1994, 6, 380-389. 
30. Bestor, T.H., Laudano, A., Mattaliano, R., Ingram, V. Cloning and sequencing 
of a cDNA encoding DNA methyltransferase of mouse cells. The 
carboxylterminal domain of the mammalian enzymes is related to bacterial 
restriction methyltransferases. J. Mol. Biol. 1988, 203, 971-983. 
31. Bestor, T.H. Cloning of a mammalian DNA methyltransferase. Gene 1988, 74, 
9-12. 
32. Robertson, K.D., Uzvolgyi, E., Liang, G., Talmadge, C., Sumegi, J., Gonzales, 
F.A., Jones, P. A. The human DNA methyltransferases (DNMTs) 1, 3A and 3B: 
coordinate mRNA expression in normal tissues and overexpression in tumors. 
Nucleic Acids Res. 1999, 27, 2291-2298. 
 216 |References  
33. Mertineit, C., Yoder, J.A., Taketo, T., Laird, D.W., Trasler, J. M., Bestor, T.H. 
Sex-specific exons control DNA methyltransferase in mammalian germ cells. 
Development 1998, 125, 889-897. 
34. Pradhan, S., Talbot, D., Sha, M., Benner, J., Hornstra, L., Li, E., Jaenisch, R., 
Roberts, R.J. Baculovirus-mediated expression and characterization of the full-
length murine DNA methyltransferase. Nucleic Acids Res. 1997, 25, 4666-4673. 
35. Pradhan, S., Bacolla, A., Wells, R.D., Roberts, R.J. Recombinant human DNA 
(cytosine-5) methyltransferase. I. Expression, purification, and comparison of de 
novo and maintenance methylation. J. Biol. Chem. 1999, 274, 33002-33010. 
36. Prokhortchouk, E., Defossez, P.A. The cell biology of DNA methylation in 
mammals, Biochim. Biophys. Acta 2008, 1783, 2167-2173. 
37. Takashima, S., Takehashi, M., Lee, J., Chuma, S., Okano, M., Hata, K., Suetake, 
I., Nakatsuji, N., Miyoshi, H., Tajima, S., Tanaka, Y., Toyokuni, S., Sasaki, H., 
Kanatsu-Shinohara, M., Shinohara, T. Abnormal DNA methyltransferase 
expression in mouse germ-line stem cells results in spermatogenic defects. Biol. 
Reprod. 2009, 81, 155-164. 
38. Chen, T., Hevi, S., Gay, F., Tsujimoto, N., He, T., Zhang, B., Ueda, Y., Li, E. 
Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer 
cells. Nat. Genet. 2007, 39, 391-396. 
39. Gaudet, F., Hodgson, J.G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, 
J.W., Leonhardt, H., Jaenisch, R. Induction of tumors in mice by genomic 
hypomethylation. Science 2003, 300, 489-492. 
40. Eden, A., Gaudet, F., Waghmare, A., Jaenisch, R. Chromosomal instability and 
tumors promoted by DNA hypomethylation. Science 2003, 300, 455. 
41. Chik, F., Szyf, M. Effects of specific DNMT gene depletion on cancer cell 
transformation and breast cancer cell invasion; toward selective DNMT 
inhibitors. Carcinogenesis 2011, 32, 224-232. 
42. Sharif, J., Koseki, H., Recruitment of DNMT1 roles of the SRA protein Np95 
(UHRF1) and other factors. Prog. Mol. Biol. Transl. Sci. 2011, 101, 289-310. 
43. Iida, T., Suetake, I., Tajima, S., Morioka, H., Ohta, S., Obuse, C., Tsurimoto, T. 
PCNA clamp facilitates action of DNA cytosine methyltransferase 1 on 
hemimethylated DNA. Genes Cells 2002, 7, 997-1007. 
44. Lan, J., Hua, S., He, X., Zhang, Y. DNA methyltransferases and methyl-binding 
proteins of mammals. Acta Biochim. Biophys. Sin. (Shanghai) 2010, 42, 243-
252. 
45. Jones, P.A., Liang, G. Rethinking how DNA methylation patterns are 
maintained. Nat. Rev. Genet. 2009, 10, 805-811. 
46. Goll, M. G., Bestor, T. H. Eukaryotic cytosine methyltransferases Annu. Rev. 
Biochem. 2005, 74, 481-514. 
47. Schaefer, M., Lyko, F. Solving the DNMT2 enigma. Chromosoma 2010, 119, 
35-40. 
 217 |References  
48. Squires, J.E., Patel, H.R., Nousch, M., Sibbritt, T., Humphreys, D.T., Parker, 
B.J., Suter, C.M., Preiss, T. Widespread occurrence of 5-methylcytosine in 
human coding and non-coding RNA. Nucleic Acids Res. 2012, 40, 5023-5033. 
49. Hermann, A., Gowher, H., Jeltsch, A. Biochemistry and biology of mammalian 
DNA methyltransferases. Cell. Mol. Life Sci. 2004, 61, 2571-2587. 
50. Espada, J., Esteller, M. DNA methylation and the functional organization of the 
nuclear compartment. Semin. Cell Dev. Biol. 2010, 21, 238-246. 
51. Hansen, R. S., Wijmenga, C., Luo, P., Stanek, A. M., Canfield, T. K., Weemaes, 
C. M., Gartler, S. M. The DNMT3B DNA methyltransferase gene is mutated in 
the ICF immunodeficiency syndrome. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 
14412-14417. 
52. Deplus, R., Brenner, C., Burgers, W. A., Putmans, P., Kouzarides, T., de 
Launoit, Y., Fuks, F. DNMT3L is a transcriptional repressor that recruits histone 
deacetylase. Nucleic Acids Res. 2002, 30, 3831-3838. 
53. Margot, J. B., Ehrenhofer-Murray, A. E., Leonhardt, H. Interactions within the 
mammalian DNA methyltransferase family. BMC Mol. Biol. 2003, 4, 7. 
54. Jia, D., Jurkowska, R. Z., Zhang, X., Jeltsch, A., Cheng, X. Structure of 
DNMT3A bound to DNMT3L suggests a model for de novo DNA methylation. 
Nature 2007, 449, 248-251. 
55. Jurkowska, R. Z., Anspach, N., Urbanke, C., Jia, D., Reinhardt, R., Nellen, W., 
Cheng, X., Jeltsch, A. Formation of nucleoprotein filaments by mammalian 
DNA methyltransferase DNMT3A in complex with regulator DNMT3L. Nucleic 
Acids Res. 2008, 36, 6656-6663. 
56. Ge, Y. Z., Pu, M. T., Gowher, H., Wu, H. P., Ding, J. P., Jeltsch, A., Xu, G. L. 
Chromatin targeting of de novo DNA methyltransferases by the PWWP domain. 
J. Biol. Chem. 2004, 279, 25447-25454. 
57. Fatemi, M, Hermann, A., Gowher, H., Jeltsch, A. DNMT3a and DNMT1 
functionally cooperate during de novo methylation of DNA. Eur. J. Biochem. 
2002, 269, 4981-4984. 
58. Kim, G. D, Ni, J., Kelesoglu, N., Roberts, R. J., Pradhan, S. Co-operation and 
communication between the human maintenance and de novo DNA (cytosine-5) 
methyltransferases. EMBO J. 2002, 21, 4183-4195. 
59. ,Xu, F., Mao, C., Ding, Y., Rui, C., Wu, L., Shi, A., Zhang, H., Zhang, L., Xu, 
Z. Molecular and enzymatic profiles of mammalian DNA methyltransferases: 
structures and targets for drugs. Curr. Med. Chem. 2010, 17, 4052-4071. 
60. Goyal, R., Reinhardt, R., Jeltsch, A. Accuracy of DNA methylation pattern 
preservation by the DNMT1 methyltransferase. Nucleic Acids Res. 2006, 34, 
1182-1188. 
61. Rhee, I., Bachman, K. E., Park, B. H., Jair, K. W., Yen, R. W., Schuebel, K. E., 
Cui, H., Feinberg, A. P., Lengauer, C., Kinzler, K. W., Baylin, S. B., Vogelstein, 
B. DNMT1 and DNMT3B cooperate to silence genes in human cancer cells. 
Nature 2002, 416, 552-556. 
 218 |References  
62. Song J, Rechkoblit O., Bestor T. H., Patel D. J. Structure of DNMT1-DNA 
complex reveals a role for autoinhibition in maintenance dna methylation. 
Science 2011, 331, 1036-1040. 
63. Qureshi, I. A., Mehler, M. F., Advances in epigenetics and epigenomics for 
neurodegenerative diseases. Curr. Neurol. Neurosci. Rep. 2011, 11, 464-473. 
64. Fuso, A., Nicolia, V., Cavallaro, R. A., Scarpa, S. DNA methylase and 
demethylase activities are modulated by one-carbon metabolism in Alzheimer’s 
disease modelsl. J. Nutr. Biochem. 2011, 22, 242-251. 
65. Higuchi, F., Uchida, S., Yamagata, H., Otsuki, K., Hobara, T., Abe, N., Shibata, 
T., Watanabe, Y. State-dependent changes in the expression of DNA 
methyltransferases in mood disorder patients. J. Psychiatr. Res. 2011, 45, 1295-
1300. 
66. Lopez-Pedrera, C.,Perez-Sanchez, C., Ramos-Casals, M., Santos-Gonzalez, M., 
Rodriguez-Ariza, A., Cuadrado, M. J. Cardiovascular risk in systemic 
autoimmune diseases: epigenetic mechanisms of immune regulatory functions. 
Clin. Dev. Immunol. 2012, 2012, 1-10. 
67. Sacconi, S., Camano, P., de Greef, J. C., Lemmers, R. J., Salviati, L., Boileau, 
P., Lopez de Munain, A. A., Van der Maarel, S. M., Desnuelle, C. Patients with 
a phenotype consistent with facioscapulohumeral muscular dystrophy display 
genetic and epigenetic heterogeneity. J. Med. Genet. 2011, 49, 41-46. 
68. Bressler, J., Shimmin, L. C., Boerwinkle, E., Hixson, J. E. Global DNA 
methylation and risk of subclinical atherosclerosis in young adults: the 
pathobiological determinants of atherosclerosis in youth (PDAY) study. 
Atherosclerosis 2011, 219, 958-962. 
69. Rodriguez, J., Frigola, J., Vendrell, E., Risques, R. A., Fraga, M .F., Morales, C., 
Moreno, V., Esteller, M., Capella, G., Ribas, M., Peinado, M. A. Chromosomal 
instability correlates with genome-wide DNA demethylation in human primary 
colorectal cancers. Cancer Res. 2006, 66, 8462-9468. 
70. Farinha, N.J., Shaker, S., Lemaire, M., Momparler, L., Bernstein, M., 
Momparler, R. L. Activation of expression of p15, p73 and E-cadherin in 
leukemic cells by different concentrations of 5-aza-20-deoxycytidine 
(decitabine). Anticancer Res. 2004, 24, 75-78. 
71. Gore, S. D., Baylin, S., Sugar, E., Carraway, H., Miller, C. B., Carducci, M., 
Grever, M.; Galm, O., Dauses, T., Karp, J. E., Rudek, M. A., Zhao, M., Smith, 
B. D., Manning, J., Jiemjit, A., Dover, G., Mays, A., Zwiebel, J., Murgo, A., 
Weng, L. J., Herman, J. G. Combined DNA methyltransferase and histone 
deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006, 
66, 6361-6369. 
72. Jung, Y., Park, J., Kim, T., Park, J. H., Jong, H. S., Im, S. A., Robertson, K., 
Bang, Y. J., Kim, T. Y. Potential advantages of DNA methyltransferase 1 
(DNMT1)-targeted inhibition for cancer therapy. J. Mol. Med. 2007, 85, 1137-
1148. 
 219 |References  
73. Suzuki, M.; Sunaga, N.; Shames, D. S.; Toyooka, S.; Gazdar, A. F.; Minna, J. D. 
RNA interference-mediated knockdown of DNA methyltransferase 1 leads to 
promoter demethylation and gene re-expression in human lung and breast cancer 
cells. Cancer Res. 2004, 64, 3137–3143. 
74. Mund, C., Brueckner, B., Lyko, F. Reactivation of epigenetically silenced genes 
by DNA methyltransferase inhibitors: basic concepts and clinical applications. 
Epigenetics 2006, 1, 7-13. 
75. Wijermans, P. W., Lubbert, M., Verhoef, G., Klimek, V., Bosly, A. An 
epigenetic approach to the treatment of advanced MDS; the experience with the 
DNA demethylating agent 5-aza-20-deoxycytidine (decitabine) in 177 patients. 
Ann. Hematol. 2005, 84, 9-17. 
76. Lemaire, M., Momparler, L. F., Raynal, N. J., Bernstein, M. L., Momparler, R. 
L. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic 
action of 5-aza-2ꞌ- deoxycytidine. Cancer Chemother. Pharmacol. 2009, 63, 
411-416. 
77. Yang, A. S., Estecio, M. R., Garcia-Manero, G., Kantarjian, H. M., Issa, J. P. 
Comment on “Chromosomalinstability and tumors promoted by DNA 
hypomethylation” and “Induction of tumors in nice by genomic 
hypomethylation”. Science 2003, 302, 1153.  
78. Brueckner, B., Rius, M., Markelova, M. R., Fichtner, I., Hals, P. A., Sandvold, 
M. L., Lyko, F. Delivery of 5-azacytidine to human cancer cells by elaidic acid 
esterification increases therapeutic drug efficacy. Mol. Cancer Ther. 2010, 9, 
1256-1264. 
79. Yoo, C.B., Jeong, S., Egger, G., Liang, G., Phiasivongsa, P., Tang, C., Redkar, 
S., Jones, P. A. Delivery of 5-aza-2ꞌ-deoxycytidine to cells using 
oligodeoxynucleotides. Cancer Res. 2007, 67, 6400-6408. 
80. http://clinicaltrials.gov/show/NCT01696032  
81. Shen, L., Kantarjian, H., Guo, Y., Lin, E., Shan, J., Huang, X., Berry, D., 
Ahmed, S., Zhu, W., Pierce, S. DNA Methylation Predicts Survival and 
Response to Therapy in Patients with Myelodysplastic Syndromes. J. Clin. 
Oncol. 2010, 28, 605-613. 
82. Walter, E. D. Genistein (an isoflavone glucoside) and its aglucone, genistein, 
from soybeans. J. Am. Chem. Soc. 1941, 63, 3273-3276. 
83. Yang, C. S., Wang, X., Lu, G., Picinich, S. C. Cancer prevention by tea: animal 
studies, molecular mechanisms and human relevance. Nat. Rev. Cancer 2009, 9, 
429-439. 
84.  Yang S.C., Fang M.,  Lambert J.D., Yan P., Huang T.H.M Reversal of 
hypermethylation and reactivation of genes by dietary polyphenolic compounds. 
Nutr Rev 2008, 66, 18-20. 
85. Lee W.J., Shim J.Y., Zhu B.T. Mechanisms for the inhibition of DNA 
methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol. 2005, 
68, 1018-1030. 
 220 |References  
86. Hoshino, O., Murakata, M., Yamada, K. A convenient synthesis of a 
bromotyrosine derived metabolite, psammaplin A, from psammaplysilla sp. 
Bioorg. Med. Chem. Lett. 1992, 2, 1561-1562. 
87. Pina, I. C., Gautschi, J. T., Wang, G. Y., Sanders, M. L., Schmitz, F. J., France, 
D., Cornell-Kennon, S., Sambucetti, L. C., Remiszewski, S. W., Perez, L. B., 
Bair, K. W., Crews, P. Psammaplins from the sponge Pseudoceratina purpurea: 
inhibition of both histone deacetylase and DNA methyltransferase. J. Org. 
Chem. 2003, 68, 3866-3873. 
88. Godert, A. M., Angelino, N., Woloszynska-Read, A., Morey, S. R., James, S. R., 
Karpf, A. R., Sufrin, J. R. An improved synthesis of psammaplin A. Bioorg. 
Med. Chem. Lett. 2006, 16, 3330-3333. 
89. Baud, M. G., Leiser, T., Haus, P., Samlal, S., Wong, A. C., Wood, R. J., 
Petrucci, V., Gunaratnam, M., Hughes, S. M., Buluwela, L., Turlais, F., Neidle, 
S., Meyer- Almes, F. J., White, A. J., Fuchter, M. J. Defining the mechanism of 
action and enzymatic selectivity of psammaplin A against its epigenetic targets. 
J. Med. Chem. 2012, 55, 1731-1750. 
90. Liu, Z., Xie, Z., Jones, W., Pavlovicz, R. E., Liu, S., Yu, J., Li, P. K., Lin, J., 
Fuchs, J. R., Marcucci, G., Li, C., Chan, K. K. Curcumin is a potent DNA 
hypomethylation agent. Bioorg. Med. Chem. Lett. 2009, 19, 706-709. 
91. Burgos-Morón, E., Calderón-Montaño, J.M., Salvador, J., Robles, A., López-
Lázaro, M., The dark side of curcumin. International Journal of Cancer 2010, 
126, 1771–1775. 
92. Reuter S, Gupta S.C., Park B., Goel A., Aggarwal B.B. Epigenetic changes 
induced by curcumin and other natural compounds. Genes Nutr. 2011, 6, 93-108 
93. Nagaraju G.P., Zhu S., Wen J., Farris A.B., Adsay V.N., Diaz R., Snyder J.P., 
Mamoru S., El-Rayes B.F. Novel synthetic curcumin analogues EF31 and 
UBS109 are potent DNA hypomethylating agents in pancreatic cancer. 
CancerLetters, 2013, 341, 195-203 
94. Kuck, D., Singh, N., Lyko, F., Medina-Franco, J. L. Novel and selective DNA 
methyltransferase inhibitors: docking-based virtual screening and experimental 
evaluation. Bioorg. Med. Chem. 2010, 18, 822-829. 
95. Kuck, D., Caulfield, T., Lyko, F., Medina-Franco, J. L. Nanaomycin A 
selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in 
human cancer cells. Mol. Cancer Ther. 2010, 9, 3015-3023. 
96. Siedlecki, P., Garcia Boy, R., Musch, T., Brueckner, B., Suhai, S., Lyko, F., 
Zielenkiewicz, P. Discovery of two novel, small-molecule inhibitors of DNA 
methylation. J. Med. Chem. 2006, 49, 678-683. 
97. Brueckner, B., Garcia Boy, R., Siedlecki, P., Musch, T., Kliem, H. C., 
Zielenkiewicz, P., Suhai, S., Wiessler, M., Lyko, F. Epigenetic reactivation of 
tumor suppressor genes by a novel small-molecule inhibitor of human DNA 
Methyltransferases. Cancer Res. 2005, 65, 6305-6311. 
 221 |References  
98. Stresemann, C., Brueckner, B., Musch, T., Stopper, H., Lyko, F. Functional 
diversity of DNA methyltransferase inhibitors in human cancer cell lines. 
Cancer Res. 2006, 66, 2794-2800. 
99. Mai, A., Altucci, L. Epi-drugs to fight cancer: from chemistry to cancer 
treatment, the road ahead. Int. J. Biochem. Cell Biol. 2009, 41, 199-213. 
100. Cornacchia, E., Golbus, J., Maybaum, J., Strahler, J., Hanash, S., Richardson, 
B. Hydralazine and procainamide inhibit T cell DNA methylation and induce 
autoreactivity. J. Immunol. 1988, 140, 2197-2200. 
101. Segura-Pacheco, B., Trejo-Becerril, C., Perez-Cardenas, E., Taja-Chayeb, L., 
Mariscal, I., Chavez, A., Lizano, M., Duenas-Gonzalez, A. Reactivation of 
tumor suppressor genes by the cardiovascular drugs hydralazine and 
procainamide and their potential use in cancer therapy. Clin. Cancer Res. 2003, 
9, 1596-1603. 
102. Deng, C., Lu, Q., Zhang, Z., Rao, T., Attwood, J., Yung, R., Richardson, B. 
Hydralazine may induce autoimmunity by inhibiting extracellular signal-
regulated kinase pathway signaling. Arthritis Rheum. 2003, 48, 746-756. 
103. Brueckner, B., Kuck, D., Lyko, F. DNA methyltransferase inhibitors for 
cancer therapy. Cancer J. 2007, 13, 17-22.  
104. Chuang, J. C., Yoo, C. B., Kwan, J. M., Li, T. W., Liang, G., Yang, A. S., 
Jones, P. A. Comparison of biological effects of Non-Nucleoside DNA 
methylation inhibitors versus 5-Aza-2′-Deoxycytidine. Mol. Cancer Ther. 2005, 
4, 1515-1520. 
105. Coronel, J., Cetina, L., Pacheco, I., Trejo-Becerril, C., Gonzalez- Fierro, A., 
de la Cruz-Hernandez, E., Perez-Cardenas, E., Taja-Chayeb, L., Arias-Bofill, D., 
Candelaria, M., et al. A double-blind, placebo-controlled, randomized phase III 
trial of chemotherapy plus epigenetic therapy with hydralazine valproate for 
advanced cervical cancer: preliminary results. Med Oncol 2010, 28, 540-546. 
106. Candelaria, M., Herrera, A., Labardini, J., Gonzalez-Fierro, A., Trejo-
Becerril, C., Taja-Chayeb, L., Perez-Cardenas, E., de la Cruz-Hernandez, E., 
Arias-Bofill, D., Vidal, S., et al. Hydralazine and magnesium valproate as 
epigenetic treatment for myelodysplastic syndrome: preliminary results of a 
Phase-II trial. Ann. Hematol. 2011, 90, 379-387. 
107. Zambrano, P., Segura-Pacheco, B., Perez-Cardenas, E., Cetina, L., Revilla- 
Vazquez, A., Taja-Chayeb, L., Chavez-Blanco, A., Angeles, E., Cabrera, G., 
Sandoval, K., Trejo-Becerril, C., Chanona-Vilchis, J., Duenas-Gonzalez, A. A 
phase I study of hydralazine to demethylate and reactivate the expression of 
tumor suppressor genes, BMC Cancer 2005, 5, 44. 
108. Villar-Garea, A., Fraga, M. F., Espada, J., Esteller, M. Procaine is a DNA-
demethylating agent with growth-inhibitory effects in human cancer cells. 
Cancer Res. 2003, 63, 4984-4989. 
109. Stresemann, C., Brueckner, B., Musch, T., Stopper, H., Lyko, F. Functional 
diversity of DNA methyltransferase inhibitors in human cancer cell lines. 
Cancer Res. 2006, 66, 2794-2800. 
 222 |References  
110. Datta, J., Ghoshal, K., Denny, W. A., Gamage, S. A., Brooke, D. G., 
Phiasivongsa, P., Redkar, S., Jacob, S. T. A new class of quinoline-based DNA 
hypomethylating agents reactivates tumor suppressor genes by blocking DNA 
methyltransferase 1 activity and inducing its degradation. Cancer Res. 2009, 69, 
4277-4285. 
111. Chen, S.M., Leupin, W., Rance, M., Chazin, W.J. Two dimensional NMR 
studies of d(GGTTAATGCGGT). (ACCGCATTAACC) complexed with the 
minor groove binding drug SN-6999. Biochemistry, 1992, 31, 4406-4413. 
112. Adams, A., Leong, C., Denny, W.A., Guss, J.M. Structures of two minor-
groove-binding quinolinium quaternary salts complexed with 
d(CGCGAATTCGCG)(2) at 1.6 and 1.8 Angstrom resolution. Acta Crystallogr 
D Biol Crystallogr 2005, 61,1348-1353. 
113. Wu, J., Grunstein, M. 25 Years after the nucleosome model: chromatin 
modifications. Trends Biochem. Sci. 2000, 25, 612-623. 
114.  Luger, K., Mader, A.W., Richmond, R.K., Sargent, D.F., Richmond, T.J. 
Crystal structure of the nucleosome core particle at 2,8 Å resolution. Nature 
1997, 389, 251-260. 
115. Jendwein, T., Allis, C.D. Translating the histone code. Science 2001, 293, 
1074-1080. 
116. Gaspar-Maia, A., Alajem, A., Meshorer, E., Ramalho-Santos, M. Open 
chromatin in pluripotency and reprogramming. Nature Reviews Molecular Cell 
Biology 2011, 12, 36-47. 
117. Petty, E. and Pillus, L. Balancing chromatin remodeling and histone 
modifications in transcription. Trends in Genetics 2013, 29, 621-629. 
118. Clapier, C. R. and Cairns, R. B. The biology of chromatin remodeling 
complexes. Annual Review of Biochemistry 2009, 78, 273-304. 
119. Dawson, M.A. and Kouzarides, T. Cancer epigenetics: from mechanism to 
therapy. Cell 2012, 150, 12-27. 
120. Turner, B. M. Histone acetylation and an epigenetic code. BioEssay 2000, 22, 
836-845. 
121. Xu, Y.Z., Kanagaratham, C. and Radzioch D. Biochemistry, Genetics and 
Molecular Biology. "Chromatin Remodelling", ISBN 978-953-51-1087-3, April 
17, 2013. 
122. Wolffe, A.P. and Hayes, J.J. Chromatin disruption and modification. Nucleic 
Acid Res 1999, 27,711-720. 
123.  Hecht, A., Laroche, T., Strahl-Bolsinger, S., Gasser, S.M., Grunstein, M. 
Histone H3 and H4 N-termini interact with SIR3 and SIR4 proteins: a molecular 
model for the formation of heterochromatin in yeast. Cell 1995, 80,583-592. 
124. Edmonson, D.G., Smith, M.M., Roth, S.Y. Repression domain of the yeast 
global repressor Tup1 interacts directly with histones H3 and H4. Genes Dev. 
1996, 10, 1247-1259. 
 223 |References  
125. Metzger, E., Imhof, A., Patel, D., Kahl, P., Hoffmeyer, K., Friedrichs, N., 
Muller, J.M., Greschik, H., Kirfel, J., Ji, S. Phosphorylation of histone H3T6 by 
PKCbeta(I) controls demethylation at histone H3K4. Nature 2010, 464, 792-796. 
126. Baek, S.H. When signaling kinases meet histones and histone modifiers in the 
nucleus. Mol Cell. 2011, 42, 274-284.  
127. Thorne, A. W., Sautiere, P., Briand, G., Crane-Robinson, C. The structure of 
ubiquitinated histone H2B. The EMBO Journal 1987, 6, 1005-1010. 
128.  Osley, M. A. Regulation of histone H2A and H2B ubiquitylation. Briefings 
in Functional Genomics & Proteomics 2006, 5, 179-189. 
129. Wang, H., Wang, L., Erdjument-Bromage, H., Vidal, M., Tempst, P., Jones, 
R. S., Zhang, Y. Role of histone H2A ubiquitination in Polycomb silencing. 
Nature 2004, 431, 873-878. 
130. Fierz, B., Chatterjee, C., McGinty, R. K., Bar-Dagan, M., Raleigh, D. P., 
Muir, T. W. Histone H2B ubiquitylation disrupts local and higher-order 
chromatin compaction. Nature Chemical Biology 2011, 7, 113-119. 
131. Johnsen, S. A. The enigmatic role of H2Bub1 in cancer. FEBS Letters 2012, 
586, 1592-1601. 
132. Kim, J., Guermah, M., McGinty, R. K., Lee, J. S., Tang, Z., Milne, T. A., ... 
& Roeder, R. G. RAD6-mediated transcription-coupled H2B ubiquitylation 
directly stimulates H3K4 methylation in human cells. Cell 2009, 137, 459-471. 
133. Shema, E., Tirosh, I., Aylon, Y., Huang, J., Ye, C., Moskovits, N., Oren, M. 
The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative 
tumor suppressor through selective regulation of gene expression. Genes & 
Development 2008, 22, 2664-2676.  
134. Moyal, L., Lerenthal, Y., Gana-Weisz, M., Mass, G., So, S., Wang, S. Y., 
Shiloh, Y. Requirement of ATM-dependent monoubiquitylation of histone H2B 
for timely repair of DNA double-strand breaks. Molecular Cell 2011, 41, 529-
542. 
135. Groth, A., Rocha, W., Verreault, A., Almouzni, G. Chromatin challenges 
during DNA replication and repair. Cell 2007, 128, 721-733. 
136.  Shahbazian, M.D,, Grunstein, M. Functions of site-specific histone 
acetylation and deacetylation. Annu Rev Biochem 2007, 76, 75-100. 
137. Davie, J.R. Covalent modifications of histones expression from chromatin 
templates. Curr Opin Genet Dev 1998, 8, 173-178. 
138. Davie, J.R., Spencer, V.A. Control of histone modifications. J Cell Biochem 
1999,141-148. 
139. Turner, B.M. Histone acetylation and epigenetic code. Bioessays 2000, 22, 
836-845. 
140. Brownell, J. E., Allis, C. D. Special HATs for special occasions: linking 
histone acetylation to chromatin assembly and gene activation. Curr. Opin. 
Genes Dev.1996, 6, 176-184  
141. Lee, K. K., Workman, J. L. Histone acetyltransferase complexes: one size 
doesn't fit all. Nat Rev Mol Cell Biol 2007, 8, 284-295  
 224 |References  
142. Gu, W., Roeder, R. G. Activation of p53 sequencespecific DNA binding by 
acetylation of the p53 C-terminal domain. Cell 1997, 90, 595-606. 
143. Dornan, D., Shimizu, H., Perkins, N. D., Hupp, T. R. DNA-dependent 
acetylation of p53 by the transcription coactivator p300. J. Biol. Chem. 2003 
,278, 13431-13441. 
144. Zhang, Y.; Fang, H.; Jiao, J., Xu, W. The structure and function of histone 
deacetylases: the target for anti-cancer therapy. Curr. Med.Chem. 2008, 15, 
2840-2849 
145. de Ruijter, A.J., van Gennip, A.H., Caron, H.N., Kemp, S., van Kuilenburg, 
A.B., Histone deacetylases (HDACs): characterization of the classical HDAC 
family. Biochem. J. 2003, 370, 737-749. 
146. Gregoretti, I.V., Lee, Y.M., Goodson, H.V. Molecular evolution of the 
histone deacetylase family: functional implications of phylogenetic analysis. J. 
Mol. Biol. 2004, 338, 17-31. 
147. Kao, H.Y., Lee, C.H., Komarov, A. Isolation and characterization of 
mammalian HDAC10, a novel histone deacetylase. J Biol Chem 2002, 277, 187-
193. 
148. Gao, L., Cueto, M.A., Asselbergs, F., Ataoja, P. Cloning and functional 
characterization of HDAC11, a novel member of the human histone deacetylase 
family. J Biol Chem 2002, 277, 25748-25755. 
149. Grozinger, C.M., Hassig, C.A., Schreiber, S.L. Three proteins define a class 
of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci USA 
1999, 96, 4868-4873. 
150. Yang, X. J., Seto, E. The Rpd3/Hda1 family of lysine deacetylases: from 
bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008, 9, 206-218. 
151. Marks, P. A., Xu, W. S. Histone deacetylase inhibitors: potential in cancer 
therapy. J. Cell. Biochem. 2009, 107, 600-608 
152. Huang, Y., Myers, S.J., Dingledine, R. Transcriptional repression by REST: 
recruitment of Sin3A and histone deacetylase to neuronal genes. Nat. Neurosci. 
1999, 2, 867-872. 
153. Ahringer, J. NuRD and SIN3 histone deacetylase complexes in development. 
Trends Genet., 2000, 16, 351-356. 
154. McKinsey, T.A., Zhang, C.L., Lu, J., Olson, E.N. Signal-dependent nuclear 
export of a histone deacetylase regulates muscle differentiation. Nature 2000, 
408, 106-111. 
155. Verdin, E., Dequiedt, F., Kasler, H.G. Class II histone deacetylases: versatile 
regulators. Trends Genet. 2003; 19, 286-293. 
156. Berdeaux, R., Goebel, N., Banaszynski, L., Takemori, H., Wandless, T., 
Shelton, G.D., Montminy, M. SIK1 is a class II HDAC kinase that promotes 
survival of skeletal myocytes. Nat. Med. 2007, 13, 597-603. 
157. Chang, S., Bezprozvannaya, S., Li, S., Olson, E.N. An expression screen 
reveals modulators of class II histone deacetylase phosphorylation. Proc. Natl. 
Acad. Sci. USA 2005, 102, 8120-8125. 
 225 |References  
158. Bertos, N.R., Wang, A.H., Yang, X.Y. Class II histone deacetylases: 
structure, function and regulation. Biochem Cell Biol 2001, 79, 243-252. 
159. Yang, X.Y., Seto, E. Collaborative spirit of histone deacetylases in regulating 
chromatin structure and gene expression. Curr Opin Genet Dev 2000,13,143-
153. 
160. Frye, RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like 
proteins. Biochem Biophys Res Commun 2000, 273, 793-798. 
161. Chang, J.H., Kim, H.C., Hwang, K.Y., Lee, J.W., Jackson, S.P., Bell, S.D., 
Cho, Y. Structural basis for the NAD
+
-dependent deacetylase mechanism of Sir 
2. J Biol Chem 2002, 277, 34489-34498. 
162. Brunmeir, R., Lagger, S., Seiser, C. Histone deacetylase HDAC1/HDAC2-
controlled embryonic development and cell differentiation. Int J Dev Biol 2009, 
53, 275-289. 
163. Jurkin, J., Zupkovitz, G., Lagger, S., Grausenburger, R., Hagelkruys, A., 
Kenner, L., Seiser, C. Distinct and redundant functions of histone deacetylases 
HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle 2011, 
10,406-412. 
164. Weichert, W., Roske, A., Niesporek, S., Noske, A., Buckendahl, A.C., Dietel, 
M., Gekeler, V., Boehm, M., Beckers, T., Denkert, C. Class I histone 
deacetylase expression has independent prognostic impact in human colorectal 
cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin. 
Cancer Res. 2008, 14, 1669-1677. 
165. Rikimaru, T., Taketomi, A., Yamashita, Y., Shirabe, K., Hamatsu, T., 
Shimada, Y., Maehara, M. Clinical significance of histone deacetylase 1 
expression in patients with hepatocellular carcinoma. Oncology 2007, 72, 69-74. 
166. Glaser, K.B., Li, J., Staver, M.J., Wie, R.Q., Albert, D.H., Davidsen, S.K. 
Role of class I and class II histone deacetylases in carcinoma cells using siRNA. 
Biochem. Biophys. Res. Commun. 2003,; 310,529-536. 
167. Senese, S., Zaragoza, K., Minardi, S., Muradore, I., Ronzoni, S., Passafaro, 
A., Bernard, L., Draetta, G.F., Alcalay, M., Seiser, C., Chiocca, S. Role for 
histone deacetylase 1 in human tumor cell proliferation. Mol. Cell. Biol. 2007, 
27, 4784-4795. 
168. Huang, B.H., Laban, M., Leung, C.H., Lee, L., Lee, C.K., Salto-Tellez, M., 
Raju, G.C., Hooi, S.C. Inhibition of histone deacetylase 2 increasesapoptosis and 
p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death 
Differ. 2005, 12, 395-404. 
169. Harms, K.L., Chen, X. Histone deacetylase 2 modulates p53transcriptional 
activities through regulation of p53-DNA binding activity. Cancer Res. 2007, 
67, 3145-3152. 
170. Taplick, J., Kurtev, V., Kroboth, K., Posch, M., Lechner, T., Seiser, C. 
Homooligomerisation and nuclear localisation of mouse histone deacetylase 1. J 
Mol Biol 2001, 308, 27-38. 
 226 |References  
171. Luo, Y., Jian, W., Stavreva, D., Fu, X., Hager, G., Bungert, J., Huang, S., 
Qiu, Y. Transregulation of histone deacetylase activities through acetylation. J 
Biol Chem 2009, 284, 34901-34910. 
172. Yamaguchi, T., Cubizolles, F., Zhang, Y., Reichert, N., Kohler, H., Seiser, C., 
Matthias P. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S 
progression. Genes Dev 2010, 24, 455-469. 
173. He, S., Sun, J.M., Li, L., Davie, J.R. Differential intranuclear organization of 
transcription factors Sp1 and Sp3. Mol Biol Cell 2005, 16, 4073-4083. 
174. Wysocka, J., Myers, M. P., Laherty, C. D., Eisenman, R. N., Herr, W. Human 
Sin3 deacetylase and trithorax-related Set1/Ash2 histone H3-K4 
methyltransferase are tethered together selectively by the cell-proliferation factor 
HCF-1. Genes & development 2003, 17, 896-911. 
175. Fleischer, T. C., Yun, U. J., Ayer, D. E. Identification and characterization of 
three new components of the mSin3A corepressor complex. Molecular and 
cellular biology 2003, 23, 3456-3467. 
176. Hayakawa, T., Nakayama, J. Physiological roles of class I HDAC complex 
and histone demethylase. J Biomed Biotechnol 2011, 129383. 
177.  Denslow, S.A., Wade, P.A: The human Mi-2/NuRD complex and gene 
regulation. Oncogene 2007, 26,5433-5438. 
178.  Wang, Y., Zhang, H., Chen, Y.P., Sun, Y.M., Yang, F., Yu, W.H., Liang, J., 
Sun, L.Y., Yang, X.H., Shi, L., Li, R.F., Li, Y.Y., Zhang, Y., Li, Q., Yi, X., 
Shang, Y.F. LSD1 is a subunit of the NuRD complex and targets the metastasis 
programs in breast cancer. Cell 2009; 138, 660-672. 
179. Lee, M.G., Wynder, C., Cooch, N., Shiekhattar, R. An essential role for 
CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 2005, 
437,432-435. 
180. Shi, Y.J., Matson, C., Lan, F., Iwase, S., Baba, T., Shi, Y. Regulation of 
LSD1 histone demethylase activity by its associated factors. Mol Cell 2005, 
19,857-864. 
181. Guan, J.S., Haggarty, S.J., Giacometti, E., Dannenberg, J.H., Joseph, N., Gao, 
J., Nieland, T.J., Zhou, Y., Wang, X., Mazitschek, R., Bradner, J.E., DePinho, 
R.A., Jaenisch, R., Tsai, L.H. HDAC2 negatively regulates memory formation 
andsynaptic plasticity. Nature 2009, 459, 55-60. 
182. Karolczak-Bayatti, M., Sweeney, M., Cheng, J., Edey, L., Robson, S. C., 
Ulrich, S. M., Europe-Finner, G. N. Acetylation of heat shock protein 20 
(Hsp20) regulates human myometrial activity. Journal of Biological Chemistry 
2011, 286, 34346-34355. 
183. Bhaskara, S., Knutson, S. K., Jiang, G., Chandrasekharan, M. B., Wilson, A. 
J., Zheng, S., Hiebert, S. W. Hdac3 is essential for the maintenance of chromatin 
structure and genome stability. Cancer cell 2010,18, 436-447. 
184. Moser, M. A., Hagelkruys, A., Seiser, C. Transcription and beyond: the role 
of mammalian class I lysine deacetylases. Chromosoma 2013,1-12. 
 227 |References  
185. Waltregny, D., Glenisson, W., Tran, S. L., North, B. J., Verdin, E., Colige, 
A., Castronovo, V. Histone deacetylase HDAC8 associates with smooth muscle 
α-actin and is essential for smooth muscle cell contractility. FASEB J 2005, 19, 
966-968. 
186. Wolfson, N. A., Pitcairn, C. A., Fierke, C. A. HDAC8 substrates: histones 
and beyond. Biopolymers 2013, 99, 112-126. 
187. Hu, E., Chen, Z., Fredrickson, T., Zhu, Y., Kirkpatrick, R., Zhang, G. F., 
Winkler, J. Cloning and characterization of a novel human class I histone 
deacetylase that functions as a transcription repressor. Journal of Biological 
Chemistry 2000, 275, 15254-15264. 
188. Waltregny, D., de Leval, L., Glénisson, W., Ly Tran, S., North, B. J., 
Bellahcène, A., Castronovo, V. Expression of histone deacetylase 8, a class I 
histone deacetylase, is restricted to cells showing smooth muscle differentiation 
in normal human tissues. The American journal of pathology 2004, 165, 553-
564. 
189. Parra, M., Verdin, E. Regulatory signal transduction pathways for class IIa 
histone deacetylases. Current opinion in pharmacology 2010, 10, 454-460. 
190. McKinsey, T.A. Derepression of pathological cardiac genes by members of 
the CaMkinase superfamily. Cardiovasc Res 2007, 73, 667-677. 
191. Backs, J., Backs, T., Bezprozvannaya, S., McKinsey, T.A., Olson, E.N. 
Histone deacetylase 5 acquires calcium/calmodulindependent kinase II 
responsiveness by oligomerization with histone deacetylase 4. Mol Cell Biol 
2008,; 28, 3437-3445. 
192. Bolger, T.A., Yao, T.P. Intracellular trafficking of histone deacetylase 4 
regulates neuronal cell death. J Neurosci 2005, 25, 9544-9553. 
193. Soriano, F. X., Chawla, S., Skehel, P., Hardingham, G. E. SMRT‐mediated 
co‐shuttling enables export of class IIa HDACs independent of their CaM kinase 
phosphorylation sites. Journal of neurochemistry 2013, 124, 26-35. 
194. Martin, M., Kettmann, R., Dequiedt, F. Class IIa histone deacetylases: 
regulating the regulators. Oncogene 2007, 26, 5450-5467. 
195. Martin, M., Kettmann, R., Dequiedt, F. Class IIa histone deacetylases: 
conducting development and differentiation. Int J Dev Biol 2009, 53, 291-301. 
196. Potthoff, M.J., Olson, E.N. MEF2: a central regulator of diverse 
developmental programs. Development 2007, 134, 4131-4140. 
197. Morin, R.D., Mendez-Lago, M., Mungall, A.J., Goya, R., Mungall, K.L., 
Corbett, R.D., Johnson, N.A., Severson, T.M., Chiu, R., Field, M. Frequent 
mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 
476, 298-303. 
198. Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., 
Trifonov, V., Kasper, L.H., Lerach, S., Tang, H., Ma, J. Inactivating mutations 
of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471, 189-195. 
 228 |References  
199. Lu, J., McKinsey, T.A., Zhang, C.L., Olson,E.N. Regulation of skeletal 
myogenesis by association of the MEF2 transcription factor with class II histone 
deacetylases. Mol. Cell 2000, 6, 233-244. 
200. Wang, A.H., Yang, X.J. Histone deacetylase 4 possesses intrinsic nuclear 
import and export signals. Mol. Cell Biol. 2001, 21, 5992-6005. 
201. Han, A., He, J., Wu, Y., Liu, J.O., Chen, L. Mechanism of recruitment of 
class II histone deacetylases by myocyte enhancer factor-2. J. Mol. Biol. 2005, 
345, 91-102. 
202. Jayathilaka, N., Han, A., Gaffney, K. J., Dey, R., Jarusiewicz, J. A., 
Noridomi, K., Chen, L. Inhibition of the function of class IIa HDACs by 
blocking their interaction with MEF2. Nucleic acids research 2012, 40, 5378-
5388. 
203. Vega, R. B., Matsuda, K., Oh, J.; Barbosa, A. C., Yang, X., Meadows, E., 
McAnally, J., Pomajzl, C., Shelton, J. M., Richardson, J. A. Histone deacetylase 
4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004, 119, 555-
566. 
204. Chauchereau, A., Mathieu, M., de Saintignon, J., Ferreira, R., Pritchard, L. L., 
Mishal, Z., Dejean, A., Harel-Bellan, A. HDAC4 mediates transcriptional 
repression by the acute promyelocytic leukaemia-associated protein PLZF. 
Oncogene 2004, 23, 8777-8784. 
205. Chang, S., McKinsey, T. A., Zhang, C. L., Richardson, J. A., Hill, J. A., 
Olson, E. N. Histone deacetylases 5 and 9 govern responsiveness of the heart to 
a subset of stress signals and play redundant roles in heart development. Mol. 
Cell. Biol. 2004, 24, 8467-8476. 
206. Zhang, C. L., McKinsey, T. A., Chang, S., Antos, C. L., Hill, J. A., Olson, E. 
N. Class II histone deacetylases act as signal-responsive repressors of cardiac 
hypertrophy. Cell 2002, 110, 479-488. 
207. Dequiedt, F., Kasler, H., Fischle, W., Kiermer, V., Weinstein, M., Herndier, 
B. G., Verdin, E. HDAC7, a thymus-specific class II histone deacetylase, 
regulates Nur77 transcription and TCR mediated apoptosis. Immunity 2003, 18, 
687-698. 
208. Chang, S., Young, B. D., Li, S., Qi, X., Richardson, J. A., Olson, E. N. 
Histone deacetylase 7 maintains vascular integrity by repressing matrix 
metalloproteinase 10. Cell 2006, 126, 321- 334. 
209. Zhu, C., Chen, Q., Xie, Z., Ai, J., Tong, L., Ding, J., Geng, M. The role of 
histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-
Myc. J Mol Med (Berl) 2011, 89, 279-289. 
210. Zhang, G., Wang, Z. RNA interference of HDAC7 expression in 
hepatocellular carcinoma. Journal of Central South University. Medical sciences 
2010, 35, 718-724. 
211. Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., 
Warnow, T., Mazitschek, R. Chemical phylogenetics of histone deacetylases. 
Nature chemical biology 2010, 6, 238-243. 
 229 |References  
212. Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., 
Yoshida, M., Wang, X.F., Yao, T.P. HDAC6 is a microtubule-associated 
deacetylase, Nature 2002, 417, 455-458. 
213. Kovacs, J.J., Murphy, P.J., Gaillard, S., Zhao, X., Wu, J.T., Nicchitta, C.V., 
Yoshida, M., Toft, D.O., Pratt, W.B., Yao, T.P. HDAC6 regulates Hsp90 
acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. 
Cell 2005, 18, 601-607. 
214. Namdar, M., Perez, G., Ngo, L., Marks, P. A. Selective inhibition of histone 
deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells 
to anticancer agents. Proceedings of  the National Academy of Sciences 2010, 
107, 20003-20008. 
215. Kawaguchi, Y., Kovacs, J.J., McLaurin, A., Vance, J.M., Ito, A., Yao, T.P. 
The deacetylase HDAC6 regulates aggresome formation and cell viability in 
response to misfolded protein stress. Cell 2003, 115, 727-738. 
216. Pandey, U.B., Nie, Z., Batlevi, Y., McCray, B.A., Ritson, G.P., Nedelsky, 
N.B., Schwartz, S.L., Di Prospero, N.A., Knight, M.A., Schuldiner, O., 
Padmanabhan, R., Hild M. HDAC6 rescues neurodegeneration and provides an 
essential link between autophagy and the UPS. Nature 2007, 447, 859-863. 
217. Lee, J. H., Jeong, E. G., Choi, M. C., Kim, S. H., Park, J. H., Song, S. H., 
Park, J., Bang, Y. J., Kim, T. Y. Inhibition of histone deacetylase 10 induces 
thioredoxin-interacting protein and causes accumulation of reactive oxygen 
species in SNU-620 human gastric cancer cells. Mol. Cells 2010, 30, 107-112.  
218. Villagra, A., Sotomayor, E.M., Seto, E. Histone deacetylases and the 
immunological network: implications in cancer and inflammation. Oncogene 
2010, 29,157-173. 
219. Deubzer, H. E., Schier, M. C., Oehme, I., Lodrini, M., Haendler, B., Sommer, 
A., Witt, O. HDAC11 is a novel drug target in carcinomas. International Journal 
of Cancer 2012. 
220. Shore, D., Squire, M., Nasmyth, K.A. Characterization of two genes required 
for the position-effect control of yeast mating-type genes. EMBO J. 1984, 3, 
2817-2823. 
221. Tissenbaum, H.A., Guarente, L. Increased dosage of a sir-2 gene extends 
lifespan in Caenorhabditis elegans. Nature 2001, 410, 227-230.  
222.  Rogina, B., Helfand, S.L. Sir2 mediates longevity in the fly through a 
pathway related to calorie restriction. Proc Natl Acad Sci U S A 2004,101, 
15998-16003. 
223. Du, J., Zhou, Y., Su, X., Yu, J. J., Khan, S., Jiang, H., Lin, H. Sirt5 is a NAD-
dependent protein lysine demalonylase and desuccinylase. Science. 2011, 334, 
806-809. 
224. Michan, S., Sinclair, D. Sirtuins in mammals: insights into their biological 
function. Biochem. J. 2007, 404, 1-13. 
225. Martínez-Redondo, P., Vaquero, A. The diversity of histone versus 
nonhistone Sirtuin substrates. Genes & Cancer 2013. 
 230 |References  
226. Aquilano, K., Vigilanza, P., Baldelli, S., Pagliei, B., Rotilio, G., Ciriolo,M.R. 
Peroxisome proliferator-activated receptor gamma co-activator 1alpha (PGC-
1alpha) and sirtuin 1 (SIRT1) reside in mitochondria: possible direct function in 
mitochondrial biogenesis. J. Biol. Chem. 2010, 285, 21590-21599. 
227. Tanno, M., Sakamoto, J., Miura, T., Shimamoto, K., Horio, Y. 
Nucleocytoplasmic shuttling of the NAD
+
-dependent histone deacetylase SIRT1. 
J. Biol. Chem. 2007, 282, 6823-6832. 
228. Vaquero, A., Scher, M. B., Lee, D. H., Sutton, A., Cheng, H. L., Alt, F. W., 
Reinberg, D. SirT2 is a histone deacetylase with preference for histone H4 Lys 
16 during mitosis. Genes Dev. 2006, 20, 1256-1261.  
229. Huang, J. Y., Hirschey, M. D., Shimazu, T., Ho, L., Verdin, E. Mitochondrial 
sirtuins. Biochim. Biophys. Acta 2010, 1804, 1645-1651. 
230. Gertz, M., Steegborn, C. Function and regulation of the mitochondrial Sirtuin 
isoform Sirt5 in Mammalia. Biochimica et Biophysica Acta (BBA)-Proteins and 
Proteomics 2010, 1804,1658-1665. 
231. Mostoslavsky, R., Chua, K. F., Lombard, D. B., Pang, W. W., Fischer, M. R., 
Gellon, L., Alt, F. W. Genomic instability and aging-like phenotype in the 
absence of mammalian SIRT6. Cell 2006, 124, 315-329.  
232. Ford, E., Voit, R., Liszt, G., Magin, C., Grummt, I., Guarente, L. Mammalian 
Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes 
Dev.2006, 20, 1075-1080. 
233. Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S. I., Frye, R. A., Pandita, T. 
K., Weinberg, R. A. hSIR2 (SIRT1) functions as an NAD-dependent p53 
deacetylase. Cell 2001, 107, 149-159. 
234. Herranz, D., Serrano, M. SIRT1: recent lessons from mouse models. Nature 
Reviews Cancer 2010, 10, 819-823. 
235. Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., 
Puigserver, P. Nutrient control of glucose homeostasis through a complex of 
PGC-1α and SIRT1. Nature 2005, 434, 113-118. 
236. Bordone, L., Motta, M. C., Picard, F., Robinson, A., Jhala, U. S., Apfeld, J., 
Guarente, L. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic β 
cells. PLoS biology 2005, 4, e31. 
237. Chen, D., Steele, A. D., Lindquist, S., Guarente, L. Increase in activity during 
calorie restriction requires Sirt1. Science 2005, 310, 1641-1641. 
238. Li, X., Zhang, S., Blander, G., Tse, J.G., Krieger, M., Guarente, L. SIRT1 
deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 2007, 
28, 91-106. 
239. Vaquero, A., Sternglanz, R., Reinberg, D. NAD+-dependent deacetylation of 
H4 lysine 16 by class III HDACs. Oncogene 2007, 26, 5505-5520. 
240. North, B.J., Marshall, B.L., Borra, M.T., Denu, J.M., Verdin, E. The human 
Sir2 ortholog, SIRT2, is an NAD
+
-dependent tubulin deacetylase. Mol. Cell 
2003, 11,437-444. 
 231 |References  
241. North, B.J., Verdin, E. Mitotic regulation of SIRT2 by cyclin-dependent 
kinase 1-dependent phosphorylation. J. Biol. Chem 2007, 282,19546-19555.  
242.  Inoue, T., Nakayama, Y., Yamada, H., Li, Y.C., Yamaguchi, S. SIRT2 
downregulation confers resistance to microtubule inhibitors by prolonging 
chronic mitotic arrest. Cell Cycle 2009, 8, 1279-1291. 
243. Tang, B.L., Chua, C.E. SIRT2, tubulin deacetylation, and oligodendroglia 
differentiation. Cell Motil. Cytoskeleton 2008, 65, 179-182. 
244. Wu, F., Schweizer, C., Rudinskiy, N., Taylor, D.M., Kazantsev, A., Luthi-
Carter, R., Fraering, P.C. Novel gamma-secretase inhibitors uncover a common 
nucleotide-binding site in JAK3, SIRT2, and PS1. FASEB J. 2010, 24, 2464-
2474. 
245. Lombard, D.B., Alt, F.W., Cheng, H.L., Bunkenborg, J., Streeper, R.S., 
Mostoslavsky, R., Kim, J., Yancopoulos, G., Valenzuela, D., Murphy, A. 
Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine 
acetylation. Mol Cell Biol 2007, 27, 8807-8814. 
246. Hebert, A.S., Dittenhafer-Reed, K.E., Yu, W., Bailey, D.J., Selen, E.S., 
Boersma, M.D., Carson, J.J., Tonelli, M., Balloon, A.J., Higbee, A.J. Calorie 
restriction and SIRT3 trigger global reprogramming of the mitochondrial protein 
acetylome. Mol Cell 2013, 49, 186-199. 
247. Hirschey, M.D., Shimazu, T., Goetzman, E., Jing, E., Schwer, B., Lombard, 
D.B., Grueter, C.A., Harris, C., Biddinger, S., Ilkayeva, O.R. SIRT3 regulates 
mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 
2010, 464, 121-125. 
248. Schwer, B., Bunkenborg, J., Verdin, R.O., Andersen, J.S., Verdin, E. 
Reversible lysine acetylation controls the activity of the mitochondrial enzyme 
acetyl-CoA synthetase 2. Proc Natl Acad Sci U S A 2006, 103, 10224-10229. 
249. Cimen, H., Han, M.J., Yang, Y., Tong, Q., Koc, H., Koc, E.C. Regulation of 
succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. 
Biochemistry 2010, 49, 304-311. 
250. Hallows, W.C., Yu, W., Smith, B.C., Devires, M.K., Ellinger, J.J., Someya, 
S., Shortreed, M.R., Prolla, T., Markley, J.L., Smith, L.M., Zhao, S., Guan, K.L., 
Denu, J.M. Sirt3 promotes the urea cycle and fatty acid oxidation during dietary 
restriction. Mol. Cell 2011, 41, 139-149. 
251. Dölle, C., Rack, J. G., Ziegler, M. NAD and ADP‐ribose metabolism in 
mitochondria. FEBS Journal 2013. 
252. Haigis, M. C., Mostoslavsky, R., Haigis, K. M., Fahie, K., Christodoulou, D. 
C., Murphy, A. J., Guarente, L. SIRT4 inhibits glutamate dehydrogenase and 
opposes the effects of calorie restriction in pancreatic β cells. Cell 2006, 126, 
941-954. 
253. Ahuja, N., Schwer, B., Carobbio, S., Waltregny, D., North, B. J., Castronovo, 
V., Verdin, E. Regulation of insulin secretion by SIRT4, a mitochondrial ADP-
ribosyltransferase. Journal of Biological Chemistry 2007, 282, 33583-33592. 
 232 |References  
254. Nasrin, N., Wu, X., Fortier, E., Feng, Y., Bare, O. C., Chen, S., Bordone, L. 
SIRT4 regulates fatty acid oxidation and mitochondrial gene expression in liver 
and muscle cells. Journal of Biological Chemistry 2010, 285, 31995-32002. 
255. Laurent, G., German, N. J., Saha, A. K., de Boer, V. C., Davies, M., Koves, 
T. R., Haigis, M. C. SIRT4 coordinates the balance between lipid synthesis and 
catabolism by repressing malonyl CoA decarboxylase. Molecular cell 2013, 50, 
686-698. 
256. Nakagawa, T., Lomb, D.J., Haigis, M.C., Guarente, L. SIRT5 Deacetylates 
carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 2009, 
137,560-570. 
257. Fischer, F., Gertz, M., Suenkel, B., Lakshminarasimhan, M., Schutkowski, 
M., Steegborn, C. Sirt5 deacylation activities show differential sensitivities to 
nicotinamide inhibition. PLoS One 2012, 7, e45098. 
258. Nakamura, Y., Ogura, M., Ogura, K., Tanaka, D., Inagaki, N. SIRT5 
deacetylates and activates urate oxidase in liver mitochondria of mice. FEBS 
Lett 2012, 586, 4076-4081.  
259.  Wu, X.W., Muzny, D.M., Lee, C.C., Caskey, C.T. Two independent 
mutational events in the loss of urate oxidase during hominoid evolution. J Mol 
Evol 1992, 34, 78-84.  
260. Verdin, E., Hirschey, M. D., Finley, L. W. S., Haigis, M. C. Sirtuin regulation 
of mitochondria: energy production, apoptosis, and signaling. Trends Biochem. 
Sci. 2010, 35, 669-675. 
261. Carafa, V., Nebbioso, A., Altucci, L. Sirtuins and disease: the road ahead. 
Frontiers in pharmacology 2012, 3. 
262. Michishita, E., McCord, R.A., Berber, E., Kioi, M., Padilla-Nash, H., 
Damian, M., Cheung, P., Kusumoto, R., Kawahara, T.L., Barrett, J.C., Chang, 
H.Y., Bohr, V.A., Ried, T., Gozani, O., Chua, K.F. SIRT6 is a histone H3 lysine 
9 deacetylase that modulates telomeric chromatin. Nature 2008, 452, 492-496.  
263. Mao, Z., Hine, C., Tian, X., Van Meter, M., Au, M., Vaidya, A., Seluanov, 
A., Gorbunova, V. SIRT6 promotes DNA repair under stress by activating 
PARP1. Science 2011, 332, 1443-1446. 
264. Gil, R., Barth, S., Kanfi, Y., Cohen, H. Y. SIRT6 exhibits nucleosome-
dependent deacetylase activity. Nucleic acids research 2013, 41, 8537-8545. 
265. Jiang, H., Khan, S., Wang, Y., Charron, G., He, B., Sebastian, C., Du, J., 
Kim, R., Ge, E., Mostoslavsky, R., Hang, H.C., Hao, Q., Lin, H. SIRT6 
regulates TNF- secretion through hydrolysis of long-chain fatty acyl lysine. 
Nature 2013, 496, 110-113. 
266. Zhong, L., D’Urso, A., Toiber, D., Sebastian, C., Henry, R.E., Vadysirisack, 
D.D., Guimaraes, A., Marinelli, B., Wikstrom, J.D., Nir, T., Clish, C.B., 
Vaitheesvaran, B., Iliopoulos, O., Kurland, I., Dor, Y., Weissleder, R., Shirihai, 
O.S., Ellisen, L.W., Espinosa, J.M., Mostoslavsky, R. The histone deacetylase 
Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 2010, 140, 280-293. 
 233 |References  
267. Sebastián, C., Zwaans, B. M., Silberman, D. M., Gymrek, M., Goren, A., 
Zhong, L., Mostoslavsky, R. The histone deacetylase SIRT6 is a tumor 
suppressor that controls cancer metabolism. Cell 2012, 151, 1185-1199. 
268. McCord, R. A., Michishita, E., Hong, T., Berber, E., Boxer, L. D., Kusumoto, 
R., Chua, K. F. SIRT6 stabilizes DNA-dependent protein kinase at chromatin for 
DNA double-strand break repair. Aging (Albany NY) 2009, 1, 109. 
269. Barber, M.F., Michishita-Kioi, E., Xi, Y., Tasselli, L., Kioi, M., Moqtaderi, 
Z., Tennen, R.I., Paredes, S., Young, N.L., Chen, K. SIRT7 links H3K18 
deacetylation to maintenance of oncogenic transformation. Nature 2012, 487, 
114-118. 
270. Kim, J.K., Noh, J.H., Jung, K.H., Eun, J.W., Bae, H.J., Kim, M.G., Chang, 
Y.G., Shen, Q., Park, W.S., Lee, J.Y. Sirtuin7 oncogenic potential in human 
hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-
5p and MiR-125b. Hepatology 2013, 57, 1055-1067. 
271. Chen, S., Seiler, J., Santiago-Reichelt, M., Felbel, K., Grummt, I., Voit, R. 
Repression of RNA polymerase I upon stress is caused by inhibition of RNA-
dependent deacetylation of PAF53 by SIRT7. Molecular cell 2013, 52, 303-313. 
272. Vakhrusheva, O., Smolka, C., Gajawada, P., Kostin, S., Boettger, T., Kubin, 
T., Bober, E. Sirt7 increases stress resistance of cardiomyocytes and prevents 
apoptosis and inflammatory cardiomyopathy in mice. Circulation research 
2008, 102, 703-710. 
273. Pereira, C. V., Lebiedzinska, M., Wieckowski, M. R., Oliveira, P. J.. 
Regulation and protection of mitochondrial physiology by sirtuins. 
Mitochondrion 2012, 12, 66-76. 
274. Sanders, B. D., Jackson, B., Marmorstein, R. Structural basis for sirtuin 
function: What we know and what we don't. Biochimica et Biophysica Acta 
(BBA)-Proteins and Proteomics 2010, 1804,1604-1616. 
275. Chakrabarty, S. P., Balaram, H. Reversible binding of zinc in Plasmodium 
falciparum Sir2: structure and activity of the apoenzyme. Biochim. Biophys. 
Acta 2010, 1804, 1743-1750. 
276. Min, J., Landry, J., Sternglanz, R., Xu, R.M. Crystal structure of a SIR2 
homolog-NAD complex, Cell 2001, 105, 269-279. 
277. Prasad, G. S., Sridhar, V., Yamaguchi, M., Hatefi, Y., Stout, C. D. Crystal 
structure of transhydrogenase domain III at 1.2 Å resolution. Nat. Struct. Biol. 
1999, 6, 1126-1131. 
278. Hawse, W.F., Hoff, K.G., Fatkins, D.G., Daines, A., Zubkova, O.V., 
Schramm, V.L., Zheng, W., Wolberger, C. Structural Insights into Intermediate 
Steps in the Sir2 Deacetylation Reaction. Structure 2008, 16, 1368-1377. 
279. Fraga, M.F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., 
Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., Iyer, N.G., Perez-
Rosado, A., Calvo, E., Lopez, J.A., Cano, A., Calasanz, M.J., Colomer, D., Piris, 
M.A., Ahn, N., Imhof, A., Caldas, C., Jenuwein, T., Esteller, M. Loss of 
 234 |References  
acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common 
hallmark of human cancer. Nat. Genet. 2005, 37, 391-400. 
280. Choi, J.H., Song, Y.S., Yoon, J.S., Song, K.W., Lee, Y.Y. Enhancer of zeste 
homolog 2 expression is associated with tumor cell proliferation and metastasis 
in gastric cancer. Apmis 2010, 118, 196-202. 
281. Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Ando, Y., Mita, K., 
Hamaguchi, M., Hara, Y., Kobayashi, S., Iwase, H. Quantitation of HDAC1 
mRNA expression in invasive carcinoma of the breast. Breast Cancer Res. 
Treat. 2005, 94, 11-16.  
282. Fritzsche, F.R., Weichert, W., Roske, A., Gekeler, V., Beckers, T., Stephan, 
C., Jung, K., Scholman, K., Denkert, C., Dietel, M., Kristiansen, G. Class I 
histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC 
Cancer 2008, 8, 381. 
283. Adams, H., Fritzsche, F.R., Dirnhofer, S., Kristiansen, G., Tzankov, A. Class 
I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin’s 
lymphoma. Expert Opin. Ther. Targets 2010, 14, 577-584. 
284. Jung, K.H., Noh, J.H., Kim, J.K., Eun, J.W., Bae, H.J., Xie, H.J., Chang, 
Y.G., Kim, M.G., Park, H., Lee, J.Y., Nam, S.W. HDAC2 overexpression 
confers oncogenic potential to human lung cancer cells by deregulating 
expression of apoptosis and cell cycle proteins. J. Cell. Biochem. 2012, 113, 
2167-2177. 
285. Oehme, I., Deubzer, H.E., Wegener, D., Pickert, D., Linke, J.P., Hero, B., 
Kopp-Schneider, A., Westermann, F., Ulrich, S.M., von Deimling, A., Fischer, 
M., Witt, O. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin. 
Cancer Res. 2009, 15, 91-99. 
286. Park, S.Y., Jun, J.A., Jeong, K.J., Heo, H.J., Sohn, J.S., Lee, H.Y., Park, C.G., 
Kang, J. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. 
Oncol. Rep. 2011, 25, 1677-1681. 
287. Xie, H.J., Noh, J.H., Kim, J.K., Jung, K.H., Eun, J.W., Bae, H.J., Kim, M.G., 
Chang, Y.G., Lee, J.Y., Park, H., Nam, S.W. HDAC1 inactivation induces 
mitotic defect and caspaseindependent autophagic cell death in liver cancer. 
PLoS One 2012, 7, 34265. 
288. Sun, J.Y., Xu, L., Tseng, H., Ciccarelli, B., Fulciniti, M., Hunter, Z.R., 
Maghsoudi, K., Hatjiharissi, E., Zhou, Y., Yang, G., Zhu, B., Liu, X., Gong, P., 
Ioakimidis, L., Sheehy, P., Patterson, C.J., Munshi, N.C., O’Connor, O.A., 
Treon, S.P. Histone deacetylase inhibitors demonstrate significant preclinical 
activity as single agents, and in combination with bortezomib in Waldenstrom’s 
macroglobulinemia. Clin. Lymphoma. Myeloma Leuk. 2011, 11, 152-156. 
289. Ozdag, H., Teschendorff, A.E., Ahmed, A.A., Hyland, S.J., Blenkiron, C., 
Bobrow, L., Veerakumarasivam, A., Burtt, G., Subkhankulova, T., Arends, M.J., 
Collins, V.P., Bowtell, D., Kouzarides, T., Brenton, J.D., Caldas, C. Differential 
expression of selected histone modifier genes in human solid cancers. BMC 
Genomics 2006, 7, 90. 
 235 |References  
290. Stark, M., Hayward, N. Genome-wide loss of heterozygosity and copy 
number analysis in melanoma using high-density single-nucleotide 
polymorphism arrays. Cancer Res. 2007, 67, 2632-2642. 
291. Sjoblom, T., Jones, S., Wood, L.D., Parsons, D.W., Lin, J., Barber, T.D., 
Mandelker, D., Leary, R.J., Ptak, J., Silliman, N., Szabo, S., Buckhaults, P., 
Farrell, C., Meeh, P., Markowitz, S.D., Willis, J., Dawson, D., Willson, J.K., 
Gazdar, A.F., Hartigan, J., Wu, L., Liu, C., Parmigiani, G., Park, B.H., 
Bachman, K.E., Papadopoulos, N., Vogelstein, B., Kinzler, K.W., Velculescu, 
V.E. The consensus coding sequences of human breast and colorectal cancers. 
Science 2006, 314, 268-274. 
292. Milde, T., Oehme, I., Korshunov, A., Kopp-Schneider, A., Remke, M., 
Northcott, P., Deubzer, H.E., Lodrini, M., Taylor, M.D., von Deimling, A., 
Pfister, S., Witt, O. HDAC5 and HDAC9 in medulloblastoma: novel markers for 
risk stratification and role in tumor cell growth. Clin. Cancer Res. 2010, 16, 
3240-3252. 
293. Lachenmayer, A., Toffanin, S., Cabellos, L., Alsinet, C., Hoshida, Y., 
Villanueva, A., Minguez, B., Tsai, H.W., Ward, S.C., Thung, S., Friedman, S.L., 
Llovet, J.M. Combination therapy for hepatocellular carcinoma: additive 
preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J. 
Hepatol. 2012, 56, 1343-1350. 
294. Weichert, W. HDAC expression and clinical prognosis in human 
malignancies. Cancer Lett. 2009, 280, 168-176. 
295. Moreno, D.A., Scrideli, C.A., Cortez, M.A., de Paula Queiroz, R., Valera, 
E.T., da Silva Silveira, V., Yunes, J.A., Brandalise, S.R., Tone, L.G. Differential 
expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and 
survival in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 2010, 
150, 665-673. 
296. Skov, V., Larsen, T.S., Thomassen, M., Riley, C.H., Jensen, M.K., Bjerrum, 
O.W., Kruse, T.A., Hasselbalch, H.C. Increased gene expression of histone 
deacetylases in patients with Philadelphia-negative chronic myeloproliferative 
neoplasms. Leuk. Lymphoma. 2012, 53, 123-129. 
297. Lee, Y.S., Lim, K.H., Guo, X., Kawaguchi, Y., Gao, Y., Barrientos, T., 
Ordentlich, P., Wang, X.F., Counter, C.M., Yao, T.P. The cytoplasmic 
deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer 
Res. 2008, 68, 7561-7569. 
298. Sakuma, T., Uzawa, K., Onda, T., Shiiba, M., Yokoe, H., Shibahara, T., 
Tanzawa, H. Aberrant expression of histone deacetylase 6 in oral squamous cell 
carcinoma. Int. J. Oncol. 2006, 29, 117-124. 
299. Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Omoto, Y., Ando, Y., 
Mita, K., Hamaguchi, M., Hayashi, S., Iwase, H. HDAC6 expression is 
correlated with better survival in breast cancer. Clin. Cancer Res. 2004, 10, 
6962-6968. 
 236 |References  
300. Saji, S., Kawakami, M., Hayashi, S., Yoshida, N., Hirose, M., Horiguchi, S., 
Itoh, A., Funata, N., Schreiber, S.L., Yoshida, M., Toi, M. Significance of 
HDAC6 regulation via estrogen signaling for cell motility and prognosis in 
estrogen receptorpositive breast cancer. Oncogene 2005, 24, 4531-4539. 
301. Gao, L., Alumkal, J. Epigenetic regulation of androgen receptor signaling in 
prostate cancer. Epigenetics 2010, 5, 100-104. 
302. Hsieh, T.H., Tsai, C.F., Hsu, C.Y., Kuo, P.L., Lee, J.N., Chai, C.Y., Hou, 
M.F., Chang, C.C., Ko, Y.C., Tsai, E.M. Phthalates stimulate the epithelial to 
mesenchymal transition through an HDAC6-dependent mechanism in human 
breast epithelial stem cells. Toxicol. Sci. 2012, 128, 365-376.  
303. Kaluza, D., Kroll, J., Gesierich, S., Yao, T.P., Boon, R.A., Hergenreider, E., 
Tjwa, M., Rossig, L., Seto, E., Augustin, H.G., Zeiher, A.M., Dimmeler, S., 
Urbich, C. Class IIb HDAC6 regulates endothelial cell migration and 
angiogenesis by deacetylation of cortactin. Embo J. 2011, 30, 4142-4156. 
304. Li, D., Xie, S., Ren, Y., Huo, L., Gao, J., Cui, D., Liu, M., Zhou, J. 
Microtubule-associated deacetylase HDAC6 promotes angiogenesis by 
regulating cell migration in an EB1-dependent manner. Protein Cell 2011¸2, 
150-160. 
305. Aldana-Masangkay, G.I., Rodriguez-Gonzalez, A., Lin, T., Ikeda, A.K., 
Hsieh, Y.T., Kim, Y.M., Lomenick, B., Okemoto, K., Landaw, E.M., Wang, D., 
Mazitschek, R., Bradner, J.E., Sakamoto, K.M. Tubacin suppresses proliferation 
and induces apoptosis of acute lymphoblastic leukemia cells. Leuk. Lymphoma 
2011, 52, 1544-1555. 
306. Santo, L., Hideshima, T., Kung, A.L., Tseng, J.C., Tamang, D., Yang, M., 
Jarpe, M., van Duzer, J.H., Mazitschek, R., Ogier, W.C., Cirstea, D., Rodig, S., 
Eda, H., Scullen, T., Canavese, M., Bradner, J., Anderson, K.C., Jones, S.S., 
Raje, N. Preclinical activity, pharmacodynamic, and pharmacokinetic properties 
of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in 
multiple myeloma. Blood 2012, 119, 2579-2589. 
307. Chen, W. Y., Wang, D. H., Yen, R. C., Luo, J., Gu, W., Baylin, S. B. Tumor 
suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-
damage responses. Cell. 2005, 123,437-448. 
308. Zhang, Y., Zhang, M., Dong, H., Yong, S., Li, X., Olashaw, N., Zhang, X. 
Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene 2009, 
28, 445-460. 
309. Suzuki, K., Hayashi, R., Ichikawa, T., Imanishi, S., Yamada, T., Inomata, M., 
Tobe, K. SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung 
metastasis of breast cancer in mice. Oncol Rep. 2012, 27, 1726-1732. 
310. Noguchi, A., Li, X., Kubota, A., Kikuchi, K., Kameda, Y., Zheng, H., 
Takano, Y. SIRT1 expression is associated with good prognosis for head and 
neck squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral 
Radiol. 2013, 115,385-392. 
 237 |References  
311. Hiratsuka, M., Inoue, T., Toda, T., Kimura, N., Shirayoshi, Y., Kamitani, H., 
Oshimura, M. Proteomics-based identification of differentially expressed genes 
in human gliomas:down-regulation of SIRT2 gene. Biochem Biophys Res 
Commun. 2003, 309,558-566. 
312. Peters, C.J., Rees, J.R., Hardwick, R.H. Oesophageal Cancer Clinical and 
Molecular Stratification (OCCAMS) Study Group. A 4-gene signature predicts 
survival of patients with resected adenocarcinoma of the esophagus, junction, 
and gastric cardia. Gastroenterology. 2010, 139,1995-2004. 
313. Kim, H. S., Vassilopoulos, A., Wang, R. H., Lahusen, T., Xiao, Z., Xu, X., 
Deng, C. X. SIRT2 maintains genome integrity and suppresses tumorigenesis 
through regulating APC/C activity. Cancer Cell. 2011, 20, 487-499. 
314. He, X., Nie, H., Hong, Y., Sheng, C., Xia, W., Ying, W. SIRT2 activity is 
required for the survival of C6 glioma cells. Biochem Biophys Res Commun. 
2012, 417, 468-472. 
315. Li, Y., Matsumori, H., Nakayama, Y., Osaki, M., Kojima, H., Kurimasa, A., 
Inoue, T. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 
MAPK activation-dependent p300 decrease, eventually leading to apoptosis. 
Genes Cells. 2011, 16, 34-45. 
316. Finley, L. W., Carracedo, A., Lee, J., Souza, A., Egia, A., Zhang, J., Haigis, 
M. C. SIRT3 opposes reprogramming of cancer cell metabolism through 
HIF1alpha destabilization. Cancer Cell. 2011, 19, 416-428. 
317. Lai, C. C., Lin, P. M., Lin, S. F., Hsu, C. H., Lin, H. C., Hu, M. L., Yang, M. 
Y. Altered expression of SIRT gene family in head and neck squamous cell 
carcinoma. Tumour Biol. 2013, 34, 1847-1854. 
318. Roth M, Chen WY. Sorting out functions of sirtuins in cancer. Oncogene. 
2013. 
319. Alhazzazi, T. Y., Kamarajan, P., Joo, N., Huang, J. Y., Verdin, E., D'Silva, N. 
J., Kapila, Y. L. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral 
cancer. Cancer 2011, 117, 1670-1678. 
320. Ashraf, N., Zino, S., Macintyre, A., Kingsmore, D., Payne, A. P., George, W. 
D., Shiels, P. G. Altered sirtuin expression is associated with node-positive 
breast cancer. Br J Cancer. 2006, 95, 1056-1061. 
321. Jeong, S. M., Xiao, C., Finley, L. W., Lahusen, T., Souza, A. L., Pierce, K., 
Haigis, M. C. SIRT4 has tumor-suppressive activity and regulates the cellular 
metabolic response to DNA damage by inhibiting mitochondrial glutamine 
metabolism. Cancer Cell. 2013, 23, 450-463. 
322. Newman, J.C., He, W., Verdin, E. Mitochondrial protein acylation and 
intermediary metabolism: regulation by sirtuins and implications for metabolic 
disease. J Biol Chem 2012, 287, 42436-42443. 
323. Yang, B., Zwaans, B.M., Eckersdorff, M., Lombard, D.B. The sirtuin SIRT6 
deacetylates H3 K56Ac in vivo to promote genomic stability. Cell Cycle. 2009, 
8, 2662-2663. 
 238 |References  
324. Das, C., Lucia, M. S., Hansen, K. C., Tyler, J. K. CBP/p300-mediated 
acetylation of histone H3 on lysine 56. Nature 2009, 459, 113-117. 
325. Van Meter, M., Mao, Z., Gorbunova, V., Seluanov, A. SIRT6 overexpression 
induces massive apoptosis in cancer cells but not in normal cells. Cell cycle 
2011, 10, 3153-3158. 
326. Bauer, I., Grozio, A., Lasigliè, D., Basile, G., Sturla, L., Magnone, M., 
Nencioni, A. The NAD
+
-dependent histone deacetylase SIRT6 promotes 
cytokine production and migration in pancreatic cancer cells by regulating Ca
2+
 
responses. Journal of Biological Chemistry 2012, 287, 40924-40937. 
327. Kim, J. K., Noh, J. H., Jung, K. H., Eun, J. W., Bae, H. J., Kim, M. G., Nam, 
S. W. SIRT7 oncogenic potential in human hepatocellular carcinoma and its 
regulation by the tumor suppressors mir-125a-5p and mir-125b. Hepatology 
2013, 57, 1055-1067. 
328. De Nigris, F., Cerutti, J., Morelli, C., Califano, D., Chiariotti, L., Viglietto, 
G., Fusco, A. Isolation of a SIR-like gene, SIR-T8, that is overexpressed in 
thyroid carcinoma cell lines and tissues. Br J Cancer 2002, 86, 917-923. 
329. Barber, M. F., Michishita-Kioi, E., Xi, Y., Tasselli, L., Kioi, M., Moqtaderi, 
Z., Chua, K. F. SIRT7 links H3K18 deacetylation to maintenance of oncogenic 
transformation. Nature 2012, 487, 114-118. 
330. Buglio, D., Khaskhely, N.M., Voo, K.S., Martinez-Valdez, H., Liu, Y.J., 
Younes, A. HDAC11 plays an essential role in regulating OX40 ligand 
expression in Hodgkin lymphoma. Blood 2011, 117, 2910-2917. 
331. Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., 
Marks, P. A., Pavletich, N. P. Structures of a histone deacetylase homologue 
bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193. 
332. Tsuji, N., Kobayashi, M., Nagashima, K., Wakisaka, Y., Koizumi, K. A new 
antifungal antibiotic, trichostatin. J Antibiot 1976; 29, 1-6. 
333. Tsuji, N., Kobayashi, M. Trichostatin C, a glucopyranosyl hydroxamate. J 
Antibiot 1978, 31, 939-944. 
334.  Yoshida, M., Nomura, S., Beppu, T. Effects of trichostatins on differentiation 
of murine erythroleukemia cells. Cancer Res 1987, 47,3688-3691. 
335. Yoshida, M., Horinouchi, S., Beppu, T. Trichostatin and trapoxin: novel 
chemical probes for the role of histone acetylation in chromatin structure and 
function. Bioessays 1995, 17, 423-430. 
336. Yoshida, M., Kijima, M., Akita, M., Beppu, T. Potent and specific inhibition 
of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J 
Biol Chem 1990, 265, 17174-17179. 
337. Sauve, A. A., Youn, D. Y. Sirtuins: NAD+dependent deacetylase mechanism 
and regulation. Current opinion in chemical biology 2012, 16, 535-543. 
338. Hoff, K. G., Avalos, J. L., Sens, K., Wolberger, C. Insights into the Sirtuin 
Mechanism from Ternary Complexes Containing NAD
+
 and Acetylated Peptide. 
Structure 2006, 14,1231-1240. 
339. http://clinicaltrials.gov/ 
 239 |References  
340. Yeo, W., Chung, H. C., Chan, S. L., Wang, L. Z., Lim, R., Picus, J., Goh, B. 
C. Epigenetic therapy using belinostat for patients with unresectable 
hepatocellular carcinoma: a multicenter phase I/II study with biomarker and 
pharmacokinetic analysis of tumors from patients in the Mayo Phase II 
Consortium and the Cancer Therapeutics Research Group. Journal of Clinical 
Oncology 2012, 30, 3361-3367. 
341. Giaccone, G., Rajan, A., Berman, A., Kelly, R. J., Szabo, E., Lopez-Chavez, 
A., Loehrer, P. J. Phase II study of belinostat in patients with recurrent or 
refractory advanced thymic epithelial tumors. Journal of Clinical Oncology 
2011, 29, 2052-2059. 
342. Hainsworth, J. D., Infante, J. R., Spigel, D. R., Arrowsmith, E. R., Boccia, R. 
V., Burris, H. A. A phase II trial of panobinostat, a histone deacetylase inhibitor, 
in the treatment of patients with refractory metastatic renal cell carcinoma. 
Cancer Invest. 2011, 7, 451-455.  
343. Dokmanovic, M., Clarke, C., Marks, P. A. Histone deacetylase inhibitors: 
overview and perspectives. Molecular cancer research 2007, 5, 981-989. 
344. Barbetti, V., Gozzini, A., Rovida, E., Morandi, A., Spinelli, E., Fossati, G., 
Santini, V. Selective anti-leukaemic activity of low-dose histone deacetylase 
inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene 2008, 27, 1767-
1778.  
345. Guerini, V., Barbui, V., Spinelli, O., Salvi, A., Dellacasa, C., Carobbio, A., 
Rambaldi, A. The histone deacetylase inhibitor ITF2357 selectively targets cells 
bearing mutated JAK2(V617F). Leukemia 2008, 22, 740-747. 
346. Viviani, S., Bonfante, V., Fasola, C., Valagussa, P., Gianni, A.M. Phase II 
study of the histone-deacetylase inhibitor ITF2357 in relasped/refractory 
Hodgkin’s lymphoma patients. J Clin Oncol. 2008, 7, 47. 
347. Adimoolam, S., Sirisawad, M., Chen, J., Thiemann, P., Ford, J. M., Buggy, J. 
J. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits 
homologous recombination. Proc Natl Acad Sci U S A. 2007, 104, 19482-19487. 
348. Undevia, S. D., Janisch, L., Schilsky, R. L., Loury, D., Balasubramanian, S., 
Mani, C., Ratain, M. J. Phase I study of the safety, pharmacokinetics (PK) and 
pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-
24781. J Clin Oncol. 2008, 26, S14514. 
349. Arts, J., Angibaud, P., Marien, A., Floren, W., Janssens, B., King, P., Van 
Dun, J., Janssen, L., Geerts, T., Tuman, R. R306465 is a novel potent inhibitor 
of class I histone deacetylases with broadspectrum antitumoral activity against 
solid and haematological malignancies. Br. J. Cancer 2007, 97, 1344-1353. 
350. Mithraprabhu, S., Khong, T., Jones, S. S., Spencer, A. Histone deacetylase 
(HDAC) inhibitors as single agents induce multiple myeloma cell death 
principally through the inhibition of class I HDAC. British journal of 
haematology 2013. 
351. Mandl-Weber, S., Meinel, F.G., Jankowsky, R., Oduncu, F., Schmidmaier, 
R., Baumann, P. The novel inhibitor of histone deacetylase resminostat 
 240 |References  
(ras2410) inhibits proliferation and induces apoptosis in multiple myeloma (mm) 
cells. Br. J. Haematol. 2010, 149, 518-528. 
352. Brunetto, A.T., Ang, J.E., Lal, R., Olmos, D., Frentzas, S., Mais, A., Hauns, 
B., Mollenhauer, M., Lahu, G., de Bono, J.S. A first-in-human phase I study of 
4sc-201, an oral histone deacetylase (hdac) inhibitor, in patients with advanced 
solid tumors. J. Clin. Oncol. 2009, 27, 3530. 
353. Bitzer, M., Horger, M., Ganten, T.M., Lauer, U.M., Woerns, M.A., Siveke, 
J.T., Dollinger, M.M., Gerken, G., Wege, H., Giannini, E.G., Hentsch, B. 
Efficacy, safety, tolerability, and pk of the hdac inhibitor resminostat in 
sorafenib-refractory hepatocellular carcinoma (hcc): Phase II shelter study. J. 
Clin. Oncol. 2012, 30, 4115. 
354. Grassadonia, A., Cioffi, P., Simiele, F., Iezzi, L., Zilli, M., Natoli, C. Role of 
Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the 
Treatment of Solid Malignancies. Cancers 2013, 5, 919-942. 
355. A) Massa, S., Mai, A., Sbardella, G., Esposito, M., Ragno, R., Loidl, P., 
Brosch, G. 3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a New Class 
of Synthetic Histone Deacetylase Inhibitors. J. Med. Chem. 2001, 44, 2069-
2072. B) Mai, A., Massa, S., Cerbara, I., Valente, S., Ragno, R., Bottoni, P., 
Scatena, R., Loidl, P., Brosch, G. 3-(4-Aroyl-1-methyl-1H-2- pyrrolyl)-N-
hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase 
Inhibitors. 2. Effect of Pyrrole C2 and/or C4 Substitutions on Biological 
Activity. J. Med. Chem. 2004, 47, 1098-1109. C) Mai, A., Valente, S., 
Nebbioso, A., Simeoni, S., Ragno, R., Massa, S., Altucci, L. New pyrrole-based 
histone deacetylase inhibitors: Binding mode, enzyme-and cell-based 
investigations. The International Journal of Biochemistry & Cell Biology 2009, 
41, 235-247. 
356. Illi, B., Russo, C. D., Colussi, C., Rosati, J., Pallaoro, M., Spallotta, F., Rotili, 
D., Valente, S., Ragone, G., Martelli, F., Biglioli, P., Steinkuhler, C., Gallinari, 
P., Mai, A., Capogrossi M. C., Gaetano, C. Nitric oxide modulates chromatin 
folding in human endothelial cells via protein phosphatase 2A activation and 
class II histone deacetylases nuclear shuttling. Circulation research 2008, 102, 
51-58. 
357. Venza, I., Visalli, M., Oteri, R., Cucinotta, M., Teti, D., Venza, M. Class 
II‐specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL‐8 
expression in human melanoma cells. Pigment cell & melanoma research 2013. 
358. Closse, A.; Huguenin, R. Isolation and structural clarification of 
chlamydocin. Helv. Chim. Acta 1974, 57, 533-545. 
359. Singh, S. B., Zink, D. L., Polishook, J. D., Dombrowski, A. W., Darkin-
Rattray, S. J., Schmatz, D. M., Goetz, M. A. Apicidins: novel cyclic 
tetrapeptides as coccidiostats and antimalarial agents from Fusarium 
pallidoroseum. Tetrahedron Lett. 1996, 37, 8077-8080. 
360. Colletti, S. L., Myers, R. W., Darkin-Rattray, S. J., Gurnett, A. M., Dulski, P. 
M., Galuska, S., Meinke, P. T. Broad spectrum antiprotozoal agents that inhibit 
 241 |References  
histone deacetylase: structure-activity relationships of apicidin. Part 1. Bioorg. 
Med. Chem. Lett. 2001, 11, 107-111. 
361. Komatsu, Y., Tomizaki, K., Tsukamoto, M., Kato, T. Cyclic Hydroxamic-
acid-containing Peptide 31, a potent synthetic histone deacetylase inhibitor with 
antitumor activity. Cancer Res. 2001, 61, 4459- 4466. 
362. Ueda, H., Nakajima, H., Hori, Y., Fujita, T., Nishimura, M., Goto, T., 
Okuhara, M. FR901228, a novel antitumor bicyclic depsipeptide produced by 
Chromobacterium violaceum n
o
. 968. J Antibiot. 1994, 47, 301-310.  
363. Furumai, R., Matsuyama, A., Kobashi, N., Lee, K.H., Nishiyama, M., 
Nakajima, H., Tanaka, A., Komatsu, Y., Nishino, N., Yoshida, M., Horinouchi, 
S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone 
deacetylases. Cancer Res. 2002, 62, 4916-4921. 
364. Mwakwari, S. C., Patil, V., Guerrant, W., Oyelere, A. K. Macrocyclic histone 
deacetylase inhibitors. Current topics in medicinal chemistry 2010, 10, 1423. 
365. Chen, J. S., Faller, D. V. Short-chain fatty acid inhibitors of histone 
deacetylases: promising anticancer.Curr. Cancer Drug Targets 2003, 3, 219-
236. 
366. Watson, J., Glasg, M. B. Butyric acid in the treatment of cancer. Lancet 1933, 
746-748. 
367. Kim, S. W., Hooker, J. M., Otto, N., Win, K., Muench, L., Shea, C., Fowler, 
J. S. Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, 
valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs 
by PET. Nuclear medicine and biology 2013, 40, 912-918. 
368. Gottlicher, M., Minucci, S., Zhu, P., Kramer, O.H., Schimpf, A., Giavara, S., 
Sleeman, J.P., Lo Coco, F., Nervi, C., Pelicci, P.G., Heinzel, T. Valproic acid 
defines a novel class of HDAC inhibitors inducing differentiation of transformed 
cells. EMBO J 2001, 20, 6969-6978. 
369. Ververis, K., Hiong, A., Karagiannis, T. C., Licciardi, P. V. Histone 
deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics: 
targets & therapy 2013, 7, 47. 
370. Soriano, A. O., Yang, H., Faderl, S., Estrov, Z., Giles, F., Ravandi, F., 
Garcia-Manero, G. Safety and clinical activity of the combination of 5-
azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia 
and myelodysplastic syndrome. Blood. 2007, 110, 2302-2308. 
371. Candelaria, M., Gallardo-Rincón, D., Arce, C., Cetina, L., Aguilar-Ponce, J. 
L., Arrieta, O., Duenas-Gonzalez, A. A phase II study of epigenetic therapy with 
hydralazine and magnesium valproate to overcome chemotherapy resistance in 
refractory solid tumors. Ann Oncol. 2007, 18, 1529-1538. 
372. Suzuki, T., Ando, T., Tsuchiya, K., Fukazawa, N., Saito, A., Mariko, Y., 
Nakanishi, O. Synthesis and histone deacetylase inhibitory activity of new 
benzamide derivatives. Journal of medicinal chemistry 1999, 42, 3001-3003. 
373. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., 
Suzuki, T., Tsuruno, T., Nakanishi, O. A synthetic inhibitor of histone 
 242 |References  
deacetylase, MS-27-275, with marked in vivo antitumor activity against human 
tumors. Proc. Natl. Acad.Sci. U.S.A. 1999, 96, 4592-4597. 
374. Kummar, S., Gutierrez, M., Gardner, E. R., Donovan, E., Hwang, K., Chung, 
E. J., Murgo, A. J. Phase I trial of MS-275, a histone deacetylase inhibitor, 
administered weekly in refractory solid tumors and lymphoid malignancies. Clin 
Cancer Res. 2007, 13, 5411-5417.  
375.  Gore, L., Rothenberg, M. L., O'Bryant, C. L., Schultz, M. K., Sandler, A. B., 
Coffin, D., Eckhardt, S. G. A phase I and pharmacokinetic study of the oral 
histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors 
and lymphomas. Clin Cancer Res. 2008, 14, 4517-4525.  
376. Gojo, I., Jiemjit, A., Trepel, J. B., Sparreboom, A., Figg, W. D., Rollins, S., 
Karp, J. E. Phase 1 and pharmacologic study of MS-275, a histone deacetylase 
inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007, 
109, 2781-2790. 
377. Wozniak, A., O'Shaughnessy, J., Fiorica, J., Grove, W. Phase II trial of CI-
994 in patients (pts) with advanced nonsmall cell lung cancer (NSCLC). Proc 
Am Soc Clin Oncol. 1999, 18.  
378. Copley-Merriman, K., Von Pawel, J.,Shepherd F. Randomized phase 2 study 
of the oral histone deacetylase inhibitor CI-994 plus gemcitabine vs placebo plus 
gemcitabine in second-line nonsmall cell lung cancer (NSCLC): health-related 
quality of life results. Proc Am Soc Clin Oncol 2002, 21, 324. 
379. Le Tourneau, C., Siu, L.L. Promising antitumor activity with MGCD0103, a 
novel isotypeselective histone deacetylase inhibitor. Expert Opin Investig Drugs 
2008, 17, 1247-1254. 
380. Jackson, M. D., Schmidt, M. T., Oppenheimer, N. J., Denu, J. M. Mechanism 
of nicotinamide inhibition and transglycosidation by Sir2 histone/protein 
deacetylases. J. Biol. Chem. 2003, 278, 50985-50998. 
381. Fatkins, D. G., Zheng, W. Substituting Nε-thioacetyl-lysine for Nε-acetyl-
lysine in peptide substrates as a general approach to inhibiting human NAD
+
-
dependent protein deacetylases. International journal of molecular sciences 
2008, 9, 1-11. 
382. Smith, B.C., Denu, J.M. Mechanism-based inhibition of Sir2 deacetylases by 
thioacetyl-lysine peptide. Biochemistry 2007, 46, 14478-14486. 
383. Kiviranta, P.H., Suuronen, T., Wallén, E.A., Leppänen, J., Tervonen, J., 
Kyrylenko, S., Salminen, A., Poso, A., Jarho, E.M. N(epsilon)-thioacetyl-lysine-
containing tri-, tetra-, and pentapeptides as SIRT1 and SIRT2 inhibitors. J Med 
Chem. 2009, 52, 2153-2156.  
384. Suzuki, T., Asaba, T., Imai, E., Tsumoto, H., Nakagawa, H., Miyata, N. 
Identification of a cell-active non-peptide sirtuin inhibitor containing N-
thioacetyl lysine. Bioorganic & medicinal chemistry letters 2009, 19, 5670-
5672. 
385. Grozinger, C. M., Chao, E. D., Blackwell, H. E., Moazed, D., and Schreiber, 
S. L. Identification of a class of small molecule inhibitors of the sirtuin family of 
 243 |References  
NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 2001, 
276, 38837-38843. 
386. Ota, H., Tokunaga, E., Chang, K., Hikasa, M., Iijima, K., Eto, M., Kaneki, M. 
Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated 
Ras-MAPK signaling in human cancer cells. Oncogene 2006, 25, 176-185. 
387. Orecchia, A., Scarponi, C., Di Felice, F., Cesarini, E., Avitabile, S, Mai, A., 
Failla, C. M. Sirtinol treatment reduces inflammation in human dermal 
microvascular endothelial cells. PLoS One 2011, 6, e24307. 
388. A) Mai, A., Massa, S., Lavu, S., Pezzi, R., Simeoni, S., Ragno, R., Sinclair, 
D. A. Design, synthesis, and biological evaluation of sirtinol analogues as class 
III histone/protein deacetylase (Sirtuin) inhibitors. J. Med. Chem. 2005, 48, 
7789-7795. B) Lara, E., Mai, A., Calvanese, V., Altucci, L., Lopez-Nieva, P., 
Martinez-Chantar, M. L., Fraga, M. F. Salermide, a Sirtuin inhibitor with a 
strong cancer-specific proapoptotic effect. Oncogene 2009, 28, 781-791. 
389. Heltweg, B., Gatbonton, T., Schuler, A. D., Posakony, J., Li, H., Goehle, S., 
Bedalov, A. Antitumor activity of a smallmolecule inhibitor of human silent 
information regulator 2 enzymes. Cancer. Res. 2006, 66, 4368-4377. 
390. Medda, F., Russell, R. J., Higgins, M., McCarthy, A. R., Campbell, J., 
Slawin, A. M., Westwood, N. J. Novel cambinol analogs as sirtuin inhibitors: 
synthesis, biological evaluation, and rationalization of activity. J. Med. Chem. 
2009, 52, 2673-2682. 
391. Howitz, K.T., Bitterman, K.J., Cohen, H.Y., Lamming, D.W., Lavu, S., 
Wood, J.G., Zipkin, R.E., Chung, P., Kisielewski, A., Zhang, L.L., Scherer, B., 
Sinclair, D.A. Small molecule activators of sirtuins extend Saccharomyces 
cerevisiae lifespan, Nature 2003, 425, 191-196. 
392. Trapp, J., Meier, R., Hongwiset, D., Kassack, M. U., Sippl, W., Jung, M. 
Structure- activity studies on suramin analogues as inhibitors of NAD
+
-
dependent histone deacetylases (sirtuins). ChemMedChem 2007, 2, 1419-1431. 
393. Schuetz, A., Min, J., Antoshenko, T., Wang, C. L., Allali-Hassani, A., Dong, 
A., Plotnikov, A. N. Structural basis of inhibition of the human NAD
+
-
dependent deacetylase SIRT5 by suramin. Structure 2007, 15, 377-389. 
394. Bedalov, A., Gatbonton, T., Irvine, W. P., Gottschling, D. E., Simon, J. A. 
Identification of a small molecule inhibitor of Sir2p. Proc. Natl. Acad. Sci. USA 
2001, 98, 15113-15118. 
395. Posakony, J., Hirao, M., Stevens, S., Simon, J. A., Bedalov, A. Inhibitors of 
Sir2: evaluation of splitomicin analogues. Journal of medicinal chemistry 2004, 
47, 2635-2644. 
396. Napper, A. D., Hixon, J., McDonagh, T., Keavey, K., Pons, J. F., Barker, J., 
Curtis, R. Discovery of indoles as potent and selective inhibitors of the 
deacetylase SIRT1. Journal of medicinal chemistry 2005, 48, 8045-8054. 
397. Solomon, J. M., Pasupuleti, R., Xu, L., McDonagh, T., Curtis, R., DiStefano, 
P. S., Huber, L. J. Inhibition of SIRT1 catalytic activity increases p53 
 244 |References  
acetylation but does not alter cell survival following DNA damage. Molecular 
and cellular biology 2006, 26, 28-38. 
398. Gertz, M., Fischer, F., Nguyen, G. T. T., Lakshminarasimhan, M., 
Schutkowski, M., Weyand, M., Steegborn, C. Ex-527 inhibits Sirtuins by 
exploiting their unique NAD
+
-dependent deacetylation mechanism. Proceedings 
of the National Academy of Sciences 2013, 110, 2772-2781. 
399. Outeiro, T.F., Kontopoulos, E., Altmann, S.M., Kufareva, I., Strathearn, K.E., 
Amore, A.M., Volk, C.B., Maxwell, M.M., Rochet, J.C., McLean, P.J., Young, 
A.B., Abagyan, R., Feany, M.B., Hyman, B.T., Kazantsev, A.G. Sirtuin 2 
inhibitors rescue alphasynuclein- mediated toxicity in models of Parkinson's 
disease. Science 2007, 317, 516-519. 
400. Garske, A.L., Smith, B.C., Denu, J.M. Linking SIRT2 to Parkinson's disease. 
ACS Chem. Biol. 2007, 2, 529-532. 
401. Jin, L., Galonek, H., Israelian, K., Choy, W., Morrison, M., Xia, Y., 
Westphal, C. H. Biochemical characterization, localization, and tissue 
distribution of the longer form of mouse SIRT3. Protein Science 2009, 18,514-
525. 
402. Nguyen, G. T. T., Schaefer, S., Gertz, M., Weyand, M., Steegborn, C. 
Structures of human sirtuin 3 complexes with ADP-ribose and with carba-NAD
+
 
and SRT1720: binding details and inhibition mechanism. Acta 
Crystallographica Section D: Biological Crystallography 2013, 69, 1423-1432. 
403. Trapp, J., Jochum, A., Meier, R., Saunders, L., Marshall, B., Kunick, C., 
Jung, M. Adenosine mimetics as inhibitors of NAD
+
-dependent histone 
deacetylases, from kinase to sirtuin inhibition. Journal of medicinal chemistry 
2006, 49, 7307-7316. 
404. Suenkel, B., Fischer, F., Steegborn, C. Inhibition of the human deacylase 
Sirtuin 5 by the indole GW5074. Bioorg. Med. Chem. Lett., 2013, 23, 143-147. 
405. Murray, K. The occurrence of ε-N-methyl lysine in histones. Biochemistry 
1964, 3, 10-15. 
406. Paik, W. K., Kim, S. ε-N-dimethyllysine in histones. Biochem.Biophys. Res. 
Commun. 1967, 27, 479-483. 
407. Gershey, E. L., Haslett, G. W., Vidali, G., Allfrey, V. G. Chemical studies of 
histone methylation. Evidence for the occurrence of 3-methylhistidine in avian 
erythrocyte histone fractions. J. Biol. Chem. 1969, 244, 4871-4877. 
408. Greer, E. L., Shi, Y. Histone methylation: a dynamic mark in health, disease 
and inheritance. Nature Reviews Genetics 2012, 13, 343-357. 
409. Suzuki, T., Terashima, M., Tange, S., Ishimura, A. Roles of histone 
methyl‐modifying enzymes in development and progression of cancer. Cancer 
science 2013, 104, 795-800. 
410. Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Shi, 
Y Histone demethylation mediated by the nuclear amine oxidase homolog 
LSD1. Cell 2004, 119, 941-953. 
 245 |References  
411. Zhang, Y. and D. Reinberg. Transcription regulation by histone methylation: 
interplay between different covalent modifications of the core histone tails. 
Genes Dev 2001, 15, 2343-2360. 
412. Krivtsov, A.V., Armstrong, S.A. MLL translocations, histone modifications 
and leukaemia stem-cell development. Nat Rev Cancer 2007, 7, 823-833. 
413. Li, Z., Luo, R. T., Mi, S., Sun, M., Chen, P., Bao, J., Thirman, M. J. 
Consistent deregulation of gene expression between human and murine MLL 
rearrangement leukemias. Cancer Res 2009, 69, 1109-1116. 
414. Kroon, E., Krosl, J., Thorsteinsdottir, U., Baban, S., Buchberg, A.M., 
Sauvageau, G. Hoxa9 transforms primary bone marrow cells through specific 
collaboration with Meis1a but not Pbx1b. EMBO J 1998,17, 3714-3725. 
415. Okada, Y., Feng, Q., Lin, Y., Jiang, Q., Li, Y., Coffield, V. M., Zhang, Y. 
hDOT1L links histone methylation to leukemogenesis. Cell 2005, 12, 167-178. 
416. Balakrishnan, A., Bleeker, F.E., Lamba, S., Rodolfo, M., Daniotti, M., 
Scarpa, A., van Tilborg, A.A., Leenstra, S., Zanon, C., Bardelli, A. Novel 
somatic and germline mutations in cancer candidate genes in glioblastoma, 
melanoma, and pancreatic carcinoma. Cancer Res. 2007, 67, 3545-3550. 
417. Madan, V., Madan, B., Brykczynska, U., Zilbermann, F., Hogeveen, K., 
Dohner, K., Dohner, H., Weber, O., Blum, C., Rodewald, H.R., Sassone-Corsi, 
P., Peters, A.H., Fehling, H.J. Impaired function of primitive hematopoietic cells 
in mice lacking the Mixed-Lineage-Leukemia homolog MLL5. Blood 2009, 113, 
1444-1454. 
418. Strahl, B.D., Grant, P.A., Briggs, S.D., Sun, Z.W., Bone, J.R., Caldwell, J.A., 
Allis, C. D. Set2 is a nucleosomal histone H3-selective methyltransferase that 
mediates transcriptional repression. Mol Cell Biol 2002, 22, 1298-306. 
419. Nimura, K., Ura, K., Shiratori, H., Ikawa, M., Okabe, M., Schwartz, R. J., & 
Kaneda, Y. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf–
Hirschhorn syndrome. Nature 2009, 460, 287-291. 
420. Rayasam, G. V., Wendling, O., Angrand, P. O., Mark, M., Niederreither, K., 
Song, L., Losson, R.. NSD1 is essential for early post-implantation development 
and has a catalytically active SET domain. EMBO J 2003, 22, 3153-3163. 
421. Wang, G.G., Cai, L., Pasillas, M.P., Kamps, M.P. NUP98-NSD1 links 
H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell 
Biol 2007, 9, 804-812. 
422. Kim, J. Y., Kee, H. J., Choe, N. W., Kim, S. M., Eom, G. H., Baek, H. J., 
Seo, S. B. Multiple myeloma- related WHSC1/MMSET isoform RE-IIBP is a 
histone methyltransferase with transcriptional repression activity. Mol Cell Biol 
2008, 28, 2023-2034 
423. Marango, J., Shimoyama, M., Nishio, H., Meyer, J. A., Min, D. J., Sirulnik, 
A., Licht, J. D. The MMSET protein is a histone methyltransferase with 
characteristics of a transcriptional corepressor. Blood 2008, 111, 3145-3154. 
 246 |References  
424. Angrand, P. O., Apiou, F., Stewart, A. F., Dutrillaux, B., Losson, R., 
Chambon, P.NSD3, a new SET domain-containing gene, maps to 8p12 and is 
amplified in human breast cancer cell lines. Genomics 2001, 74, 79-88. 
425. Rosati, R., La Starza, R., Veronese, A., Aventin, A., Schwienbacher, C., 
Vallespi, T., Mecucci, C. NUP98 is fused to the NSD3 gene in acute myeloid 
leukemia associated with t(8;11)(p11.2;p15). Blood 2002, 99, 3857-3860. 
426. Kirmizis, A., Bartley, S. M., Kuzmichev, A., Margueron, R., Reinberg, D., 
Green, R., & Farnham, P. J. Silencing of human polycomb target genes is 
associated with methylation of histone H3 Lys 27. Genes Dev. 2004, 18,1592-
1605. 
427. Saramäki, O. R., Tammela, T. L., Martikainen, P. M., Vessella, R. L., & 
Visakorpi, T. The gene for polycomb group protein enhancer of zeste homolog 2 
(EZH2) is amplified in late-stage prostate cancer. Genes Chromosom. Cancer 
2006, 45, 639-645. 
428. Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., 
Chinnaiyan, A. M. EZH2 is a marker of aggressive breast cancer and promotes 
neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 
2003, 100, 11606-11611. 
429. Morin, R. D., Johnson, N. A., Severson, T. M., Mungall, A. J., An, J., Goya, 
R., Paul, J.E., Boyle, M., Woolcock, B.W., Kuchenbauer, FYap, ., D., 
Humphries, R.K., Griffith, O.L., Shah, S., Zhu, H., Kimbara, M., Shashkin, P., 
Charlot, J.F., Tcherpakov, M., Corbett, R., Marra, M.A. Somatic mutations 
altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of 
germinal-center origin. Nat.Genet. 2010, 42, 181-185. 
430. Tachibana, M., Ueda, J., Fukuda, M., Takeda, N., Ohta, T., Iwanari, H., 
Shinkai, Y. Histone methyltransferases G9a and GLP form heteromeric 
complexes and are both crucial for methylation of euchromatin at H3-K9. Genes 
Dev. 2005, 19, 815-826. 
431. Wu, H., Chen, X., Xiong, J., Li, Y., Li, H., Ding, X., Liu, S., Chen, S., Gao, 
S., Zhu, B. Histone methyltransferase G9a contributes to H3K27 methylation in 
vivo. Cell Res 2011, 21, 365-367. 
432. Weiss, T., Hergeth, S., Zeissler, U., Izzo, A., Tropberger, P., Zee, B.M., 
Dundr, M., Garcia, B.A., Daujat, S., Schneider, R. Research histone H1 variant-
specific lysine methylation by G9a/KMT1C and Glp1/KMT1D. Epigenetics 
Chromatin 2010, 3, 7.  
433. Rountree, M.R., Selker, E.U. DNA methylation and the formation of 
heterochromatin in Neurospora crassa. Heredity 2010, 105, 38-44. 
434. Estève, P. O., Chin, H. G., Smallwood, A., Feehery, G. R., Gangisetty, O., 
Karpf, A. R., Pradhan, S. Direct interaction between DNMT1 and G9a 
coordinates DNA and histone methylation during replication. Genes Dev 2006, 
20, 3089-3103. 
435. Chen, M. W., Hua, K. T., Kao, H. J., Chi, C. C., Wei, L. H., Johansson, G., 
Kuo, M. L. H3K9 histone methyltransferase G9a promotes lung cancer invasion 
 247 |References  
and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 
2010, 70, 7830-7840. 
436. Shinkai, Y., Tachibana, M. H3K9 methyltransferase G9a and the related 
molecule GLP. Genes & development 2011, 25, 781-788. 
437. Lehnertz, B., Ueda, Y., Derijck, A.A., Braunschweig, U., Perez-Burgos, L., 
Kubicek, S., Chen, T., Li, E., Jenuwein, T., Peters, A.H.Suv39h-mediated 
histone H3 lysine 9 methylation directs DNA methylation to major satellite 
repeats at pericentric heterochromatin. Curr Biol 2003, 13, 1192-1200. 
438. Rice, J. C., Briggs, S. D., Ueberheide, B., Barber, C. M., Shabanowitz, J., 
Hunt, D. F., Allis, C. D. Histone methyltransferases direct different degrees of 
methylation to define distinct chromatin domains. Mol. Cell 2003, 12, 1591-
1598. 
439. Kim, K. C., Geng, L., Huang, S. Inactivation of a histone methyltransferase 
by mutations in human cancers. Cancer Res. 2003, 63, 7619-7623. 
440. Rea, S., Eisenhaber, F., O'Carroll, D., Strahl, B. D., Sun, Z. W., Schmid, M., 
Jenuwein, T. Regulation of chromatin structureby site-specific histone H3 
methyltransferases, Nature 2000, 406, 593-599. 
441. Nielsen, S. J., Schneider, R., Bauer, U. M., Bannister, A. J., Morrison, A., 
O'Carroll, D., Kouzarides, T. Rb targets histone H3 methylation and HP1 to 
promoters. Nature 2001, 412, 561-565. 
442. Du, Y., Carling, T., Fang, W., Piao, Z., Sheu, J. C., Huang, S. 
Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a 
member of a histone/ protein methyltransferase superfamily. Cancer Res. 2001, 
61, 8094-8099.  
443. Tokumaru, Y., Nomoto, S., Jerónimo, C., Henrique, R., Harden, S., Trink, B., 
Sidransky, D. Biallelic inactivation of the RIZ1 gene in human gastric cancer. 
Oncogene 2003, 22, 6954-6958. 
444. Varier, R. A., Timmers, H. T. Histone lysine methylation and demethylation 
pathways in cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 
2011, 1815, 75-89. 
445. Metzger, E., Wissmann, M., Yin, N., Muller, J.M., Schneider, R., Peters, 
A.H., Gunther, T., Buettner, R., Schule, R. LSD1 demethylates repressive 
histone marks to promote androgen receptor- dependent transcription. Nature 
2005, 437, 436-439. 
446. Huang, J., Sengupta, R., Espejo, A. B., Lee, M. G., Dorsey, J. A., Richter, M., 
Berger, S. L.. p53 is regulated by the lysine demethylase LSD1. Nature 2007, 
449, 105-108.  
447. Wang, J., Hevi, S., Kurash, J. K., Lei, H., Gay, F., Bajko, J., Chen, T. The 
lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA 
methylation. Nature Genet. 2009, 41, 125-129. 
448. Kontaki, H., Talianidis, I. Lysine methylation regulates E2F1-induced cell 
death. Mol. Cell 2010, 39, 152-160. 
 248 |References  
449. Karytinos, A., Forneris, F., Profumo, A., Ciossani, G., Battaglioli, E., Binda, 
C., Mattevi, A. A novel mammalian flavin-dependent histone demethylase. 
Journal of Biological Chemistry 2009, 284, 17775-17782. 
450. Forneris, F., Binda, C., Battaglioli, E., Mattevi, A. LSD1: oxidative chemistry 
for multifaceted functions in chromatin regulation. Trends in biochemical 
sciences 2008, 33, 181-189. 
451. Garcia-Bassets, I., Kwon, Y. S., Telese, F., Prefontaine, G. G., Hutt, K. R., 
Cheng, C. S., Rosenfeld, M. G. Histone methylation-dependent mechanisms 
impose ligand dependency for gene activation by nuclear receptors. Cell 2007, 
128, 505-518. 
452. Forneris, F., Binda, C., Vanoni, M. A., Battaglioli, E., Mattevi, A. Human 
histone demethylase LSD1 reads the histone code. Journal of Biological 
Chemistry 2005, 280, 41360-41365. 
453. Culhane, J. C., Cole, P. A. LSD1 and the chemistry of histone demethylation. 
Current opinion in chemical biology 2007, 11, 561-568. 
454. Chen, Y., Yang, Y., Wang, F., Wan, K., Yamane, K., Zhang, Y., Lei, M. 
Crystal structure of human histone lysine-specific demethylase 1 (LSD1). Proc. 
Natl. Acad. Sci. 2006,103,13956-13961.  
455. Stavropoulos, P., Blobel, G., Hoelz, A. Crystal structure and mechanism of 
human lysine-specific demethylase-1. Nature structural & molecular biology 
2006, 13, 626-632. 
456. Binda, C., Coda, A., Angelini, R., Federico, R., Ascenzi, P., Mattevi, A. A 30 
Å long U-shaped catalytic tunnel in the crystal structure of polyamine oxidase. 
Structure 1999, 7, 265-276. 
457. Binda, C., Angelini, R., Federico, R., Ascenzi, P., Mattevi, A. Structural 
bases for inhibitor binding and catalysis in polyamine oxidase. Biochemistry 
2001, 40, 2766-2776. 
458. Wissmann, M., Yin, N., Müller, J. M., Greschik, H., Fodor, B. D., Jenuwein, 
T., Schüle, R. Cooperative demethylation by JMJD2C and LSD1 promotes 
androgen receptor-dependent gene expression. Nature cell biology 2007, 9, 347-
353. 
459. Hu, Q., Kwon, Y. S., Nunez, E., Cardamone, M. D., Hutt, K. R., Ohgi, K. A., 
Fu, X. D. Enhancing nuclear receptor-induced transcription requires nuclear 
motor and LSD1-dependent gene networking in interchromatin granules. Proc 
Natl Acad Sci U S A 2008, 105, 19199-19204. 
460. Dallman, J. E., Allopenna, J., Bassett, A., Travers, A., & Mandel, G. A 
conserved role but different partners for the transcriptional corepressor CoREST 
in fly and mammalian nervous system formation. J Neurosci 2004, 24, 7186-
7193. 
461. Saleque, S., Kim, J., Rooke, H. M., Orkin, S. H. Epigenetic regulation of 
hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors 
CoREST and LSD1. Mol Cell 2007, 27, 562-572. 
 249 |References  
462. Su, S. T., Ying, H. Y., Chiu, Y. K., Lin, F. R., Chen, M. Y., Lin, K. I. 
Involvement of histone demethylase LSD1 in Blimp-1-mediated gene repression 
during plasma cell differentiation. Mol Cell Biol 2009, 29, 1421-1431. 
463. Tsai, W. W., Nguyen, T. T., Shi, Y., & Barton, M. C. p53-targeted LSD1 
functions in repression of chromatin structure and transcription in vivo. Mol Cell 
Biol 2008, 28, 5139-5146. 
464. Liu, L., Souto, J., Liao, W., Jiang, Y., Li, Y., Nishinakamura, R., Yang, J. 
Histone lysine-specific demethylase 1 (LSD1) protein is involved in Sal-like 
Protein 4 (SALL4)-mediated transcriptional repression in hematopoietic stem 
cells. Journal of Biological Chemistry 2013, 288, 34719-34728. 
465. Ooi, S. K., Qiu, C., Bernstein, E., Li, K., Jia, D., Yang, Z., Bestor, T. H. 
DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation 
of DNA. Nature 2007, 448, 714-717. 
466. Lin, T., Ponn, A., Hu, X., Law, B. K., Lu, J. Requirement of the histone 
demethylase LSD1 in Snai1-mediated transcriptional repression during 
epithelial-mesenchymal transition. Oncogene 2010, 29, 4896-4904. 
467. Baron, R., Binda, C., Tortorici, M., McCammon, J. A., Mattevi, A. Molecular 
mimicry and ligand recognition in binding and catalysis by the histone 
demethylase LSD1-CoREST complex. Structure 2011, 19, 212-220. 
468. Forneris, F., Binda, C., Adamo, A., Battaglioli, E., Mattevi, A. Structural 
basis of LSD1-CoREST selectivity in histone H3 recognition. Journal of 
Biological Chemistry 2007, 282, 20070-20074. 
469. Barrallo-Gimeno, A., Nieto, M.A. Evolutionary history of the Snail/ Scratch 
superfamily. Trends Genet. 2009, 25, 248-252. 
470. Peinado, H., Olmeda, D., Cano, A. Snail, Zeb and bHLH factors in tumour 
progression: an alliance against the epithelial phenotype?. Nature Reviews 
Cancer 2007, 7, 415-428. 
471. Kahl, P., Gullotti, L., Heukamp, L. C., Wolf, S., Friedrichs, N., Vorreuther, 
R., Buettner, R. Androgen receptor coactivators lysine-specific histone 
demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate 
cancer recurrence. Cancer research 2006, 66, 11341-11347.  
472. Kauffman, E. C., Robinson, B. D., Downes, M. J., Powell, L. G., Lee, M. M., 
Scherr, D. S., Mongan, N. P. Role of androgen receptor and associated lysine-
demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human 
bladder cancer. Mol. Carcinog. 2011, 50, 931-944. 
473. Schulte, J. H., Lim, S., Schramm, A., Friedrichs, N., Koster, J., Versteeg, R., 
Kirfel, J. Lysine-specific demethylase 1 is strongly expressed in poorly 
differentiated neuroblastoma: implications for therapy. Cancer Res. 2009, 69, 
2065-2071. 
474. Lv, T., Yuan, D., Miao, X., Lv, Y., Zhan, P., Shen, X., & Song, Y. Over-
expression of LSD1 promotes proliferation, migration and invasion in non-small 
cell lung cancer PLoS One 2012, 7, e35065. 
 250 |References  
475. Zhao, Z. K., Dong, P., Gu, J., Chen, L., Zhuang, M., Lu, W. J., Liu, Y. B. 
Overexpression of LSD1 in hepatocellular carcinoma: a latent target for the 
diagnosis and therapy of hepatoma. Tumor Biology 2013, 34, 173-180.  
476. Hayami, S., Kelly, J. D., Cho, H. S., Yoshimatsu, M., Unoki, M., Tsunoda, 
T., Hamamoto, R. Overexpression of LSD1 contributes to human carcinogenesis 
through chromatin regulation in various cancers. Int. J. Cancer 2011, 128, 574-
586. 
477. L.P. Vu, L. Luciani, S.D. Nimer Histone-modifying enzymes: their role in the 
pathogenesis of acute leukemia and their therapeutic potential Int. J. Hematol. 
2013, 1-12. 
478. Lokken, A. A., Zeleznik-Le, N. J. Breaking the LSD1/KDM1A addiction: 
therapeutic targeting of the epigenetic modifier in AML. Cancer Cell 2012, 21, 
451-453. 
479. Harris, W. J., Huang, X., Lynch, J. T., Spencer, G. J., Hitchin, J. R., Li, Y., 
Somervaille, T. C. The histone demethylase KDM1A sustains the oncogenic 
potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21, 473-487. 
480. Amente, S., Lania, L., Majello, B. The histone LSD1 demethylase in 
stemness and cancer transcription programs. Biochimica et Biophysica Acta 
(BBA)-Gene Regulatory Mechanisms 2013, 1829, 981-986. 
481. Yatim, A., Benne, C., Sobhian, B., Laurent-Chabalier, S., Deas, O., Judde, J. 
G., Benkirane, M. NOTCH1 nuclear interactome reveals key regulators of its 
transcriptional activity and oncogenic function. Mol. Cell 2012, 48, 445-458. 
482. Yang ,Z., Jiang, J., Stewart, D.M., Qi, S., Yamane, K., Li, J., Zhang, Y., 
Wong, J. AOF1 is a histone H3K4 demethylase possessing demethylase activity-
independent repression function. Cell Res 2010, 20, 276-287.  
483. Højfeldt, J. W., Agger, K., Helin, K. Histone lysine demethylases as targets 
for anticancer therapy. Nature Reviews Drug Discovery 2013. 
484. Fang, R., Chen, F., Dong, Z., Hu, D., Barbera, A. J., Clark, E. A., Shi, Y. G. 
LSD2/KDM1B and its cofactor NPAC/ GLYR1 endow a structural and 
molecular model for regulation of H3K4 demethylation. Mol. Cell 2013, 49, 
558-570. 
485. Fang, R., Barbera, A.J., Xu, Y., Rutenberg, M., Leonor, T., Bi, Q., Lan, F., 
Mei, P., Yuan, G.C., Lian, C., Shi, Y.G. Human LSD2/KDM1b/AOF1 regulates 
gene transcription by modulating intragenic H3K4me2 methylation. Mol Cell 
2010, 39, 222-233.  
486. Ciccone, D.N., Su, H., Hevi, S., Gay, F., Lei, H., Bajko, J., Xu, G., Li, E., 
Chen, T. KDM1B is a histone H3K4 demethylase required to establish maternal 
genomic imprints. Nature 2009, 46, 415-418.  
487. Takeuchi, T., Yamazaki, Y., Katoh-Fukui, Y., Tsuchiya, R., Kondo, S., 
Motoyama, J., Higashinakagawa, T. Gene trap capture of a novel mouse gene, 
jumonji, required for neural tube formation. Genes Dev. 1995, 9, 1211-1222. 
 251 |References  
488. Tsukada, Y. I., Fang, J., Erdjument-Bromage, H., Warren, M. E., Borchers, C. 
H., Tempst, P., Zhang, Y. Histone demethylation by a family of JmjC domain-
containing proteins. Nature 2005, 439, 811-816. 
489. Arrowsmith, C.H., Bountra, C., Fish, P.V., Lee, K., Schapira, M.. Epigenetic 
protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 2012, 
11, 384-400. 
490. McDonough, M. A., Loenarz, C., Chowdhury, R., Clifton, I. J., & Schofield, 
C. J. Structural studies on human 2-oxoglutarate dependent oxygenases. Current 
opinion in structural biology 2010, 20,659-672. 
491. Hoffmann, I., Roatsch, M., Schmitt, M. L., Carlino, L., Pippel, M., Sippl, W., 
Jung, M. The role of histone demethylases in cancer therapy. Molecular 
Oncology 2012, 6, 683-703. 
492. Ng, S.S., Kavanagh, K.L., McDonough, M.A., Butler, D., Pilka, E.S., 
Lienard, B.M.R., Bray, J.E., Savitsky, P., Gileadi, O., von Delft, F., Oppermann, 
U. Crystal structures of histone demethylase JMJD2A reveal basis for substrate 
specificity. Nature 2007, 448, 87-91. 
493. Han, Z., Liu, P., Gu, L., Zhang, Y., Li, H., Chen, S., Chai, J. Structural basis 
for histone demethylation by JHDM1. Front Sci 2007, 1, 52-61. 
494. Yue, W.W., Hozjan, V., Ge, W., Loenarz, C., Cooper, C.D.O., Schofield, 
C.J., Kavanagh, K.L., Oppermann, U., McDonough, M.A. Crystal structure of 
the PHF8 Jumonji domain, an Ne-methyl lysine demethylase. FEBS Lett 2010, 
584, 825-830. 
495. Chen, Z., Zang, J., Whetstine, J., Hong, X., Davrazou, F., Kutateladze, T. G., 
Zhang, G. Structural insights into histone demethylation by JMJD2 family 
members. Cell 2006, 125, 691-702. 
496. Couture, J. F., Collazo, E., Ortiz-Tello, P. A., Brunzelle, J. S. Trievel, R. C. 
Specificity and mechanism of JMJD2A, a trimethyllysine-specific histone 
demethylase. Nature Struct. Mol. Biol. 2007, 14, 689-695. 
497. Horton, J.R., Upadhyay, A.K., Qi, H.H., Zhang, X., Shi, Y., Cheng, X. 
Enzymatic and structural insights for substrate specificity of a family of jumonji 
histone lysine demethylases. Nat Struct Mol Biol 2010, 17, 38-43. 
498. He, J., Kallin, E. M., Tsukada, Y. I., Zhang, Y. The H3K36 demethylase 
Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15Ink4b. 
Nat Struct Mol Biol 2008, 15, 1169-1175. 
499. Lagarou, A., Mohd-Sarip, A., Moshkin, Y. M., Chalkley, G. E., Bezstarosti, 
K., Demmers, J. A., Verrijzer, C. P. dKDM2 couples histone H2A ubiquitylation 
to histone H3 demethylation during Polycomb group silencing. Genes & 
development 2008, 22, 2799-2810. 
500. Frescas, D., Guardavaccaro, D., Bassermann, F., Koyama-Nasu, R., Pagano, 
M. JHDM1B/FBXL10 is a nucleolar protein that represses transcription of 
ribosomal RNA genes. Nature 2007, 450, 309-313. 
 252 |References  
501. Wu, X., Johansen, J. V. & Helin, K. Fbxl10/Kdm2b recruits Polycomb 
repressive complex 1 to CpG islands and regulates H2A ubiquitylation. Mol. 
Cell 2013, 49, 1134-1146. 
502. Farcas, A. M., Blackledge, N. P., Sudbery, I., Long, H. K., McGouran, J. F., 
Rose, N. R., Klose, R. J. KDM2B links the Polycomb Repressive Complex 1 
(PRC1) to recognition of CpG islands. Elife 2012, 1, e00205. 
503. Suzuki, T., Minehata, K. I., Akagi, K., Jenkins, N. A., Copeland, N. G. 
Tumor suppressor gene identification using retroviral insertional mutagenesis in 
Blm-deficient mice. EMBO l 2006, 25, 3422-3431. 
504. Pfau, R., Tzatsos, A., Kampranis, S. C., Serebrennikova, O. B., Bear, S. E., & 
Tsichlis, P. N.. Members of a family of JmjC domain-containing oncoproteins 
immortalize embryonic fibroblasts via a JmjC domain-dependent process. Proc 
Natl Acad Sci U S A., 2008, 105, 1907-1912. 
505. Frescas, D., Guardavaccaro, D., Kuchay, S. M., Kato, H., Poleshko, A., 
Basrur, V., Pagano, M.. KDM2A represses transcription of centromeric satellite 
repeats and maintains the heterochromatic state. Cell Cycle 2008, 7, 3539-3547. 
506. Yamane, K., Toumazou, C., Tsukada, Y. I., Erdjument-Bromage, H., Tempst, 
P., Wong, J., & Zhang, Y. JHDM2A, a JmjC-containing H3K9 demethylase, 
facilitates transcription activation by androgen receptor. Cell 2006, 125, 483-
495. 
507. Heery, D. M., Kalkhoven, E., Hoare, S., Parker, M. G. A signature motif in 
transcriptional co-activators mediates binding to nuclear receptors. Nature 1997, 
387, 733-736. 
508. Inagaki, T., Tachibana, M., Magoori, K., Kudo, H., Tanaka, T., Okamura, M., 
Sakai, J. Obesity and metabolic syndrome in histone demethylase 
JHDM2a‐deficient mice. Genes to Cells 2009, 14, 991-1001. 
509. Liu, Z., Zhou, S., Liao, L., Chen, X., Meistrich, M., Xu, J. Jmjd1a 
demethylase-regulated histone modification is essential for cAMP-response 
element modulator-regulated gene expression and spermatogenesis. Journal of 
Biological Chemistry 2010, 285, 2758-2770. 
510. Krieg, A. J., Rankin, E. B., Chan, D., Razorenova, O., Fernandez, S., Giaccia, 
A. J.. Regulation of the histone demethylase JMJD1A by hypoxia-inducible 
factor 1α enhances hypoxic gene expression and tumor growth. Molecular and 
cellular biology 2010, 30, 344-353. 
511. Park, S. J., Kim, J. G., Son, T. G., Yi, J. M., Kim, N. D., Yang, K., Heo, K. 
The histone demethylase JMJD1A regulates adrenomedullin-mediated cell 
proliferation in hepatocellular carcinoma under hypoxia. Biochemical and 
biophysical research communications 2013, 434, 722-727. 
512. Hu, Z., Gomes, I., Horrigan, S. K., Kravarusic, J., Mar, B., Arbieva, Z., 
Westbrook, C. A. A novel nuclear protein, 5qNCA (LOC51780) is a candidate 
for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31. 
Oncogene 2001, 20, 6946-6954. 
 253 |References  
513. Brauchle, M., Yao, Z., Arora, R., Thigale, S., Clay, I., Inverardi, B., Ruffner, 
H. Protein complex interactor analysis and differential activity of KDM3 
subfamily members towards H3K9 methylation. PloS one 2013, 8, e60549. 
514. Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A. H., 
Schlegelberger, B., Schmitt, C. A. Oncogene-induced senescence as an initial 
barrier in lymphoma development. Nature 2005, 436, 660-665. 
515. Cloos, P. A., Christensen, J., Agger, K., Maiolica, A., Rappsilber, J., Antal, 
T., Helin, K. The putative oncogene GASC1 demethylates tri- and dimethylated 
lysine 9 on histone H3. Nature 2006, 442, 307-311. 
516. Liu, G., Bollig-Fischer, A., Kreike, B., van de Vijver, M. J., Abrams, J., 
Ethier, S. P., Yang, Z. Q. Genomic amplification and oncogenic properties of the 
GASC1 histone demethylase gene in breast cancer. Oncogene 2009, 28, 4491-
4500. 
517. Rui, L., Emre, N. C., Kruhlak, M. J., Chung, H. J., Steidl, C., Slack, G., 
Staudt, L. M. Cooperative epigenetic modulation by cancer amplicon genes. 
Cancer Cell 2010, 18, 590-605 .  
518. Di Tacchio, L., Le, H. D., Vollmers, C., Hatori, M., Witcher, M., Secombe, 
J., Panda, S. Histone lysine demethylase JARID1a activates CLOCK-BMAL1 
and influences the circadian clock. Science 2011, 333, 1881-1885. 
519. Benevolenskaya, E.V., Murray, H.L., Branton, P., Young, R.A., Kaelin, 
W.G., Binding of pRB to the PHD protein RBP2 promotes cellular 
differentiation. Mol Cell 2005, 18, 623-635. 
520. Zeng, J., Ge, Z., Wang, L., Li, Q., Wang, N., Björkholm, M., Xu, D. The 
histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition 
triggers senescence of cancer cells. Gastroenterology 2010, 138, 981-992. 
521. Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, 
S., Settleman, J. A chromatin-mediated reversible drug-tolerant state in cancer 
cell subpopulations. Cell 2010, 141, 69-80. 
522. Schmitz, S. U., Albert, M., Malatesta, M., Morey, L., Johansen, J. V., Bak, 
M., Helin, K. Jarid1b targets genes regulating development and is involved in 
neural differentiation. EMBO J. 2011, 30, 4586-4600. 
523. Lu, P. J., Sundquist, K., Baeckstrom, D., Poulsom, R., Hanby, A., Meier-
Ewert, S., Taylor-Papadimitriou, J. A novel gene (PLU-1) containing highly 
conserved putative DNA/chromatin binding motifs is specifically up-regulated 
in breast cancer. Journal of Biological Chemistry 1999, 274, 15633-15645. 
524. Hayami, S., Yoshimatsu, M., Veerakumarasivam, A., Unoki, M., Iwai, Y., 
Tsunoda, T., Hamamoto, R. Overexpression of the JmjC histone demethylase 
KDM5B in human carcinogenesis: involvement in the proliferation of cancer 
cells through the E2F/RB pathway. Mol Cancer 2010, 9, 59. 
525. Xiang, Y., Zhu, Z., Han, G., Ye, X., Xu, B., Peng, Z., Chen, C. D. JARID1B 
is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. 
Proceedings of the National Academy of Sciences 2007, 104, 19226-19231. 
 254 |References  
526. Yamane, K., Tateishi, K., Klose, R. J., Fang, J., Fabrizio, L. A., Erdjument-
Bromage, H., Zhang, Y. PLU-1 is an H3K4 demethylase involved in 
transcriptional repression and breast cancer cell proliferation. Molecular cell 
2007, 25, 801-812. 
527. Roesch, A., Fukunaga-Kalabis, M., Schmidt, E. C., Zabierowski, S. E., 
Brafford, P. A., Vultur, A., Herlyn, M. A temporarily distinct subpopulation of 
slow-cycling melanoma cells is required for continuous tumor growth. Cell 
2010, 141, 583-594. 
528. M. Tahiliani, P. Mei, R. Fang, T. Leonor, M. Rutenberg, F. Shimizu, J. Li, A. 
Rao, Y. Shi, The histone H3K4 demethylase SMCX links REST target genes to 
X-linked mental retardation. Nature 2007, 447, 601-605. 
529. J.A. Smith, E.A. White, M.E. Sowa, M.L. Powell, M. Ottinger, J.W. Harper, 
P.M. Howley, Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 
as E2- dependent regulators of human papillomavirus oncogene expression. 
Proceedings of the National Academy of Sciences 2010, 107, 3752-3757. 
530.  De Santa, F., Totaro, M. G., Prosperini, E., Notarbartolo, S., Testa, G., 
Natoli, G. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to 
inhibition of polycomb-mediated gene silencing. Cell 2007, 130, 1083-1094. 
531. De Santa, F., Narang, V., Yap, Z. H., Tusi, B. K., Burgold, T., Austenaa, L., 
Natoli, G. Jmjd3 contributes to the control of gene expression in LPS-activated 
macrophages. The EMBO journal 2009, 28, 3341-3352. 
532. Lee, M. G., Villa, R., Trojer, P., Norman, J., Yan, K. P., Reinberg, D., 
Shiekhattar, R. Demethylation of H3K27 regulates polycomb recruitment and 
H2A ubiquitination. Science 2007, 318, 447-450. 
533. Issaeva, I., Zonis, Y., Rozovskaia, T., Orlovsky, K., Croce, C. M., Nakamura, 
T., Canaani, E. Knockdown of ALR (MLL2) reveals ALR target genes and leads 
to alterations in cell adhesion and growth. Molecular and cellular biology 2007, 
27, 1889-1903. 
534. van Haaften, G., Dalgliesh, G. L., Davies, H., Chen, L., Bignell, G., 
Greenman, C., Wong, J. Somatic mutations of the histone H3K27 demethylase 
gene UTX in human cancer. Nature genetics 2009, 41, 521-523. 
535. Yokoyama, A., Okuno, Y., Chikanishi, T., Hashiba, W., Sekine, H., Fujiki, 
R., Kato, S. KIAA1718 is a histone demethylase that erases repressive histone 
methyl marks. Genes to Cells 2010, 15, 867-873. 
536. Kooistra, S. M., Helin, K. Molecular mechanisms and potential functions of 
histone demethylases. Nature reviews Molecular cell biology 2012, 13, 297-311. 
537. Yang, Y., Hu, L., Wang, P., Hou, H., Lin, Y., Liu, Y., Xu, Y. Structural 
insights into a dual-specificity histone demethylase ceKDM7A from 
Caenorhabditis elegans. Cell research 2010, 20, 886-898. 
538. Qi, H. H., Sarkissian, M., Hu, G. Q., Wang, Z., Bhattacharjee, A., Gordon, D. 
B., Shi, Y. Histone H4K20/H3K9 demethylase PHF8 regulates zebrafish brain 
and craniofacial development. Nature 2010, 466, 503-507. 
 255 |References  
539. Huang, C., Xiang, Y., Wang, Y., Li, X., Xu, L., Zhu, Z., Chen, C. D. Dual-
specificity histone demethylase KIAA1718 (KDM7A) regulates neural 
differentiation through FGF4. Cell research 2010, 20, 154-165. 
540. Lee, M.G., Wynder, C., Schmidt, D.M., McCafferty, D.G., Shiekhattar, R. 
Histone H3 lysine 4 demethylation is a target of nonselective antidepressive 
medications. Chem Biol. 2006,13, 563-567. 
541. Culhane, J.C., Wang, D., Yen, P.M., Cole, P.A. Comparative analysis of 
small molecules and histone substrate analogues as LSD1 lysine demethylase 
inhibitors. J Am Chem Soc. 2010, 132, 3164-3176. 
542. Yang, M., Culhane, J. C., Szewczuk, L. M., Jalili, P., Ball, H. L., Machius, 
M., Yu, H. Structural basis for the inhibition of the LSD1 histone demethylase 
by the antidepressant trans-2-phenylcyclopropylamine. Biochemistry 2007,46, 
8058-8065. 
543. Ueda, R., Suzuki, T., Mino, K., Tsumoto, H., Nakagawa, H., Hasegawa, M., 
Miyata, N. Identification of cell-active lysine specific demethylase 1–selective 
inhibitors. J Am Chem Soc. 2009,131, 17536-17537. 
544. Binda, C., Valente, S., Romanenghi, M., Pilotto, S., Cirilli, R., Karytinos, A., 
Mai, A. Biochemical, structural, and biological evaluation of tranylcypromine 
derivatives as inhibitors of histone demethylases LSD1 and LSD2. J Am Chem 
Soc. 2010, 132, 6827-6833. 
545. Liang, Y., Quenelle, D., Vogel, J. L., Mascaro, C., Ortega, A., Kristie, T. M. 
A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex 
virus lytic replication and reactivation from latency. MBio 2013, 4, e00558-12. 
546. Szewczuk, L.M., Culhane, J.C., Yang, M., Majumdar, A., Yu, H., Cole, P.A. 
Mechanistic analysis of a suicide inactivator of histone demethylase LSD1. 
Biochemistry 2007;46, 6892-902. 
547. Yang, M., Culhane, J. C., Szewczuk, L. M., Gocke, C. B., Brautigam, C. A., 
Tomchick, D. R., Yu, H. Structural basis of histone demethylation by LSD1 
revealed by suicide inactivation. Nature Structural and Molecular Biology 2007, 
14, 535-539. 
548. Wang, Y., Murray-Stewart, T., Devereux, W., Hacker, A., Frydman, B., 
Woster, P. M., Casero, R. A. Properties of purified recombinant human 
polyamine oxidase, PAOh1/SMO. Biochemical and biophysical research 
communications 2003, 304, 605-611. 
549. Bi, X., Lopez, C., Bacchi, C.J., Rattendi, D., Woster, P.M. Novel 
alkylpolyaminoguanidines and alkylpolyaminobiguanides with potent 
antitrypanosomal activity. Bioorg Med Chem Lett. 2006,16, 3229-32. 
550. Sharma, S. K., Hazeldine, S., Crowley, M. L., Hanson, A., Beattie, R., 
Varghese, S., Woster, P. M. Polyamine-based small molecule epigenetic 
modulators. MedChemComm 2012, 3, 14-21. 
551. Huang, Y., Stewart, T. M., Wu, Y., Baylin, S. B., Marton, L. J., Perkins, B., 
Casero, R. A. Novel oligoamine analogues inhibit lysine-specific demethylase 1 
 256 |References  
and induce reexpression of epigenetically silenced genes. Clin Cancer Res. 
2009,15, 7217-7228. 
552. Sharma, S. K., Wu, Y., Steinbergs, N., Crowley, M. L., Hanson, A. S., Casero 
Jr, R. A., Woster, P. M. (Bis)urea and (bis)thiourea inhibitors of lysine-specific 
demethylase 1 as epigenetic modulators. J Med Chem. 2010, 53, 5197-5212. 
553. Rose, N. R., Ng, S. S., Mecinovi , J., Li nard, B. M., Bello, S. H., Sun, Z., 
Schofield, C. J. Inhibitor Scaffolds for 2-Oxoglutarate-Dependent Histone 
Lysine Demethylases. J Med Chem. 2008, 51, 7053-7056. 
554. Chen, Z., Zang, J., Kappler, J., Hong, X., Crawford, F., Wang, Q., Zhang, G. 
Structural basis of the recognition of a methylated histone tail by JMJD2A. Proc 
Natl Acad Sci USA 2007, 104, 10818-10823.  
555. Sekirnik, R., Rose, N. R., Thalhammer, A., Seden, P. T., Mecinovi , J., 
Schofield, C. J. Inhibition of the histone lysine demethylase JMJD2A by ejection 
of structural Zn (II). ChemComm 2009, 42, 6376. 
556. Chowdhury, R., Yeoh, K. K., Tian, Y. M., Hillringhaus, L., Bagg, E. A., 
Rose, N. R., Leung, I. K., Li, X. S., Woon, E. C., Yang, M.,Mcdonough, M. A., 
King, O. N., Clifton, I. J., Klose, R. J., Claridge, T. D., Ratcliffe, P. J., Schofield, 
C. J., Kawamura, A. The oncometabolite 2-hydroxyglutarate inhibits histone 
lysine demethylases. EMBO Reports 2011, 12, 463-469. 
557. King, O. N., Li, X. S., Sakurai, M., Kawamura, A., Rose, N. R., Ng, S. S., 
Quinn, A. M., Rai, G., Mott, B. T., Beswick, P., Klose, R. J., Oppermann, U., 
Jadhav, A., Heightman, T. D., Maloney, D. J., Schofield, C. J., Simeonov, A. 
Quantitative High-Throughput Screening Identifies 8-Hydroxyquinolines As 
Cell-Active Histone Demethylase Inhibitors. Plos One 2010, 5, e15535. 
558. Chang, K. H., King, O. N., Tumber, A., Woon, E. C., Heightman, T. D., 
Mcdonough, M. A., Schofield, C. J., Rose, N. R. Inhibition of histone 
demethylases by 4-carboxy-2,2’-bipyridyl compounds Chemmedchem 2011, 6, 
759-764. 
559. Hamada, S., Suzuki, T., Mino, K., Koseki, K., Oehme, F., Flamme, I., Ozasa, 
H., Itoh, Y., Ogasawara, D., Komaarashi, H., Kato, A., Tsumoto, H., Nakagawa, 
H., Hasegawa, M., Sasaki, R.,Mizukami, T., Miyata, N. Design, synthesis, 
enzyme inhibitory activity, and effect on human cancer cells of a novel series of 
jumonji domain-containing protein 2 histone demethylase inhibitors. J Med 
Chem. 2010, 53, 5629-5638. 
560. Kruidenier, L., Chung, C. W., Cheng, Z., Liddle, J., Che, K., Joberty, G., 
Bantscheff, M., Bountra, C., Bridges, A., Diallo, H., Eberhard, D., Hutchinson, 
S., Jones, E., Katso, R., Leveridge, M., Mander, P. K., Mosley, J., Ramirez-
Molina, C., Rowland, P., Schofield, C. J., Sheppard, R. J., Smith, J. E., Swales, 
C., Tanner, R., Thomas, P., Tumber, A., Drewes, G., Oppermann, U., Patel, D. 
J., Lee, K., Wilson, D. M. A selective jumonji H3K27 demethylase inhibitor 
modulates the proinflammatory macrophage response. Nature 2012, 488, 404-
408. 
 257 |References  
561. Chen, S. M., Leupin, W., Rance, M., Chazin, W. J. Two-dimensional NMR 
studies of d (GGTTAATGCGGT). cntdot. d (ACCGCATTAACC) complexed 
with the minor groove binding drug SN-6999. Biochemistry 1992, 31, 4406-
4413. 
562. Adams, A., Leong, C., Denny, W.A., Guss, J.M. Structures of two minor-
groove-binding quinolinium quaternary salts complexed with 
d(CGCGAATTCGCG)(2) at 1.6 and 1.8 Angstrom resolution. Acta Crystallogr 
D Biol Crystallogr 2005, 61,1348-1353. 
563. Denny, W.A., Atwell, G.J., Baguley, B.C., Cain, B.F. Potential antitumor 
agents. 29. Quantitative structure-activity relationships for the antileukemic 
bisquaternary ammonium heterocycles. J Med Chem 1979, 22, 134-150. 
564. Zhang, X.; Cheng, X. Structure of the predominant protein arginine 
methyltransferase PRMT1 and analysis of its binding to substrate peptides. 
Structure 2003, 11, 509-520. 
565. Hashimoto, H.; Liu, Y.; Upadhyay, A. K.; Chang, Y.; Howerton, S. B.; 
Vertino, P. M.; Zhang, X.; Cheng, X. Recognition and potential mechanisms for 
replication and erasure of cytosine hydroxymethylation. Nucleic Acids Res. 
2012, 40, 4841-4849. 
566. Chang, Y.; Zhang, X.; Horton, J. R.; Upadhyay, A. K.; Spannhoff, A.; Liu, J.; 
Snyder, J. P.; Bedford, M. T.; Cheng, X. Structural basis for G9a-like protein 
lysine methyltransferase inhibition by BIX-01294. Nat. Struct. Mol. Biol. 2009, 
16, 312-317. 
567. Schnekenburger, M., Grandjenette, C., Ghelfi, J., Karius, T., Foliguet, B., 
Dicato, M., Diederich, M. Sustained exposure to the DNA demethylating agent, 
2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid 
leukemia by promoting differentiation, senescence, and autophagy. Biochem. 
Pharmacol. 2011, 81, 364-378. 
568. Charlet, J., Schnekenburger, M., Brown, K. W., Diederich, M. DNA 
demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic 
drugs. Biochem. Pharmacol. 2012, 83, 858-865. 
569. Dudley, K. J., Revill, K., Whitby, P., Clayton, R. N., Farrell, W. E. Genome-
wide analysis in a murine Dnmt1 knockdown model identifies epigenetically 
silenced genes in primary human pituitary tumors. Molecular Cancer Research 
2008, 6, 1567-1574. 
570. Valente, S.,  Liu, Y., Schnekenburger, M., Zwergel, C., Cosconati, S., Gros, 
C., Tardugno, M., Labella, D., Florean, C., Minden, S.,
 
Hashimoto, H., 
Chang,Y., Zhang, X., Kirsch, G., Novellino, E., Arimondo, P.B., Miele, E., 
Ferretti, E., Gulino, A., Diederich, M., Cheng, X., Mai, A.
 
Selective non-
nucleoside inhibitors of human dna methyltransferases active in cancer including 
cancer stem cells, J Med Chem, accepted.  
571. You, J. S., Jones, P. A. Cancer genetics and epigenetics: two sides of the 
same coin? Cancer Cell 2012, 22, 9-20. 
 258 |References  
572. Gros, C., Fahy, J., Halby, L., Dufau, I., Erdmann, A., Gregoire, J. M., 
Ausseil, F., Vispe, S., Arimondo, P. B. DNA methylation inhibitors in cancer: 
recent and future approaches. Biochimie 2012, 94, 2280-2296. 
573. Mai, A., Cheng, D., Bedford, M. T., Valente, S., Nebbioso, A., Perrone, A., 
Brosch, G., Sbardella, G., De Bellis, F., Miceli, M., Altucci, L. Epigenetic 
multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and 
class III deacetylase (sirtuin) inhibitors. J. Med. Chem. 2008, 51, 2279-2290. 
574. Cheng, D., Valente, S., Castellano, S., Sbardella, G., Di Santo, R., Costi, R., 
Bedford, M. T., Mai, A. Novel 3,5-bis(bromohydroxybenzylidene)piperidin-4-
ones as coactivator-associated arginine methyltransferase 1 inhibitors: enzyme 
selectivity and cellular activity. J. Med. Chem. 2011, 54, 4928-4932. 
575. Chang, Y., Ganesh, T., Horton, J. R., Spannhoff, A., Liu, J., Sun, A., Zhang, 
X., Bedford, M. T., Shinkai, Y., Snyder, J. P., Cheng, X. Adding a lysine mimic 
in the design of potent inhibitors of histone lysine methyltransferases. J. Mol. 
Biol. 2010, 400, 1-7. 
576. Upadhyay, A. K., Rotili, D., Han, J. W., Hu, R., Chang, Y., Labella, D., 
Zhang, X., Yoon, Y. S., Mai, A., Cheng, X. An analog of BIX-01294 selectively 
inhibits a family of histone H3 lysine 9 Jumonji demethylases. J. Mol. Biol. 
2012, 416, 319-327. 
577. Vedadi, M., Barsyte-Lovejoy, D., Liu, F., Rival-Gervier, S., Allali-Hassani, 
A., Labrie, V., Wigle, T. J., Dimaggio, P. A., Wasney, G. A., Siarheyeva, A., 
Dong, A., Tempel, W., Wang, S. C., Chen, X., Chau, I., Mangano, T. J., Huang, 
X. P., Simpson, C. D., Pattenden, S. G., Norris, J. L., Kireev, D. B., Tripathy, A., 
Edwards, A., Roth, B. L., Janzen, W. P., Garcia, B. A., Petronis, A., Ellis, J., 
Brown, P. J., Frye, S. V., Arrowsmith, C. H., Jin, J. A chemical probe selectively 
inhibits G9a and GLP methyltransferase activity in cells. Nat. Chem. Biol. 2011, 
7, 566-574. 
578. DeRuiter, J., Brubaker, A. N., Millen, J., Riley, T. N. Design and synthesis of 
2-(arylamino)- 4(3H)-quinazolinones as novel inhibitors of rat lens aldose 
reductase. J. Med. Chem. 1986, 29, 627-629. 
579. Lee, B. H., Yegnasubramanian, S., Lin, X., Nelson, W. G. Procainamide is a 
specific inhibitor of DNA methyltransferase 1. J. Biol. Chem. 2005, 280, 40749-
40756. 
580. Gros, C., Chauvigné, L., Poulet, A., Menon, Y., Ausseil, F., Dufau, I., 
Arimondo, P. B. Development of a universal radioactive DNA methyltransferase 
inhibition test for high-throughput screening and mechanistic studies. Nucleic 
Acids Res. 2013, 41, e185. 
581. Ceccaldi, A., Rajavelu, A., Champion, C., Rampon, C., Jurkowska, R., 
Jankevicius, G., Senamaud-Beaufort, C., Ponger, L., Gagey, N., Ali, H. D., Tost, 
J., Vriz, S., Ros, S., Dauzonne, D., Jeltsch, A., Guianvarc'h, D., Arimondo, P. B. 
C5-DNA methyltransferase inhibitors: from screening to effects on zebrafish 
embryo development. ChemBioChem 2011, 12, 1337-1345. 
 259 |References  
582. Yoo, J., Choi, S., Medina-Franco, J. L. Molecular modeling studies of the 
novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: implications 
for the mechanism of inhibition of DNMTs. PloS One 2013, 8, e62152. 
583. Rotili, D., Tarantino, D., Marrocco, B., Gros, C., Masson, V., Gregoire, J-M., 
Ausseil, F., Chang, Y., Labella, D., Cosconati, S., Di Maro, S., Novellino, E., 
Schnekenburger, M., Grandjenette, C., Bouvy, C., Diederich, M., Cheng, X., 
Arimondo, P. B., Mai. A. Identification of Quinazoline Analogues as Novel 
DNA methyltransferase 3A Inhibitors. J Med Chem submitted. 
584. a) Mai, A., Small-molecule chromatin-modifying agents: therapeutic 
applications. Epigenomics 2010, 2, 307-324; b) Conte, M., Altucci, L. Molecular 
pathways: the complexity of the epigenome in cancer and recent clinical 
advances. Clin. Cancer Res. 2012, 18, 5526-5534. 
585. Spiegel, S., Milstien, S., Grant, S. Endogenous modulators and 
pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 
2011, 31, 537-551. 
586.  a) Mai, A., Massa, S., Ragno, R., Esposito, M., Sbardella, G., Nocca, G., 
Brosch, G. Binding mode analysis of 3-(4-benzoyl-1-methyl-1 H-2-pyrrolyl)-N-
hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing 
histone hyperacetylation, growth inhibition, and terminal cell differentiation. J 
Med Chem 2002, 45(9), 1778-1784. b) Mai, A., Massa, S., Ragno, R., Cerbara, 
I., Jesacher, F., Loidl, P., Brosch, G. 3-(4-Aroyl-1-methyl-1 H-2-pyrrolyl)-N-
hydroxy-2-alkylamides as a new class of synthetic histone deacetylase 
inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies 
performed through three different docking procedures. J Med Chem 2003, 46, 
512-524. c) Ragno, R., Mai, A., Massa, S., Cerbara, I., Valente, S., Bottoni, 
P.,Brosch, G. 3-(4-Aroyl-1-methyl-1 H-pyrrol-2-yl)-N-hydroxy-2-propenamides 
as a new class of synthetic histone deacetylase inhibitors. 3. discovery of novel 
lead compounds through structure-based drug design and docking studies. J Med 
Chem 2004, 47, 1351-1359. d) Mai, A., Massa, S., Valente, S., Simeoni, S., 
Ragno, R., Bottoni, P., Brosch, G. Aroyl‐Pyrrolyl Hydroxyamides: Influence of 
pyrrole C4‐phenylacetyl substitution on histone deacetylase inhibition. 
ChemMedChem 2006, 1, 225-237. e) Valente, S., Tardugno, M., Conte, M., 
Cirilli, R., Perrone, A., Ragno, R., Mai, A. Novel cinnamyl hydroxyamides and 
2‐aminoanilides as histone deacetylase inhibitors: apoptotic induction and 
cytodifferentiation activity. ChemMedChem 2011, 6, 698-712. 
587. a) Mai, A., Massa, S., Pezzi, R., Valente, S., Loidl, P., Brosch, G. Synthesis 
and biological evaluation of 2-, 3-, and 4-acylaminocinnamyl-nhydroxyamides 
as novel synthetic HDAC inhibitors. Medicinal Chemistry 2005, 1, 245-254; b) 
Varasi, M., Thaler, F., Abate, A., Bigogno, C., Boggio, R., Carenzi, G., Mai A., 
Mercurio, C. Discovery, synthesis, and pharmacological evaluation of 
spiropiperidine hydroxamic acid based derivatives as structurally novel histone 
deacetylase (HDAC) inhibitors. J Med Chem 2011, 54, 3051-3064;  
 260 |References  
588. a) Mai, A., Jelicic, K., Rotili, D., Di Noia, A., Alfani, E., Valente, S., 
Migliaccio, G. Identification of two new synthetic histone deacetylase inhibitors 
that modulate globin gene expression in erythroid cells from healthy donors and 
patients with thalassemia. Mol. Pharmacol. 2007, 72, 1111-1123; b) Mai, A., 
Perrone, A., Nebbioso, A., Rotili, D., Valente, S., Tardugno, M., Massa S., De 
Bellis L., Altucci, L. Novel uracil-based 2-aminoanilide and 2-aminoanilide-like 
derivatives: Histone deacetylase inhibition and in-cell activities. Bioorg. Med. 
Chem. Lett. 2008, 18, 2530-2535. 
589. Itoh, Y., Suzuki, T., Kouketsu, A., Suzuki, N., Maeda, S., Yoshida, M., 
Miyata, N. Design, synthesis, structure-selectivity relationship, and effect on 
human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. 
Journal of medicinal chemistry 2007, 50, 5425-5438. 
590. Valente, S., Trisciuoglio, D., Tardugno, M., Benedetti, R., Labella, D., Secci, 
D., Mercurio, C., Boggio, R., Tomassi, S., Di Maro, S, Novellino, E., Altucci, 
L., Del Bufalo, D., Mai, A., Cosconati, S. tert‐Butylcarbamate‐containing 
histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and 
antiproliferative activities in cancer cells. ChemMedChem 2013, 8, 800-811. 
591. Mai, A., Massa, S., Pezzi, R., Simeoni, S., Rotili, D., Nebbioso, A., Brosch, 
G. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and 
biological evaluation of novel (aryloxopropenyl) pyrrolyl hydroxyamides. 
Journal of medicinal chemistry, 2005, 48, 3344-3353. 
592. Lahm, A., Paolini, C., Pallaoro, M., Nardi, M. C., Jones, P., Neddermann, P., 
Gallinari, P. Unraveling the hidden catalytic activity of vertebrate class IIa 
histone deacetylases. Proceedings of the National Academy of Sciences 2007, 
104, 17335-17340. 
593. Zou, H., Wu, Y., Navre, M., Sang, B. C. Characterization of the two catalytic 
domains in histone deacetylase 6. Biochemical and biophysical research 
communications 2006, 341, 45-50. 
594. Roy, A., Kucukural, A., Zhang, Y. I-TASSER: a unified platform for 
automated protein structure and function prediction. Nature protocols 2010, 5, 
725-738. 
595. Butler, K. V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., Kozikowski, A. 
P. Rational design and simple chemistry yield a superior, neuroprotective 
HDAC6 inhibitor, tubastatin A. Journal of the American Chemical Society 2010, 
132, 10842-10846. 
596. Schuetz, A., Min, J., Allali-Hassani, A., Schapira, M., Shuen, M., Loppnau, 
P., Vedavi M. Arrowsmith, C. H. Human HDAC7 harbors a class IIa histone 
deacetylase-specific zinc binding motif and cryptic deacetylase activity. Journal 
of Biological Chemistry 2008, 283, 11355-11363. 
597. Hess-Stumpp, H., Bracker, T. U., Henderson, D., Politz, O. MS-275, a potent 
orally available inhibitor of histone deacetylases the development of an 
anticancer agent. The international journal of biochemistry & cell biology 2007, 
39, 1388-1405. 
 261 |References  
598. Nebbioso, A., Clarke, N., Voltz, E., Germain, E., Ambrosino, C., Bontempo, 
P., Altucci, L. Tumor-selective action of HDAC inhibitors involves TRAIL 
induction in acute myeloid leukemia cells. Nature medicine 2004, 11, 77-84. 
599. Auzzas, L., Larsson, A., Matera, R., Baraldi, A., Desch nes-Simard, B., 
Giannini, G., Hanessian, S. Non-natural macrocyclic inhibitors of histone 
deacetylases: design, synthesis, and activity. Journal of medicinal chemistry 
2010, 53, 8387-8399. 
600. Li, Y., Shin, D., & Kwon, S. H. Histone deacetylase 6 plays a role as a 
distinct regulator of diverse cellular processes. FEBS Journal 2013, 280, 775-
793. 
601. Rotili, D., Mai, A. Targeting histone demethylases: a new avenue for the fight 
against cancer. Genes Cancer 2011, 2, 663-679. 
602. Sams-Dodd, F. Target-based drug discovery: is something wrong? Drug 
Discov. Today 2005, 10,139-147. 
603. Rather, M. A., Bhat, B. A., Qurishi, M. A. Multicomponent phytotherapeutic 
approach gaining momentum: Is the “one drug to fit all” model breaking down?. 
Phytomedicine 2013, 21, 1-14. 
604. Morphy, R., Rankovic, Z. Designed Multiple Ligands. An Emerging Drug 
Discovery Paradigm. J.Med. Chem. 2005, 48, 6523-6543. 
605. Zimmerman, G. R., Lehar, J., Keith, C. T. Multi-target therapeutics: when the 
whole is greater than the sum of the parts. Drug Discov. Today 2007, 12, 34-42. 
606. Hopkinson, R. J., Tumber, A., Yapp, C., Chowdhury, R., Aik, W., Che, K. 
H., Li, X. S., Kristensen,J. B. L., King, O. N. F., Chan, M. C., Yeoh, K. K., 
Choi, H., Walport, L. J., Thinnes, C. C., Bush, J. T., Lejeune, C., Rydzik, A. M., 
Rose, N. R., Bagg, E. A., McDonough, M. A., Krojer, T. J., Yue, W. W., Ng, S. 
S., Olsen, L., Butler, E. S., Opperman, U., Muller, S., Klose, R. J., Ratcliffe, P. 
J., Schofield, C. J., Kawamura, A. 5-Carboxy-8-hydroxyquinoline is a broad 
spectrum 2-oxoglutarate oxygenase inhibitor which causes iron translocation. 
Chem. Sci. 2013, 4, 3110-3117. 
607. Gros, L, Lorente, S. O., Jimenez, C. J., Yardley, V., Rattray, L., Wharton, H., 
Little, S., Croft, S. L., Ruiz-Perez, L. M., Gonzalez-Pacanowska, D., Gilbert, I. 
H. Evaluation of azasterols as anti-parasitics. J. Med. Chem. 2006, 49, 6094-
6103. 
608. Rose, N. R., Woon, E. C., Tumber, A., Walport, L. J., Chowdhury, R., Li, X. 
S., King, O. N., Lejeune, C., Ng, S. S., Krojer, T., Chan, M. C., Rydzik, A. M., 
Hopkinson, R. J., Che, K. H., Daniel, M., Strain-Damerell, C., Gileadi, C., 
Kochan, G., Leung, I. K., Dunford, J., Yeoh, K. K., Ratcliffe, P. J., Burgess-
Brown, N., von Delft, F.; Muller, S., Marsden, B., Brennan, P. E., McDonough, 
M. A., Oppermann, U., Klose, R. J., Schofield, C. J., Kawamura, A. Plant 
growth regulator daminozide is a selective inhibitor of human KDM2/7 histone 
demethylases. J. Med. Chem. 2012, 55, 6639-6643. 
609. Kerenyi, M. A., Shao, Z., Hsu, Y. J., Guo, G., Luc, S., O’Brien, K., Fujiwara, 
Y., Peng, C., Nguyen, M., Orkin, S. H. Histone demethylase Lsd1 represses 
 262 |References  
hematopoietic stem and progenitor cell signatures during blood cell maturation. 
Elife 2013, 2, e00633. 
610. Schenk, T., Chen, W. C., Gollner, S., Howell, L., Jin, L., Hebestreit, K., 
Klein, H. U., Popescu, A. C., Burnett, A., Mills, K., Casero, R. A. Jr., Marton, 
L., Woster, P., Minden, M. D., Dugas, M., Wang, J. C., Dick, J. E., Muller-
Tidow, C., Petrie, K., Zelent, A. Inhibition of the LSD1 (KDM1A) demethylase 
reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid 
eukemia. Nat. Med. 2012, 18, 605-611. 
611. Miceli, M., Franci, G., Dell’Aversana, C., Ricciardiello, F., Petraglia, F., 
Carissimo, A., Perone, L., Maruotti, G. M., Savarese, M., Martinelli, P., 
Cancemi, M., Altucci, L. MePR: a novel human mesenchymal progenitor model 
with characteristics of pluripotency. Stem Cells Dev. 2013, 22, 2368-2383. 
612. Rotili, D., Tomassi, S., Conte, M., Benedetti, R., Tortorici, M., Ciossani, G., 
Valente, S., Marrocco, B., Labella, D., Novellino, E., Mattevi, A., Altucci, L., 
Tumber, A., Yapp, C., King, O. N. F., Hopkinson, R. J., Kawamura, A., 
Schofield, C. J., Mai. A. Pan-histone demethylase inhibitors simultaneously 
targeting Jumonji C and lysine specific demethylases display high anticancer 
activities. J Med Chem, accepted. 
613. Kubicek, S., O'Sullivan, R. J., August, E. M., Hickey, E. R., Zhang, Q., 
Teodoro, M. L., Jenuwein, T. Reversal of H3K9me2 by a small-molecule 
inhibitor for the G9a histone methyltransferase. Molecular cell 2007, 25, 473-
481. 
614. Liu, F., Chen, X., Allali-Hassani, A., Quinn, A. M., Wasney, G. A., Dong, A., 
Jin, J. Discovery of a 2, 4-diamino-7-aminoalkoxyquinazoline as a potent and 
selective inhibitor of histone lysine methyltransferase G9a. Journal of medicinal 
chemistry 2009, 52, 7950-7953. 
615. Liu, F., Barsyte-Lovejoy, D., Allali-Hassani, A., He, Y., Herold, J. M., Chen, 
X., Jin, J. Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-
quinazolines. Journal of medicinal chemistry 2011, 54, 6139-6150. 
616. Kleefstra, T., Brunner, H. G., Amiel, J., Oudakker, A. R., Nillesen, W. M., 
Magee, A., van Bokhoven, H. Loss-of-function mutations in euchromatin 
histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion 
syndrome. The American Journal of Human Genetics 2006, 79, 370-377. 
617. Iwase, S., Lan, F., Bayliss, P., de la Torre-Ubieta, L., Huarte, M., Qi, H. H., 
Shi, Y. The X-linked mental retardation gene SMCX/JARID1C defines a family 
of histone H3 lysine 4 demethylases. Cell 2007, 128, 1077-1088. 
618. Lee, J. H., Lee, B. S., Shin, H., Chi, D. Y. Acetonitrile-mediated synthesis of 
2, 4-dichloroquinoline from 2-ethynylaniline and 2, 4-dichloroquinazoline from 
anthranilonitrile. Synlett, 2006, 65-68. 
619. Studier, F. W. Protein production by auto-induction in high density shaking 
cultures. Protein Expr Purif 2005, 41, 207-234. 
620. Hirao, M., Posakony, J., Nelson, M., Hruby, H., Jung, M., Simon, J. A., 
Bedalov, A. Identification of selective inhibitors of NAD
+
-dependent 
 263 |References  
deacetylases using phenotypic screens in yeast. Journal of Biological Chemistry 
2003, 278, 52773-52782.  
621. Kaeberlein, M., McDonagh, T., Heltweg, B., Hixon, J., Westman, E. A., 
Caldwell, S. D., Kennedy, B. K. Substrate-specific activation of sirtuins by 
resveratrol. Journal of Biological Chemistry 2005, 280, 17038-17045. 
622. Borra, M. T., Langer, M. R., Slama, J. T., Denu, J. M. Substrate specificity 
and kinetic mechanism of the Sir2 family of NAD
+
-dependent histone/protein 
deacetylases. Biochemistry 2004, 43, 9877-9887. 
623. Borra, M. T., Denu, J. M. Quantitative assays for characterization of the sir2 
family of NAD
+
-dependent deacetylases. Methods in enzymology 2003, 376, 
171-187. 
624. Heltweg, B., Trapp, J., Jung, M. In vitro assays for the determination of 
histone deacetylase activity. Methods 2005, 36, 332-337. 
625. de Boer, V. C., de Goffau, M. C., Arts, I. C., Hollman, P. C., Keijer, J. SIRT1 
stimulation by polyphenols is affected by their stability and metabolism. 
Mechanisms of ageing and development 2006, 127, 618-627. 
626. Marcotte, P. A., Richardson, P. R., Guo, J., Barrett, L. W., Xu, N., 
Gunasekera, A., Glaser, K. B. Fluorescence assay of SIRT protein deacetylases 
using an acetylated peptide substrate and a secondary trypsin reaction. Analytical 
biochemistry 2004, 332, 90-99. 
627. Liu, Y., Gerber, R., Wu, J., Tsuruda, T., McCarter, J. D. High-throughput 
assays for sirtuin enzymes: a microfluidic mobility shift assay and a 
bioluminescence assay. Analytical biochemistry 2008, 378, 53-59. 
628. Fan, Y., Ludewig, R., Imhof, D., Scriba, G. K. Development of a capillary 
electrophoresis‐based assay of sirtuin enzymes. Electrophoresis 2008, 29, 3717-
3723. 
629. Fan, Y., Ludewig, R., Scriba, G. K. 9-Fluorenylmethoxycarbonyl-labeled 
peptides as substrates in a capillary electrophoresis-based assay for sirtuin 
enzymes. Analytical biochemistry 2009, 387, 243-248. 
630. Smith, B. C., Hallows, W. C., Denu, J. M. A continuous microplate assay for 
sirtuins and nicotinamide-producing enzymes. Analytical biochemistry 2009, 
394, 101-109. 
631. Feng, Y., Wu, J., Chen, L., Luo, C., Shen, X., Chen, K., Liu, D. A 
fluorometric assay of SIRT1 deacetylation activity through quantification of 
nicotinamide adenine dinucleotide. Analytical biochemistry 2009, 395, 205-210. 
632. Wegener, D., Hildmann, C., Riester, D., Schwienhorst, A. Improved 
fluorogenic histone deacetylase assay for high-throughput-screening 
applications. Analytical biochemistry 2003, 321, 202-208. 
633. Lakshminarasimhan, M., Rauh, D., Schutkowski, M., & Steegborn, C. (2013). 
Sirt1 activation by resveratrol is substrate sequence-selective. Aging (Albany 
NY), 5(3), 151. 
634. He B, Du J, Lin H., Thiosuccinyl Peptides as Sirt5-Specific Inhibitors. 
Journal of the American Chemical Society 2012, 134, 1922-1925. 
 264 |References  
635. Huber, K., Schemies, J., Uciechowska, U., Wagner, J. M., Rumpf, T., 
Lewrick, F., Bracher, F. Novel 3-arylideneindolin-2-ones as inhibitors of NAD
+
-
dependent histone deacetylases (sirtuins). Journal of medicinal chemistry 2009, 
53, 1383-1386. 
636. Bradford, M. M. A rapid and sensitive method for the quantitation of 
microgram quantities of protein utilizing the principle of protein-dye binding. 
Analytical biochemistry 1976, 72, 248-254. 
 265 | Acknowledgements 
15. Acknowledgements 
First and foremost I want to thank my supervisor Prof. Antonello Mai. It has been an 
honor to be his Ph.D. student. He has introduced me to “the wonderland of 
Epigenetics” since I was a graduate student. I appreciate all his contributions of time, 
ideas, and funding to make my Ph.D. experience productive and stimulating. I would 
also like to express my sincere thanks to Dr. Dante Rotili and Dr. Sergio Valente for 
all them constant support and excellent scientific discussions. 
I am thankful to Prof. Clemens Steegborn, for providing me the opportunity to work 
in his laboratory with exciting research topics. I would also like to thank all the 
members of the biochemistry department, University of Bayreuth, Germany for all 
the support and a good working atmosphere. 
I will always be grateful to “Neverlab” group members, past and present, for their 
unconditional help, insightful discussions, and friendship. In particular, I would like 
to thank Maria Tardugno, Stefano Tomassi, Clemens Zwergel, Paolo Mellini and 
Biagina Marrocco and Alessia Lenoci for their help for my research. 
Finally I wish to thank my family and friends for their infinite love and support that 
made all of the above possible. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Imagination is more important than knowledge.  
Knowledge is limited. 
 Imagination encircles the world.” 
